0001683168-22-006887.txt : 20221013 0001683168-22-006887.hdr.sgml : 20221013 20221013171550 ACCESSION NUMBER: 0001683168-22-006887 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20221013 DATE AS OF CHANGE: 20221013 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cavitation Technologies, Inc. CENTRAL INDEX KEY: 0001376793 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE SERVICES [0700] IRS NUMBER: 204907818 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-53239 FILM NUMBER: 221309683 BUSINESS ADDRESS: STREET 1: 10019 CANOGA AVENUE CITY: CHATSWORTH, STATE: CA ZIP: 91311 BUSINESS PHONE: 818-718-0905 MAIL ADDRESS: STREET 1: 10019 CANOGA AVENUE CITY: CHATSWORTH, STATE: CA ZIP: 91311 FORMER COMPANY: FORMER CONFORMED NAME: Bioenergy Inc. DATE OF NAME CHANGE: 20060927 10-K 1 cavitation_i10k-063022.htm FORM 10-K
0001376793 false 2022 FY No No Yes Yes 0001376793 2021-07-01 2022-06-30 0001376793 2021-12-31 0001376793 2022-09-28 0001376793 2022-06-30 0001376793 2021-06-30 0001376793 2020-07-01 2021-06-30 0001376793 us-gaap:CommonStockMember 2020-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001376793 us-gaap:RetainedEarningsMember 2020-06-30 0001376793 2020-06-30 0001376793 us-gaap:CommonStockMember 2021-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001376793 us-gaap:RetainedEarningsMember 2021-06-30 0001376793 us-gaap:CommonStockMember 2020-07-01 2021-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2021-06-30 0001376793 us-gaap:RetainedEarningsMember 2020-07-01 2021-06-30 0001376793 us-gaap:CommonStockMember 2021-07-01 2022-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2022-06-30 0001376793 us-gaap:RetainedEarningsMember 2021-07-01 2022-06-30 0001376793 us-gaap:CommonStockMember 2022-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001376793 us-gaap:RetainedEarningsMember 2022-06-30 0001376793 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CVAT:DesmetBallestraMember 2021-07-01 2022-06-30 0001376793 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CVAT:EWMember 2021-07-01 2022-06-30 0001376793 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CVAT:DesmetBallestraMember 2020-07-01 2021-06-30 0001376793 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CVAT:EWMember 2020-07-01 2021-06-30 0001376793 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CVAT:EWMember 2021-07-01 2022-06-30 0001376793 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CVAT:EWMember 2020-07-01 2021-06-30 0001376793 us-gaap:LeaseholdImprovementsMember 2021-07-01 2022-06-30 0001376793 us-gaap:FurnitureAndFixturesMember 2021-07-01 2022-06-30 0001376793 us-gaap:OfficeEquipmentMember 2021-07-01 2022-06-30 0001376793 us-gaap:EquipmentMember 2021-07-01 2022-06-30 0001376793 us-gaap:OtherMachineryAndEquipmentMember 2021-07-01 2022-06-30 0001376793 us-gaap:StockOptionMember 2021-07-01 2022-06-30 0001376793 us-gaap:StockOptionMember 2020-07-01 2021-06-30 0001376793 us-gaap:WarrantMember 2021-07-01 2022-06-30 0001376793 us-gaap:WarrantMember 2020-07-01 2021-06-30 0001376793 CVAT:DesmetBallestraMember CVAT:NanoReactorSalesMember 2021-07-01 2022-06-30 0001376793 CVAT:DesmetBallestraMember CVAT:GrossProfitShareMember 2021-07-01 2022-06-30 0001376793 CVAT:DesmetBallestraMember 2021-07-01 2022-06-30 0001376793 CVAT:DesmetBallestraMember CVAT:NanoReactorSalesMember 2020-07-01 2021-06-30 0001376793 CVAT:DesmetBallestraMember CVAT:GrossProfitShareMember 2020-07-01 2021-06-30 0001376793 CVAT:DesmetBallestraMember 2020-07-01 2021-06-30 0001376793 CVAT:DesmetBallestraMember 2022-06-30 0001376793 CVAT:DesmetMember 2021-06-30 0001376793 CVAT:AmeredevMember 2021-07-01 2022-06-30 0001376793 CVAT:AmeredevMember CVAT:ReactorSalesMember 2021-07-01 2022-06-30 0001376793 CVAT:AmeredevMember CVAT:UsageFeesMember 2021-07-01 2022-06-30 0001376793 CVAT:UsageFeesMember 2020-07-01 2021-06-30 0001376793 us-gaap:EquityMethodInvestmentsMember 2021-06-30 0001376793 us-gaap:EquityMethodInvestmentsMember 2021-07-01 2022-06-30 0001376793 us-gaap:EquityMethodInvestmentsMember 2022-06-30 0001376793 CVAT:AmeredevMember 2022-06-30 0001376793 CVAT:AmeredevMember 2021-07-01 2022-06-30 0001376793 us-gaap:LeaseholdImprovementsMember 2022-06-30 0001376793 us-gaap:LeaseholdImprovementsMember 2021-06-30 0001376793 us-gaap:FurnitureAndFixturesMember 2022-06-30 0001376793 us-gaap:FurnitureAndFixturesMember 2021-06-30 0001376793 us-gaap:OfficeEquipmentMember 2022-06-30 0001376793 us-gaap:OfficeEquipmentMember 2021-06-30 0001376793 us-gaap:EquipmentMember 2022-06-30 0001376793 us-gaap:EquipmentMember 2021-06-30 0001376793 us-gaap:OtherMachineryAndEquipmentMember 2022-06-30 0001376793 us-gaap:OtherMachineryAndEquipmentMember 2021-06-30 0001376793 CVAT:PPPMember 2022-06-30 0001376793 CVAT:PPPMember 2021-06-30 0001376793 CVAT:PPP2Member 2022-06-30 0001376793 CVAT:PPP2Member 2021-06-30 0001376793 CVAT:EIDLMember 2022-06-30 0001376793 CVAT:EIDLMember 2021-06-30 0001376793 CVAT:PPPMember 2020-04-01 2020-04-16 0001376793 CVAT:PPPMember 2021-05-01 2021-05-31 0001376793 CVAT:PPPMember 2020-07-01 2021-06-30 0001376793 CVAT:PPP2Member 2020-05-01 2021-03-26 0001376793 CVAT:PPPMember 2021-07-01 2021-07-31 0001376793 CVAT:PPP2Member 2021-07-01 2022-06-30 0001376793 CVAT:EIDLMember 2020-07-01 2020-07-31 0001376793 us-gaap:CommonStockMember 2021-07-01 2022-06-30 0001376793 CVAT:WarrantsMember 2021-07-01 2022-06-30 0001376793 CVAT:CommonStockAndWarrantsMember 2021-07-01 2022-06-30 0001376793 CVAT:CashlessExerciseOfWarrantsMember 2021-07-01 2022-06-30 0001376793 CVAT:CashlessExerciseOfOptionsMember 2021-07-01 2022-06-30 0001376793 us-gaap:CommonStockMember srt:ExecutiveOfficerMember 2022-06-01 2022-06-16 0001376793 CVAT:FormerAccruedPayrollMember 2021-07-01 2022-06-30 0001376793 us-gaap:OtherLiabilitiesMember 2021-07-01 2022-06-30 0001376793 CVAT:ConsultantMember 2021-07-01 2022-03-31 0001376793 us-gaap:WarrantMember 2021-07-01 2022-06-30 0001376793 us-gaap:StockOptionMember 2020-06-30 0001376793 us-gaap:StockOptionMember 2019-07-01 2020-06-30 0001376793 us-gaap:StockOptionMember 2020-07-01 2021-06-30 0001376793 us-gaap:StockOptionMember 2021-06-30 0001376793 us-gaap:StockOptionMember 2021-07-01 2022-06-30 0001376793 us-gaap:StockOptionMember 2022-06-30 0001376793 CVAT:Price1Member 2022-06-30 0001376793 CVAT:Price1Member 2021-07-01 2022-06-30 0001376793 us-gaap:WarrantMember 2020-06-30 0001376793 us-gaap:WarrantMember 2019-07-01 2020-06-30 0001376793 us-gaap:WarrantMember 2020-07-01 2021-06-30 0001376793 us-gaap:WarrantMember 2021-06-30 0001376793 us-gaap:WarrantMember 2022-06-30 0001376793 CVAT:WarrantPrice1Member 2022-06-30 0001376793 CVAT:WarrantPrice1Member 2021-07-01 2022-06-30 0001376793 CVAT:WarrantPrice2Member 2022-06-30 0001376793 CVAT:WarrantPrice2Member 2021-07-01 2022-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. FROM THE TRANSITION PERIOD FROM _____ TO _______.

 

For the fiscal year ended June 30, 2022

 

Commission file number 000-53239

 

 

 

Cavitation Technologies, Inc.

(Exact name of Registrant as Specified in its Charter)

 

Nevada   20-4907818
(State or Other Jurisdiction of Incorporation or Organization)   (I.R.S. Employer Identification No.)

 

10019 CANOGA AVENUE, CHATSWORTH,CALIFORNIA 91311
(Address, including Zip Code, of Principal Executive Offices)

 

(818) 718-0905
(Registrant’s Telephone Number, Including Area Code)

 

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:

 

NONE

 

SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:

 

Title of Each Class:   Name of Each Exchange on Which Registered:
Common Stock, $0.001 par value   Over the Counter (Bulletin Board)

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☐    NO ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES ☐    NO ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒    NO ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES ☒    NO ☐

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K, or any amendment to this Form 10-K. ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒
      Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes ☐  No ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YES ☐    NO ☒

 

State the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant by reference to the price at which the common equity was last sold, or of the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter: $23,372,000 as of December 31, 2021 based on the closing price of $0.096 per share and 260,287,611 shares outstanding.

 

The registrant had 276,698,831 shares of common stock outstanding on September 28, 2022.

 

DOCUMENTS INCORPORATED BY REFERENCE:

 

None

 

 

   

 

 

 

CAVITATION TECHNOLOGIES, INC.

FORM 10-K ANNUAL REPORT

FOR THE YEAR ENDED JUNE 30, 2022

TABLE OF CONTENTS

 

 

  Page
PART I  
Item 1. Business 3
Item 1A. Risk Factors 9
Item 1B. Unresolved Staff Comments 9
Item 2. Properties 9
Item 3. Legal Proceedings 9
Item 4. Mine Safety Disclosures 9
   
PART II  
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 10
Item 6. Selected Financial Data 11
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 11
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 15
Item 8. Financial Statements and Supplementary Data 16
Item 9. Changes In and Disagreements With Accountants on Accounting and Financial Disclosure 36
Item 9A. Controls and Procedures 36
Item 9B. Other Information 37
   
PART III  
Item 10. Directors, Executive Officers and Corporate Governance 38
Item 11. Executive Compensation 39
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 41
Item 13. Certain Relationships and Related Transactions, and Director Independence 42
Item 14. Principal Accounting Fees and Services 42
   
PART IV  
Item 15. Exhibits, Financial Statement Schedules 44
Item 16. Form 10-K Summary 45
   
Signatures 46

 

 

 

 1 

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This annual report on Form 10-K and the exhibits attached hereto contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements concern our anticipated results and developments in our operations in future periods, planned exploration and development of our properties, plans related to our business and matters that may occur in the future. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. We use words like “expects,” “believes,” “intends,” “anticipates,” “plans,” “targets,” “projects” or “estimates” in this annual report. When used, these words and other, similar words and phrases or statements that an event, action or result “will,” “may,” “could,” or “should” result, occur, be taken or be achieved, identify “forward-looking” statements. Such forward-looking statements are subject to certain risks and uncertainties, both known and unknown, and assumptions.

 

Management has included projections and estimates in this annual report, which are based primarily on management’s experience in the industry, assessments of our results of operations, discussions and negotiations with third parties and a review of information filed by our competitors with the Securities and Exchange Commission or otherwise publicly available. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as required by law. We qualify all of the forward-looking statements contained in this annual report by the foregoing cautionary statements.

 

 

 

 

 

 

 

 

 

 2 

 

 

 

PART I

 

ITEM 1.  BUSINESS

 

Cavitation Technologies, Inc. (referred to herein, unless otherwise indicated, as “the Company,” “CTi,” “we,” “us,” and “our”) is a Nevada corporation originally incorporated under the name Bio Energy, Inc. We are a process and product development firm that has developed, patented, and commercialized environmentally friendly technology-based systems that are designed to serve large, growing, global markets such as vegetable oil refining, renewable fuels, water treatment, wines and spirits enhancement, algae oil extraction, water-oil emulsions and crude oil yield improvement. Our systems are designed to process industrial liquids at a reduced processing time, lower operating cost, improved yield while operating in environmentally friendly manner. Our patented Nano Reactor® and LPN™ are the critical components of our business and we have generated all of our revenue while utilizing these components.

 

Covid-19

 

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, has adversely affected workforces, customers, economies, and financial markets globally. It has also disrupted the normal operations of many businesses. This outbreak could decrease spending, adversely affect demand for the Company’s products, and harm the Company’s business and results of operations. During the year ended June 30, 2021, the Company believes the COVID-19 pandemic did not materially impact its operating results due to the nature of the Company’s business and its operations. The Company has not observed any impairments of its assets or a significant change in the fair value of its assets due to the COVID-19 pandemic. At this time, it is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business or results of operations, financial condition, or liquidity.

 

Vegetable Oil Refining

 

Our first commercial application for our technology has been the CTi Nano Neutralization® System which has been utilized to improve edible vegetable oil refining process. Our environmentally friendly process has been shown to reduce refining costs, increase oil yield, and limit the number of chemical additives used in chemical refining of vegetables oils. This patented process (US Patent # 7,762,715 and # 8,042,989) is designed to be incorporated into new and existing soybean, rapeseed, canola and palm vegetable oil refineries.

 

Our first pilot test of our CTi NANO Neutralization® System was conducted in 2010 at Carolina Soya, a 200-metric ton/day crude soy oil refining plant in Estill, South Carolina. Our second system, which became operational in fiscal 2011, has been continuously utilized since 2011 at the plant that processes approximately 450 metric tons per day of soy oil. Further, we have successfully shipped over 50 systems domestically and internationally. We also continuously focus on developing additional Nano Reactor® applications and managing the intellectual property issues associated with new processes and applications.

 

The global consumption of vegetable oils has grown consistently at a rate of about 4.1% p.a. from 90.5 million metric tons (MMT) in 2001 to approximately 213 million metric tons (MMT) in 2021-2022. In 2021-2022 consumption of vegetable oil was 213.2 MMT compared to 206.4 MMT in 2020-2021, an increase approximately 3% (https://www.statista.com/statistics/263978/global-vegetable-oil-production-since-2000-2001/). It is also a highly competitive commodity market in which the lowest-cost producer has the advantage.

 

Desmet Ballestra Agreement

 

On May 14, 2012, we signed a global R&D, Marketing and Technology License Agreement with Desmet Ballestra Group s.a. (Desmet), a Belgian company that is actively marketing the NANO Neutralization® System, the key component of which is our Nano Reactor® to soybean and other vegetable oil refiners. The Agreement provided Desmet (licensee) a limited, exclusive license and right to develop, design and supply our NANO Neutralization® System which incorporates Nano Reactor® devices on a global basis tools and fats and oleo chemical applications. The agreement expired in May 2015.

 

 

 3 

 

 

On January 22, 2016, Desmet and the Company executed a new three year License Agreement with essentially the same terms with the May 2012 agreement that was effective August 1, 2015. As part of the agreement, Desmet provided, under certain conditions, limited monthly advance payments of $50,000 to be applied against gross profit share from future sales. The agreement expired in August 2018.

 

On October 1, 2018, Desmet and the Company executed a new three year License Agreement with essentially the same terms with the January 2016 agreement. As part of the agreement, Desmet provided us under certain conditions, limited monthly advances of $50,000 through October 1, 2021, to be applied against gross profit share from future sales. The agreement expired in October 2021.

 

On November 1, 2021, Desmet and the Company executed a new three-year License Agreement. As part of the agreement, Desmet provides the Company monthly advances of $40,000 through November 1, 2024, to be applied against from future reactor sales.

 

Desmet, together with its affiliates, is a global engineering and equipment supply firm engaged in the development, design and supply of process equipment for oils and fats processing facilities including vegetable oil refining, biofuel, oleo chemical, seed crushing, surfactant and detergent markets. Desmet supplies these markets with services based on the latest globally sourced technologies. Desmet has relationships with major refiners globally A significant portion of global vegetable oil refineries include major refiners such as Archer Daniels Midland Company, Cargill, Inc. and Bunge Limited. Desmet has more than 40 sales representatives selling in North America, South America, Europe, and Asia. Since its founding in 1946, Desmet reports that it has built a global network that includes 1,300 employees, 17 global and 8 representative offices, and more than 6,000 lines in a variety of applications. Desmet operates a separate division for each of the above markets and the Desmet Oils & Fats division has supplied small and large plants to approximately 1,900 oil millers in 150 countries, covering over 6,300 process sections.

 

Along with Desmet, we have been working together to accelerate appropriate sales goals and installation process. Our CTi Nano Neutralization® Systems is designed to be used as an add-on process to an existing neutralization system within soybean and other vegetable oil refineries. Desmet’s focus has been on marketing our CTi Nano Neutralization® Systems to vegetable oil refiners to help them increase profits through cost savings and improved oil yields. Desmet purchases our CTi Nano Neutralization® Systems from us and installs them at the refinery as part of an integrated neutralization system. Based on successful commercial implementations, Desmet guarantees minimum economic benefits to a facility that installs our CTi Nano Neutralization® Systems. We are therefore substantially dependent on Desmet to identify prospects, complete sales contracts, install the system and manage relationships with end-users.

 

Additionally, in fiscal 2017 Desmet installed our first Nano Reactor® at a bio-diesel production plant in South America. Bio-diesel industry has been under pricing pressure for a considerable period of time and slow to adopt to newer technologies. We are continuously working with Desmet pursuing additional sales opportunities in Asia and South America, however, the acceptance of our technology has been slow and there were no sales generated in our Fiscal 2022.

  

Enviro Watertek, LLC

 

In April 2019, the Company and Delaware Water Company, LLC (Delaware) formed a limited liability company called Enviro WaterTek LLC (“Enviro” ,“EW”). Enviro is owned 50% by the Company and 50% by Delaware, and the Company accounts for its investment in Enviro under the equity method of accounting. From 2019 to 2021, Enviro had insignificant operations. This agreement covers our first commercial entrance into industrial treatment of produced and frac water. Fracking industry has seen a significant growth over the past ten years, reaching daily water consumption volume of over 58 million barrels per day. Our newly designed Low Pressure Nano Reactor (LPN™) was specifically developed to be integrated into produced water treatment system along with our proprietary chemical formulations, and has depicted measurable and quantifiable advantages over industry standard processes and equipment. Our agreement with EW provides for sales on LPN™ plus recurring revenue stream based on processing of produced and frac water volumes and utilization. Our agreement with EW has a fifteen-year term. In March 2020, global pandemic of COVID-19 has taken an unexpected negative impact on the oil and gas industry worldwide, and has consequently impaired our ability to rapidly accelerate LPN™ sales and recurring revenue stream. While the industry has gone through a major overhaul, we are seeing a gradual recovery in the industry. Our current system installations can handle approximately 25,000 barrels per day (BPD), and we received $46,000 in total revenue in our Fiscal 2022 from sale of reactors and usage fee.

 

 

 4 

 

 

Alchemy Beverages, Inc

 

In fiscal 2014, Roman Gordon, one of our shareholders and a former officer, formed a company, Cameo USA LLC (Cameo). Since its formation, Cameo has had no revenue, no operations, and has had no assets or liabilities. On June 4, 2018, Mr. Gordon contributed his 100% interest in Cameo to Cavitation Technologies, Inc. As Mr. Gordon had no reasonable and objectively supportable basis in the valuation of his investment in Cameo, there was no value assigned to the contribution of Cameo.

 

On June 29, 2018, we agreed to license Cameo to Alchemy Beverages Inc. (“ABI”). In addition, we have agreed to provide certain licensing rights related to our miniature low pressure nano-reactor (MLPN) to be used in developing and manufacturing of small home appliances to enhance alcoholic beverages. In consideration for these ABI has agreed to issue 19.9% of ABI’s outstanding common shares to us (limited to 20 million shares of ABI). ABI is a private company and in the business of producing and selling alcoholic beverages, equipment, and home appliances. Prior to this agreement, ABI was independent of CTI and had no relation to us nor to our management.

 

Pursuant to the licensing agreements, ABI will have the exclusive global marketing and distribution rights of Cameo and our patented and patent pending technologies for the processing of alcoholic beverages. We have agreed to assist in the installation and maintenance of the MLPN to ABI and will receive royalty payments ranging from 1% to 3% on all net revenues, as defined in our license agreement for the life of the applicable patents. In addition, we will receive leasing, consulting, and manufacturing fees as defined in the licensing agreement.

 

As of June 30, 2022 and the date of this report, ABI has not generated any sales under Cameo brand. Since June 2018, the Company and ABI have developed a small table top home appliance unit Barmuze® utilizing MLPN , allowing consumers to experience a new way of enjoying wines and spirits, utilizing CTi’s patented and patent pending technologies to molecularly restructure alcohol, convert harsh acids to pleasant tasting esters, and reduce levels of certain impurities commonly present in alcohol.

 

During fiscal 2022 and 2021, we have received approval for several patent applications, protecting our technology and processing rights, expanding our broad portfolio of patents.

  

During fiscals 2022 and 2021, there were no sales or royalties generated pertaining to our agreement with Alchemy Beverages, Inc. The investment in ABI has no value assigned to it, which approximates its fair value.

 

Customers Dependence

 

We continue to sell our industrial capacity Nano Reactor® and Nano Neutralization® System through our strategic partner Desmet and most of our revenue for the fiscal year ended June 30, 2022, was derived from sales of reactors to Desmet and the corresponding gross profit share. We have generated minimal revenue pertaining to our licensing agreement with EW in our fiscal 2022. We had no revenue of LPN™ due to COVID-19, whereas oil production in US has negative impact on oil & gas industry. Oil and gas industry has seen a recovery, while price of oil has spiked to around $100 per barrel, and we foresee a great opportunity for our technology providing a significant upside potential both at the point of sale and recurring revenue stream.

 

Sources and availability of raw materials and the names of principal suppliers

 

We have historically sourced reactor components from various domestic and international suppliers. We do not have any long-term contracts, agreements, or commitments with any supplier. We believe it would take approximately 30 days to find a new supplier, if necessary.

 

 

 5 

 

 

Competition

 

Our competitors who sell equipment and engineering services for the vegetable oil refining business are a myriad of companies both large and small that provide equipment and technology to oil refiners. These include known companies that have longer operating histories, more experience, and stronger financial capabilities. Competitors include Alfa Laval, and Crown Iron Works as well as many firms that provide advice and services to small and regional firms. In addition, Arisdyne Systems, a designer of cavitation devices, is marketing a system using similar technology. The vegetable oil refining business is a highly competitive commodity market in which the lowest-cost producer has the advantage. We intend to compete by offering solutions that help our clients remain or become a low-cost producer. Because the industry in which we compete has had limited new technology introduced in the last 50 years, we believe our CTi Nano Neutralization® Systems provide a unique opportunity for refiners to increase margins. We seek to differentiate ourselves by offering solutions based on our proprietary and patented designs, processes, and applications to help our clients described in our issued and patent pending applications. We compete by offering solutions that we believe can reduce operating expenses and increase oil yield vs currently applied technologies.

 

In addition, our competitors in produced and frac water treatment application range from local service providers to multi-national global corporations with considerable financial resources, engineering expertise, established and proven technologies. We believe that LPN™ is a conceptually new technology that has not been introduced in the field of water treatment applications up to now. LPN™ has demonstrated exceptional results in treating produced and frac water commercially, significantly reducing the usage of hazards chemicals during the process, meanwhile, achieving desirable water quality for industrial re-use or disposal.

 

Patents

 

Our Cavitation Generator patent was issued during fiscal 2011. In addition, we have a patent for our Multi-Stage Cavitation Device Nano Reactor® that was issued on October 25, 2011. In the fiscal 2014 we received approvals for another apparatus patent and 2 additional process patents in the US. As of June 30, 2022, our portfolio of patents included 19 issued patents in the United States and 12 issued patents internationally. Our patents cover multiple process and applications of our technology in vegetable oil refining, production of biodiesel, treatment of process and industrial water, upgrade of hydrocarbons and enhancing of alcoholic beverages. We continuously develop new technologies and applications, as we have filed new patent applications for Low Pressure Nano-Reactors LPN™. LPN™ is a highly efficient homogenizer and emulsifier that can be utilized in multiple fluids processing applications. Recently, we have filed a patent application for a small home appliance. This new product is designed directly with consumer in mind and the first step for our company to introduce our technology outside of the industrial sector where we typically sell our products.

  

Issued

 

US   Cavitation Generator   7,762,715
         
US   Multi-Stage Cavitation Device   8,042,989
         
US   Process for Producing Biodiesel Through Lower Molecular Weight Alcohol-Targeted Cavitation   8,603,198
         
US   High-Throughput Cavitation and Electro Coagulation Apparatus   8,673,129
         
US   Extraction of Oil from Algae by Hydrodynamic Cavitation for Biodiesel Production   8,709,750
         
US   Flow-Through Cavitation-Assisted Rapid Modification of Crude Oil   8,894,273
         
US   Method for Cavitation-Assisted Refining, Degumming and Dewaxing of Oil and Fat   8,911,808
         
US   Process to Remove Impurities from Triacylglycerol Oil   8,945,644
         
US   Process for Producing Biodiesel Through Lower Molecular Weight Alcohol-Targeted Cavitation   8,981,135
         
US   Process for Removing Waxes and Phospholipids from Vegetable Oils and Increasing Production of Food Grade Lecithin Therefrom   9,357,790

 

 

 6 

 

 

         
US   Method and Flow Through Hydrodynamic Cavitational Apparatus for Alterations of Beverages   9,474,301
         
US   Method for Cavitation-Assisted Refining, Degumming and Dewaxing of Oil and Fat   9,481,853
         
US   Process for Extracting Carbohydrates from Biomass and Converting the Carbohydrates into Biofuels   9,611,496
         
US   Flow-Through Cavitation-Assisted Rapid Modification of Crude Oil   9,719,025
         
US   Processes for Increasing Bioalcohol Yield from Biomass   9,944,964
         
US   Processes for Increasing Bioalcohol Yield from Biomass   9,988,651
         
US   Processes for Extracting Carbohydrates from Biomass and Converting the Carbohydrates into Biofuels   10.093.953
         
US   Variable Flow Through Cavitation Device   10,507,442

 

US   System and Method for Purification of Drinking Water, Ethanol and Alcohol Beverages of Impurities   10,781,113
         
Int’l   Process to Remove Impurities from Triacylglycerol Oil   Ar AR083000B1
         
Int’l   Cavitation Generator   Br - PI0919602-1

  

Int’l   Process to Remove Impurities from Triacylglycerol Oil   Ca - 2,809,236
         
Int’l   Process to Remove Impurities from Triacylglycerol Oil   Malaysia MY164311A
         
Int’l     Process to Remove Impurities from Triacylglycerol Oil   Mexico – MX/E/2013/015504
         
Int’l     Process to Remove Impurities from Triacylglycerol Oil   Singapore P187241
         
Int’l   Process to Remove Impurities from Triacylglycerol Oil   Mexico – MX/a/2016/006201
         
Int’l   Process to Remove Impurities from Triacylglycerol Oil   EU 10 857 392.4
         
Int’l   Method for Cavitation-Assisted Refining, Degumming and Dewaxing of Oil and Fat   Br PI0919602-1
         
Int’l   Process to Remove Impurities from Triacylglycerol Oil   Fr E 2 616 156
         
Int’l   Process to Remove Impurities from Triacylglycerol Oil   Gr 2 616 156
         
Int’l   Process to Remove Impurities from Triacylglycerol Oil   UK 2 616 156

 

 

 

 7 

 

 

 

 

US    
     
US  

System and Method for Purification of Alcohol Beverages of Impurities US 10781113

 

 

US  

Method and Device for Producing of High-Quality Alcoholic Beverages US 10876084

 

Patent Pending Update

     
US   Tabletop Beverage Cavitation Device
     
US   Method for Purification of Drinking Water, Ethanol and Alcohol Beverages of Impurities
     
US   Process for Increasing Plant Protein Yield from Biomass
     
Br   Process to Remove Impurities from Triacylglycerol Oil
     
Eu   System and Method for Purification of Drinking Water, Ethanol and Alcohol Beverages of Impurities
     
Br   Process to Remove Impurities from Triacylglycerol Oil

 

We plan on continuing to invest in research and development and file for new and improved patents. 

  

Royalty Agreements

 

On July 1, 2008, our wholly owned subsidiary entered into Patent Assignment Agreements with two parties, our President as well as our former Chief Executive Officer (CEO) who currently serves as our Technology Senior Manager, where certain devices and methods involved in our hydrodynamic cavitation processes invented by the President and former CEO/current Technology Senior Manager have been assigned to the subsidiary. In exchange, that subsidiary agreed to pay a royalty of 5% of gross revenues to each of the President and former CEO/current Technology Senior Manager for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently assumed by us on May 13, 2010, from our subsidiary. Our former CEO/current Technology Senior Manager and President both waived their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through June 30, 2022.

 

On April 30, 2008 and as amended on November 22, 2010, our wholly owned subsidiary entered into an employment agreement with its former Director of Chemical and Analytical Department (the “Inventor”) to pay, in the first year, an amount equal to 5% of actual gross revenue received by us on any patent for which the Inventor was a legally named inventor, and, in each subsequent year, 3% of actual gross revenue received by us on any such patent. Since entering into that employment agreement, and during the term of this employment agreement, we have not received any revenue on any patents for which the Inventor was a legally named inventor.

 

Governmental Approval and Regulations and Environmental Compliance

 

Due to the nature of our products, we have incurred no costs with respect to environmental compliance with federal, state, and local laws. To our knowledge, our products do not require governmental approval, and we do not foresee that governmental regulations will have a material impact on our business.

 

Employees

 

As of June 30, 2022, we had four full-time employees and had engaged several consultants and independent contractors over the past year. Members of our technical team are comprised of experienced professionals who are chemists, civil, chemical, and mechanical engineers with expertise in hydrodynamic cavitation, nano technology and water treatment. These individuals hold degrees in Civil, Chemical, and Mechanical Engineering.

 

 

 8 

 

 

Research and Development Expenditures

 

During the fiscal years ended June 30, 2022 and 2021, we spent $17,000 and $21,000, respectively, on research and development activities.

 

ITEM 1A.  RISK FACTORS

 

Not applicable for smaller reporting companies.

 

ITEM 1B.  UNRESOLVED STAFF COMMENTS

 

None.

  

ITEM 2.  PROPERTIES

 

Our corporate headquarter is located in Chatsworth, California, with an area of approximately 5,000 square foot facility, which includes office space and an area to conduct research and development. Our lease agreement for this space will end in February 2025.  Our monthly rent payments approximate $6,000 up to $7,000. We do not anticipate any material difficulties with the renewal of our rental agreement when it expires or in securing replacement facilities on commercially reasonable terms.

 

ITEM 3.  LEGAL PROCEEDINGS

 

The Company may be involved in certain legal proceedings that arise from time to time in the ordinary course of its business. Except for income tax contingencies (commencing April 1, 2009), the Company records accruals for contingencies to the extent that management concludes that the occurrence is probable and that the related amounts of loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred.

 

The Company is not aware of any pending litigations.

 

ITEM 4.  MINE SAFETY DISCLOSURES

 

Not applicable.

  

 

 9 

 

 

 

PART II

 

ITEM 5.  MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Common Stock

 

Our Common Stock is traded on the OTCQB Market under the symbol CVAT. The following table sets forth the high and low price per share based on the closing price of our Common Stock for the periods indicated.

 

      HIGH   LOW 
            
Fiscal 2021  First Quarter  $0.02   $0.01 
   Second Quarter   0.02    0.01 
   Third Quarter   0.07    0.02 
   Fourth Quarter   0.08    0.04 

 

      HIGH   LOW 
            
Fiscal 2022  First Quarter  $0.11   $0.05 
   Second Quarter   0.12    0.06 
   Third Quarter   0.12    0.04 
   Fourth Quarter   0.06    0.04 
              
Fiscal 2023  First Quarter   0.05    0.04 

 

We became a public company through a share exchange that was affected in October 2008. The first day of public trading of our stock was November 11, 2008. Since our fiscal year end was changed to June 30, public trading of our stock began in the second quarter of fiscal 2009. As of September 30, 2022, there were approximately 1,500 holders of record of our Common Stock. This does not reflect the number of persons or entities who hold stock in nominee or “street” name through various brokerage firms. The closing price of our common stock on September 23, 2022 was $0.04.

 

Dividend Policy

 

We have neither declared nor paid any dividends on our Common Stock in the preceding two fiscal years. We currently intend to retain future earnings, if any, to fund ongoing operations and finance the growth and development of our business and, therefore, do not anticipate declaring or paying cash dividends on our Common Stock for the foreseeable future. Any future decision to declare or pay dividends will be at the discretion of the Board of Directors and will be dependent upon our financial condition, results of operations, capital requirements, and such other factors as the Board of Directors deems relevant.

 

Securities Authorized for Issuance under Equity Compensation Plans

 

None.

  

 

 

 

 10 
 

 

Recent Sales of Equity Securities and Use of Proceeds

 

We sold equity securities during the year ended June 30, 2022 and 2021 as follows:

 

In July 2021, we issued 12,071,785 shares of common stock at a selling price of $0.065 per share and 12,071,785 of warrants, exercisable at $0.09 to various entities and individuals for net proceeds of $785,000. The shares were issued in reliance on Section 4(2) of the Securities Act of 1933, as amended. The shares were not offered via general solicitation to the public. No sales commissions or other remuneration was paid in connection with this issuance. 

 

In June 2021, we issued 11,269,538 shares of common stock at a selling price of $0.065 per share and 11,269,538 of warrants, exercisable at $0.09 to various entities and individuals for net proceeds of $728,000. The shares were issued in reliance on Section 4(2) of the Securities Act of 1933, as amended. The shares were not offered via general solicitation to the public. No sales commissions or other remuneration was paid in connection with this issuance.

  

Issuer Purchases of Equity Securities

 

None.

 

ITEM 6.   SELECTED FINANCIAL DATA

 

Not applicable for smaller reporting companies.

 

ITEM 7.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis should be read in conjunction with our financial statements and the related notes. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties, such as its plans, objectives, expectations and intentions. Its actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements.

 

Overview of Our Business

 

We are a Nevada corporation originally incorporated under the name Bio Energy, Inc. On January 29, 2007, we incorporated a wholly owned subsidiary, Hydrodynamic Technology, Inc. as a California corporation.

 

We have developed, patented, and commercialized proprietary technology that can be used for processing of various industrial and consumer-oriented fluids. Our patented Nano Reactor® is the critical components of the CTi Nano Neutralization® System which has been shown to reduce operating costs and increase yields in processing oils and fats. CTi holds and applied for numerous patents covering technology and various processes in US and Internationally, covering vegetable and crude oil refining, processed and frac water treatment, algae oil extraction, and alcoholic beverage enhancement. During our Fiscal 2022, we have continuously worked on developing additional technologies and products related to low pressure nano reactor (LPN™). LPN™ is designed to become a highly efficient mixer and homogenizer. We believe that LPN™ has a great commercial utilization opportunity by providing efficient and cost-effective solution in multiple fluid processing industries. LPN™ has a number of advantages over current mechanically operated mixers and homogenizers. Industrial application of our technology in produced and frac water treatment system, LPN™ along with our proprietary chemical formulations have depicted measurable and quantifiable advantages over industry standard processes and equipment. Additionally, our miniature low pressure nano reactor MLPN has become an integral part of Barmuze®, a small home appliance device for enhancing taste and extracting unwanted impurities typically present in alcoholic beverages.

 

During the year ended June 30, 2022, we recorded revenue of $1,665,000 and net loss of $619,000, respectively.

 

 

 

 

 

 11 
 

 

Inflation and potential recession

 

We are, and our suppliers are experiencing significant broad-based inflation of manufacturing and distribution costs as well as transportation challenges, partially as a result of the pandemic. Although we do not believe that inflation has had a material effect on our business, financial condition or results of operations, it may in the future. We are monitoring cost structures and evaluating to what extent any such costs can be passed on to customers, taking into account the overall impact of increasing inflation and interest rate pressures on consumers. We expect input cost inflation to continue at least throughout 2022. If we are unable to successfully manage the effects of inflation, our business, operating results, cash flows and financial condition may be adversely affected. Additionally, there have been various economic indicators that the United States economy may be entering a recession in upcoming quarters. An economic recession could potentially impact the general business environment and the capital markets, which may have a material negative impact on our financial results.

  

Management’s Plan of Operation

 

We are continuously engaged in manufacturing of our Nano Reactor® and Nano Neutralization® Systems which are designed to help refine vegetable oils such as soybean, canola and rapeseed. Additionally, we have developed LPN™’s that provide commercial opportunity in industrial water treatment, enhancement of alcoholic beverages, and MLPN being utilized in a consumer small home appliance.

 

During the year ended June 30, 2022, we incurred net loss of $619,000 and used cash in operating activities of $484,000. As of June 30, 2022, we have a working capital deficiency of $30,000 and a stockholders’ surplus of $1,110,000.

 

Management’s plan is to generate income from operations by licensing our technology globally through Desmet Ballestra Group (Desmet), agreements with EnviroWaterTek and Alchemy Beverages, Inc. In October 2018, we signed a three-year global R and D, Marketing and Technology License Agreement with Desmet for the sale and licensing of our Nano Reactor® and Nano Neutralization® Systems. This agreement is a continuation of the original agreement we signed with Desmet in May 2012. As part of the agreement, Desmet is also obligated to provide us with monthly advances of $40,000 to be applied against the sale of reactors. During the year ended June 30, 2022, advances received from Desmet amounted to $300,000 and together with previous period advances of $727,000, were recorded as revenues totaling $1,027,000. These funds service operational expenses on monthly basis.

 

Our agreement with Enviro WaterTek signed in March of 2019, has generated sales of LPN™’s and recurring revenue stream in our fiscal 2022, resulting in aggregate revenue of $46,000

 

There was no revenue produced in relationship to our agreement with Alchemy Beverages, Inc.

  

We anticipate that we may need additional funding, and we may attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. However, there is no assurance that such financing will be consummated or obtained in sufficient amounts necessary to meet our needs, or that we will be able to meet our future contractual obligations. Should management fail to obtain such financing, we may curtail its operations.

 

Critical Accounting Policies and Revenue Recognition

 

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses. The accounting policies and estimates described below are those we consider most critical in preparing its consolidated financial statements. The following is a review of the accounting policies and estimates that include significant judgments made by management using information available at the time the estimates are made. However, these estimates could change materially if different information or assumptions were used instead.

 

Note 1 of the accompanying consolidated financial statements includes a summary of significant accounting policies, estimates, and methods used in the preparation of our financial statements. Accounting estimates are an integral part of the preparation of financial statements and are based on judgments by management using its knowledge and experience about the past and current events and assumptions regarding future events, all of which we consider to be reasonable. These judgments and estimates reflect the effects of matters that are inherently uncertain and that affect the carrying value of our assets and liabilities, the disclosure of contingent liabilities and reported amounts of expenses during the reporting period.

  

 

 

 

 

 12 
 

 

Revenue Recognition

 

The Company follows the guidance of Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients.

 

Revenue from sale of our Nano Reactor® and LPN™ is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer.

 

The Company also recognizes revenue from its share of gross profit to be earned from distributors, as defined, which we treat as variable consideration and recognize using the most likely amount method. Estimates are available from our distributor which are considered in the determination of the most likely amount. However, given the lack of control over the sale to the end customer and the lack of history of prior sales, the amount of gross profit revenue recognized is limited to the actual amount of cash received under the contract which the Company has determined is not refundable and that a significant future reversal of cumulative revenue under the contract will not occur.

 

In addition, the Company also recognizes revenues from usage fees of certain reactors. Usage fees are recognized based on actual usage by the customer.

 

Leases

 

The Company accounts for leases under guidance of Accounting Standards Codification (“ASC”) 842, which requires an entity to recognize a right-of-use asset and a lease liability for virtually all leases. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company accounts for the lease and non-lease components of its office lease as a single lease component. Lease expense is recognized on a straight-line basis over the lease term.

 

Equity Method Investment

 

The Company accounts for investments in entities in which the Company has significant influence over the entity’s financial and operating policies, but does not control, using the equity method of accounting. The equity method investments are initially recorded at cost, and subsequently increased for capital contributions and allocations of net income, and decreased for capital distributions and allocations of net loss. Equity in net income (loss) from the equity method investment is allocated based on the Company’s economic interest. The Company assesses its investment in equity method investments for recoverability, and if it is determined that a loss in value of the investment is other than temporary, the Company writes down the investment to its fair value. The Company does not believe that the value of its equity method investment was impaired as of June 30, 2022.

 

Share-Based Compensation

 

The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services and for financing costs. The Company accounts for stock option and warrant grants issued and vesting to employees based on the authoritative guidance provided by the Financial Accounting Standards Board whereas the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and warrant grants issued and vesting to non- employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

  

Recent Accounting Pronouncements

 

See Note 1 of the financial statements for discussion of recent accounting pronouncements.

 

 

 13 

 

 

Results of Operations

 

Below is summary comparing fiscal 2022 and fiscal 2021.

 

   For the Years Ended         
   June 30,         
   2022   2021   $ Change   % Change 
                 
Revenue  $1,619,000   $537,000   $1,082,000    201% 
Revenue-related party   46,000    21,000    25,000    119% 
Cost of revenue   (41,000)   (20,000)   (21,000)   105% 
Gross profit   1,624,000    538,000    1,086,000    202% 
                     
General and administrative expenses   1,728,000    1,264,000    464,000    36% 
Impairment of equipment   178,000    –    178,000    100% 
Research and development expenses   17,000    21,000    (4,000)   (19)% 
Total operating expenses   1,923,000    1,285,000    638,000    50% 
                     
Income (loss/) from operations   (299,000)   (747,000)   448,000    68% 
                     
Gain on forgiveness of PPP Loan   104,000    104,000    –    -% 
Loss on settlement of liabilities   (371,000)   –    (371,000)   (100)% 
Loss from equity method investment   (48,000)    –    26,000    100% 
Interest expense   (5,000)   (6,000)   1,000    17% 
Net income (loss)  $(619,000)  $(649,000)  $115,000    (18)% 

  

Revenue

 

During the year ended June 30, 2022, revenue increased by $1,107,000 to $1,665,000 and it was derived primarily from the sales of our Nano Reactor® and CTi Nano Neutralization Systems to Desmet of $592,000 and share in gross profit of $1,027,000. In addition, the Company also recorded an aggregate revenue of $46,000 from the sale of LPN™ and water processing to Enviro Watertek, LLC.

 

During the year ended June 30, 2021, our revenue was $558,000 and it was derived from the sale of our Nano Reactor® and CTi Nano Neutralization Systems to Desmet of $541,000, in addition, we recorded an aggregate revenue of $17,000 from the sale of LPN™ and water processing usage fee to Enviro Watertek, LLC.

 

Operating Expenses

 

Operating expenses for fiscal 2022 amounted to $1,923,000 versus $1,285,000 in fiscal 2021, an increase of $638,000 or 50%. The increase in operating expenses was attributed to an increase in advertising expenses of $95,000, an impairment charge of $178,000 on equipment, an increase in consulting fees of $99,000, an increase in legal fees of $54,000, non-cash stock based compensation expense of $352,000, with major expense categories being salaries and payroll taxes of approximately $744,000, legal and professional fees of approximately $198,000, marketing services of $107,000. Research and development (R&D) expense was $17,000 and $21,000 for the fiscal years ended June 30, 2022 and 2021.

 

Operating expenses for fiscal 2021 amounted to $1,285,000 versus $1,487,000 in fiscal 2020, a decrease of $195,000 or 14%. The decrease in operating expenses was attributed to lower legal fees, office and stock compensation expense compared to fiscal 2020, and amendment of certain stock warrants issued in prior period. Non-cash expense items such as amortization and depreciation expense of $18,000, primarily amounted to a small proportion of operating expenses, with major expense categories being salaries and payroll taxes of approximately $629,000, legal and professional fees of approximately $126,000, for travel, insurance and marketing services combined $156,000. Research and development (R&D) expense was $21,000 compared to $18,000 the same as in the year ended June 30, 2020.

 

 

 14 

 

  

Net Loss

 

Our reporting net loss in fiscal 2022 was $619,000 compared to $649,000 in fiscal 2021.

 

Liquidity and Capital Resources

 

Our cash balance at June 30, 2022 was $441,000, a decrease of $922,000 compared to $1,363,000 at June 30, 2021.

 

For the year ended June 30, 2022 cash used in operating activities was $484,000, cash used in investing activities was $1,223,000, and cash generated from financing activities was $785,000.

 

For the year ended June 30, 2021 cash provided by operating activities was $250,000, cash used in investing activities was $128,000, and cash provided by financing activities was $982,000.

 

Going concern

 

During the year ended June 30, 2022, we incurred a net loss of $619,000 and used cash in operating activities of $484,000. These factors, among others, raise substantial doubt about our ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on our June 30, 2022 financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern. The Company’s financial statements do not include any adjustments that might result from the outcome of this uncertainty be necessary should we be unable to continue as a going concern.

 

Management’s plan is to generate income from operations by continuing to license its technology globally. Additionally, we anticipate generating revenues from our agreements with EW and ABI.

 

We may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet our needs, that we will be able to achieve profitable operations or that we will be able to meet our future contractual obligations. Should management fail to obtain such financing, we may curtail its operations.

 

Off-balance Sheet Arrangements

 

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

ITEM 7A.  Quantitative and Qualitative Disclosures about Market Risk.

 

Not applicable for Smaller Reporting Companies.

  

 

 15 

 

 

 

 

ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Stockholders and Board of Directors
Cavitation Technologies, Inc.
Los Angeles, CA

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of Cavitation Technologies, Inc. (the “Company”) as of June 30, 2022 and 2021, the related consolidated statements of operations, changes in stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2022 and 2021, and the results of their operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1, the Company has incurred recurring operating losses and used cash in operations since inception. These matters raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1 to the financial statements. These consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

  

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved especially challenging, subjective, or complex judgments.  The communication of the critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinion on the critical audit matters or on the accounts or disclosures to which they relates.

 

 

 16 

 

 

Estimation of variable consideration

 

As described in Notes 1 and 2 to the consolidated financial statements, the Company receives a share of the gross profit earned by one of its distributors upon such distributors sale of products which include the Company's Nano Reactor® and CTi Nano Neutralization® System products. The Company's performance obligation related to the sale of its products is completed upon the shipment of the products to the distributor. Accordingly, at such time, the expected future share of gross profit to be earned from distributors is treated as variable consideration and recognized as revenue using the most likely amount method, subject to variable consideration constraints.

 

We identified management’s estimation and valuation of variable consideration as a critical audit matter because of the significant judgement by management in estimating the Company’s share of gross profit to be earned from distributors and the high degree of auditor judgment, subjectivity, and effort in performing audit procedures and evaluating the reasonableness of the significant assumptions used in developing the estimate.

 

Our primary audit procedures related to the estimation of variable consideration included the following, among others:

 

  · We evaluated the appropriateness of the Company’s revenue recognition policy, including its compliance with applicable accounting standards.
  · We tested the completeness, accuracy, and relevance of the underlying data used in management’s estimates by testing recorded revenues to supporting documents.
  · We evaluated the reasonableness of management's estimate of variable consideration in accordance with their accounting policies based on contractual terms and historical data and variable consideration estimates, including potential variable consideration constraints.
  · We confirmed the Company’s share of gross profit with the distributor.

 

Accounting for Equity Method Investment

 

As described in Note 3 to the consolidated financial statements, in 2019, the Company and Delaware Water Company (Delaware) formed a limited liability company called Enviro WaterTek (“Enviro”) owned 50% by the Company and 50% by Delaware. In September 2021, the Company and Delaware entered into a separate agreement under Enviro for a specific project (referred to as “Ameredev”). Under the separate agreement, the Company contributed $1.2 million, and receives usage fees from Ameredev, as defined, with the balance of net income (loss) from Ameredev allocated 70% to Delaware and 30% to the Company. The Company accounts for its investment in Enviro Ameredev using the equity method of accounting based on its determination that it does not hold an absolute controlling financial interest but has the ability to exercise significant influence over the operating and financial policies of Enviro Ameredev.

 

We identified the accounting for the equity method investment as a critical audit matter because of the significance of the equity method investment to the Company’s financial statements, and the judgments made by management when assessing the results of the operations of the equity method investment. This required an increased extent of effort, and the high degree of auditor judgment, subjectivity, and effort in performing audit procedures and evaluating the reasonableness of managements assumptions used for recording the equity method investment.

 

Our primary audit procedures related to the accounting for equity method investment included the following, among others:

·We obtained and read the executed Enviro Ameredev agreements to evaluate the accuracy and completeness of the terms used in management’s assessment that the Company does not control but has significant influence over Enviro Ameredev.
·We evaluated the equity method investment and income from equity method investment by testing transactions related to the equity method investment, such as contributions, distributions, and the allocation of net income (loss).

 

We have served as the Company’s auditor since 2013.

 

/s/ Weinberg & Company, P.A.  
   
Los Angeles, California  
October 13, 2022  

 

 

 

 17 

 

 

CAVITATION TECHNOLOGIES, INC.
CONSOLIDATED BALANCE SHEETS

 

 

           
   June 30,2022   June 30, 2021 
ASSETS          
           
Current assets:          
Cash and cash equivalents  $441,000   $1,363,000 
Accounts receivable   1,000    6,000 
Inventory   48,000    25,000 
Prepaid expenses   38,000    – 
Total current assets   528,000    1,394,000 
           
Property and equipment, net   4,000    182,000 
Equity method investment   1,149,000    – 
Operating lease right-of-use asset   180,000    245,000 
Other assets   10,000    10,000 
Total assets  $1,871,000   $1,831,000 
           
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)          
           
Current liabilities:          
Accounts payable and accrued expenses  $135,000   $342,000 
Accrued payroll and payroll taxes – related parties   280,000    667,000 
Related party payable   –    1,000 
Customer advances   80,000    727,000 
Operating lease liability, current portion   63,000    58,000 
Total current liabilities   558,000    1,795,000 
           
Notes payable, non-current   150,000    254,000 
Operating lease liability, non-current portion   127,000    193,000 
Total liabilities   835,000    2,242,000 
           
Commitments and contingencies   –     –  
           
Stockholders' equity (deficit):          
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2022 and 2021, respectively   –    – 
Common stock, $0.001 par value, 1,000,000,000 shares authorized, 276,698,831 and 208,267,444 shares issued and outstanding as June 30, 2022 and 2021, respectively   277,000    208,000 
Additional paid-in capital   26,005,000    24,008,000 
Accumulated deficit   (25,246,000)   (24,627,000)
Total stockholders' equity (deficit)   1,036,000    (411,000)
Total liabilities and stockholders' equity (deficit)  $1,871,000   $1,831,000 

 

See accompanying notes to the consolidated financial statements

 

 

 18 

 

 

CAVITATION TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS

 

 

           
   For the Years Ended 
   June 30, 
   2022   2021 
         
Revenue  $1,619,000   $537,000 
Revenue - related party   46,000    21,000 
Cost of revenue   (41,000)   (20,000)
Gross profit   1,624,000    538,000 
           
General and administrative expenses   1,728,000    1,264,000 
Impairment of equipment   178,000    – 
Research and development expenses   17,000    21,000 
Total operating expenses   1,923,000    1,285,000 
           
Loss from operations   (299,000)   (747,000)
           
Other Income (Expense)          
Gain on forgiveness of PPP Loan   104,000    104,000 
Loss on settlement of liabilities   (371,000)   – 
Loss from equity method investment   (48,000)    – 
Interest expense   (5,000)   (6,000)
Other, net   (320,000)   98,000 
           
Net loss  $(619,000)  $(649,000)
           
Net loss per share,          
Basic and diluted  $(0.00)  $(0.00)
           
Weighted average shares outstanding,          
Basic and diluted   248,736,262    197,224,988 

 

See accompanying notes to the consolidated financial statements

 

 

 19 

 

 

CAVITATION TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

YEARS ENDED JUNE 30, 2022 AND 2021

 

 

                          
   Common
Stock		   Additional
Paid-in		   Accumulated     
   Shares   Amount   Capital   Deficit   Total 
Balance at June 30, 2020   196,997,906   $197,000   $23,291,000   $(23,978,000)  $(490,000)
Common stock issued for cash   11,269,538    11,000    717,000    –    728,000 
Net loss   –    –    –    (649,000)   (649,000)
Balance at June 30, 2021   208,267,444    208,000    24,008,000    (24,627,000)   (411,000)
Common stock issued for cash   12,071,785    12,000    773,000    –    785,000 
Cashless exercise of warrants   33,715,228    34,000    (34,000)    –    – 
Cashless exercise of options   6,181,818    6,000    (6,000)   –    – 
Fair value of warrants granted for services   –    –    40,000    –    40,000 
Fair value of common stock issued upon exercise of warrants and options   778,609    1,000    86,000         87,000 
Fair value of common stock issued for services   4,500,000    5,000    220,000    –    225,000 
Fair value of common stock issued to settle liabilities   11,183,947    11,000    918,000    –    929,000 
Net loss   –    –    –    (619,000)   (619,000)
Balance at June 30, 2022   276,698,831   $277,000   $26,005,000   $(25,246,000)  $1,036,000 

 

See accompanying notes to the consolidated financial statements

 

 

 

 20 

 

 

CAVITATION TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS 

 

 

           
   Years Ended June 30, 
   2022   2021 
Operating activities:          
Net loss  $(619,000)  $(649,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:          
Depreciation and amortization   –    22,000 
Fair value of common stock issued upon exercise of warrants and options   87,000    – 
Fair value of warrants granted for services   40,000    – 
Fair value of common stock issued for services   225,000    – 
Gain on forgiveness of PPP note payable   (104,000)   (104,000)
Loss on settlement of liabilities   371,000    – 
Impairment of equipment   178,000    – 
Loss from equity method investment   48,000    – 
Distribution from equity method investment   26,000    – 
Effect of changes in:   –    – 
Accounts receivable   5,000    98,000 
Inventory   (23,000)   22,000 
Prepaid expenses   (38,000)   – 
Operating lease right-of-use assets   65,000    63,000 
Accounts payable and accrued expenses   (3,000)   26,000 
Accrued payroll and payroll taxes – related parties   (33,000)   (26,000)
Related party payable   (1,000)   – 
Customer advances   (647,000)    359,000 
Operating lease liabilities   (61,000)   (61,000)
Net cash used in operating activities   (484,000)   (250,000)
           
Investing activities:          
Capital contribution to equity investment   (1,223,000)   – 
Purchase of property and equipment   –    (128,000)
Cash used in investing activities   (1,223,000)   (128,000)
           
Financing activities:          
Proceeds from notes payable   –    254,000 
Proceeds from sale of common stock   785,000    728,000 
Cash generated from financing activities   785,000    982,000 
           
Net increase in cash and cash equivalents   (922,000)   604,000 
           
Cash and cash equivalents, beginning of period   1,363,000    759,000 
Cash and cash equivalents, end of period  $441,000   $1,363,000 
           
Supplemental disclosures of cash flow information:          
Cash paid for interest  $–   $– 
Cash paid for income taxes  $–   $– 
           
Supplemental disclosures of cash flow information:          
Liabilities settled with common stock  $558,000   $– 

 

 

See accompanying notes to the consolidated financial statements

 

 

 21 

 

 

 

CAVITATION TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED JUNE 30, 2022 AND 2021

 

 

Note 1 – Organization and Summary of Significant Accounting Policies

 

Cavitation Technologies, Inc. (“the Company,” “CTi,” “we,” “us,” and “our”) is a Nevada corporation originally incorporated in January 2007 under the name Bio Energy, Inc. The Company has developed, patented, and commercialized proprietary technology used in our Nano Reactor® and LPN™ liquid processing applications.

 

Going Concern

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in accompanying consolidated financial statements, during the year ended June 30, 2022, the Company incurred a net loss of $619,000 and used cash in operating activities of $484,000. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that may result from an inability of the Company to continue as a going concern.

 

As of June 30, 2022, the Company has cash in the amount of $441,000. The Company’s ability to continue as a going concern is dependent upon its ability to continue to implement its business plan. Currently, management’s plan is to increase revenues by continuing to license its technology globally. While the Company believes in the viability of its strategy to increase revenues, there can be no assurances to that effect.

 

The Company may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet the Company’s needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

 

Covid-19

 

During the year ended June 30, 2022, the COVID-19 pandemic did not have a material net impact on our operating results. The Company has not observed any impairments of its assets or a significant change in the fair value of its assets due to the COVID-19 pandemic. At this time, it is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business or results of operations, financial condition, or liquidity.

 

As of June 30, 2022, the Company has been following the recommendations of local health authorities to minimize exposure risk for its employees, including having employees work remotely and utilizing electronic submission of invoices and payments.

  

Principles of Consolidation

 

The consolidated financial statements include the accounts of Cavitation Technologies, Inc. and its wholly owned subsidiary Hydrodynamic Technology, Inc. Intercompany transactions and balances have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates include estimates for reserves for inventory obsolescence, valuation of our equity method investments, assumptions used in valuing our stock options, stock warrants and common stock issued for services and valuation allowance for our deferred tax asset, among other items. Actual results could differ from these estimates.

 

 

 22 

 

 

Revenue Recognition

 

The Company follows the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients. Revenue from sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer. The Company also recognizes revenue from its share of gross profit to be earned from distributors, as defined, which we treat as variable consideration and recognize using the most likely amount method. Estimates are available from our distributor which are considered in the determination of the most likely amount. However, given the lack of control over the sale to the end customer and the lack of history of prior sales, the amount of gross profit revenue recognized is limited to the actual amount of cash received under the contract which the Company has determined is not refundable and that a significant future reversal of cumulative revenue under the contract will not occur. In addition, the Company also recognizes revenues from usage fees of certain reactors. Usage fees are recognized based on actual usage by the customer.

 

Cash and Cash Equivalents

 

The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents. At June 30, 2022 and 2021, the Company had no cash equivalents.

 

The Company maintains its cash with one domestic financial institution. From time to time, cash balances in this domestic bank may exceed federally insured limits provided by the Federal Deposit Insurance Corporation (“FDIC”) of up to $250,000.

 

As of June 30, 2022, and 2021, Company had deposits in excess of federally insured limit with one bank. The Company believes that no significant concentration of credit risk exists with respect to this cash balances because of its assessment of the creditworthiness and financial viability of this financial institution.

  

Accounts Receivable

 

Accounts receivable are generally recorded at the invoiced amounts net of an allowance for expected losses. The Company evaluates the collectability of our trade accounts receivable based on a number of factors. In circumstances where it becomes aware of a specific customer’s inability to meet its financial obligations to us, a specific reserve for bad debts is estimated and recorded which reduces the recognized receivable to the estimated amount that management believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on our historical losses and an overall assessment of past due trade accounts receivable outstanding. At June 30, 2022 and 2021, the Company had no reserve recorded for uncollectible accounts receivable.

 

Inventory

 

Inventory is stated at the lower of cost or net realizable value. Cost is determined on a specific item basis. Inventory is composed of finished goods and represents costs incurred to manufacture the Company’s Nano Reactor® systems and LPN™.

  

Property and Equipment

 

Property and equipment is stated at cost. Depreciation is provided using the straight-line method over the estimated useful lives of the assets. Betterments, renewals, and extraordinary repairs that extend the life of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation applicable to retired assets are removed from the Company’s accounts, and the gain or loss on dispositions, if any, is recognized in the consolidated statements of operations.

 

 

 23 

 

 

Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives. 

   
Leasehold improvements   Shorter of the life of the asset or lease term
Furniture   5-7 Years
Office equipment   5 Years
Lab equipment   4 Years
Skid systems   4 Years

 

Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value.

 

Equity Method Investment

 

The Company accounts for investments in entities in which the Company has significant influence over the entity’s financial and operating policies, but does not control, using the equity method of accounting. The equity method investments are initially recorded at cost, and subsequently increased for capital contributions and allocations of net income, and decreased for capital distributions and allocations of net loss. Equity in net income (loss) from the equity method investment is allocated based on the Company’s economic interest. Equity method investments are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If it is determined that a loss in value of the equity method investment is other than temporary, an impairment loss is measured based on the excess of the carrying amount of an investment over its estimated fair value. Impairment analyses are based on current plans, intended holding periods, and available information at the time the analysis is prepared. The Company does not believe that the value of its equity method investment was impaired as of June 30, 2022.

 

Income Taxes

 

The Company follows the asset and liability method of accounting for income taxes. The Company recognizes deferred tax assets and liabilities to reflect the estimated future tax effects, calculated at anticipated future tax rates, of future deductible or taxable amounts attributable to events that have been recognized on a cumulative basis in the financial statements. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.

  

Leases

 

The Company accounts for its leases in accordance with the guidance of FASB ASC 842, Leases. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments (see Note 3).

 

Fair Value Measurement

 

FASB ASC 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.

 

In addition to defining fair value, the standard expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which are determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

  

Level 1 - inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.

 

Level 2 - inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

 

 24 

 

 

Level 3 - inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.

 

As of June 30, 2022, and 2021, the carrying value of certain accounts such as accounts receivable, inventory, accounts payable, accrued expenses and accrued payroll approximates their fair value due to the short-term nature of such instruments.

 

Share-Based Compensation

 

We periodically issue stock options, warrants and common stock to employees and non-employees for services and capital raising transactions. We account for share-based payments under the guidance of FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. We estimate the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. We estimate the fair value of restricted stock awards to employees and directors using the market price of our common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services.

 

Under ASC 718, the amount of cash or other assets transferred (or liabilities incurred) to repurchase an equity award shall be charged to equity, to the extent that the amount paid does not exceed the fair value of the equity instruments repurchased at the repurchase date. Any excess of the repurchase price over the fair value of the instruments repurchased shall be recognized as additional compensation cost.

  

Advertising Costs

 

Advertising costs, including marketing expense, incurred in the normal course of operations are expensed as incurred. Advertising expenses amounted to $106,000 and $12,000 for the years ended June 30, 2022 and 2021 respectively and was reported as part of General and administrative expenses in the accompanying Consolidated Statements of Operations.

 

Research and Development Costs

 

Research and development expenses relate primarily to the development, design, testing of preproduction prototypes and models, compensation, and consulting fees, and are expensed as incurred. Total research and development costs recorded during the years ended June 30, 2022 and 2021 amounted to $17,000 and $21,000, respectively.

 

Warranty Policy

 

The Company provides a limited warranty with every set of reactors sold, typically 2 to 5 years. The Company has not experienced significant claims under its warranty policy, and management determined no accrual for warranty reserve was necessary at June 30, 2022 and 2021.

  

Net (Loss) Per Share

 

The Company’s computation of loss per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income per share, the treasury stock method assumes that outstanding options and warrants were exercised and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

 

 

 25 

 

 

The following table sets forth the computation of basic and diluted loss per common share. 

        
   June 30, 
   2022   2021 
         
Net loss  $(619,000)  $(649,000)
           
Weighted average common shares – basic   248,736,262    197,224,988 
Dilutive effect of outstanding stock options and warrants   –    – 
Weighted average shares – diluted   248,736,262    197,224,988 
           
Net loss per common share:          
Basic and Diluted  $(0.00)  $(0.00)

  

There were no adjustments to net income (loss) required for purposes of computing diluted earnings per share. At June 30, 2022 and 2021, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of its diluted earnings per share, as their effect would have been anti-dilutive. 

        
   June 30, 2022   June 30, 2021 
Options   1,250,000    11,000,000 
Warrants   61,427,834    98,966,049 

 

Concentrations

 

During the year ended June 30, 2022, we recorded 97% of our revenue from Desmet Ballestra (Desmet) and 3% from Enviro Watertek, LLC (EW) (see Note 2).

 

During the year ended June 30, 2021, we recorded 96% of our revenue from Desmet and 3% from EW (see Note 2).

  

At June 30, 2022 and 2021, 100% of accounts receivable were due from EW.

 

Segment

 

As of June 30, 2022, the Company operated one reportable business segment. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying consolidated financial statements.

 

Recent Accounting Pronouncements

 

In June 2016, the Financial Accounting Standards Board (the "FASB") issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning July 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

 

 

 26 

 

 

Note 2 – Contracts with Desmet Ballestra

 

The Company has the following agreements with Desmet Ballestra (Desmet), a company located in Europe:

 

a.October 2021 Agreement – In October 2021, the Company executed a three-year agreement with Desmet that is a continuation of the October 2018 agreement (See B below). In accordance with ASC 606, the Company recognizes revenue from the sale of reactors at the time of shipment of the Nano reactor hardware as shipment is deemed to be the Company’s only performance obligation and the Company had no more continuing obligation other than the reactor’s two-year standard warranty. Desmet pays for such reactors on credit terms and the amount of a sale is recorded as a receivable upon acceptance by Desmet. In addition, Desmet agreed to provide the Company monthly advances of $40,000 through October 1, 2024 to be applied against future sales of reactors.

 

b.October 2018 Agreement (expired in October 2021, see “A” above) - In October 2018, the Company signed a three-year global Research and Development (R&D), Marketing and Technology License Agreement with Desmet for the sale and licensing of the Company’s reactors. This agreement was a continuation of an original agreement the Company signed with Desmet in fiscal 2012 and amended in fiscal 2016.

 

As part of the October 2018 agreement, Desmet provided the Company monthly advances of $50,000 through October 1, 2021, to be applied against the Company’s gross profit share from future sales. In accordance with ASC 606, the Company determined that the gross profit to be earned from Desmet was a variable consideration and evaluated the amount of the potential payments and the likelihood that the payments would be received using the most likely amount approach (subject to the variable consideration constraint). Estimates were available from our distributor which were considered in the determination of the most likely amount. However, given the lack of control over the sale to the end customer and the lack of history of prior sales, the Company considered these as variable revenue constraints, and as such, the amount of gross profit share revenue recognized was limited to the actual amount of cash received under the contract which the Company had determined was not refundable and probable that a significant revenue reversal would not occur. Further, the Company had not been able to develop an expectation of the actual collection based on its historical experience. The Company also had no control with regards to the sale and installation of Nano Reactor® and CTi Nano Neutralization® System, between Desmet and the end customer. Under the October 2021 agreement (See “A” above), the Company is no longer entitled to revenue from a share of gross profit to be earned from distributors.

 

During the year ended June 30, 2022, the Company recorded sales of $592,000 from Nano Reactor® sales from Desmet, and $1,027,000 from gross profit share for a total revenue of $1,619,000 from Desmet.

 

During the year ended June 30, 2021, the Company recorded sales of $346,000 from Nano Reactor® sales and $191,000 from gross profit share for a total revenue of $537,000 from Desmet.

 

As of June 30, 2022, advances received from Desmet related to future sales of reactors amounted to $80,000. At June 30, 2022, there were no advances received from Desmet related to the Company’s future gross profit share. At June 30, 2021, advances received from Desmet related to the Company’s future gross profit share amounted to $727,000.

 

Note 3 - Investment in equity method investment

 

In 2019, the Company and Delaware Water Company, LLC (Delaware) formed a limited liability company called Enviro WaterTek LLC (“Enviro”). Enviro is owned 50% by the Company and 50% by Delaware, and the Company accounts for its investment in Enviro under the equity method. From 2019 to 2021, Enviro had no operations.

 

In September 2021, the Company and Delaware entered into a separate agreement under Enviro for a specific project (referred to as “Ameredev”). Delaware has certain contracts in place to provide recycled water to operators of certain active oil and gas wells. Under the agreement, the Company contributed $1.2 million that was used by Ameredev to increase the capacity of certain pipelines and water treatment facilities operated by Delaware. Pursuant to the agreement, for each barrel of recycled water that Ameredev sells, Delaware will receive $0.10 per barrel, and the Company will receive $0.05 per barrel (referred to as usage fees), with the balance of net income (loss) from Ameredev being allocated 70% to Delaware and 30% to the Company. The Ameredev agreement will terminate the earlier of three years (unless extended by unanimous agreement of the Board and Members of Ameredev) from the date of the agreement or by unanimous agreement of the Board and Members of Ameredev.

 

 

 27 

 

 

During the year ended June 30, 2022, the Company recorded total revenues from Ameredev of $46,000, made up of $32,000 from the sale of reactors, and $13,000 from usage fees. During the year ended June 30, 2022, the Company recognized a loss of $48,000 related to the equity method investment.

 

During the year ended June 30, 2021, the Company recorded revenues of $21,000 from the usage fee. During the year ended June 30, 2021, there was no income or loss recognized for the equity method investment.

 

The following table summarizes the activity of the Company’s equity method investment:  

     
   June 30, 2022 
Balance at beginning of period  $– 
Contributions to equity method investment   1,223,000 
Loss from equity method investment   (48,000) 
Distribution from equity method investment   (26,000)
Balance at end of period  $1,149,000 

  

A summarized balance sheet as of June 30, 2022, for Ameredev, and a summarized statement of operations for the year ended June 30, 2022, for Ameredev is presented below:

 

Balance Sheet: 

    
   Amount 
Cash  $11,000 
Property and equipment  $1,223,000 
Total assets  $1,234,000 
      
Accounts payable  $43,000 
Partners equity  $1,191,000 
Total liabilities and equity  $1,234,000 

 

Income Statement: 

   Amount 
Revenue  $165,000 
Usage fees paid to Cavitation and Delaware   (41,000)
Operating expenses   (282,000)
Net loss  $(158,000) 

 

Note 4 – Operating Lease

 

The Company leases certain warehouse and corporate office space under an operating lease agreement. We determine if an arrangement is a lease at inception. Lease assets are presented as operating lease right-of-use assets and the related liabilities are presented as lease liabilities in our consolidated balance sheets.

 

Operating lease right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in lease arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The Company’s incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives.

 

 

 28 

 

 

The components of lease expense and supplemental cash flow information related to leases for the period are as follows: 

          
   June 30,   June 30, 
   2022   2021 
         
Lease costs:          
Operating lease (included in general and administrative in the Company’s consolidated statement of operations)  $78,000   $74,000 
           
Other information:          
Cash paid for amounts included in the measurement of lease liabilities  $72,000   $71,000 
           
Weighted average remaining lease term – operating leases (in years)   2.6    3.6 
Average discount rate – operating leases   4%    4% 
           
The supplemental balance sheet information related to leases for the period is as follows:          
Long-term right-of-use assets  $180,000   $245,000 
           
Short-term operating lease liabilities  $63,000   $58,000 
Long-term operating lease liabilities   127,000    193,000 
Total operating lease liabilities  $190,000   $251,000 

  

Supplemental cash flow information related to the lease liabilities are as follows: 

     
   Operating 
Year Ending June 30:  Lease 
2023  $75,000 
2024   78,000 
2025   47,000 
Total lease payments   200,000 
Less: Imputed interest/present value   (10,000)
Present value of lease liabilities  $190,000 

 

Note 5 - Property and Equipment

 

Property and equipment consist of the following as of June 30, 2022 and 2021: 

          
   June 30,   June 30, 
   2022   2021 
         
Leasehold improvement  $2,000   $2,000 
Furniture   27,000    27,000 
Office equipment   2,000    2,000 
Equipment   306,000    484,000 
Systems   187,000    187,000 
    524,000    702,000 
Less: accumulated depreciation and amortization   (520,000)   (520,000)
Property and equipment, net  $4,000   $182,000 

 

 

 29 

 

 

Depreciation expense for the years ended June 30, 2022 and 2021 amounted to $0 and $22,000, respectively and was recorded as part of General and Administrative expenses in the accompanying Consolidated Statements of Operations.

 

In June 2022, the Company determined to cease further development and construction of certain testing equipment and a result, the Company write-down certain capitalized equipment costs of $178,000 that we considered abandoned. For the year ended June 30, 2021, the Company did not recognize any impairment for its property and equipment.

 

Note 6 – Related Party Transactions

 

At June 30, 2021, accrued salaries and estimated payroll taxes due to current and former officers of the Company totaled $667,000. During the year ended June 30, 2022, the Company paid $27,000 of accrued payroll expenses, reduced estimated payroll taxes by $44,000, and transferred $316,000 to an unrelated party, which was subsequently settled through the issuance of 6,855,700 shares of common stock (see Note 8). As of June 30, 2022, outstanding balance of accrued payroll and payroll taxes-related parties totaled $280,000.

  

Note 7 – Notes Payable 

        
   June 30,   June 30, 
   2022   2021 
         
A.      Note Payable - PPP#1  $–   $– 
B.      Note Payable - PPP#2   –    104,000 
C.      Note Payable - EIDL   150,000    150,000 
Total  $150,000   $254,000 

 

  A. On April 16, 2020, the Company was granted a loan for $104,000 (PPP #1) pursuant to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief and Economic Security Act (the “Cares Act”). PPP #1 loan was scheduled to mature in April 2022 had a 1% per annum interest rate, and was subject to the terms and conditions applicable to loans administered by the Small Business Administration (“SBA”) under the CARES Act. The Company applied ASC 470, Debt, to account for PPP #1 loan. In May, 2021, the SBA approved the forgiveness of PPP #1 loan of $104,000, and we recognized a gain on extinguishment of PPP #1 loan of $104,000 during the year ended June 30, 2021.
     
  B. On March 26, 2021, the Company was granted a of $104,000 (PPP #2) pursuant to the PPP that was scheduled to mature in March 2026. PPP #2 loan had an interest rate of 1% per annum, was unsecured, and guaranteed by the Small Business Administration (the “SBA”). In July 2021, the SBA approved the forgiveness of PPP #2 loan of $104,000, and we recognized a gain on extinguishment of PPP #2 loan of $104,000 during the year ended June 30, 2022.

 

  C. In July 2020, the Company received a loan of $150,000 from the SBA under its Economic Injury Disaster Loan (EIDL) assistance program. The EIDL loan is payable over 30 years, bears interest at a rate of 3.75% per annum and secured by all tangible and intangible property of the Company. The Company was in compliance with the terms of the EIDL loan as of June 30, 2021. As of June 30, 2022 and 2021, the outstanding balance of the note payable was $150,000, respectively.

 

 

 30 

 

 

Note 8 - Stockholders’ Deficit

 

Preferred Stock

 

On March 17, 2009, the Company filed an Amended and Restated Articles of Incorporation and created two new series of preferred stock, the first of which is designated Series A Preferred Stock and the second of which is designated as Series B Preferred Stock. The total number of shares of Common Stock which this corporation has authority to issue is 1,000,000,000 shares of Common Stock and 10,000,000 shares of Preferred Stock of which 5,000,000 shares are designated as Series A Preferred Stock, and 5,000,000 shares are designated as Series B Preferred Stock, with the rights, preferences and privileges of the Series B Preferred Stock to be designated by the Board of Directors. Each share of Common Stock and Preferred Stock has a par value of $0.001. As of June 30, 2022, and 2021, there are no shares of Series A or Series B Preferred Stock issued and outstanding.

  

Common Stock

 

Year Ending June 30, 2022

 

During the year ended June 30, 2022, the Company issued 12,071,785 shares of common stock and 12,071,785 fully vested warrant to purchase common stock over a period of 5 years with an exercise price of $0.09 per share in exchange for net cash proceeds of $785,000.

 

During the year ended June 30, 2022, the Company issued 34,407,709 shares of common stock to warrant holders who exercised their 50,110,000 warrants on a cashless basis.

 

During the year ended June 30, 2022, the Company issued 6,267,946 shares of common stock to option holders who exercised their 8,500,000 options on a cashless basis.

 

The Company issued an additional 778,609 with a fair value of $87,000 to the warrant and option holders who exercised their cashless exercise options above. These shares of common stock were valued based on the closing price of the Company’s common stock on the date the shares were issued.

 

During the year ended June 30, 2022, the Company issued 500,000 shares of common stock valued at $25,000 for services rendered. These shares of common stock were valued based on the closing price of the Company’s common stock on the date the Company entered into the agreement related to the issuance.

 

On June 16, 2022, the company granted an executive officer 4,000,000 shares of common stock as part of the officer's compensation valued at $200,000. These shares of common stock were valued based on the closing price of the Company’s common stock on the date the Company entered into the agreement related to the issuance.

 

During the year ended June 30, 2022, the Company issued 6,855,700 shares of common stock with a fair value of $718,000 to settle $316,000 of liabilities related to former accrued payroll (see Note 6) and $31,000 of additional liabilities. A loss on settlement of $371,000 was recognized. In addition, during the year ended June 30, 2022, the Company issued 4,331,260 shares of common stock with a fair value of valued at $211,000 to settle outstanding liabilities of $211,000, with no gain or recognized. These shares of common stock were valued based on the closing price of the Company’s common stock on the date the Company entered into the agreements related to such issuance.

 

Year Ending June 30, 2021

 

During the year ended June 30, 2021, the Company issued 11,269,538 shares of common stock and 11,269,538 fully vested warrants to purchase common stock over a period of five years with an exercise price of $0.09 per share in exchange for net cash proceeds of $728,000.

 

 

 

 31 

 

 

Stock Options

 

The Company has not adopted a formal stock option plan. However, it has assumed outstanding stock options resulting from the acquisition of its wholly owned subsidiary, Hydrodynamic Technology, Inc. In addition, the Company has made periodic non-plan grants. A summary of the stock option activity from June 30, 2022 and 2021 is as follows: 

               
           Weighted- 
           Average 
       Weighted-   Remaining 
       Average   Contractual 
       Exercise   Life 
   Options   Price   (Years) 
             
Outstanding at June 30, 2020   11,000,000   $0.03    6.07 
- Granted   –    –    – 
- Forfeited   –    –    – 
- Exercised   –    –    – 
- Expired   –    –    – 
Outstanding at June 30, 2021   11,000,000   $0.03    6.07 
- Granted   –    –    – 
- Forfeited   –    –    – 
- Exercised   (8,500,000)   0.03    6.07 
- Expired   (1,250,000)   0.03    0.67 
Outstanding at June 30, 2022   1,250,000   $0.03    0.43 

 

As of June 30, 2022, all outstanding options were fully vested and exercisable. The intrinsic value of the outstanding options as of June 30, 2022 was $25,000. The following table summarizes additional information concerning options outstanding and exercisable at June 30, 2022.

                               
      Options Outstanding     Options Exercisable  
            Weighted     Weighted           Weighted  
            Average     Average           Average  
Exercise     Number     Remaining     Exercise     Number     Remaining  
Price     of Shares     Life (Years)     Price     of Shares     Life (Years)  
                                 
$ 0.03       1,250,000       0.87     $ 0.03       1,250,000       0.87  
          1,250,000                       1,250,000          

  

Warrants

 

A summary of the Company’s warrant activity and related information from as of June 30, 2022 and 2021 is as follows.  

               
           Weighted- 
           Average 
       Weighted-   Remaining 
       Average   Contractual 
       Exercise   Life 
Warrants      Price   (Years) 
             
Outstanding at June 30, 2020   87,696,511   $0.07    5.64 
Granted   11,269,538    0.09    5.00 
Exercised   –           
Expired   –           
Outstanding at June 30, 2021   98,966,049    0.07    4.49 
Granted   12,571,785    0.09    5.00 
Exercised   (50,110,000)          
Expired   –           
Outstanding at June 30, 2022   61,427,834   $0.09    2.81 

 

 

 32 

 

  

As of June 30, 2022, all outstanding warrants were fully vested and exercisable. The intrinsic value of the outstanding warrants as of June 30, 2022 was $216,000. The following table summarizes additional information concerning warrants outstanding and exercisable at June 30, 2022.

                                       
    Warrants Outstanding     Warrants Exercisable  
          Weighted     Weighted           Weighted  
          Average     Average           Average  
Exercise   Number     Remaining     Exercise     Number     Exercise  
Price   of Shares     Life (Years)     Price     of Shares     Price  
                               
$0.03 - $0.05     18,626,518       2.63     $ 0.04       18,626,518     $ 0.04  
$0.08 - $0.12     42,801,316       2.89     $ 0.10       42,801,316     $ 0.10  
      61,427,834                       61,427,834          

 

Year Ending June 30, 2022

 

During the year ended June 30, 2022, the Company granted warrants to purchase 12,071,785 shares of common stock in relation to the issuance of common stock (see Common Stock above).

 

On August 1, 2021, the Company granted a service provider a warrant exercisable for 500,000 shares of common stock at an exercise price of $0.09 per share, these warrants were valued at $40,000.

 

The fair value of the warrant awards was estimated using the Black-Scholes method based on the following weighted-average assumptions: 

       
    June 30,  
    2021  
       
Risk-free interest rate     0.66%  
Contractual terms (years)     5 years  
Expected volatility     258%  
Expected dividend yield     0%  

 

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the warrants; the contractual terms represents full contractual term the warrants; expected volatility is based upon historical volatility of the Company’s common stock; and the expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future.

 

Year Ending June 30, 2021

 

During the year ended June 30, 2021, the Company granted warrants to purchase 11,269,538 shares of common stock in relation to the issuance of common stock (see Common Stock above).

 

 

 

 

 33 
 

 

 

Note 9 - Income Taxes

 

For the year ended June 30, 2022, the Company recorded no provision for income taxes due to the Company’s taxable net loss position. For the year ended June 30, 2021, the Company recorded no provision for income taxes due to available Federal and State net operating loss (NOL) carryforwards that are available to reduce taxable income.

 

A reconciliation of the effective income tax to statutory US federal income tax is as follows: 

          
   June 30,   June 30, 
   2022   2021 
Federal statutory rate   (21)%   (21)%
State income taxes, net of Federal benefit   (7)%   (7)%
Valuation allowance   28%    28% 
Income tax provision   –    – 

 

Deferred income taxes result from temporary differences in the recognition of income and expenses for the financial reporting purposes and for tax purposes. The components of deferred tax assets are presented below.

 

At June 30, 2022, the Company had available Federal NOL carryforwards of approximately $10.5 million that are available to reduce future taxable income. The Federal NOL carry forward expires through 2037. The NOLs are subject to statutory limitations under Internal Revenue Code Section 382 regarding substantial changes in ownership of companies with loss carry forwards.

 

During the year ended June 30, 2022 and 2021, management has determined that it is more likely than not that the Company will not be able to realize the tax benefit of the carryforwards due to recurring operating losses. Based on their valuation, the Company determined that the net deferred tax assets, do not meet the requirements to realize, and as such, the Company has provided a full valuation allowance against them.

 

At June 30, 2022 and 2021, significant component of the Company’s deferred tax assets and liabilities are as follows: 

          
   June 30,   June 30, 
   2022   2021 
Net Operating loss carryforwards    $3,063,000   $2,758,000 
Stock compensation expense     938,000     840,000 
Total net deferred tax assets     4,001,000     3,598,000 
Less valuation discount     (4,001,000)   (3,598,000)
Net deferred tax assets  $–   $– 

   

Accounting rules prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. The Company classifies interest and penalties as a component of interest and other expenses. To date, there have been no interest or penalties assessed or paid.

  

The Company measures and records uncertain tax positions by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized.

 

 

 34 
 

 

 

Note 10 – Commitments and Contingencies

 

Royalty Agreements

 

On July 1, 2008, the Company’s wholly owned subsidiary entered into Patent Assignment Agreements with two parties, its President as well as its former Chief Executive Officer (CEO) and current Technology Senior Manager, where certain devices and methods involved in the hydrodynamic cavitation processes invented by the President and former CEO/ current Technology Senior Manager have been assigned to the Company. In exchange, the Company agreed to pay a royalty of 5% of gross revenues to each of the President and former CEO/ current Technology Senior Manager for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently assigned to Cavitation Technologies on May 13, 2010. The Company’s former CEO/ current Technology Senior Manager and President both waived their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through June 30, 2022 and 2021.

 

On April 30, 2008 (as amended November 22, 2010), the Company’s wholly owned subsidiary entered into an employment agreement with the Director of Chemical and Analytical Department (the “Inventor”) providing that the Inventor shall receive an amount equal to 5% of actual gross royalties received from the royalty stream in the first year in which the Company receives royalty payments from the patent which the Inventor was the legally named inventor, and 3% of actual gross royalties received by the Company resulting from the patent in each subsequent year. As of June 30, 2022, and 2022 no patents have been granted in which this person is the legally named inventor.

 

 

 

 

 

 

 

 

 35 

 

 

 

ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

ITEM 9A.  CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

In accordance with rule 13a-15(a), our management must maintain disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities and Exchange Act of 1934, or the Exchange Act, to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

 

In accordance with Rule 13a-15(b) and (c), management must also evaluate the effectiveness of these disclosure control and procedures at the end of each fiscal year. As of June 30, 2022, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, our principal executive officer and principal financial officer concluded that these disclosure controls and procedures were not effective as of June 30, 2022.

 

Report of Management on Internal Control over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange Act. Our internal control over financial reporting is designed under the supervision of our principal executive and principal financial officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

 

(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;

 

(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and

 

(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.

 

Under the supervision and with the participation of our management, including our Principal Executive Officer and Principal Financial Officer, we conducted an evaluation of the effectiveness of our internal controls and procedures, (as defined under Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (Exchange Act)) as of the year ended June 30, 2021. Management conducted as assessment of our internal control over financial reporting based on the framework and criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework (2013). Our management concluded that as of June 30, 2022, our internal control over financial reporting was not effective, and that material weaknesses existed in the following areas as of June 30, 2022:

 

  1. We do not employ full time in-house personnel with the technical knowledge to identify and address some of the reporting issues surrounding certain complex or non-routine transactions. With respect to material, complex and non-routine transactions, management has and will continue to seek guidance from third-party experts and/or consultants to gain a thorough understanding of these transactions;

 

  2. We have ineffective controls over segregation of duties due to limited resources and number of employees.

 

 

 36 

 

  

We are in the continuous process of improving our internal control over financial reporting in an effort to eliminate these material weaknesses through improved supervision and training of our staff, but additional effort is needed to fully remedy these deficiencies. We intend to hire the necessary staff to address the weaknesses once additional capital is obtained which will allow full operations to commence. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal control over financial reporting during the year ended June 30, 2022 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Attestation

 

Pursuant to Item 308(b) of Regulation S-K, as amended by the Dodd-Frank Wall Street Reform and Consumer Protection Act (Wall Street Reform Act), this report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. The Wall Street Reform Act permanently exempts small public companies from the requirement to obtain an external audit on the effectiveness of internal financial reporting controls.

 

ITEM 9B.  Other Information

 

None.

 

 

 

 37 

 

 

 

PART III

 

ITEM 10. Directors, Executive Officers and Corporate Governance.

 

Person   Age     Position
             
Igor Gorodnitsky     62     President, PEO, Secretary and Director
Naum Voloshin     59     Principal Accounting Officer
James Fuller     82     Director
Jerry Bailey PhD     82     Director

 

Audit committee standing members consisted of Igor Gorodnitsky and James Fuller as of June 30, 2021. We anticipate forming compensation, governance, and other committees as necessary.

 

Igor Gorodnitsky. Mr. Gorodnitsky has been our President and member of the Board of Directors since September 26, 2008, and he became the Company's Secretary and Principal Executive Officer in November of 2012. Mr. Gorodnitsky developed expertise in handling and processing hazardous waste material. As a Senior Haz-Mat Specialist, he coordinated and successfully completed more than 500 emergency response Haz-mat clean-ups over the past 20 years. He coordinated and supervised Haz Mat projects, emergency and routine spill clean-ups, and confined space entry tasks. He coordinated and scheduled manpower and purchased and scheduled equipment and materials for containment and treatment of spills. He successfully managed, coordinated and supervised projects including Hazscanning, sampling, lab-packing, manifesting, profiling, labeling, and other special procedures for a variety of commercial clients and municipalities. He is a chemist by training and holds numerous certifications and licenses including Hazwoper Training Program, Confined Space Entry and Gas Vapour HazCating, Certified Uniform Waste Manifest Training, Basic and Intermediate HazCating, On-Scene Incident Commander Emergency, Site Remediation Methods, Underground Storage Tank Removal, Health & Safety Supervisor Certification, Hazardous Certification, and Tosco Refinery Safety. Mr. Gorodnitsky was president of Express Environmental Corp. since its inception in 1980 until he sold his interest in January 2009. Based on his significant industry experience and management skills it was determined that Mr. Gorodnitsky should serve on the Company’s Board.

 

James Fuller. Mr. Fuller is an independent director and has been Chairman of our Audit Committee and Independent Financial Expert since February 2010. He was formerly a Vice President of the New York Stock Exchange and director of the Securities Investor Protection Corporation. In addition to his over 30 years of experience in the securities markets, Mr. Fuller sat on the Board of Trustees of the University of California, Santa Cruz and previously served as Chairman of their Audit Committee and Independent Financial Expert. Jim is a partner at Baytree Capital Associates, LLC. He received his BS in Political Science from San Jose State University and his MBA from California State University - Fresno. Mr. Fuller also served as a Director of Propell Technologies Group, Inc (OTCQB: Propell), a public company engaged in oil and gas exploration from October 14, 2011 until February 17, 2015. Based on Mr. Fuller’s extensive experience in finance as well as his prior public company experience it was determined that Mr. Fuller should serve on the Company’s Board.

 

Naum Voloshin. Mr. Voloshin has over 30 years of experience in investment banking, business operations and marketing. Prior to joining CTi, Mr. Voloshin has worked for several developmental stage companies in US, Europe and Asia. The scope of his duties was to provide management, financial reporting, funding, and marketing expertise.

 

Jerry Bailey PhD. Mr. Bailey has over 50 years of experience in the international petroleum industry. He is a former President of Exxon - Arabian Gulf and prior to that, served in various operating capacities for major oil producers throughout the Middle East and in the U.S. onshore and offshore sectors. Dr. Bailey is currently the Chairman of Bailey Petroleum, LLC, a consulting firm for major oil and gas exploration and development corporations. In addition, during his extensive career, Dr. Bailey has served in a variety of C-Suite and Board capacities for several oil & gas enterprises. Dr. Bailey holds a BS Degree in Chemical Engineering from the University of Houston, an MS Degree in Chemical Engineering from the New Jersey Institute of Technology, a PhD Degree from Columbia Pacific University and is a graduate of Engineering Doctoral Studies from Lamar University.

 

 

 38 

 

 

Family Relationships

 

Roman Gordon is a founder and current Global Technology Manger of the Company. He was a former member of the Company’s Board of Directors and Chief Technology Officer up to July 15, 2016. He is also the brother of Mr. Igor Gorodnitsky, President, Principal Executive Officer and member of the Company’s Board of Directors.

  

Section 16(a) Beneficial Ownership Reporting Compliance

 

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our executive officers, directors, persons who own more than 10% of our common stock, and immediate family members living in the same household to file an Initial Statement of Beneficial Ownership on Form 3 and changes in ownership on Form 4 with the Securities and Exchange Commission (the "SEC"). Such "insiders" are required by SEC rules to furnish us with copies of all Section 16(a) forms they file.

 

Based on a review of Forms 3, 4, and 5 and amendments thereto furnished to us during fiscal 2020 updated forms were filed, ended June 30, 2021, there were no delinquent forms filed during the year.

 

Director Independence

 

Although our common stock is not listed on a national securities exchange, for purposes of independence we use the definition of independence applied by the NASDAQ stock market. The Board has determined that Mr. Fuller is an” independent” in accordance with such definition. Mr. Gorodnitsky is not independent due to his current positions with the Company.

 

Code of Ethics

 

We have adopted a Code of Business Conduct and Ethics that applies to all officers, directors and employees. A copy may also be obtained free of charge by mailing a request in writing to: Cavitation Technologies, Inc., 10019 Canoga Ave., Chatsworth, CA 91311 USA. If we make any substantive amendments to the Code of Business Conduct and Ethics or grant any waiver from a provision of the Code to any executive officer or director, we will promptly disclose the nature of the amendment or waiver in a current report on Form 8-K.

 

ITEM 11. Executive Compensation.

 

Summary Compensation Table

 

The following table sets forth a summary of cash and non-cash compensation awarded, earned or paid for services rendered to us during the years ended June 30, 2022 and 2021 by our “named executive officers,” consisting of (i) each individual serving as principal executive officer, and (ii) our Chief Financial Officer/Chief Operating Officer, our other executive officer.

 

   Year   Salary   Bonus   Stock Awards (1)   Warrant Awards   Non-Equity Incentive Plan Compen-
sation		   Changes in Pension Value and Non-Qualified Deferred Compen-
sation		   All Other Compen-
sation		   Totals 
Igor Gorodnitsky   2022   $187,933   $–   $–   $–   $–   $–   $–   $187,933 
President, Principal Executive Officer   2021   $173,800   $–   $–   $–   $–   $–   $–   $173,800 
                                              
Naum Voloshin   2022   $207,746   $–   $200,000   $–   $–   $–   $–   $407,746 
Principal Accounting Officer   2021   $173,800   $–   $–   $–   $–   $–   $–   $173,800 

  

 

 

 39 

 

 

Outstanding Equity Awards at Fiscal Year-End

 

The table below reflects all outstanding equity awards made to each of the named executive officers that are outstanding as of June 30, 2022

  

   Restricted Stock Awards
Name  Restricted Stock grant date  Number of securities Underlying Restricted Stock Awards # Exercisable   Number of securities Underlying Restricted Stock Awards # Unexercisable   Restricted Stock Awards Grant Price 
Naum Voloshin  6/21/2022   4,000,000    –    0.05 
Principal Accounting Officer                  

 

The fair value of each restricted stock grant is the market value of the stock on the grant date.

 

Employment Agreements

 

Our executive officers work as at-will employees.

 

Code Section 162(m) Provisions

 

Section 162(m) of the U.S. Internal Revenue Code, or the Code, generally disallows a tax deduction to public companies for compensation in excess of $1 million paid to the Chief Executive Officer or any of the four most highly compensated officers. Performance-based compensation arrangements may qualify for an exemption from the deduction limit if they satisfy various requirements under Section 162(m). Although we consider the impact of this rule when developing and implementing our executive compensation programs, we believe it is important to preserve flexibility in designing compensation programs. Accordingly, we have not adopted a policy that all compensation must qualify as deductible under Section 162(m) of the Code. While our stock options are intended to qualify as “performance-based compensation” (as defined by the Code), amounts paid under our other compensation programs may not qualify as such. 

  

2022 Director Compensation

 

The following table sets forth information for the fiscal year ended June 30, 2022 regarding the compensation of our directors who at June 30, 2022 were not also named executive officers.

 

    Fees                 Non-equity                    
    Earned                 inventive     Non-qualified              
    or paid     Stock     Option     plan     deferred     All other        
    in cash     Awards     Awards     compensation     compensation     compensation     Total  
Name   ($)     ($)     ($)     ($)     Earnings     ($)     ($)  
                                           
James Fuller (1)   $ –     $ –     $ –     $ –     $ –     $ –     $ –  
Jerry Bailey   $ –     $ –     $ –     $ –     $ –     $ –     $ –  

 

 

 40 

 

 

As of June 30, 2022, the following table sets forth the number of aggregate outstanding option awards held by each of our directors who were not also named executive officers:

 

    Aggregate 
    Number of 
Name   Option Awards 
    – 

 

 

ITEM 12.  Security Ownership of Certain Beneficial Owners and Management

 

The following table provides information regarding the beneficial ownership of our common stock as of September 30, 2022, (the “Evaluation Date”) by: (i) each of our current directors, (ii) each of our named executive officers, and (iii) all such directors and executive officers as a group. We know of no other person or group of affiliated persons who beneficially own more than five percent of our common stock. The table is based upon information supplied by our officers, directors and principal stockholders and a review of Schedules 13D and 13G, if any, filed with the SEC. Unless otherwise indicated in the footnotes to the table and subject to community property laws where applicable, we believe that each of the stockholders named in the table has sole voting and investment power with respect to the shares indicated as beneficially owned.

 

Applicable percentages are based on 276,698,831 shares outstanding as of the Evaluation Date, adjusted as required by rules promulgated by the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, the rules include shares of our common stock issuable pursuant to the exercise of stock options or warrants that are either immediately exercisable or exercisable within 60 days of the Evaluation Date. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person.

  

            Amount and        
            Nature of        
            Beneficial     Percent of  
Name of Beneficial Owner           Ownership     Class (1)  
Igor Gorodnitsky   (2)         13,927,681       5.0 % 
President, Principal Executive Officer, Director                        
                         
James Fuller   (3)         2,837,500       1.0 % 
Chairman of Audit Committee, Director                        
                         
Naum Voloshin   (4)         10, 212,390       3.7 % 
Principal Accounting Officer                        
Dr. Gerald Bailey   (5)         400,000       *  
Director                        
                         
Directors and Officers             27,377,571       9.8 % 
(as a group, four individuals)                        

 

* Less than 1%
(1) Unless otherwise set forth below, the mailing address of Executive Officers, Directors and 5% or greater holders is in care of the Company,
(2) Consists of 13,927,681 shares of common stock
(3) Consists of 837,500 shares of common stock and warrants exercisable for 2,000,000[warrant list shows 1,500,000] shares of common stock, all of which re vested
(4) Consists of 10,212,390 shares of common stock, including 4,000,000 restricted shares granted to Mr. Voloshin on June 21,, 2022.
(5) Consists of warrants exercisable for 400,000 shares of common stock

 

 

 41 

 

 

ITEM 13. Certain Relationships and Related Transactions

 

Certain Related Party Transactions

 

Since the beginning of our last fiscal year , there has not been, and there is not currently proposed, any transaction or series of similar transactions to which we were or will be a party in which the amount involved exceeded or will exceed the lesser of $120,000 or one percent of the average of our total assets at year-end for the last two completed fiscal years and in which any of our directors, executive officers, holders of more than five percent of any class of our voting securities or any member of the immediate family of the foregoing persons had or will have a direct or indirect material interest.

 

Accrued Payroll and Payroll Taxes

 

As of June 30, 2022, and 2021, the Company had accrued unpaid salaries to officers and former officers amounting to $247,000 and $667,000 respectively.

 

Cameo USA LLC

 

In fiscal 2014, Roman Gordon, one of the Company’s shareholders and a former officer, formed a company called Cameo USA LLC (Cameo). Since its formation, Cameo has had no revenue, no operations, and has had no assets or liabilities. On June 4, 2018, Mr. Gordon contributed his 100% interest in Cameo to the Company. As Mr. Gordon had no basis in his investment in Cameo, there was no value assigned to the contribution of Cameo. Subsequent to the contribution of Cameo to the Company, Cameo was sold to Alchemy Beverages Inc.

  

Director Independence

 

As our common stock is currently traded on the OTC Bulletin Board, we are not subject to the rules of any national securities exchange which require that a majority of a listed company's directors and specified committees of the board of directors meet independence standards prescribed by such rules. For the purpose of preparing the disclosures in this Report on Form 10-K regarding director independence, we have used the definition of "independent director" set forth in the Marketplace Rules of The NASDAQ, which defines an "independent director" generally as a person other than an executive officer or employee of the Company or any other individual having a relationship which, in the opinion of the Company's board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Consistent with these standards, we believe that James Fuller is an Independent Financial Expert.

 

ITEM 14.  Principal Accounting Fees and Services

 

Independent Registered Public Accounting Firm’s Fee Summary

 

The following table provides information regarding the fees billed to us by Weinberg & Company, P.A. for the years ended June 30, 2022 and 2021. All fees described below were approved by the Board:

   

  

June 30,

2022

  

June 30,

2021

 
         
Audit Fees and Expenses (1)  $112,000   $99,000 
Audit Related Fees (2)  $–   $– 
All Other Fees  $15,000   $13,000 

 

  (1) Audit fees and expenses were for professional services rendered for the audit and reviews of the consolidated financial statements of the Company, professional services rendered for issuance of consents and assistance with review of documents filed with the SEC.

 

  (2) The audit related fees were for professional services rendered for additional filing for registration statements and forms with the SEC.

 

 

 42 

 

 

Pre-Approval Policies and Procedures

 

Consistent with SEC policies regarding auditor independence, the Audit Committee has responsibility for appointing, setting compensation and overseeing the work of the independent registered public accounting firm. In recognition of this responsibility, the Audit Committee has established a policy to pre-approve all audit and permissible non-audit services provided by the independent registered public accounting firm.

 

Prior to the engagement of the independent registered public accounting firm for the next year’s audit, management will submit a list of services and related fees expected to be rendered during that year for audit services, audit-related services, tax services and other fees to the Audit Committee for approval.

 

 

 43 

 

 

 

PART IV

 

ITEM 15.  EXHIBITS, FINANCIAL STATEMENT SCHEDULES

 

(a) The following documents are filed as part of this annual report on Form 10-K:

 

1.   Financial Statements

 

The financial statements are filed as part of this report under Item 8 “Financial Statements and Supplementary Data”.

 

2.   Financial Statement Schedules

 

All other schedules are omitted because they are not applicable or the required information is presented in the financial statements and notes thereto.

 

3.   Exhibits

 

The exhibits required by Item 601 of Regulation S-K are included in Item 15(b) below.

 

(b) - Exhibits.

 

        Incorporated by Reference
Exhibit    Filed        
Number Exhibit Description Herewith Form  Pd. Ending Exhibit  Filing Date
             
3(i)(a) Articles of Incorporation - original name of Bioenergy, Inc.   SB-2 N/A 3.1 October 19, 2006
3(i)(b) Articles of Incorporation - Amended and Restated   10-Q December 31, 2008 3.1 February 17, 2009
3(i)(c) Articles of Incorporation - Amended and Restated   10-Q June 30, 2009 3.1 May 14, 2009
3(i)(d) Articles of Incorporation - Amended; increase in authorized shares   8-K N/A N/A October 29, 2009
3(i)(e) Articles of Incorporation - Certificate of Amendment; forward split   10-Q December 31, 2009 3.1 November 16, 2009
10.1 Patent Assignment Agreement between the Company and Roman Gordon dated July 1, 2008.   8-K June 30, 2009 10.1 May 18, 2010
10.2 Patent Assignment Agreement between the Company and Igor Gorodnitsky dated July 1, 2008.   8-K June 30, 2009 10.2 May 18, 2010
10.3 Assignment of Patent Assignment Agreement between the Company and Roman Gordon   8-K June 30, 2009 10.3 May 18, 2010
10.4 Assignment of Patent Assignment Agreement between the Company and Igor Gorodnitsky   8-K June 30, 2009 10.4 May 18, 2010
10.5 Employment Agreement between the Company and Roman Gordon date March 17, 2008   10K/A June 30, 2009 10.3 October 20, 2011
10.6 Employment Agreement between the Company and Igor Gorodnitsky dated March 17, 2008   10K/A June 30, 2009 10.4 October 20, 2011
10.7 Employment Agreement with R.L. Hartshorn dated Sept. 22, 2009   10-Q December 31, 2011 10.7 February 10, 2012
10.8 Employment and Confidentiality and Invention Assignment Agreement between the Company and Varvara Grichko dated April 30, 2008   10-Q December 31, 2010 10.3 February 11, 2011

 

 

 44 

 

 

10.9 Board of Director Agreement - James Fuller   10-Q December 31, 2011 10.12 October 20, 2011
10.1 Technology and License Agreement with Desmet Ballestra dated 14 May 2012   10-K June 30, 2012 10.1 October 15, 2012
10.11 Convertible Note Payable - Prolific Group LLC - $25,000   10-Q December 31, 2011 10.4 February 10, 2012
10.12 Convertible Note Payable - Tripod Group LLC - $30,000   10-Q December 31, 2011 10.41 February 10, 2012
14.1 Code of Business Conduct and Ethics*   10-K June 30, 2011 14.1 September 28, 2011
31.1 Certificate of Principal Executive Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002 X        
31.2 Certificate of Principal Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002 X        
32.1 Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X        
32.2 Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X        

 

101.INS Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) X  
101.SCH Inline XBRL Taxonomy Extension Schema Document X  
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document X  
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document X  
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document X  
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document X  
104 Cover Page Interactive Data File (embedded within the Inline XBRL document) X  

 

 

* In accordance with Regulation S-K 406 of the Securities Act of 1934, we undertake to provide to any person without charge, upon request, a copy of our “Code of Business Conduct and Ethics”. A copy may be requested by sending an email to info@cavitationtechnologies.com.

 

(c) - Financial Statement Schedules

 

See Item (a) 2 above.

 

ITEM 16. SUMMARY. FORM 10-K SUMMARY

 

Not applicable

 

 

 45 

 

 

 

SIGNATURES

 

PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THIS REPORT HAS BEEN SIGNED BELOW BY THE FOLLOWING PERSONS ON BEHALF OF THE REGISTRANT AND IN THE CAPACITIES AND ON THE DATES INDICATED

 

SIGNATURE   TITLE   DATE
         
/s/ Igor Gorodnitsky   President; Member of Board of Directors   October __, 2022
Igor Gorodnitsky   (Principal Executive Officer)    
         
/s/ N. Voloshin   Chief Financial Officer   October __, 2022
N. Voloshin   (Principal Financial Officer)    
         
/s/ James Fuller   Audit Committee Chairman,   October __, 2022
James Fuller   Independent Financial Expert    

 

 

 

 46 

 

 EX-31.1 2 cavitation_ex3101.htm CERTIFICATION

Exhibit 31.1

 

Certification

 

I, Igor Gorodnitsky, certify that:

 

1. I have reviewed this annual report for the fiscal year ended June 30, 2022 on Form 10-K of Cavitation Technologies, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: October __, 2022 /s/ IGOR GORODNITSKY
  Name: Igor Gorodnitsky
  Title: Chief Executive Officer
 EX-31.2 3 cavitation_ex3102.htm CERTIFICATION

Exhibit 31.2

 

Certification

 

I, Naum Voloshin, certify that:

 

1. I have reviewed this annual report for the fiscal year ended June 30, 2022 on Form 10-K of Cavitation Technologies, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: October __, 2022 /s/ N. VOLOSHIN
  Name: Naum Voloshin
  Title: Chief Financial Officer

 

 EX-32.1 4 cavitation_ex3201.htm CERTIFICATION

Exhibit 32.1

 

CERTIFICATION

 

I, Igor Gorodnitsky, Chief Executive Officer of Cavitation Technologies, Inc. (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

 

The Annual Report on Form 10-K of the Company for the year ended June 30, 2022 (the "Report") fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. § 78m); and

 

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: October __, 2022 /s/ IGOR GORODNITSKY
  Name: Igor Gorodnitsky
  Title: Chief Executive Officer

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-32.2 5 cavitation_ex3202.htm CERTIFICATION

Exhibit 32.2

 

CERTIFICATION

 

I, Naum Voloshin, Principal Financial Officer of Cavitation Technologies, Inc. (the "Company"), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

 

The Annual Report on Form 10-K of the Company for the year ended June 30, 2022 (the "Report") fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. § 78m); and

 

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: October __, 2022 /s/ Naum VOLOSHIN
  Name: Naum Voloshin
  Title: Principal Financial Officer

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 GRAPHIC 6 image_001.jpg GRAPHIC begin 644 image_001.jpg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cvat-20220630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Contracts with Desmet Ballestra link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Investment in equity method investment link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Operating Lease link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Stockholders’ Deficit link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Investment in equity method investment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Operating Lease (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Stockholders’ Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Organization and Summary of Significant Accounting Policies (Details- Property and Equipment) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Organization and Summary of Significant Accounting Policies (Details- Net Loss Per Share) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details - Antidilutive shares) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Contracts with Desmet Ballestra (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Investment in equity method investment (Details - Rollforward) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Investment in equity method investment (Details - Ameredev) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Investment in equity method investment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Operating Lease (Details - Lease Cost) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Operating Lease (Details - Operating Lease Minimum payments) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Stockholders' Deficit (Details - Option activity) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Stockholders' Deficit (Details - Options by exercise price) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Stockholders' Deficit (Details - Warrant activity) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Stockholders' Deficit (Details - Warrants by exercise price) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Stockholders' Deficit (Details - Assumptions) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Stockholders’ Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Income Taxes (Details- Tax Reconciliation) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Income Taxes (Details- Deferred Tax Assets and Liabilities) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 cvat-20220630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 cvat-20220630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 cvat-20220630_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Customer [Axis] Desmet Ballestra [Member] E W [Member] Accounts Receivable [Member] Long-Lived Tangible Asset [Axis] Leasehold Improvements [Member] Furniture and Fixtures [Member] Office Equipment [Member] Equipment [Member] Other Machinery and Equipment [Member] Antidilutive Securities [Axis] Equity Option [Member] Warrant [Member] Product and Service [Axis] Nano Reactor Sales [Member] Gross Profit Share [Member] Counterparty Name [Axis] Desmet [Member] Ameredev [Member] Reactor Sales [Member] Usage Fees [Member] Investment Type [Axis] Equity Method Investments [Member] Equity Method Investment, Nonconsolidated Investee [Axis] Investment, Name [Axis] Long-Term Debt, Type [Axis] PPP [Member] P P P 2 [Member] EIDL [Member] Class of Stock [Axis] Warrants [Member] Common Stock And Warrants [Member] Award Type [Axis] Cashless Exercise Of Warrants [Member] Cashless Exercise Of Options [Member] Related Party [Axis] Executive Officer [Member] Transaction Type [Axis] Former Accrued Payroll [Member] Other Liabilities [Member] Consultant [Member] Exercise Price Range [Axis] Price 1 [Member] $0.03-$0.05 [Member] $0.08-$0.12 [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Auditor Name Auditor Location Auditor Firm ID Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Accounts receivable Inventory Prepaid expenses Total current assets Property and equipment, net Equity method investment Operating lease right-of-use asset Other assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable and accrued expenses Accrued payroll and payroll taxes – related parties Related party payable Customer advances Operating lease liability, current portion Total current liabilities Notes payable, non-current Operating lease liability, non-current portion Total liabilities Commitments and contingencies Stockholders' equity (deficit): Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2022 and 2021, respectively Common stock, $0.001 par value, 1,000,000,000 shares authorized, 276,698,831 and 208,267,444 shares issued and outstanding as June 30, 2022 and 2021, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity (deficit) Total liabilities and stockholders' equity (deficit) Preferred Stock, par value Preferred Stock, shares authorized Preferred Stock, shares issued Preferred Stock, shares outstanding Common Stock, par value Common Stock, shares authorized Common Stock, shares issued Common Stock, shares outstanding Income Statement [Abstract] Revenue Revenue - related party Cost of revenue Gross profit General and administrative expenses Impairment of equipment Research and development expenses Total operating expenses Loss from operations Other Income (Expense) Gain on forgiveness of PPP Loan Loss on settlement of liabilities Loss from equity method investment Interest expense Other, net Net loss Net loss per share, Weighted average shares outstanding, Earnings Per Share, Basic Earnings Per Share, Diluted Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Common stock issued for cash Common stock issued for cash, shares Cashless exercise of warrants Net loss [custom:CommonStockIssuedUponExerciseOfWarrants] Cashless exercise of options [custom:FairValueOfCommonStockIssuedUponExerciseOfWarrantsAndOptionsShares] Common stock issued upon exercise of options, shares Fair value of warrants granted for services Common stock issued upon exercise of warrants, shares [custom:CommonStockIssuedUponExerciseOfWarrantsShares] Fair value of common stock issued upon exercise of warrants and options [custom:FairValueOfCommonStockIssuedForServicesShares] Fair value of common stock issued for services [custom:FairValueOfCommonStockIssuedAsCompensation] Fair value of common stock issued as compensation, shares [custom:FairValueOfCommonStockIssuedAsCompensationShares] Fair value of common stock issued to settle liabilities Fair value of common stock issued to settle liabilities, shares Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] Operating activities: Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation and amortization Fair value of common stock issued upon exercise of warrants and options Fair value of warrants granted for services Fair value of common stock issued for services Gain on forgiveness of PPP note payable Loss on settlement of liabilities Loss from equity method investment Distribution from equity method investment Effect of changes in: Accounts receivable Inventory Prepaid expenses Operating lease right-of-use assets Accounts payable and accrued expenses Accrued payroll and payroll taxes – related parties Related party payable Customer advances Operating lease liabilities Net cash used in operating activities Investing activities: Capital contribution to equity investment Purchase of property and equipment Cash used in investing activities Financing activities: Proceeds from notes payable Proceeds from sale of common stock Cash generated from financing activities Net increase in cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Supplemental disclosures of cash flow information: Cash paid for interest Cash paid for income taxes Liabilities settled with common stock Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Summary of Significant Accounting Policies Revenue from Contract with Customer [Abstract] Contracts with Desmet Ballestra Equity Method Investments and Joint Ventures [Abstract] Investment in equity method investment Operating Lease Operating Lease Property, Plant and Equipment [Abstract] Property and Equipment Related Party Transactions [Abstract] Related Party Transactions Debt Disclosure [Abstract] Notes Payable Equity [Abstract] Stockholders’ Deficit Income Tax Disclosure [Abstract] Income Taxes Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Going Concern Covid-19 Principles of Consolidation Use of Estimates Revenue Recognition Cash and Cash Equivalents Accounts Receivable Inventory Property and Equipment Equity Method Investment Income Taxes Leases Fair Value Measurement Share-Based Compensation Advertising Costs Research and Development Costs Warranty Policy Net (Loss) Per Share Concentrations Segment Recent Accounting Pronouncements Property and equipment useful life Basic and diluted loss per common share Schedule of antidilutive shares Schedule of equity method investment Statement of operations for Ameredev Lease cost table Schedule of lease liability maturities Schedule Property and Equipment Schedule of notes payable Stock Option activity table Schedule of options outstanding and exercisable Schedule of warrant activity Schedule of warrants outstanding and exercisable Assumptions Income Tax Provision Schedule of Deferred Tax Assets Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property and equipment useful life Weighted average common shares – basic Dilutive effect of outstanding stock options and warrants Weighted average shares – diluted Net loss per common share: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive shares Schedule of Product Information [Table] Product Information [Line Items] Net Income (Loss) Attributable to Parent Net Cash Provided by (Used in) Operating Activities Cash Cash Equivalents, at Carrying Value Advertising expense Research and development expense Concentration risk percentage Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Revenues Contract with Customer, Liability Investment Income [Table] Net Investment Income [Line Items] Balance at beginning of period Contributions to equity method investment Equity in earnings of equity method investment Proceeds from Equity Method Investment, Distribution Balance at end of period Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Line Items] Property and equipment Total assets Accounts payable Partners equity Total liabilities and equity Revenue Usage fees paid to Cavitation and Delaware Operating Expenses Net income Revenue from Contract with Customer, Including Assessed Tax Income (Loss) from Equity Method Investments Operating lease cost Cash paid for amounts included in the measurement of lease liabilities Weighted average remaining lease term - operating leases (in years) Average discount rate - operating leases Long-term right-of-use assets Short-term operating lease liabilities Long-term operating lease liabilities Total operating lease liabilities 2023 2024 2025 Total lease payments Less: Imputed interest/present value Present value of lease liabilities Property and Equipment Less: Accumulated depreciation and amortization Depreciation expense Equipment Expense Employee-related Liabilities Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Notes Payable Proceeds from loan Interest rate Debt Instrument, Decrease, Forgiveness Gain on forgiveness of note payable Note payable Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Options outstanding, beginning balance Weighted average exercise price, options outstanding, beginning price Weighted average remaining contractual life, options outstanding Options granted Weighted average exercise price, options granted Options forfeited Weighted average exercise price, options forfeited Options exercised Weighted average exercise price, options exercised Options expired Weighted average exercise price, options expired Weighted-Average Remaining Contractual Life Exercised Weighted-Average Remaining Contractual Life Expired Options outstanding, ending balance Weighted average exercise price, options outstanding, ending price Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Weighted average exercise price options outstanding Number of shares outstanding Weighted average remaining life options outstanding Number of shares exercisable Weighted average remaining life options exercisable Warrants outstanding, beginning balance Weighted average exercise price, warrants outstanding, beginning price Weighted average remaining contractual life Warrants granted Weighted average exercise price, warrants granted Weighted average remaing contractual life, warrants granted Warrants exercised Warrants expired Warrants outstanding, ending balance Weighted average exercise price, warrants outstanding, ending price Number of warrant shares outstanding Weighted average remaining life warrants outstanding Weighted average exercise price warrants outstanding Number of warrant shares exercisable Weighted average exercise price warrants exercisable Risk free interest rate Expected term (years) Expected volatility Expected dividend yield Schedule of Stock by Class [Table] Class of Stock [Line Items] Stock issued new, shares [custom:WarrantsIssuedNewShares] Proceeds from Issuance or Sale of Equity Conversion of Stock, Shares Issued Conversion of Stock, Shares Converted [custom:StockIssuedToWarrantAndOptionHoldersShares] [custom:StockIssuedToWarrantAndOptionHoldersValue] Stock issued new, shares Stock Issued During Period, Value, Issued for Services Shares issued for compensation, shares Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture [custom:StockIssuedForLiabilitiesShares] [custom:StockIssuedForLiabilitiesValue] Gain (Loss) on Extinguishment of Debt Warrants granted to purchase common stock Warrant exercisable price per share Net cash proceeds Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Warrants issued for services shares Exercise price Warrants issued for services value Federal statutory rate State income taxes, net of Federal benefit Net operating loss/carryforward Income tax provision Net Operating loss carryforwards   Stock compensation expense   Total net deferred tax assets   Less valuation discount   Net deferred tax assets Net operating loss Working capital Weighted average remaing contractual life, warrants granted Number of warrant shares exercisable Weighted average exercise price warrants exercisable Assets, Current Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Cost of Revenue Gross Profit Operating Expenses Interest Expense Nonoperating Income (Expense) Shares, Outstanding Issuance of Stock and Warrants for Services or Claims FairValueOfWarrantsGrantedForServices FairValueOfCommonStockIssuedForServicesCashFlow Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Increase (Decrease) in Employee Related Liabilities Increase (Decrease) in Due to Related Parties Increase (Decrease) in Contract with Customer, Liability Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Lessee, Operating Leases [Text Block] Inventory, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Property, Plant and Equipment, Estimated Useful Lives Equity Method Investments RevenueFromJointVenture UsageFees Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance EX-101.PRE 11 cvat-20220630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover - USD ($)
 12 Months Ended
Jun. 30, 2022
Sep. 28, 2022
Dec. 31, 2021
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Jun. 30, 2022    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Current Fiscal Year End Date --06-30    
Entity File Number 000-53239    
Entity Registrant Name Cavitation Technologies, Inc.    
Entity Central Index Key 0001376793    
Entity Tax Identification Number 20-4907818    
Entity Incorporation, State or Country Code NV    
Entity Address, Address Line One 10019 CANOGA AVENUE,    
Entity Address, City or Town CHATSWORTH,    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 91311    
City Area Code (818)    
Local Phone Number 718-0905    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 23,372,000
Entity Common Stock, Shares Outstanding   276,698,831  
Auditor Name Weinberg & Company, P.A.    
Auditor Location Los Angeles, California    
Auditor Firm ID 572    
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2022
Jun. 30, 2021
Current assets:    
Cash and cash equivalents $ 441,000 $ 1,363,000
Accounts receivable 1,000 6,000
Inventory 48,000 25,000
Prepaid expenses 38,000 0
Total current assets 528,000 1,394,000
Property and equipment, net 4,000 182,000
Equity method investment 1,149,000 0
Operating lease right-of-use asset 180,000 245,000
Other assets 10,000 10,000
Total assets 1,871,000 1,831,000
Current liabilities:    
Accounts payable and accrued expenses 135,000 342,000
Accrued payroll and payroll taxes – related parties 280,000 667,000
Related party payable 0 1,000
Customer advances 80,000 727,000
Operating lease liability, current portion 63,000 58,000
Total current liabilities 558,000 1,795,000
Notes payable, non-current 150,000 254,000
Operating lease liability, non-current portion 127,000 193,000
Total liabilities 835,000 2,242,000
Commitments and contingencies
Stockholders' equity (deficit):    
Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2022 and 2021, respectively 0 0
Common stock, $0.001 par value, 1,000,000,000 shares authorized, 276,698,831 and 208,267,444 shares issued and outstanding as June 30, 2022 and 2021, respectively 277,000 208,000
Additional paid-in capital 26,005,000 24,008,000
Accumulated deficit (25,246,000) (24,627,000)
Total stockholders' equity (deficit) 1,036,000 (411,000)
Total liabilities and stockholders' equity (deficit) $ 1,871,000 $ 1,831,000
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Jun. 30, 2022
Jun. 30, 2021
Statement of Financial Position [Abstract]    
Preferred Stock, par value $ 0.001 $ 0.001
Preferred Stock, shares authorized 10,000,000 10,000,000
Preferred Stock, shares issued 0 0
Preferred Stock, shares outstanding 0 0
Common Stock, par value $ 0.001 $ 0.001
Common Stock, shares authorized 1,000,000,000 1,000,000,000
Common Stock, shares issued 276,698,831 208,267,444
Common Stock, shares outstanding 276,698,831 208,267,444
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Income Statement [Abstract]    
Revenue $ 1,619,000 $ 537,000
Revenue - related party 46,000 21,000
Cost of revenue (41,000) (20,000)
Gross profit 1,624,000 538,000
General and administrative expenses 1,728,000 1,264,000
Impairment of equipment 178,000 0
Research and development expenses 17,000 21,000
Total operating expenses 1,923,000 1,285,000
Loss from operations (299,000) (747,000)
Other Income (Expense)    
Gain on forgiveness of PPP Loan 104,000 104,000
Loss on settlement of liabilities (371,000) 0
Loss from equity method investment (48,000) 0
Interest expense (5,000) (6,000)
Other, net (320,000) 98,000
Net loss $ (619,000) $ (649,000)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - $ / shares
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Income Statement [Abstract]    
Earnings Per Share, Basic $ (0.00) $ (0.00)
Earnings Per Share, Diluted $ (0.00) $ (0.00)
Weighted Average Number of Shares Outstanding, Basic 248,736,262 197,224,988
Weighted Average Number of Shares Outstanding, Diluted 248,736,262 197,224,988
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Jun. 30, 2020 $ 197,000 $ 23,291,000 $ (23,978,000) $ (490,000)
Beginning balance, shares at Jun. 30, 2020 196,997,906      
Common stock issued for cash $ 11,000 717,000 728,000
Common stock issued for cash, shares 11,269,538      
Net loss (649,000) $ (649,000)
Fair value of common stock issued as compensation, shares       11,269,538
Ending balance, value at Jun. 30, 2021 $ 208,000 24,008,000 (24,627,000) $ (411,000)
Ending balance, shares at Jun. 30, 2021 208,267,444      
Common stock issued for cash $ 12,000 773,000 785,000
Common stock issued for cash, shares 12,071,785      
Cashless exercise of warrants $ 34,000 (34,000)
Net loss (619,000) (619,000)
Cashless exercise of options $ 6,000 (6,000)
[custom:FairValueOfCommonStockIssuedUponExerciseOfWarrantsAndOptionsShares] 778,609      
Common stock issued upon exercise of options, shares 6,181,818      
Fair value of warrants granted for services 40,000 40,000
Common stock issued upon exercise of warrants, shares 33,715,228      
Fair value of common stock issued upon exercise of warrants and options $ 1,000 86,000   87,000
Fair value of common stock issued for services $ 5,000 220,000 225,000
Fair value of common stock issued as compensation, shares 4,500,000      
Fair value of common stock issued to settle liabilities $ 11,000 918,000 929,000
Fair value of common stock issued to settle liabilities, shares 11,183,947      
Ending balance, value at Jun. 30, 2022 $ 277,000 $ 26,005,000 $ (25,246,000) $ 1,036,000
Ending balance, shares at Jun. 30, 2022 276,698,831      
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Operating activities:    
Net loss $ (619,000) $ (649,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization 0 22,000
Fair value of common stock issued upon exercise of warrants and options 87,000 0
Fair value of warrants granted for services 40,000 0
Fair value of common stock issued for services 225,000 0
Gain on forgiveness of PPP note payable (104,000) (104,000)
Loss on settlement of liabilities 371,000 0
Impairment of equipment 178,000 0
Loss from equity method investment 48,000 0
Distribution from equity method investment 26,000 0
Effect of changes in:    
Accounts receivable 5,000 98,000
Inventory (23,000) 22,000
Prepaid expenses (38,000) 0
Operating lease right-of-use assets 65,000 63,000
Accounts payable and accrued expenses (3,000) 26,000
Accrued payroll and payroll taxes – related parties (33,000) (26,000)
Related party payable (1,000) 0
Customer advances (647,000) 359,000
Operating lease liabilities (61,000) (61,000)
Net cash used in operating activities (484,000) (250,000)
Investing activities:    
Capital contribution to equity investment (1,223,000)
Purchase of property and equipment (128,000)
Cash used in investing activities (1,223,000) (128,000)
Financing activities:    
Proceeds from notes payable 254,000
Proceeds from sale of common stock 785,000 728,000
Cash generated from financing activities 785,000 982,000
Net increase in cash and cash equivalents (922,000) 604,000
Cash and cash equivalents, beginning of period 1,363,000 759,000
Cash and cash equivalents, end of period 441,000 1,363,000
Supplemental disclosures of cash flow information:    
Cash paid for interest 0 0
Cash paid for income taxes 0 0
Liabilities settled with common stock $ 558,000 $ 0
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Summary of Significant Accounting Policies
 12 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Summary of Significant Accounting Policies

Note 1 – Organization and Summary of Significant Accounting Policies

 

Cavitation Technologies, Inc. (“the Company,” “CTi,” “we,” “us,” and “our”) is a Nevada corporation originally incorporated in January 2007 under the name Bio Energy, Inc. The Company has developed, patented, and commercialized proprietary technology used in our Nano Reactor® and LPN™ liquid processing applications.

 

Going Concern

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in accompanying consolidated financial statements, during the year ended June 30, 2022, the Company incurred a net loss of $619,000 and used cash in operating activities of $484,000. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that may result from an inability of the Company to continue as a going concern.

 

As of June 30, 2022, the Company has cash in the amount of $441,000. The Company’s ability to continue as a going concern is dependent upon its ability to continue to implement its business plan. Currently, management’s plan is to increase revenues by continuing to license its technology globally. While the Company believes in the viability of its strategy to increase revenues, there can be no assurances to that effect.

 

The Company may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet the Company’s needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

 

Covid-19

 

During the year ended June 30, 2022, the COVID-19 pandemic did not have a material net impact on our operating results. The Company has not observed any impairments of its assets or a significant change in the fair value of its assets due to the COVID-19 pandemic. At this time, it is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business or results of operations, financial condition, or liquidity.

 

As of June 30, 2022, the Company has been following the recommendations of local health authorities to minimize exposure risk for its employees, including having employees work remotely and utilizing electronic submission of invoices and payments.

  

Principles of Consolidation

 

The consolidated financial statements include the accounts of Cavitation Technologies, Inc. and its wholly owned subsidiary Hydrodynamic Technology, Inc. Intercompany transactions and balances have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates include estimates for reserves for inventory obsolescence, valuation of our equity method investments, assumptions used in valuing our stock options, stock warrants and common stock issued for services and valuation allowance for our deferred tax asset, among other items. Actual results could differ from these estimates.

 

Revenue Recognition

 

The Company follows the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients. Revenue from sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer. The Company also recognizes revenue from its share of gross profit to be earned from distributors, as defined, which we treat as variable consideration and recognize using the most likely amount method. Estimates are available from our distributor which are considered in the determination of the most likely amount. However, given the lack of control over the sale to the end customer and the lack of history of prior sales, the amount of gross profit revenue recognized is limited to the actual amount of cash received under the contract which the Company has determined is not refundable and that a significant future reversal of cumulative revenue under the contract will not occur. In addition, the Company also recognizes revenues from usage fees of certain reactors. Usage fees are recognized based on actual usage by the customer.

 

Cash and Cash Equivalents

 

The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents. At June 30, 2022 and 2021, the Company had no cash equivalents.

 

The Company maintains its cash with one domestic financial institution. From time to time, cash balances in this domestic bank may exceed federally insured limits provided by the Federal Deposit Insurance Corporation (“FDIC”) of up to $250,000.

 

As of June 30, 2022, and 2021, Company had deposits in excess of federally insured limit with one bank. The Company believes that no significant concentration of credit risk exists with respect to this cash balances because of its assessment of the creditworthiness and financial viability of this financial institution.

  

Accounts Receivable

 

Accounts receivable are generally recorded at the invoiced amounts net of an allowance for expected losses. The Company evaluates the collectability of our trade accounts receivable based on a number of factors. In circumstances where it becomes aware of a specific customer’s inability to meet its financial obligations to us, a specific reserve for bad debts is estimated and recorded which reduces the recognized receivable to the estimated amount that management believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on our historical losses and an overall assessment of past due trade accounts receivable outstanding. At June 30, 2022 and 2021, the Company had no reserve recorded for uncollectible accounts receivable.

 

Inventory

 

Inventory is stated at the lower of cost or net realizable value. Cost is determined on a specific item basis. Inventory is composed of finished goods and represents costs incurred to manufacture the Company’s Nano Reactor® systems and LPN™.

  

Property and Equipment

 

Property and equipment is stated at cost. Depreciation is provided using the straight-line method over the estimated useful lives of the assets. Betterments, renewals, and extraordinary repairs that extend the life of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation applicable to retired assets are removed from the Company’s accounts, and the gain or loss on dispositions, if any, is recognized in the consolidated statements of operations.

 

Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives. 

   
Leasehold improvements   Shorter of the life of the asset or lease term
Furniture   5-7 Years
Office equipment   5 Years
Lab equipment   4 Years
Skid systems   4 Years

 

Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value.

 

Equity Method Investment

 

The Company accounts for investments in entities in which the Company has significant influence over the entity’s financial and operating policies, but does not control, using the equity method of accounting. The equity method investments are initially recorded at cost, and subsequently increased for capital contributions and allocations of net income, and decreased for capital distributions and allocations of net loss. Equity in net income (loss) from the equity method investment is allocated based on the Company’s economic interest. Equity method investments are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If it is determined that a loss in value of the equity method investment is other than temporary, an impairment loss is measured based on the excess of the carrying amount of an investment over its estimated fair value. Impairment analyses are based on current plans, intended holding periods, and available information at the time the analysis is prepared. The Company does not believe that the value of its equity method investment was impaired as of June 30, 2022.

 

Income Taxes

 

The Company follows the asset and liability method of accounting for income taxes. The Company recognizes deferred tax assets and liabilities to reflect the estimated future tax effects, calculated at anticipated future tax rates, of future deductible or taxable amounts attributable to events that have been recognized on a cumulative basis in the financial statements. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.

  

Leases

 

The Company accounts for its leases in accordance with the guidance of FASB ASC 842, Leases. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments (see Note 3).

 

Fair Value Measurement

 

FASB ASC 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.

 

In addition to defining fair value, the standard expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which are determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

  

Level 1 - inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.

 

Level 2 - inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 - inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.

 

As of June 30, 2022, and 2021, the carrying value of certain accounts such as accounts receivable, inventory, accounts payable, accrued expenses and accrued payroll approximates their fair value due to the short-term nature of such instruments.

 

Share-Based Compensation

 

We periodically issue stock options, warrants and common stock to employees and non-employees for services and capital raising transactions. We account for share-based payments under the guidance of FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. We estimate the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. We estimate the fair value of restricted stock awards to employees and directors using the market price of our common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services.

 

Under ASC 718, the amount of cash or other assets transferred (or liabilities incurred) to repurchase an equity award shall be charged to equity, to the extent that the amount paid does not exceed the fair value of the equity instruments repurchased at the repurchase date. Any excess of the repurchase price over the fair value of the instruments repurchased shall be recognized as additional compensation cost.

  

Advertising Costs

 

Advertising costs, including marketing expense, incurred in the normal course of operations are expensed as incurred. Advertising expenses amounted to $106,000 and $12,000 for the years ended June 30, 2022 and 2021 respectively and was reported as part of General and administrative expenses in the accompanying Consolidated Statements of Operations.

 

Research and Development Costs

 

Research and development expenses relate primarily to the development, design, testing of preproduction prototypes and models, compensation, and consulting fees, and are expensed as incurred. Total research and development costs recorded during the years ended June 30, 2022 and 2021 amounted to $17,000 and $21,000, respectively.

 

Warranty Policy

 

The Company provides a limited warranty with every set of reactors sold, typically 2 to 5 years. The Company has not experienced significant claims under its warranty policy, and management determined no accrual for warranty reserve was necessary at June 30, 2022 and 2021.

  

Net (Loss) Per Share

 

The Company’s computation of loss per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income per share, the treasury stock method assumes that outstanding options and warrants were exercised and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

 

The following table sets forth the computation of basic and diluted loss per common share. 

        
   June 30, 
   2022   2021 
         
Net loss  $(619,000)  $(649,000)
           
Weighted average common shares – basic   248,736,262    197,224,988 
Dilutive effect of outstanding stock options and warrants   –    – 
Weighted average shares – diluted   248,736,262    197,224,988 
           
Net loss per common share:          
Basic and Diluted  $(0.00)  $(0.00)

  

There were no adjustments to net income (loss) required for purposes of computing diluted earnings per share. At June 30, 2022 and 2021, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of its diluted earnings per share, as their effect would have been anti-dilutive. 

        
   June 30, 2022   June 30, 2021 
Options   1,250,000    11,000,000 
Warrants   61,427,834    98,966,049 

 

Concentrations

 

During the year ended June 30, 2022, we recorded 97% of our revenue from Desmet Ballestra (Desmet) and 3% from Enviro Watertek, LLC (EW) (see Note 2).

 

During the year ended June 30, 2021, we recorded 96% of our revenue from Desmet and 3% from EW (see Note 2).

  

At June 30, 2022 and 2021, 100% of accounts receivable were due from EW.

 

Segment

 

As of June 30, 2022, the Company operated one reportable business segment. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying consolidated financial statements.

 

Recent Accounting Pronouncements

 

In June 2016, the Financial Accounting Standards Board (the "FASB") issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning July 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

 
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Contracts with Desmet Ballestra
 12 Months Ended
Jun. 30, 2022
Revenue from Contract with Customer [Abstract]  
Contracts with Desmet Ballestra

Note 2 – Contracts with Desmet Ballestra

 

The Company has the following agreements with Desmet Ballestra (Desmet), a company located in Europe:

 

a.October 2021 Agreement – In October 2021, the Company executed a three-year agreement with Desmet that is a continuation of the October 2018 agreement (See B below). In accordance with ASC 606, the Company recognizes revenue from the sale of reactors at the time of shipment of the Nano reactor hardware as shipment is deemed to be the Company’s only performance obligation and the Company had no more continuing obligation other than the reactor’s two-year standard warranty. Desmet pays for such reactors on credit terms and the amount of a sale is recorded as a receivable upon acceptance by Desmet. In addition, Desmet agreed to provide the Company monthly advances of $40,000 through October 1, 2024 to be applied against future sales of reactors.

 

b.October 2018 Agreement (expired in October 2021, see “A” above) - In October 2018, the Company signed a three-year global Research and Development (R&D), Marketing and Technology License Agreement with Desmet for the sale and licensing of the Company’s reactors. This agreement was a continuation of an original agreement the Company signed with Desmet in fiscal 2012 and amended in fiscal 2016.

 

As part of the October 2018 agreement, Desmet provided the Company monthly advances of $50,000 through October 1, 2021, to be applied against the Company’s gross profit share from future sales. In accordance with ASC 606, the Company determined that the gross profit to be earned from Desmet was a variable consideration and evaluated the amount of the potential payments and the likelihood that the payments would be received using the most likely amount approach (subject to the variable consideration constraint). Estimates were available from our distributor which were considered in the determination of the most likely amount. However, given the lack of control over the sale to the end customer and the lack of history of prior sales, the Company considered these as variable revenue constraints, and as such, the amount of gross profit share revenue recognized was limited to the actual amount of cash received under the contract which the Company had determined was not refundable and probable that a significant revenue reversal would not occur. Further, the Company had not been able to develop an expectation of the actual collection based on its historical experience. The Company also had no control with regards to the sale and installation of Nano Reactor® and CTi Nano Neutralization® System, between Desmet and the end customer. Under the October 2021 agreement (See “A” above), the Company is no longer entitled to revenue from a share of gross profit to be earned from distributors.

 

During the year ended June 30, 2022, the Company recorded sales of $592,000 from Nano Reactor® sales from Desmet, and $1,027,000 from gross profit share for a total revenue of $1,619,000 from Desmet.

 

During the year ended June 30, 2021, the Company recorded sales of $346,000 from Nano Reactor® sales and $191,000 from gross profit share for a total revenue of $537,000 from Desmet.

 

As of June 30, 2022, advances received from Desmet related to future sales of reactors amounted to $80,000. At June 30, 2022, there were no advances received from Desmet related to the Company’s future gross profit share. At June 30, 2021, advances received from Desmet related to the Company’s future gross profit share amounted to $727,000.

 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investment in equity method investment
 12 Months Ended
Jun. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]  
Investment in equity method investment

Note 3 - Investment in equity method investment

 

In 2019, the Company and Delaware Water Company, LLC (Delaware) formed a limited liability company called Enviro WaterTek LLC (“Enviro”). Enviro is owned 50% by the Company and 50% by Delaware, and the Company accounts for its investment in Enviro under the equity method. From 2019 to 2021, Enviro had no operations.

 

In September 2021, the Company and Delaware entered into a separate agreement under Enviro for a specific project (referred to as “Ameredev”). Delaware has certain contracts in place to provide recycled water to operators of certain active oil and gas wells. Under the agreement, the Company contributed $1.2 million that was used by Ameredev to increase the capacity of certain pipelines and water treatment facilities operated by Delaware. Pursuant to the agreement, for each barrel of recycled water that Ameredev sells, Delaware will receive $0.10 per barrel, and the Company will receive $0.05 per barrel (referred to as usage fees), with the balance of net income (loss) from Ameredev being allocated 70% to Delaware and 30% to the Company. The Ameredev agreement will terminate the earlier of three years (unless extended by unanimous agreement of the Board and Members of Ameredev) from the date of the agreement or by unanimous agreement of the Board and Members of Ameredev.

 

During the year ended June 30, 2022, the Company recorded total revenues from Ameredev of $46,000, made up of $32,000 from the sale of reactors, and $13,000 from usage fees. During the year ended June 30, 2022, the Company recognized a loss of $48,000 related to the equity method investment.

 

During the year ended June 30, 2021, the Company recorded revenues of $21,000 from the usage fee. During the year ended June 30, 2021, there was no income or loss recognized for the equity method investment.

 

The following table summarizes the activity of the Company’s equity method investment:  

     
   June 30, 2022 
Balance at beginning of period  $– 
Contributions to equity method investment   1,223,000 
Loss from equity method investment   (48,000) 
Distribution from equity method investment   (26,000)
Balance at end of period  $1,149,000 

  

A summarized balance sheet as of June 30, 2022, for Ameredev, and a summarized statement of operations for the year ended June 30, 2022, for Ameredev is presented below:

 

Balance Sheet: 

    
   Amount 
Cash  $11,000 
Property and equipment  $1,223,000 
Total assets  $1,234,000 
      
Accounts payable  $43,000 
Partners equity  $1,191,000 
Total liabilities and equity  $1,234,000 

 

Income Statement: 

   Amount 
Revenue  $165,000 
Usage fees paid to Cavitation and Delaware   (41,000)
Operating expenses   (282,000)
Net loss  $(158,000) 

 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Operating Lease
 12 Months Ended
Jun. 30, 2022
Operating Lease  
Operating Lease

Note 4 – Operating Lease

 

The Company leases certain warehouse and corporate office space under an operating lease agreement. We determine if an arrangement is a lease at inception. Lease assets are presented as operating lease right-of-use assets and the related liabilities are presented as lease liabilities in our consolidated balance sheets.

 

Operating lease right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in lease arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The Company’s incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives.

 

The components of lease expense and supplemental cash flow information related to leases for the period are as follows: 

          
   June 30,   June 30, 
   2022   2021 
         
Lease costs:          
Operating lease (included in general and administrative in the Company’s consolidated statement of operations)  $78,000   $74,000 
           
Other information:          
Cash paid for amounts included in the measurement of lease liabilities  $72,000   $71,000 
           
Weighted average remaining lease term – operating leases (in years)   2.6    3.6 
Average discount rate – operating leases   4%    4% 
           
The supplemental balance sheet information related to leases for the period is as follows:          
Long-term right-of-use assets  $180,000   $245,000 
           
Short-term operating lease liabilities  $63,000   $58,000 
Long-term operating lease liabilities   127,000    193,000 
Total operating lease liabilities  $190,000   $251,000 

  

Supplemental cash flow information related to the lease liabilities are as follows: 

     
   Operating 
Year Ending June 30:  Lease 
2023  $75,000 
2024   78,000 
2025   47,000 
Total lease payments   200,000 
Less: Imputed interest/present value   (10,000)
Present value of lease liabilities  $190,000 

 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment
 12 Months Ended
Jun. 30, 2022
Property, Plant and Equipment [Abstract]  
Property and Equipment

Note 5 - Property and Equipment

 

Property and equipment consist of the following as of June 30, 2022 and 2021: 

          
   June 30,   June 30, 
   2022   2021 
         
Leasehold improvement  $2,000   $2,000 
Furniture   27,000    27,000 
Office equipment   2,000    2,000 
Equipment   306,000    484,000 
Systems   187,000    187,000 
    524,000    702,000 
Less: accumulated depreciation and amortization   (520,000)   (520,000)
Property and equipment, net  $4,000   $182,000 

 

Depreciation expense for the years ended June 30, 2022 and 2021 amounted to $0 and $22,000, respectively and was recorded as part of General and Administrative expenses in the accompanying Consolidated Statements of Operations.

 

In June 2022, the Company determined to cease further development and construction of certain testing equipment and a result, the Company write-down certain capitalized equipment costs of $178,000 that we considered abandoned. For the year ended June 30, 2021, the Company did not recognize any impairment for its property and equipment.

 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions
 12 Months Ended
Jun. 30, 2022
Related Party Transactions [Abstract]  
Related Party Transactions

Note 6 – Related Party Transactions

 

At June 30, 2021, accrued salaries and estimated payroll taxes due to current and former officers of the Company totaled $667,000. During the year ended June 30, 2022, the Company paid $27,000 of accrued payroll expenses, reduced estimated payroll taxes by $44,000, and transferred $316,000 to an unrelated party, which was subsequently settled through the issuance of 6,855,700 shares of common stock (see Note 8). As of June 30, 2022, outstanding balance of accrued payroll and payroll taxes-related parties totaled $280,000.

  
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Notes Payable
 12 Months Ended
Jun. 30, 2022
Debt Disclosure [Abstract]  
Notes Payable

Note 7 – Notes Payable 

        
   June 30,   June 30, 
   2022   2021 
         
A.      Note Payable - PPP#1  $–   $– 
B.      Note Payable - PPP#2   –    104,000 
C.      Note Payable - EIDL   150,000    150,000 
Total  $150,000   $254,000 

 

  A. On April 16, 2020, the Company was granted a loan for $104,000 (PPP #1) pursuant to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief and Economic Security Act (the “Cares Act”). PPP #1 loan was scheduled to mature in April 2022 had a 1% per annum interest rate, and was subject to the terms and conditions applicable to loans administered by the Small Business Administration (“SBA”) under the CARES Act. The Company applied ASC 470, Debt, to account for PPP #1 loan. In May, 2021, the SBA approved the forgiveness of PPP #1 loan of $104,000, and we recognized a gain on extinguishment of PPP #1 loan of $104,000 during the year ended June 30, 2021.
     
  B. On March 26, 2021, the Company was granted a of $104,000 (PPP #2) pursuant to the PPP that was scheduled to mature in March 2026. PPP #2 loan had an interest rate of 1% per annum, was unsecured, and guaranteed by the Small Business Administration (the “SBA”). In July 2021, the SBA approved the forgiveness of PPP #2 loan of $104,000, and we recognized a gain on extinguishment of PPP #2 loan of $104,000 during the year ended June 30, 2022.

 

  C. In July 2020, the Company received a loan of $150,000 from the SBA under its Economic Injury Disaster Loan (EIDL) assistance program. The EIDL loan is payable over 30 years, bears interest at a rate of 3.75% per annum and secured by all tangible and intangible property of the Company. The Company was in compliance with the terms of the EIDL loan as of June 30, 2021. As of June 30, 2022 and 2021, the outstanding balance of the note payable was $150,000, respectively.

 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders’ Deficit
 12 Months Ended
Jun. 30, 2022
Equity [Abstract]  
Stockholders’ Deficit

Note 8 - Stockholders’ Deficit

 

Preferred Stock

 

On March 17, 2009, the Company filed an Amended and Restated Articles of Incorporation and created two new series of preferred stock, the first of which is designated Series A Preferred Stock and the second of which is designated as Series B Preferred Stock. The total number of shares of Common Stock which this corporation has authority to issue is 1,000,000,000 shares of Common Stock and 10,000,000 shares of Preferred Stock of which 5,000,000 shares are designated as Series A Preferred Stock, and 5,000,000 shares are designated as Series B Preferred Stock, with the rights, preferences and privileges of the Series B Preferred Stock to be designated by the Board of Directors. Each share of Common Stock and Preferred Stock has a par value of $0.001. As of June 30, 2022, and 2021, there are no shares of Series A or Series B Preferred Stock issued and outstanding.

  

Common Stock

 

Year Ending June 30, 2022

 

During the year ended June 30, 2022, the Company issued 12,071,785 shares of common stock and 12,071,785 fully vested warrant to purchase common stock over a period of 5 years with an exercise price of $0.09 per share in exchange for net cash proceeds of $785,000.

 

During the year ended June 30, 2022, the Company issued 34,407,709 shares of common stock to warrant holders who exercised their 50,110,000 warrants on a cashless basis.

 

During the year ended June 30, 2022, the Company issued 6,267,946 shares of common stock to option holders who exercised their 8,500,000 options on a cashless basis.

 

The Company issued an additional 778,609 with a fair value of $87,000 to the warrant and option holders who exercised their cashless exercise options above. These shares of common stock were valued based on the closing price of the Company’s common stock on the date the shares were issued.

 

During the year ended June 30, 2022, the Company issued 500,000 shares of common stock valued at $25,000 for services rendered. These shares of common stock were valued based on the closing price of the Company’s common stock on the date the Company entered into the agreement related to the issuance.

 

On June 16, 2022, the company granted an executive officer 4,000,000 shares of common stock as part of the officer's compensation valued at $200,000. These shares of common stock were valued based on the closing price of the Company’s common stock on the date the Company entered into the agreement related to the issuance.

 

During the year ended June 30, 2022, the Company issued 6,855,700 shares of common stock with a fair value of $718,000 to settle $316,000 of liabilities related to former accrued payroll (see Note 6) and $31,000 of additional liabilities. A loss on settlement of $371,000 was recognized. In addition, during the year ended June 30, 2022, the Company issued 4,331,260 shares of common stock with a fair value of valued at $211,000 to settle outstanding liabilities of $211,000, with no gain or recognized. These shares of common stock were valued based on the closing price of the Company’s common stock on the date the Company entered into the agreements related to such issuance.

 

Year Ending June 30, 2021

 

During the year ended June 30, 2021, the Company issued 11,269,538 shares of common stock and 11,269,538 fully vested warrants to purchase common stock over a period of five years with an exercise price of $0.09 per share in exchange for net cash proceeds of $728,000.

 

Stock Options

 

The Company has not adopted a formal stock option plan. However, it has assumed outstanding stock options resulting from the acquisition of its wholly owned subsidiary, Hydrodynamic Technology, Inc. In addition, the Company has made periodic non-plan grants. A summary of the stock option activity from June 30, 2022 and 2021 is as follows: 

               
           Weighted- 
           Average 
       Weighted-   Remaining 
       Average   Contractual 
       Exercise   Life 
   Options   Price   (Years) 
             
Outstanding at June 30, 2020   11,000,000   $0.03    6.07 
- Granted   –    –    – 
- Forfeited   –    –    – 
- Exercised   –    –    – 
- Expired   –    –    – 
Outstanding at June 30, 2021   11,000,000   $0.03    6.07 
- Granted   –    –    – 
- Forfeited   –    –    – 
- Exercised   (8,500,000)   0.03    6.07 
- Expired   (1,250,000)   0.03    0.67 
Outstanding at June 30, 2022   1,250,000   $0.03    0.43 

 

As of June 30, 2022, all outstanding options were fully vested and exercisable. The intrinsic value of the outstanding options as of June 30, 2022 was $25,000. The following table summarizes additional information concerning options outstanding and exercisable at June 30, 2022.

                               
      Options Outstanding     Options Exercisable  
            Weighted     Weighted           Weighted  
            Average     Average           Average  
Exercise     Number     Remaining     Exercise     Number     Remaining  
Price     of Shares     Life (Years)     Price     of Shares     Life (Years)  
                                 
$ 0.03       1,250,000       0.87     $ 0.03       1,250,000       0.87  
          1,250,000                       1,250,000          

  

Warrants

 

A summary of the Company’s warrant activity and related information from as of June 30, 2022 and 2021 is as follows.  

               
           Weighted- 
           Average 
       Weighted-   Remaining 
       Average   Contractual 
       Exercise   Life 
Warrants      Price   (Years) 
             
Outstanding at June 30, 2020   87,696,511   $0.07    5.64 
Granted   11,269,538    0.09    5.00 
Exercised   –           
Expired   –           
Outstanding at June 30, 2021   98,966,049    0.07    4.49 
Granted   12,571,785    0.09    5.00 
Exercised   (50,110,000)          
Expired   –           
Outstanding at June 30, 2022   61,427,834   $0.09    2.81 

 

As of June 30, 2022, all outstanding warrants were fully vested and exercisable. The intrinsic value of the outstanding warrants as of June 30, 2022 was $216,000. The following table summarizes additional information concerning warrants outstanding and exercisable at June 30, 2022.

                                       
    Warrants Outstanding     Warrants Exercisable  
          Weighted     Weighted           Weighted  
          Average     Average           Average  
Exercise   Number     Remaining     Exercise     Number     Exercise  
Price   of Shares     Life (Years)     Price     of Shares     Price  
                               
$0.03 - $0.05     18,626,518       2.63     $ 0.04       18,626,518     $ 0.04  
$0.08 - $0.12     42,801,316       2.89     $ 0.10       42,801,316     $ 0.10  
      61,427,834                       61,427,834          

 

Year Ending June 30, 2022

 

During the year ended June 30, 2022, the Company granted warrants to purchase 12,071,785 shares of common stock in relation to the issuance of common stock (see Common Stock above).

 

On August 1, 2021, the Company granted a service provider a warrant exercisable for 500,000 shares of common stock at an exercise price of $0.09 per share, these warrants were valued at $40,000.

 

The fair value of the warrant awards was estimated using the Black-Scholes method based on the following weighted-average assumptions: 

       
    June 30,  
    2021  
       
Risk-free interest rate     0.66%  
Contractual terms (years)     5 years  
Expected volatility     258%  
Expected dividend yield     0%  

 

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the warrants; the contractual terms represents full contractual term the warrants; expected volatility is based upon historical volatility of the Company’s common stock; and the expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future.

 

Year Ending June 30, 2021

 

During the year ended June 30, 2021, the Company granted warrants to purchase 11,269,538 shares of common stock in relation to the issuance of common stock (see Common Stock above).

 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes
 12 Months Ended
Jun. 30, 2022
Income Tax Disclosure [Abstract]  
Income Taxes

Note 9 - Income Taxes

 

For the year ended June 30, 2022, the Company recorded no provision for income taxes due to the Company’s taxable net loss position. For the year ended June 30, 2021, the Company recorded no provision for income taxes due to available Federal and State net operating loss (NOL) carryforwards that are available to reduce taxable income.

 

A reconciliation of the effective income tax to statutory US federal income tax is as follows: 

          
   June 30,   June 30, 
   2022   2021 
Federal statutory rate   (21)%   (21)%
State income taxes, net of Federal benefit   (7)%   (7)%
Valuation allowance   28%    28% 
Income tax provision   –    – 

 

Deferred income taxes result from temporary differences in the recognition of income and expenses for the financial reporting purposes and for tax purposes. The components of deferred tax assets are presented below.

 

At June 30, 2022, the Company had available Federal NOL carryforwards of approximately $10.5 million that are available to reduce future taxable income. The Federal NOL carry forward expires through 2037. The NOLs are subject to statutory limitations under Internal Revenue Code Section 382 regarding substantial changes in ownership of companies with loss carry forwards.

 

During the year ended June 30, 2022 and 2021, management has determined that it is more likely than not that the Company will not be able to realize the tax benefit of the carryforwards due to recurring operating losses. Based on their valuation, the Company determined that the net deferred tax assets, do not meet the requirements to realize, and as such, the Company has provided a full valuation allowance against them.

 

At June 30, 2022 and 2021, significant component of the Company’s deferred tax assets and liabilities are as follows: 

          
   June 30,   June 30, 
   2022   2021 
Net Operating loss carryforwards    $3,063,000   $2,758,000 
Stock compensation expense     938,000     840,000 
Total net deferred tax assets     4,001,000     3,598,000 
Less valuation discount     (4,001,000)   (3,598,000)
Net deferred tax assets  $–   $– 

   

Accounting rules prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. The Company classifies interest and penalties as a component of interest and other expenses. To date, there have been no interest or penalties assessed or paid.

  

The Company measures and records uncertain tax positions by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized.

 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Commitments and Contingencies
 12 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 10 – Commitments and Contingencies

 

Royalty Agreements

 

On July 1, 2008, the Company’s wholly owned subsidiary entered into Patent Assignment Agreements with two parties, its President as well as its former Chief Executive Officer (CEO) and current Technology Senior Manager, where certain devices and methods involved in the hydrodynamic cavitation processes invented by the President and former CEO/ current Technology Senior Manager have been assigned to the Company. In exchange, the Company agreed to pay a royalty of 5% of gross revenues to each of the President and former CEO/ current Technology Senior Manager for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently assigned to Cavitation Technologies on May 13, 2010. The Company’s former CEO/ current Technology Senior Manager and President both waived their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through June 30, 2022 and 2021.

 

On April 30, 2008 (as amended November 22, 2010), the Company’s wholly owned subsidiary entered into an employment agreement with the Director of Chemical and Analytical Department (the “Inventor”) providing that the Inventor shall receive an amount equal to 5% of actual gross royalties received from the royalty stream in the first year in which the Company receives royalty payments from the patent which the Inventor was the legally named inventor, and 3% of actual gross royalties received by the Company resulting from the patent in each subsequent year. As of June 30, 2022, and 2022 no patents have been granted in which this person is the legally named inventor.

 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

Going Concern

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in accompanying consolidated financial statements, during the year ended June 30, 2022, the Company incurred a net loss of $619,000 and used cash in operating activities of $484,000. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that may result from an inability of the Company to continue as a going concern.

 

As of June 30, 2022, the Company has cash in the amount of $441,000. The Company’s ability to continue as a going concern is dependent upon its ability to continue to implement its business plan. Currently, management’s plan is to increase revenues by continuing to license its technology globally. While the Company believes in the viability of its strategy to increase revenues, there can be no assurances to that effect.

 

The Company may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet the Company’s needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.

 
Covid-19

Covid-19

 

During the year ended June 30, 2022, the COVID-19 pandemic did not have a material net impact on our operating results. The Company has not observed any impairments of its assets or a significant change in the fair value of its assets due to the COVID-19 pandemic. At this time, it is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business or results of operations, financial condition, or liquidity.

 

As of June 30, 2022, the Company has been following the recommendations of local health authorities to minimize exposure risk for its employees, including having employees work remotely and utilizing electronic submission of invoices and payments.

  
Principles of Consolidation

Principles of Consolidation

 

The consolidated financial statements include the accounts of Cavitation Technologies, Inc. and its wholly owned subsidiary Hydrodynamic Technology, Inc. Intercompany transactions and balances have been eliminated in consolidation.

 
Use of Estimates

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates include estimates for reserves for inventory obsolescence, valuation of our equity method investments, assumptions used in valuing our stock options, stock warrants and common stock issued for services and valuation allowance for our deferred tax asset, among other items. Actual results could differ from these estimates.

 
Revenue Recognition

Revenue Recognition

 

The Company follows the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients. Revenue from sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer. The Company also recognizes revenue from its share of gross profit to be earned from distributors, as defined, which we treat as variable consideration and recognize using the most likely amount method. Estimates are available from our distributor which are considered in the determination of the most likely amount. However, given the lack of control over the sale to the end customer and the lack of history of prior sales, the amount of gross profit revenue recognized is limited to the actual amount of cash received under the contract which the Company has determined is not refundable and that a significant future reversal of cumulative revenue under the contract will not occur. In addition, the Company also recognizes revenues from usage fees of certain reactors. Usage fees are recognized based on actual usage by the customer.

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents. At June 30, 2022 and 2021, the Company had no cash equivalents.

 

The Company maintains its cash with one domestic financial institution. From time to time, cash balances in this domestic bank may exceed federally insured limits provided by the Federal Deposit Insurance Corporation (“FDIC”) of up to $250,000.

 

As of June 30, 2022, and 2021, Company had deposits in excess of federally insured limit with one bank. The Company believes that no significant concentration of credit risk exists with respect to this cash balances because of its assessment of the creditworthiness and financial viability of this financial institution.

  
Accounts Receivable

Accounts Receivable

 

Accounts receivable are generally recorded at the invoiced amounts net of an allowance for expected losses. The Company evaluates the collectability of our trade accounts receivable based on a number of factors. In circumstances where it becomes aware of a specific customer’s inability to meet its financial obligations to us, a specific reserve for bad debts is estimated and recorded which reduces the recognized receivable to the estimated amount that management believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on our historical losses and an overall assessment of past due trade accounts receivable outstanding. At June 30, 2022 and 2021, the Company had no reserve recorded for uncollectible accounts receivable.

 
Inventory

Inventory

 

Inventory is stated at the lower of cost or net realizable value. Cost is determined on a specific item basis. Inventory is composed of finished goods and represents costs incurred to manufacture the Company’s Nano Reactor® systems and LPN™.

  
Property and Equipment

Property and Equipment

 

Property and equipment is stated at cost. Depreciation is provided using the straight-line method over the estimated useful lives of the assets. Betterments, renewals, and extraordinary repairs that extend the life of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation applicable to retired assets are removed from the Company’s accounts, and the gain or loss on dispositions, if any, is recognized in the consolidated statements of operations.

 

Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives. 

   
Leasehold improvements   Shorter of the life of the asset or lease term
Furniture   5-7 Years
Office equipment   5 Years
Lab equipment   4 Years
Skid systems   4 Years

 

Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value.

 
Equity Method Investment

Equity Method Investment

 

The Company accounts for investments in entities in which the Company has significant influence over the entity’s financial and operating policies, but does not control, using the equity method of accounting. The equity method investments are initially recorded at cost, and subsequently increased for capital contributions and allocations of net income, and decreased for capital distributions and allocations of net loss. Equity in net income (loss) from the equity method investment is allocated based on the Company’s economic interest. Equity method investments are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If it is determined that a loss in value of the equity method investment is other than temporary, an impairment loss is measured based on the excess of the carrying amount of an investment over its estimated fair value. Impairment analyses are based on current plans, intended holding periods, and available information at the time the analysis is prepared. The Company does not believe that the value of its equity method investment was impaired as of June 30, 2022.

 
Income Taxes

Income Taxes

 

The Company follows the asset and liability method of accounting for income taxes. The Company recognizes deferred tax assets and liabilities to reflect the estimated future tax effects, calculated at anticipated future tax rates, of future deductible or taxable amounts attributable to events that have been recognized on a cumulative basis in the financial statements. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.

  
Leases

Leases

 

The Company accounts for its leases in accordance with the guidance of FASB ASC 842, Leases. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments (see Note 3).

 
Fair Value Measurement

Fair Value Measurement

 

FASB ASC 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.

 

In addition to defining fair value, the standard expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which are determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

  

Level 1 - inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.

 

Level 2 - inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

 

Level 3 - inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.

 

As of June 30, 2022, and 2021, the carrying value of certain accounts such as accounts receivable, inventory, accounts payable, accrued expenses and accrued payroll approximates their fair value due to the short-term nature of such instruments.

 
Share-Based Compensation

Share-Based Compensation

 

We periodically issue stock options, warrants and common stock to employees and non-employees for services and capital raising transactions. We account for share-based payments under the guidance of FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. We estimate the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. We estimate the fair value of restricted stock awards to employees and directors using the market price of our common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services.

 

Under ASC 718, the amount of cash or other assets transferred (or liabilities incurred) to repurchase an equity award shall be charged to equity, to the extent that the amount paid does not exceed the fair value of the equity instruments repurchased at the repurchase date. Any excess of the repurchase price over the fair value of the instruments repurchased shall be recognized as additional compensation cost.

  
Advertising Costs

Advertising Costs

 

Advertising costs, including marketing expense, incurred in the normal course of operations are expensed as incurred. Advertising expenses amounted to $106,000 and $12,000 for the years ended June 30, 2022 and 2021 respectively and was reported as part of General and administrative expenses in the accompanying Consolidated Statements of Operations.

 
Research and Development Costs

Research and Development Costs

 

Research and development expenses relate primarily to the development, design, testing of preproduction prototypes and models, compensation, and consulting fees, and are expensed as incurred. Total research and development costs recorded during the years ended June 30, 2022 and 2021 amounted to $17,000 and $21,000, respectively.

 
Warranty Policy

Warranty Policy

 

The Company provides a limited warranty with every set of reactors sold, typically 2 to 5 years. The Company has not experienced significant claims under its warranty policy, and management determined no accrual for warranty reserve was necessary at June 30, 2022 and 2021.

  
Net (Loss) Per Share

Net (Loss) Per Share

 

The Company’s computation of loss per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income per share, the treasury stock method assumes that outstanding options and warrants were exercised and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.

 

The following table sets forth the computation of basic and diluted loss per common share. 

        
   June 30, 
   2022   2021 
         
Net loss  $(619,000)  $(649,000)
           
Weighted average common shares – basic   248,736,262    197,224,988 
Dilutive effect of outstanding stock options and warrants   –    – 
Weighted average shares – diluted   248,736,262    197,224,988 
           
Net loss per common share:          
Basic and Diluted  $(0.00)  $(0.00)

  

There were no adjustments to net income (loss) required for purposes of computing diluted earnings per share. At June 30, 2022 and 2021, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of its diluted earnings per share, as their effect would have been anti-dilutive. 

        
   June 30, 2022   June 30, 2021 
Options   1,250,000    11,000,000 
Warrants   61,427,834    98,966,049 

 
Concentrations

Concentrations

 

During the year ended June 30, 2022, we recorded 97% of our revenue from Desmet Ballestra (Desmet) and 3% from Enviro Watertek, LLC (EW) (see Note 2).

 

During the year ended June 30, 2021, we recorded 96% of our revenue from Desmet and 3% from EW (see Note 2).

  

At June 30, 2022 and 2021, 100% of accounts receivable were due from EW.

 
Segment

Segment

 

As of June 30, 2022, the Company operated one reportable business segment. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying consolidated financial statements.

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In June 2016, the Financial Accounting Standards Board (the "FASB") issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning July 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Property and equipment useful life
   
Leasehold improvements   Shorter of the life of the asset or lease term
Furniture   5-7 Years
Office equipment   5 Years
Lab equipment   4 Years
Skid systems   4 Years
Basic and diluted loss per common share
        
   June 30, 
   2022   2021 
         
Net loss  $(619,000)  $(649,000)
           
Weighted average common shares – basic   248,736,262    197,224,988 
Dilutive effect of outstanding stock options and warrants   –    – 
Weighted average shares – diluted   248,736,262    197,224,988 
           
Net loss per common share:          
Basic and Diluted  $(0.00)  $(0.00)
Schedule of antidilutive shares
        
   June 30, 2022   June 30, 2021 
Options   1,250,000    11,000,000 
Warrants   61,427,834    98,966,049 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investment in equity method investment (Tables)
 12 Months Ended
Jun. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]  
Schedule of equity method investment
     
   June 30, 2022 
Balance at beginning of period  $– 
Contributions to equity method investment   1,223,000 
Loss from equity method investment   (48,000) 
Distribution from equity method investment   (26,000)
Balance at end of period  $1,149,000 
Statement of operations for Ameredev
    
   Amount 
Cash  $11,000 
Property and equipment  $1,223,000 
Total assets  $1,234,000 
      
Accounts payable  $43,000 
Partners equity  $1,191,000 
Total liabilities and equity  $1,234,000 

 

Income Statement: 

   Amount 
Revenue  $165,000 
Usage fees paid to Cavitation and Delaware   (41,000)
Operating expenses   (282,000)
Net loss  $(158,000) 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Operating Lease (Tables)
 12 Months Ended
Jun. 30, 2022
Operating Lease  
Lease cost table
          
   June 30,   June 30, 
   2022   2021 
         
Lease costs:          
Operating lease (included in general and administrative in the Company’s consolidated statement of operations)  $78,000   $74,000 
           
Other information:          
Cash paid for amounts included in the measurement of lease liabilities  $72,000   $71,000 
           
Weighted average remaining lease term – operating leases (in years)   2.6    3.6 
Average discount rate – operating leases   4%    4% 
           
The supplemental balance sheet information related to leases for the period is as follows:          
Long-term right-of-use assets  $180,000   $245,000 
           
Short-term operating lease liabilities  $63,000   $58,000 
Long-term operating lease liabilities   127,000    193,000 
Total operating lease liabilities  $190,000   $251,000 
Schedule of lease liability maturities
     
   Operating 
Year Ending June 30:  Lease 
2023  $75,000 
2024   78,000 
2025   47,000 
Total lease payments   200,000 
Less: Imputed interest/present value   (10,000)
Present value of lease liabilities  $190,000 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment (Tables)
 12 Months Ended
Jun. 30, 2022
Property, Plant and Equipment [Abstract]  
Schedule Property and Equipment
          
   June 30,   June 30, 
   2022   2021 
         
Leasehold improvement  $2,000   $2,000 
Furniture   27,000    27,000 
Office equipment   2,000    2,000 
Equipment   306,000    484,000 
Systems   187,000    187,000 
    524,000    702,000 
Less: accumulated depreciation and amortization   (520,000)   (520,000)
Property and equipment, net  $4,000   $182,000 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Notes Payable (Tables)
 12 Months Ended
Jun. 30, 2022
Debt Disclosure [Abstract]  
Schedule of notes payable
        
   June 30,   June 30, 
   2022   2021 
         
A.      Note Payable - PPP#1  $–   $– 
B.      Note Payable - PPP#2   –    104,000 
C.      Note Payable - EIDL   150,000    150,000 
Total  $150,000   $254,000 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders’ Deficit (Tables)
 12 Months Ended
Jun. 30, 2022
Equity [Abstract]  
Stock Option activity table
               
           Weighted- 
           Average 
       Weighted-   Remaining 
       Average   Contractual 
       Exercise   Life 
   Options   Price   (Years) 
             
Outstanding at June 30, 2020   11,000,000   $0.03    6.07 
- Granted   –    –    – 
- Forfeited   –    –    – 
- Exercised   –    –    – 
- Expired   –    –    – 
Outstanding at June 30, 2021   11,000,000   $0.03    6.07 
- Granted   –    –    – 
- Forfeited   –    –    – 
- Exercised   (8,500,000)   0.03    6.07 
- Expired   (1,250,000)   0.03    0.67 
Outstanding at June 30, 2022   1,250,000   $0.03    0.43 
Schedule of options outstanding and exercisable
                               
      Options Outstanding     Options Exercisable  
            Weighted     Weighted           Weighted  
            Average     Average           Average  
Exercise     Number     Remaining     Exercise     Number     Remaining  
Price     of Shares     Life (Years)     Price     of Shares     Life (Years)  
                                 
$ 0.03       1,250,000       0.87     $ 0.03       1,250,000       0.87  
          1,250,000                       1,250,000          
Schedule of warrant activity
               
           Weighted- 
           Average 
       Weighted-   Remaining 
       Average   Contractual 
       Exercise   Life 
Warrants      Price   (Years) 
             
Outstanding at June 30, 2020   87,696,511   $0.07    5.64 
Granted   11,269,538    0.09    5.00 
Exercised   –           
Expired   –           
Outstanding at June 30, 2021   98,966,049    0.07    4.49 
Granted   12,571,785    0.09    5.00 
Exercised   (50,110,000)          
Expired   –           
Outstanding at June 30, 2022   61,427,834   $0.09    2.81 
Schedule of warrants outstanding and exercisable
                                       
    Warrants Outstanding     Warrants Exercisable  
          Weighted     Weighted           Weighted  
          Average     Average           Average  
Exercise   Number     Remaining     Exercise     Number     Exercise  
Price   of Shares     Life (Years)     Price     of Shares     Price  
                               
$0.03 - $0.05     18,626,518       2.63     $ 0.04       18,626,518     $ 0.04  
$0.08 - $0.12     42,801,316       2.89     $ 0.10       42,801,316     $ 0.10  
      61,427,834                       61,427,834          
Assumptions
       
    June 30,  
    2021  
       
Risk-free interest rate     0.66%  
Contractual terms (years)     5 years  
Expected volatility     258%  
Expected dividend yield     0%  
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes (Tables)
 12 Months Ended
Jun. 30, 2022
Income Tax Disclosure [Abstract]  
Income Tax Provision
          
   June 30,   June 30, 
   2022   2021 
Federal statutory rate   (21)%   (21)%
State income taxes, net of Federal benefit   (7)%   (7)%
Valuation allowance   28%    28% 
Income tax provision   –    – 
Schedule of Deferred Tax Assets
          
   June 30,   June 30, 
   2022   2021 
Net Operating loss carryforwards    $3,063,000   $2,758,000 
Stock compensation expense     938,000     840,000 
Total net deferred tax assets     4,001,000     3,598,000 
Less valuation discount     (4,001,000)   (3,598,000)
Net deferred tax assets  $–   $– 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Summary of Significant Accounting Policies (Details- Property and Equipment)
 12 Months Ended
Jun. 30, 2022
Leasehold Improvements [Member]  
Property, Plant and Equipment [Line Items]  
Property and equipment useful life Shorter of the life of the asset or lease term
Furniture and Fixtures [Member]  
Property, Plant and Equipment [Line Items]  
Property and equipment useful life 5-7 Years
Office Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property and equipment useful life 5 Years
Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property and equipment useful life 4 Years
Other Machinery and Equipment [Member]  
Property, Plant and Equipment [Line Items]  
Property and equipment useful life 4 Years
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Summary of Significant Accounting Policies (Details- Net Loss Per Share) - USD ($)
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Net loss $ (619,000) $ (649,000)
Weighted average common shares – basic 248,736,262 197,224,988
Dilutive effect of outstanding stock options and warrants 0 0
Weighted average shares – diluted 248,736,262 197,224,988
Net loss per common share:    
Earnings Per Share, Basic $ (0.00) $ (0.00)
Earnings Per Share, Diluted $ (0.00) $ (0.00)
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Summary of Significant Accounting Policies (Details - Antidilutive shares) - shares
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Equity Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive shares 1,250,000 11,000,000
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive shares 61,427,834 98,966,049
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Product Information [Line Items]    
Net Income (Loss) Attributable to Parent $ 619,000 $ 649,000
Net Cash Provided by (Used in) Operating Activities 484,000 250,000
Cash 441,000  
Cash Equivalents, at Carrying Value 0 0
Advertising expense 106,000 12,000
Research and development expense $ 17,000 $ 21,000
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Desmet Ballestra [Member]    
Product Information [Line Items]    
Concentration risk percentage 97.00% 96.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | E W [Member]    
Product Information [Line Items]    
Concentration risk percentage 3.00% 3.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | E W [Member]    
Product Information [Line Items]    
Concentration risk percentage 100.00% 100.00%
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Contracts with Desmet Ballestra (Details Narrative) - USD ($)
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Desmet [Member]    
Disaggregation of Revenue [Line Items]    
Contract with Customer, Liability   $ 727,000
Desmet Ballestra [Member]    
Disaggregation of Revenue [Line Items]    
Revenues $ 1,619,000 537,000
Contract with Customer, Liability 80,000  
Desmet Ballestra [Member] | Nano Reactor Sales [Member]    
Disaggregation of Revenue [Line Items]    
Revenues 592,000 346,000
Desmet Ballestra [Member] | Gross Profit Share [Member]    
Disaggregation of Revenue [Line Items]    
Revenues $ 1,027,000 $ 191,000
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investment in equity method investment (Details - Rollforward) - USD ($)
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Net Investment Income [Line Items]    
Contributions to equity method investment $ 1,223,000
Equity in earnings of equity method investment (48,000) 0
Proceeds from Equity Method Investment, Distribution (26,000) 0
Equity Method Investments [Member]    
Net Investment Income [Line Items]    
Balance at beginning of period 0  
Contributions to equity method investment 1,223,000  
Equity in earnings of equity method investment (48,000)  
Proceeds from Equity Method Investment, Distribution (26,000)  
Balance at end of period $ 1,149,000 $ 0
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investment in equity method investment (Details - Ameredev) - USD ($)
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Schedule of Equity Method Investments [Line Items]    
Cash $ 441,000  
Property and equipment 4,000 $ 182,000
Total assets 1,871,000 1,831,000
Total liabilities and equity 1,871,000 1,831,000
Operating Expenses (1,923,000) $ (1,285,000)
Ameredev [Member]    
Schedule of Equity Method Investments [Line Items]    
Revenue 165,000  
Usage fees paid to Cavitation and Delaware (41,000)  
Operating Expenses (282,000)  
Net income (158,000)  
Ameredev [Member]    
Schedule of Equity Method Investments [Line Items]    
Cash 11,000  
Property and equipment 1,223,000  
Total assets 1,234,000  
Accounts payable 43,000  
Partners equity 1,191,000  
Total liabilities and equity $ 1,234,000  
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Investment in equity method investment (Details Narrative) - USD ($)
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Revenue from Contract with Customer, Including Assessed Tax $ 1,619,000 $ 537,000
Income (Loss) from Equity Method Investments 48,000 0
Usage Fees [Member]    
Revenue from Contract with Customer, Including Assessed Tax   $ 21,000
Ameredev [Member]    
Revenue from Contract with Customer, Including Assessed Tax 46,000  
Income (Loss) from Equity Method Investments 48,000  
Ameredev [Member] | Reactor Sales [Member]    
Revenue from Contract with Customer, Including Assessed Tax 32,000  
Ameredev [Member] | Usage Fees [Member]    
Revenue from Contract with Customer, Including Assessed Tax $ 13,000  
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Operating Lease (Details - Lease Cost) - USD ($)
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Operating Lease    
Operating lease cost $ 78,000 $ 74,000
Cash paid for amounts included in the measurement of lease liabilities $ 72,000 $ 71,000
Weighted average remaining lease term - operating leases (in years) 2 years 7 months 6 days 3 years 7 months 6 days
Average discount rate - operating leases 4.00% 4.00%
Long-term right-of-use assets $ 180,000 $ 245,000
Short-term operating lease liabilities 63,000 58,000
Long-term operating lease liabilities 127,000 193,000
Total operating lease liabilities $ 190,000 $ 251,000
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Operating Lease (Details - Operating Lease Minimum payments) - USD ($)
Jun. 30, 2022
Jun. 30, 2021
Operating Lease    
2023 $ 75,000  
2024 78,000  
2025 47,000  
Total lease payments 200,000  
Less: Imputed interest/present value (10,000)  
Present value of lease liabilities $ 190,000 $ 251,000
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment (Details) - USD ($)
Jun. 30, 2022
Jun. 30, 2021
Property, Plant and Equipment [Line Items]    
Property and Equipment $ 524,000 $ 702,000
Less: Accumulated depreciation and amortization (520,000) (520,000)
Property and equipment, net 4,000 182,000
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment 2,000 2,000
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment 27,000 27,000
Office Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment 2,000 2,000
Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment 306,000 484,000
Other Machinery and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment $ 187,000 $ 187,000
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Property and Equipment (Details Narrative) - USD ($)
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 0 $ 22,000
Equipment Expense $ 178,000  
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Related Party Transactions (Details Narrative) - USD ($)
Jun. 30, 2022
Jun. 30, 2021
Related Party Transactions [Abstract]    
Employee-related Liabilities $ 280,000 $ 667,000
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Notes Payable (Details) - USD ($)
Jun. 30, 2022
Jun. 30, 2021
Debt Instrument [Line Items]    
Notes Payable $ 150,000 $ 254,000
PPP [Member]    
Debt Instrument [Line Items]    
Notes Payable 0 0
P P P 2 [Member]    
Debt Instrument [Line Items]    
Notes Payable 0 104,000
EIDL [Member]    
Debt Instrument [Line Items]    
Notes Payable $ 150,000 $ 150,000
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Notes Payable (Details Narrative) - USD ($)
 1 Months Ended 11 Months Ended 12 Months Ended
Jul. 31, 2021
May 31, 2021
Jul. 31, 2020
Apr. 16, 2020
Mar. 26, 2021
Jun. 30, 2022
Jun. 30, 2021
Debt Instrument [Line Items]              
Gain on forgiveness of note payable           $ 104,000 $ 104,000
Note payable           150,000 254,000
PPP [Member]              
Debt Instrument [Line Items]              
Proceeds from loan       $ 104,000      
Interest rate       1.00%      
Debt Instrument, Decrease, Forgiveness $ 104,000 $ 104,000          
Gain on forgiveness of note payable             104,000
Note payable           0 0
P P P 2 [Member]              
Debt Instrument [Line Items]              
Proceeds from loan         $ 104,000    
Interest rate         1.00%    
Gain on forgiveness of note payable           104,000  
Note payable           0 104,000
EIDL [Member]              
Debt Instrument [Line Items]              
Proceeds from loan     $ 150,000        
Interest rate     3.75%        
Note payable           $ 150,000 $ 150,000
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Deficit (Details - Option activity) - Equity Option [Member] - $ / shares
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Options outstanding, beginning balance 11,000,000 11,000,000  
Weighted average exercise price, options outstanding, beginning price $ 0.03 $ 0.03  
Weighted average remaining contractual life, options outstanding 5 months 4 days 6 years 25 days 6 years 25 days
Options granted 0 0  
Weighted average exercise price, options granted $ 0 $ 0  
Options forfeited 0 0  
Weighted average exercise price, options forfeited $ 0 $ 0  
Options exercised (8,500,000) 0  
Weighted average exercise price, options exercised $ 0.03 $ 0  
Options expired (1,250,000) 0  
Weighted average exercise price, options expired $ 0.03 $ 0  
Weighted-Average Remaining Contractual Life Exercised 6 years 25 days    
Weighted-Average Remaining Contractual Life Expired 8 months 1 day    
Options outstanding, ending balance 1,250,000 11,000,000 11,000,000
Weighted average exercise price, options outstanding, ending price $ 0.03 $ 0.03 $ 0.03
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Deficit (Details - Options by exercise price) - $ / shares
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2020
Equity Option [Member]      
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]      
Weighted average exercise price options outstanding $ 0.03 $ 0.03 $ 0.03
Number of shares outstanding 1,250,000 11,000,000 11,000,000
Weighted average remaining life options outstanding 5 months 4 days 6 years 25 days 6 years 25 days
Number of shares exercisable 1,250,000    
Price 1 [Member]      
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]      
Weighted average exercise price options outstanding $ 0.03    
Number of shares outstanding 1,250,000    
Weighted average remaining life options outstanding 10 months 13 days    
Number of shares exercisable 1,250,000    
Weighted average remaining life options exercisable 10 months 13 days    
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Deficit (Details - Warrant activity) - $ / shares
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Weighted average exercise price, warrants outstanding, beginning price $ 0.09    
Warrants granted   11,269,538  
Weighted average exercise price, warrants outstanding, ending price   $ 0.09  
Warrant [Member]      
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]      
Warrants outstanding, beginning balance 98,966,049 87,696,511  
Weighted average exercise price, warrants outstanding, beginning price $ 0.07 $ 0.07  
Weighted average remaining contractual life 2 years 9 months 21 days 4 years 5 months 26 days 5 years 7 months 20 days
Warrants granted 12,571,785 11,269,538  
Weighted average exercise price, warrants granted $ 0.09 $ 0.09  
Weighted average remaing contractual life, warrants granted 5 years 5 years  
Warrants exercised (50,110,000) 0  
Warrants expired 0 0  
Warrants outstanding, ending balance 61,427,834 98,966,049 87,696,511
Weighted average exercise price, warrants outstanding, ending price $ 0.09 $ 0.07 $ 0.07
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Deficit (Details - Warrants by exercise price) - $ / shares
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2020
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]      
Weighted average exercise price warrants outstanding   $ 0.09  
Warrant [Member]      
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]      
Number of warrant shares outstanding 61,427,834 98,966,049 87,696,511
Weighted average remaining life warrants outstanding 2 years 9 months 21 days 4 years 5 months 26 days 5 years 7 months 20 days
Weighted average exercise price warrants outstanding $ 0.09 $ 0.07 $ 0.07
Number of warrant shares exercisable 61,427,834    
$0.03-$0.05 [Member]      
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]      
Number of warrant shares outstanding 18,626,518    
Weighted average remaining life warrants outstanding 2 years 7 months 17 days    
Weighted average exercise price warrants outstanding $ 0.04    
Number of warrant shares exercisable 18,626,518    
Weighted average exercise price warrants exercisable $ 0.04    
$0.08-$0.12 [Member]      
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]      
Number of warrant shares outstanding 42,801,316    
Weighted average remaining life warrants outstanding 2 years 10 months 20 days    
Weighted average exercise price warrants outstanding $ 0.10    
Number of warrant shares exercisable 42,801,316    
Weighted average exercise price warrants exercisable $ 0.10    
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Deficit (Details - Assumptions) - Warrant [Member]
 12 Months Ended
Jun. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk free interest rate 0.66%
Expected term (years) 5 years
Expected volatility 258.00%
Expected dividend yield 0.00%
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders’ Deficit (Details Narrative) - USD ($)
 1 Months Ended 9 Months Ended 12 Months Ended
Jun. 16, 2022
Mar. 31, 2022
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2020
Class of Stock [Line Items]          
[custom:StockIssuedToWarrantAndOptionHoldersShares]     778,609    
[custom:StockIssuedToWarrantAndOptionHoldersValue]     $ 87,000    
Stock issued new, shares       11,269,538  
Stock Issued During Period, Value, Issued for Services     225,000    
Gain (Loss) on Extinguishment of Debt     (104,000) $ (104,000)  
Warrants granted to purchase common stock       11,269,538  
Warrant exercisable price per share       $ 0.09  
Net cash proceeds       $ 728,000  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value     25,000    
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding     $ 216,000    
Consultant [Member]          
Class of Stock [Line Items]          
Warrants issued for services shares   500,000      
Warrants issued for services value   $ 40,000      
Common Stock [Member]          
Class of Stock [Line Items]          
Stock issued new, shares     12,071,785 11,269,538  
Stock issued new, shares     4,500,000    
Stock Issued During Period, Value, Issued for Services     $ 5,000    
Former Accrued Payroll [Member]          
Class of Stock [Line Items]          
[custom:StockIssuedForLiabilitiesShares]     6,855,700    
[custom:StockIssuedForLiabilitiesValue]     $ 718,000    
Gain (Loss) on Extinguishment of Debt     $ 371,000    
Other Liabilities [Member]          
Class of Stock [Line Items]          
[custom:StockIssuedForLiabilitiesShares]     4,331,260    
[custom:StockIssuedForLiabilitiesValue]     $ 211,000    
Cashless Exercise Of Warrants [Member]          
Class of Stock [Line Items]          
Conversion of Stock, Shares Issued     34,407,709    
Conversion of Stock, Shares Converted     50,110,000    
Cashless Exercise Of Options [Member]          
Class of Stock [Line Items]          
Conversion of Stock, Shares Issued     6,267,946    
Conversion of Stock, Shares Converted     8,500,000    
Warrant [Member]          
Class of Stock [Line Items]          
Warrants granted to purchase common stock     12,571,785 11,269,538  
Warrant exercisable price per share     $ 0.09 $ 0.07 $ 0.07
Exercise price     $ 0.09    
Common Stock [Member]          
Class of Stock [Line Items]          
Stock issued new, shares     12,071,785    
Stock issued new, shares     500,000    
Stock Issued During Period, Value, Issued for Services     $ 25,000    
Common Stock [Member] | Executive Officer [Member]          
Class of Stock [Line Items]          
Shares issued for compensation, shares 4,000,000        
Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture $ 200,000        
Warrants [Member]          
Class of Stock [Line Items]          
[custom:WarrantsIssuedNewShares]     12,071,785    
Common Stock And Warrants [Member]          
Class of Stock [Line Items]          
Proceeds from Issuance or Sale of Equity     $ 785,000    
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes (Details- Tax Reconciliation)
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Income Tax Disclosure [Abstract]    
Federal statutory rate (21.00%) (21.00%)
State income taxes, net of Federal benefit (7.00%) (7.00%)
Net operating loss/carryforward 28.00% 28.00%
Income tax provision 0.00% 0.00%
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes (Details- Deferred Tax Assets and Liabilities) - USD ($)
Jun. 30, 2022
Jun. 30, 2021
Income Tax Disclosure [Abstract]    
Net Operating loss carryforwards   $ 3,063,000 $ 2,758,000
Stock compensation expense   938,000 840,000
Total net deferred tax assets   4,001,000 3,598,000
Less valuation discount   (4,001,000) (3,598,000)
Net deferred tax assets $ 0 $ 0
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Income Taxes (Details Narrative)
$ in Thousands
Jun. 30, 2022
USD ($)
Income Tax Disclosure [Abstract]  
Net operating loss $ 10,500
XML 61 cavitation_i10k-063022_htm.xml IDEA: XBRL DOCUMENT 0001376793 2021-07-01 2022-06-30 0001376793 2021-12-31 0001376793 2022-09-28 0001376793 2022-06-30 0001376793 2021-06-30 0001376793 2020-07-01 2021-06-30 0001376793 us-gaap:CommonStockMember 2020-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001376793 us-gaap:RetainedEarningsMember 2020-06-30 0001376793 2020-06-30 0001376793 us-gaap:CommonStockMember 2021-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001376793 us-gaap:RetainedEarningsMember 2021-06-30 0001376793 us-gaap:CommonStockMember 2020-07-01 2021-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2021-06-30 0001376793 us-gaap:RetainedEarningsMember 2020-07-01 2021-06-30 0001376793 us-gaap:CommonStockMember 2021-07-01 2022-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2022-06-30 0001376793 us-gaap:RetainedEarningsMember 2021-07-01 2022-06-30 0001376793 us-gaap:CommonStockMember 2022-06-30 0001376793 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001376793 us-gaap:RetainedEarningsMember 2022-06-30 0001376793 CVAT:DesmetBallestraMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2022-06-30 0001376793 CVAT:EWMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2022-06-30 0001376793 CVAT:DesmetBallestraMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2021-06-30 0001376793 CVAT:EWMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2021-06-30 0001376793 CVAT:EWMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2022-06-30 0001376793 CVAT:EWMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2021-06-30 0001376793 us-gaap:LeaseholdImprovementsMember 2021-07-01 2022-06-30 0001376793 us-gaap:FurnitureAndFixturesMember 2021-07-01 2022-06-30 0001376793 us-gaap:OfficeEquipmentMember 2021-07-01 2022-06-30 0001376793 us-gaap:EquipmentMember 2021-07-01 2022-06-30 0001376793 us-gaap:OtherMachineryAndEquipmentMember 2021-07-01 2022-06-30 0001376793 us-gaap:StockOptionMember 2021-07-01 2022-06-30 0001376793 us-gaap:StockOptionMember 2020-07-01 2021-06-30 0001376793 us-gaap:WarrantMember 2021-07-01 2022-06-30 0001376793 us-gaap:WarrantMember 2020-07-01 2021-06-30 0001376793 CVAT:DesmetBallestraMember CVAT:NanoReactorSalesMember 2021-07-01 2022-06-30 0001376793 CVAT:DesmetBallestraMember CVAT:GrossProfitShareMember 2021-07-01 2022-06-30 0001376793 CVAT:DesmetBallestraMember 2021-07-01 2022-06-30 0001376793 CVAT:DesmetBallestraMember CVAT:NanoReactorSalesMember 2020-07-01 2021-06-30 0001376793 CVAT:DesmetBallestraMember CVAT:GrossProfitShareMember 2020-07-01 2021-06-30 0001376793 CVAT:DesmetBallestraMember 2020-07-01 2021-06-30 0001376793 CVAT:DesmetBallestraMember 2022-06-30 0001376793 CVAT:DesmetMember 2021-06-30 0001376793 CVAT:AmeredevMember 2021-07-01 2022-06-30 0001376793 CVAT:AmeredevMember CVAT:ReactorSalesMember 2021-07-01 2022-06-30 0001376793 CVAT:AmeredevMember CVAT:UsageFeesMember 2021-07-01 2022-06-30 0001376793 CVAT:UsageFeesMember 2020-07-01 2021-06-30 0001376793 us-gaap:EquityMethodInvestmentsMember 2021-06-30 0001376793 us-gaap:EquityMethodInvestmentsMember 2021-07-01 2022-06-30 0001376793 us-gaap:EquityMethodInvestmentsMember 2022-06-30 0001376793 CVAT:AmeredevMember 2022-06-30 0001376793 CVAT:AmeredevMember 2021-07-01 2022-06-30 0001376793 us-gaap:LeaseholdImprovementsMember 2022-06-30 0001376793 us-gaap:LeaseholdImprovementsMember 2021-06-30 0001376793 us-gaap:FurnitureAndFixturesMember 2022-06-30 0001376793 us-gaap:FurnitureAndFixturesMember 2021-06-30 0001376793 us-gaap:OfficeEquipmentMember 2022-06-30 0001376793 us-gaap:OfficeEquipmentMember 2021-06-30 0001376793 us-gaap:EquipmentMember 2022-06-30 0001376793 us-gaap:EquipmentMember 2021-06-30 0001376793 us-gaap:OtherMachineryAndEquipmentMember 2022-06-30 0001376793 us-gaap:OtherMachineryAndEquipmentMember 2021-06-30 0001376793 CVAT:PPPMember 2022-06-30 0001376793 CVAT:PPPMember 2021-06-30 0001376793 CVAT:PPP2Member 2022-06-30 0001376793 CVAT:PPP2Member 2021-06-30 0001376793 CVAT:EIDLMember 2022-06-30 0001376793 CVAT:EIDLMember 2021-06-30 0001376793 CVAT:PPPMember 2020-04-01 2020-04-16 0001376793 CVAT:PPPMember 2021-05-01 2021-05-31 0001376793 CVAT:PPPMember 2020-07-01 2021-06-30 0001376793 CVAT:PPP2Member 2020-05-01 2021-03-26 0001376793 CVAT:PPPMember 2021-07-01 2021-07-31 0001376793 CVAT:PPP2Member 2021-07-01 2022-06-30 0001376793 CVAT:EIDLMember 2020-07-01 2020-07-31 0001376793 us-gaap:CommonStockMember 2021-07-01 2022-06-30 0001376793 CVAT:WarrantsMember 2021-07-01 2022-06-30 0001376793 CVAT:CommonStockAndWarrantsMember 2021-07-01 2022-06-30 0001376793 CVAT:CashlessExerciseOfWarrantsMember 2021-07-01 2022-06-30 0001376793 CVAT:CashlessExerciseOfOptionsMember 2021-07-01 2022-06-30 0001376793 srt:ExecutiveOfficerMember us-gaap:CommonStockMember 2022-06-01 2022-06-16 0001376793 CVAT:FormerAccruedPayrollMember 2021-07-01 2022-06-30 0001376793 us-gaap:OtherLiabilitiesMember 2021-07-01 2022-06-30 0001376793 CVAT:ConsultantMember 2021-07-01 2022-03-31 0001376793 us-gaap:WarrantMember 2021-07-01 2022-06-30 0001376793 us-gaap:StockOptionMember 2020-06-30 0001376793 us-gaap:StockOptionMember 2019-07-01 2020-06-30 0001376793 us-gaap:StockOptionMember 2020-07-01 2021-06-30 0001376793 us-gaap:StockOptionMember 2021-06-30 0001376793 us-gaap:StockOptionMember 2021-07-01 2022-06-30 0001376793 us-gaap:StockOptionMember 2022-06-30 0001376793 CVAT:Price1Member 2022-06-30 0001376793 CVAT:Price1Member 2021-07-01 2022-06-30 0001376793 us-gaap:WarrantMember 2020-06-30 0001376793 us-gaap:WarrantMember 2019-07-01 2020-06-30 0001376793 us-gaap:WarrantMember 2020-07-01 2021-06-30 0001376793 us-gaap:WarrantMember 2021-06-30 0001376793 us-gaap:WarrantMember 2022-06-30 0001376793 CVAT:WarrantPrice1Member 2022-06-30 0001376793 CVAT:WarrantPrice1Member 2021-07-01 2022-06-30 0001376793 CVAT:WarrantPrice2Member 2022-06-30 0001376793 CVAT:WarrantPrice2Member 2021-07-01 2022-06-30 iso4217:USD shares iso4217:USD shares pure 0001376793 false 2022 FY No No Yes Yes 10-K true false 2022-06-30 --06-30 000-53239 Cavitation Technologies, Inc. NV 20-4907818 10019 CANOGA AVENUE, CHATSWORTH, CA 91311 (818) 718-0905 Non-accelerated Filer true false false 23372000 276698831 Weinberg & Company, P.A. Los Angeles, California 572 441000 1363000 1000 6000 48000 25000 38000 0 528000 1394000 4000 182000 1149000 0 180000 245000 10000 10000 1871000 1831000 135000 342000 280000 667000 0 1000 80000 727000 63000 58000 558000 1795000 150000 254000 127000 193000 835000 2242000 0.001 0.001 10000000 10000000 0 0 0 0 0 0 0.001 0.001 1000000000 1000000000 276698831 276698831 208267444 208267444 277000 208000 26005000 24008000 -25246000 -24627000 1036000 -411000 1871000 1831000 1619000 537000 46000 21000 41000 20000 1624000 538000 1728000 1264000 178000 0 17000 21000 1923000 1285000 -299000 -747000 104000 104000 -371000 0 -48000 0 5000 6000 -320000 98000 -619000 -649000 -0.00 -0.00 -0.00 -0.00 248736262 248736262 197224988 197224988 196997906 197000 23291000 -23978000 -490000 11269538 11000 717000 728000 -649000 -649000 208267444 208000 24008000 -24627000 -411000 12071785 12000 773000 785000 33715228 34000 -34000 6181818 6000 -6000 40000 40000 778609 1000 86000 87000 4500000 5000 220000 225000 11183947 11000 918000 929000 -619000 -619000 276698831 277000 26005000 -25246000 1036000 -619000 -649000 0 22000 87000 0 40000 0 225000 0 104000 104000 -371000 -0 178000 0 -48000 -0 26000 0 -5000 -98000 23000 -22000 38000 -0 65000 63000 -3000 26000 -33000 -26000 -1000 0 -647000 359000 -61000 -61000 -484000 -250000 1223000 128000 -1223000 -128000 254000 785000 728000 785000 982000 -922000 604000 1363000 759000 441000 1363000 0 0 0 0 558000 0 <p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zTNrXdhULQN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1 – <span id="xdx_82D_zGn24p7Co3cg">Organization and Summary of Significant Accounting Policies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cavitation Technologies, Inc. (“the Company,” “CTi,” “we,” “us,” and “our”) is a Nevada corporation originally incorporated in January 2007 under the name Bio Energy, Inc. The Company has developed, patented, and commercialized proprietary technology used in our <i>Nano Reactor®</i> and <i>LPN™ </i>liquid processing applications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zzIwU6bLZODd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86C_zK4bpz7dBxrc">Going Concern</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in accompanying consolidated financial statements, during the year ended June 30, 2022, the Company incurred a net loss of $<span id="xdx_905_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20210701__20220630_zqXtsSCSwpOg">619,000 </span>and used cash in operating activities of $<span id="xdx_90F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20210701__20220630_zHw27IwaZGRl">484,000</span>. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that may result from an inability of the Company to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, the Company has cash in the amount of $<span id="xdx_90D_eus-gaap--Cash_c20220630_pp0p0" title="Cash">441,000</span>. The Company’s ability to continue as a going concern is dependent upon its ability to continue to implement its business plan. Currently, management’s plan is to increase revenues by continuing to license its technology globally. While the Company believes in the viability of its strategy to increase revenues, there can be no assurances to that effect.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet the Company’s needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84B_ecustom--Covid19PolicyTextBlock_zwpsxqwJeMNd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_865_zR81le3vRIc3">Covid-19</span> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2022, the COVID-19 pandemic did not have a material net impact on our operating results. The Company has not observed any impairments of its assets or a significant change in the fair value of its assets due to the COVID-19 pandemic. At this time, it is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business or results of operations, financial condition, or liquidity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, the Company has been following the recommendations of local health authorities to minimize exposure risk for its employees, including having employees work remotely and utilizing electronic submission of invoices and payments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zxbr5haobQnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_860_zGoTSdAw5ePh">Principles of Consolidation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include the accounts of Cavitation Technologies, Inc. and its wholly owned subsidiary Hydrodynamic Technology, Inc. Intercompany transactions and balances have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--UseOfEstimates_zy50HmVESbq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_866_z5npbs5G6qih">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates include estimates for reserves for inventory obsolescence, valuation of our equity method investments, assumptions used in valuing our stock options, stock warrants and common stock issued for services and valuation allowance for our deferred tax asset, among other items. Actual results could differ from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--RevenueRecognitionPolicyTextBlock_zsDl6yaSXQij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86A_zJPjRlzzqKUh">Revenue Recognition</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients. Revenue from sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer. The Company also recognizes revenue from its share of gross profit to be earned from distributors, as defined, which we treat as variable consideration and recognize using the most likely amount method. Estimates are available from our distributor which are considered in the determination of the most likely amount. However, given the lack of control over the sale to the end customer and the lack of history of prior sales, the amount of gross profit revenue recognized is limited to the actual amount of cash received under the contract which the Company has determined is not refundable and that a significant future reversal of cumulative revenue under the contract will not occur. In addition, the Company also recognizes revenues from usage fees of certain reactors. Usage fees are recognized based on actual usage by the customer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zwy3rmIKJxBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_868_zZ2b0DcdE4mj">Cash and Cash Equivalents</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents. At June 30, 2022 and 2021, the Company had <span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20220630_zzqzxKA3IcZ"><span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20210630_z6oktnZlPNZh">no</span></span> cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains its cash with one domestic financial institution. From time to time, cash balances in this domestic bank may exceed federally insured limits provided by the Federal Deposit Insurance Corporation (“FDIC”) of up to $250,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, and 2021, Company had deposits in excess of federally insured limit with one bank. The Company believes that no significant concentration of credit risk exists with respect to this cash balances because of its assessment of the creditworthiness and financial viability of this financial institution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p id="xdx_84C_eus-gaap--ReceivablesPolicyTextBlock_zFGsdzNVioK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86F_zjMBE8rYpjBf">Accounts Receivable</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable are generally recorded at the invoiced amounts net of an allowance for expected losses. The Company evaluates the collectability of our trade accounts receivable based on a number of factors. In circumstances where it becomes aware of a specific customer’s inability to meet its financial obligations to us, a specific reserve for bad debts is estimated and recorded which reduces the recognized receivable to the estimated amount that management believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on our historical losses and an overall assessment of past due trade accounts receivable outstanding. At June 30, 2022 and 2021, the Company had no reserve recorded for uncollectible accounts receivable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zbM263sEkZig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86E_zaO84cKE5wL4">Inventory</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventory is stated at the lower of cost or net realizable value. Cost is determined on a specific item basis. Inventory is composed of finished goods and represents costs incurred to manufacture the Company’s <i>Nano Reactor® </i>systems and <i>LPN</i>™.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_za2e2FVaaxkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_864_zMbzVEbOjYuf">Property and Equipment</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment is stated at cost. Depreciation is provided using the straight-line method over the estimated useful lives of the assets. Betterments, renewals, and extraordinary repairs that extend the life of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation applicable to retired assets are removed from the Company’s accounts, and the gain or loss on dispositions, if any, is recognized in the consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives. </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--PropertyAndEquipmentUsefulLife_z22NE5ERS8Ce" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details- Property and Equipment)"> <tr style="vertical-align: top"> <td style="white-space: nowrap; text-align: justify"><span id="xdx_8BA_z3c1mL66QZg5" style="display: none">Property and equipment useful life</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="white-space: nowrap; width: 30%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="width: 5%; text-align: justify"> </td> <td style="width: 65%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210701__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zqOGeGkkhV24" title="Property and equipment useful life">Shorter of the life of the asset or lease term</span></span></td></tr> <tr style="vertical-align: top"> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210701__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zhcGFH7K5M1" title="Property and equipment useful life">5-7 Years</span></span></td></tr> <tr style="vertical-align: top"> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210701__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zPC0n7YLgf8e" title="Property and equipment useful life">5 Years</span></span></td></tr> <tr style="vertical-align: top"> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab equipment</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210701__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zOJeowJWBaqa" title="Property and equipment useful life">4 Years</span></span></td></tr> <tr style="vertical-align: top"> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Skid systems </span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210701__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherMachineryAndEquipmentMember_zUBVj18josG5" title="Property and equipment useful life">4 Years</span></span></td></tr> </table> <p id="xdx_8AD_zTrnA2PzXAKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--EquityMethodInvestmentsPolicy_zUrgYeKDOxF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Equity Method Investment</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for investments in entities in which the Company has significant influence over the entity’s financial and operating policies, but does not control, using the equity method of accounting. The equity method investments are initially recorded at cost, and subsequently increased for capital contributions and allocations of net income, and decreased for capital distributions and allocations of net loss. Equity in net income (loss) from the equity method investment is allocated based on the Company’s economic interest. Equity method investments are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If it is determined that a loss in value of the equity method investment is other than temporary, an impairment loss is measured based on the excess of the carrying amount of an investment over its estimated fair value. Impairment analyses are based on current plans, intended holding periods, and available information at the time the analysis is prepared. The Company does not believe that the value of its equity method investment was impaired as of June 30, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--IncomeTaxPolicyTextBlock_zlem1rr40ure" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_867_zZEEOh55G8z5">Income Taxes</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the asset and liability method of accounting for income taxes. The Company recognizes deferred tax assets and liabilities to reflect the estimated future tax effects, calculated at anticipated future tax rates, of future deductible or taxable amounts attributable to events that have been recognized on a cumulative basis in the financial statements. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zZPefekPiHQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86C_zFuu4EqcMAW1">Leases</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for its leases in accordance with the guidance of FASB ASC 842, Leases. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments (see Note 3).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z08xqL6zYZgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_860_z9Qkyg2qiUl8">Fair Value Measurement</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to defining fair value, the standard expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which are determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 - inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 - inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 - inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, and 2021, the carrying value of certain accounts such as accounts receivable, inventory, accounts payable, accrued expenses and accrued payroll approximates their fair value due to the short-term nature of such instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p id="xdx_842_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zWGiqBeIrYx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zsqgkCsEZP5b">Share-Based Compensation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We periodically issue stock options, warrants and common stock to employees and non-employees for services and capital raising transactions. We account for share-based payments under the guidance of FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. We estimate the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. We estimate the fair value of restricted stock awards to employees and directors using the market price of our common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 718, the amount of cash or other assets transferred (or liabilities incurred) to repurchase an equity award shall be charged to equity, to the extent that the amount paid does not exceed the fair value of the equity instruments repurchased at the repurchase date. Any excess of the repurchase price over the fair value of the instruments repurchased shall be recognized as additional compensation cost.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p id="xdx_84F_eus-gaap--AdvertisingCostsPolicyTextBlock_zKcM3Wn8aHr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_860_zWzVHaV6bSJ4">Advertising Costs</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising costs, including marketing expense, incurred in the normal course of operations are expensed as incurred. Advertising expenses amounted to $<span id="xdx_90A_eus-gaap--AdvertisingExpense_c20210701__20220630_pp0p0" title="Advertising expense">106,000</span> and $<span id="xdx_904_eus-gaap--AdvertisingExpense_c20200701__20210630_pp0p0" title="Advertising expense">12,000</span> for the years ended June 30, 2022 and 2021 respectively and was reported as part of General and administrative expenses in the accompanying Consolidated Statements of Operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zGNHRfpkQbj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86F_zjJpfJL8vSo">Research and Development Costs</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses relate primarily to the development, design, testing of preproduction prototypes and models, compensation, and consulting fees, and are expensed as incurred. Total research and development costs recorded during the years ended June 30, 2022 and 2021 amounted to $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20210701__20220630_pp0p0" title="Research and development expense">17,000</span> and $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20200701__20210630_pp0p0" title="Research and development expense">21,000</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--StandardProductWarrantyPolicy_zWer3ovOxk8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_866_z5Lvl9gfWkx9">Warranty Policy</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company provides a limited warranty with every set of reactors sold, typically 2 to 5 years. The Company has not experienced significant claims under its warranty policy, and management determined no accrual for warranty reserve was necessary at June 30, 2022 and 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zdppEy3rcyri" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86D_z0sQfAdis0vf">Net (Loss) Per Share</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s computation of loss per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income per share, the treasury stock method assumes that outstanding options and warrants were exercised and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the computation of basic and diluted loss per common share. </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zCASwGjmOyTk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details- Net Loss Per Share)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B8_zUf85OCwAgnb" style="display: none"> Basic and diluted loss per common share</span></td><td> </td> <td colspan="2" id="xdx_498_20210701__20220630_z6zdNSF3NkJ1" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_494_20200701__20210630_zFyIOOrFq011" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLoss_zLwpqvdc1f8j" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(619,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(649,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i_pdd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Weighted average common shares – basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">248,736,262</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">197,224,988</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_d0_z6NBhrQ8eznf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Dilutive effect of outstanding stock options and warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Weighted average shares – diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">248,736,262</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">197,224,988</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--EarningsPerSharesBasicAndDilutedAbstract_z9tswhfWZVJe" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Net loss per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and Diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20210701__20220630_zsOFfOyhYsTb"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_c20210701__20220630_zEsRUXiSg3x7">(0.00</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20200701__20210630_zVICibBzGjN3"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_c20200701__20210630_ztr7Of5ZP9Ld">(0.00</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8AD_zsabTvINNZ4i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no adjustments to net income (loss) required for purposes of computing diluted earnings per share. At June 30, 2022 and 2021, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of its diluted earnings per share, as their effect would have been anti-dilutive. </p> <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ztRDkxlmxQ18" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details - Antidilutive shares)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B4_zOjHSC57T8rg" style="display: none">Schedule of antidilutive shares</span></td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; padding-bottom: 2.5pt">Options</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zEPU2iDHaw71" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Antidilutive shares">1,250,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Antidilutive shares">11,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Warrants</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zRFs5v4OoW95" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">61,427,834</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">98,966,049</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zcn2ChDeiKqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zGZ6P8Mm5Rx" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_866_z2AtDn9uZ9H2">Concentrations</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2022, we recorded <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DesmetBallestraMember_zt4Itg5pe3Rh" title="Concentration risk percentage">97</span>% of our revenue from Desmet Ballestra (Desmet) and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--EWMember_z5SY1HrSj8v2" title="Concentration risk percentage">3</span>% from Enviro Watertek, LLC (EW) (see Note 2).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2021, we recorded <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20200701__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DesmetBallestraMember_zeiqnWcywoff" title="Concentration risk percentage">96</span>% of our revenue from Desmet and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20200701__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--EWMember_zyE97D5YPmzg" title="Concentration risk percentage">3</span>% from EW (see Note 2).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2022 and 2021, <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--EWMember_zq0G50JEHHsd" title="Concentration risk percentage"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20200701__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--EWMember_zCtQiXGXho4l">100</span></span>% of accounts receivable were due from EW.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zkPv4NH1BVL2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_865_z2z3d2jrBqBb">Segment</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, the Company operated one reportable business segment. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zlp8FK26HIn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_867_zpL8QwEEcPhk">Recent Accounting Pronouncements</span> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the Financial Accounting Standards Board (the "FASB") issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning July 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_842_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zzIwU6bLZODd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86C_zK4bpz7dBxrc">Going Concern</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in accompanying consolidated financial statements, during the year ended June 30, 2022, the Company incurred a net loss of $<span id="xdx_905_eus-gaap--NetIncomeLoss_iN_pp0p0_di_c20210701__20220630_zqXtsSCSwpOg">619,000 </span>and used cash in operating activities of $<span id="xdx_90F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20210701__20220630_zHw27IwaZGRl">484,000</span>. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that may result from an inability of the Company to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, the Company has cash in the amount of $<span id="xdx_90D_eus-gaap--Cash_c20220630_pp0p0" title="Cash">441,000</span>. The Company’s ability to continue as a going concern is dependent upon its ability to continue to implement its business plan. Currently, management’s plan is to increase revenues by continuing to license its technology globally. While the Company believes in the viability of its strategy to increase revenues, there can be no assurances to that effect.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may also attempt to raise additional debt and/or equity financing to fund operations and to provide additional working capital. There is no assurance that such financing will be available in the future or obtained in sufficient amounts necessary to meet the Company’s needs, that the Company will be able to achieve profitable operations or that the Company will be able to meet its future contractual obligations. Should management fail to obtain such financing, the Company may curtail its operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> -619000 -484000 441000 <p id="xdx_84B_ecustom--Covid19PolicyTextBlock_zwpsxqwJeMNd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_865_zR81le3vRIc3">Covid-19</span> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2022, the COVID-19 pandemic did not have a material net impact on our operating results. The Company has not observed any impairments of its assets or a significant change in the fair value of its assets due to the COVID-19 pandemic. At this time, it is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business or results of operations, financial condition, or liquidity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, the Company has been following the recommendations of local health authorities to minimize exposure risk for its employees, including having employees work remotely and utilizing electronic submission of invoices and payments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p id="xdx_842_eus-gaap--ConsolidationPolicyTextBlock_zxbr5haobQnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_860_zGoTSdAw5ePh">Principles of Consolidation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements include the accounts of Cavitation Technologies, Inc. and its wholly owned subsidiary Hydrodynamic Technology, Inc. Intercompany transactions and balances have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--UseOfEstimates_zy50HmVESbq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_866_z5npbs5G6qih">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates include estimates for reserves for inventory obsolescence, valuation of our equity method investments, assumptions used in valuing our stock options, stock warrants and common stock issued for services and valuation allowance for our deferred tax asset, among other items. Actual results could differ from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--RevenueRecognitionPolicyTextBlock_zsDl6yaSXQij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86A_zJPjRlzzqKUh">Revenue Recognition</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the services it transfers to its clients. Revenue from sale of our Nano Reactors is recognized when products are shipped from our manufacturing facilities as this is our sole performance obligation under these contracts and we have no continuing obligation to the customer. The Company also recognizes revenue from its share of gross profit to be earned from distributors, as defined, which we treat as variable consideration and recognize using the most likely amount method. Estimates are available from our distributor which are considered in the determination of the most likely amount. However, given the lack of control over the sale to the end customer and the lack of history of prior sales, the amount of gross profit revenue recognized is limited to the actual amount of cash received under the contract which the Company has determined is not refundable and that a significant future reversal of cumulative revenue under the contract will not occur. In addition, the Company also recognizes revenues from usage fees of certain reactors. Usage fees are recognized based on actual usage by the customer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zwy3rmIKJxBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_868_zZ2b0DcdE4mj">Cash and Cash Equivalents</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers highly liquid investments with original maturities of three months or less to be cash equivalents. At June 30, 2022 and 2021, the Company had <span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20220630_zzqzxKA3IcZ"><span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20210630_z6oktnZlPNZh">no</span></span> cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains its cash with one domestic financial institution. From time to time, cash balances in this domestic bank may exceed federally insured limits provided by the Federal Deposit Insurance Corporation (“FDIC”) of up to $250,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, and 2021, Company had deposits in excess of federally insured limit with one bank. The Company believes that no significant concentration of credit risk exists with respect to this cash balances because of its assessment of the creditworthiness and financial viability of this financial institution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> 0 0 <p id="xdx_84C_eus-gaap--ReceivablesPolicyTextBlock_zFGsdzNVioK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86F_zjMBE8rYpjBf">Accounts Receivable</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable are generally recorded at the invoiced amounts net of an allowance for expected losses. The Company evaluates the collectability of our trade accounts receivable based on a number of factors. In circumstances where it becomes aware of a specific customer’s inability to meet its financial obligations to us, a specific reserve for bad debts is estimated and recorded which reduces the recognized receivable to the estimated amount that management believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on our historical losses and an overall assessment of past due trade accounts receivable outstanding. At June 30, 2022 and 2021, the Company had no reserve recorded for uncollectible accounts receivable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zbM263sEkZig" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86E_zaO84cKE5wL4">Inventory</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventory is stated at the lower of cost or net realizable value. Cost is determined on a specific item basis. Inventory is composed of finished goods and represents costs incurred to manufacture the Company’s <i>Nano Reactor® </i>systems and <i>LPN</i>™.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_za2e2FVaaxkk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_864_zMbzVEbOjYuf">Property and Equipment</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment is stated at cost. Depreciation is provided using the straight-line method over the estimated useful lives of the assets. Betterments, renewals, and extraordinary repairs that extend the life of the assets are capitalized; other repairs and maintenance charges are expensed as incurred. The cost and related accumulated depreciation applicable to retired assets are removed from the Company’s accounts, and the gain or loss on dispositions, if any, is recognized in the consolidated statements of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are recorded at cost and depreciated using the straight-line method over the following estimated useful lives. </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--PropertyAndEquipmentUsefulLife_z22NE5ERS8Ce" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details- Property and Equipment)"> <tr style="vertical-align: top"> <td style="white-space: nowrap; text-align: justify"><span id="xdx_8BA_z3c1mL66QZg5" style="display: none">Property and equipment useful life</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="white-space: nowrap; width: 30%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="width: 5%; text-align: justify"> </td> <td style="width: 65%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210701__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zqOGeGkkhV24" title="Property and equipment useful life">Shorter of the life of the asset or lease term</span></span></td></tr> <tr style="vertical-align: top"> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210701__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zhcGFH7K5M1" title="Property and equipment useful life">5-7 Years</span></span></td></tr> <tr style="vertical-align: top"> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210701__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zPC0n7YLgf8e" title="Property and equipment useful life">5 Years</span></span></td></tr> <tr style="vertical-align: top"> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab equipment</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210701__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zOJeowJWBaqa" title="Property and equipment useful life">4 Years</span></span></td></tr> <tr style="vertical-align: top"> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Skid systems </span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210701__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherMachineryAndEquipmentMember_zUBVj18josG5" title="Property and equipment useful life">4 Years</span></span></td></tr> </table> <p id="xdx_8AD_zTrnA2PzXAKa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_ecustom--PropertyAndEquipmentUsefulLife_z22NE5ERS8Ce" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details- Property and Equipment)"> <tr style="vertical-align: top"> <td style="white-space: nowrap; text-align: justify"><span id="xdx_8BA_z3c1mL66QZg5" style="display: none">Property and equipment useful life</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="white-space: nowrap; width: 30%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="width: 5%; text-align: justify"> </td> <td style="width: 65%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210701__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zqOGeGkkhV24" title="Property and equipment useful life">Shorter of the life of the asset or lease term</span></span></td></tr> <tr style="vertical-align: top"> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210701__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zhcGFH7K5M1" title="Property and equipment useful life">5-7 Years</span></span></td></tr> <tr style="vertical-align: top"> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210701__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zPC0n7YLgf8e" title="Property and equipment useful life">5 Years</span></span></td></tr> <tr style="vertical-align: top"> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab equipment</span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210701__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zOJeowJWBaqa" title="Property and equipment useful life">4 Years</span></span></td></tr> <tr style="vertical-align: top"> <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Skid systems </span></td> <td style="text-align: justify"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210701__20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherMachineryAndEquipmentMember_zUBVj18josG5" title="Property and equipment useful life">4 Years</span></span></td></tr> </table> Shorter of the life of the asset or lease term 5-7 Years 5 Years 4 Years 4 Years <p id="xdx_847_eus-gaap--EquityMethodInvestmentsPolicy_zUrgYeKDOxF2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Equity Method Investment</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for investments in entities in which the Company has significant influence over the entity’s financial and operating policies, but does not control, using the equity method of accounting. The equity method investments are initially recorded at cost, and subsequently increased for capital contributions and allocations of net income, and decreased for capital distributions and allocations of net loss. Equity in net income (loss) from the equity method investment is allocated based on the Company’s economic interest. Equity method investments are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If it is determined that a loss in value of the equity method investment is other than temporary, an impairment loss is measured based on the excess of the carrying amount of an investment over its estimated fair value. Impairment analyses are based on current plans, intended holding periods, and available information at the time the analysis is prepared. The Company does not believe that the value of its equity method investment was impaired as of June 30, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p id="xdx_844_eus-gaap--IncomeTaxPolicyTextBlock_zlem1rr40ure" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_867_zZEEOh55G8z5">Income Taxes</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the asset and liability method of accounting for income taxes. The Company recognizes deferred tax assets and liabilities to reflect the estimated future tax effects, calculated at anticipated future tax rates, of future deductible or taxable amounts attributable to events that have been recognized on a cumulative basis in the financial statements. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p id="xdx_846_eus-gaap--LesseeLeasesPolicyTextBlock_zZPefekPiHQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86C_zFuu4EqcMAW1">Leases</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for its leases in accordance with the guidance of FASB ASC 842, Leases. The Company determines whether a contract is, or contains, a lease at inception. Right-of-use assets represent the Company’s right to use an underlying asset during the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments (see Note 3).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p id="xdx_84A_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z08xqL6zYZgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_860_z9Qkyg2qiUl8">Fair Value Measurement</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 820-10 requires entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet for which it is practicable to estimate fair value. ASC 820-10 defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to defining fair value, the standard expands the disclosure requirements around fair value and establishes a fair value hierarchy for valuation inputs. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels which are determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 1 - inputs are based upon unadjusted quoted prices for identical instruments traded in active markets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 2 - inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Level 3 - inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, and 2021, the carrying value of certain accounts such as accounts receivable, inventory, accounts payable, accrued expenses and accrued payroll approximates their fair value due to the short-term nature of such instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p id="xdx_842_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zWGiqBeIrYx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86B_zsqgkCsEZP5b">Share-Based Compensation</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We periodically issue stock options, warrants and common stock to employees and non-employees for services and capital raising transactions. We account for share-based payments under the guidance of FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. We estimate the fair value of stock option and warrant awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. We estimate the fair value of restricted stock awards to employees and directors using the market price of our common stock on the date of grant, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in our Statements of Operations. Recognition of compensation expense for non-employees is in the same period and manner as if the Company had paid cash for the services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 718, the amount of cash or other assets transferred (or liabilities incurred) to repurchase an equity award shall be charged to equity, to the extent that the amount paid does not exceed the fair value of the equity instruments repurchased at the repurchase date. Any excess of the repurchase price over the fair value of the instruments repurchased shall be recognized as additional compensation cost.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p id="xdx_84F_eus-gaap--AdvertisingCostsPolicyTextBlock_zKcM3Wn8aHr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_860_zWzVHaV6bSJ4">Advertising Costs</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Advertising costs, including marketing expense, incurred in the normal course of operations are expensed as incurred. Advertising expenses amounted to $<span id="xdx_90A_eus-gaap--AdvertisingExpense_c20210701__20220630_pp0p0" title="Advertising expense">106,000</span> and $<span id="xdx_904_eus-gaap--AdvertisingExpense_c20200701__20210630_pp0p0" title="Advertising expense">12,000</span> for the years ended June 30, 2022 and 2021 respectively and was reported as part of General and administrative expenses in the accompanying Consolidated Statements of Operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 106000 12000 <p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zGNHRfpkQbj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86F_zjJpfJL8vSo">Research and Development Costs</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses relate primarily to the development, design, testing of preproduction prototypes and models, compensation, and consulting fees, and are expensed as incurred. Total research and development costs recorded during the years ended June 30, 2022 and 2021 amounted to $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_c20210701__20220630_pp0p0" title="Research and development expense">17,000</span> and $<span id="xdx_909_eus-gaap--ResearchAndDevelopmentExpense_c20200701__20210630_pp0p0" title="Research and development expense">21,000</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 17000 21000 <p id="xdx_844_eus-gaap--StandardProductWarrantyPolicy_zWer3ovOxk8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_866_z5Lvl9gfWkx9">Warranty Policy</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company provides a limited warranty with every set of reactors sold, typically 2 to 5 years. The Company has not experienced significant claims under its warranty policy, and management determined no accrual for warranty reserve was necessary at June 30, 2022 and 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zdppEy3rcyri" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86D_z0sQfAdis0vf">Net (Loss) Per Share</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s computation of loss per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income available to common stockholders divided by the weighted average common shares outstanding for the period. Diluted income per share reflects the potential dilution, using the treasury stock method, that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company as if they had been converted at the beginning of the periods presented, or issuance date, if later. In computing diluted income per share, the treasury stock method assumes that outstanding options and warrants were exercised and the proceeds are used to purchase common stock at the average market price during the period. Options and warrants may have a dilutive effect under the treasury stock method only when the average market price of the common stock during the period exceeds the exercise price of the options and warrants. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the computation of basic and diluted loss per common share. </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zCASwGjmOyTk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details- Net Loss Per Share)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B8_zUf85OCwAgnb" style="display: none"> Basic and diluted loss per common share</span></td><td> </td> <td colspan="2" id="xdx_498_20210701__20220630_z6zdNSF3NkJ1" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_494_20200701__20210630_zFyIOOrFq011" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLoss_zLwpqvdc1f8j" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(619,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(649,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i_pdd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Weighted average common shares – basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">248,736,262</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">197,224,988</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_d0_z6NBhrQ8eznf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Dilutive effect of outstanding stock options and warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Weighted average shares – diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">248,736,262</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">197,224,988</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--EarningsPerSharesBasicAndDilutedAbstract_z9tswhfWZVJe" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Net loss per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and Diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20210701__20220630_zsOFfOyhYsTb"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_c20210701__20220630_zEsRUXiSg3x7">(0.00</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20200701__20210630_zVICibBzGjN3"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_c20200701__20210630_ztr7Of5ZP9Ld">(0.00</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8AD_zsabTvINNZ4i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no adjustments to net income (loss) required for purposes of computing diluted earnings per share. At June 30, 2022 and 2021, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of its diluted earnings per share, as their effect would have been anti-dilutive. </p> <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ztRDkxlmxQ18" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details - Antidilutive shares)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B4_zOjHSC57T8rg" style="display: none">Schedule of antidilutive shares</span></td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; padding-bottom: 2.5pt">Options</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zEPU2iDHaw71" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Antidilutive shares">1,250,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Antidilutive shares">11,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Warrants</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zRFs5v4OoW95" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">61,427,834</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">98,966,049</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zcn2ChDeiKqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zCASwGjmOyTk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details- Net Loss Per Share)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B8_zUf85OCwAgnb" style="display: none"> Basic and diluted loss per common share</span></td><td> </td> <td colspan="2" id="xdx_498_20210701__20220630_z6zdNSF3NkJ1" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_494_20200701__20210630_zFyIOOrFq011" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLoss_zLwpqvdc1f8j" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(619,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">(649,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i_pdd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Weighted average common shares – basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">248,736,262</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">197,224,988</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_d0_z6NBhrQ8eznf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Dilutive effect of outstanding stock options and warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Weighted average shares – diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">248,736,262</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">197,224,988</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--EarningsPerSharesBasicAndDilutedAbstract_z9tswhfWZVJe" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Net loss per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and Diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_eus-gaap--EarningsPerShareBasic_c20210701__20220630_zsOFfOyhYsTb"><span id="xdx_901_eus-gaap--EarningsPerShareDiluted_c20210701__20220630_zEsRUXiSg3x7">(0.00</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20200701__20210630_zVICibBzGjN3"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_c20200701__20210630_ztr7Of5ZP9Ld">(0.00</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> -619000 -649000 248736262 197224988 0 0 248736262 197224988 -0.00 -0.00 -0.00 -0.00 <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ztRDkxlmxQ18" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization and Summary of Significant Accounting Policies (Details - Antidilutive shares)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B4_zOjHSC57T8rg" style="display: none">Schedule of antidilutive shares</span></td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; padding-bottom: 2.5pt">Options</td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zEPU2iDHaw71" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Antidilutive shares">1,250,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: Black 2.5pt double; width: 14%; text-align: right" title="Antidilutive shares">11,000,000</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Warrants</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zRFs5v4OoW95" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">61,427,834</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200701__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">98,966,049</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1250000 11000000 61427834 98966049 <p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zGZ6P8Mm5Rx" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_866_z2AtDn9uZ9H2">Concentrations</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2022, we recorded <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DesmetBallestraMember_zt4Itg5pe3Rh" title="Concentration risk percentage">97</span>% of our revenue from Desmet Ballestra (Desmet) and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--EWMember_z5SY1HrSj8v2" title="Concentration risk percentage">3</span>% from Enviro Watertek, LLC (EW) (see Note 2).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2021, we recorded <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_c20200701__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DesmetBallestraMember_zeiqnWcywoff" title="Concentration risk percentage">96</span>% of our revenue from Desmet and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_c20200701__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--EWMember_zyE97D5YPmzg" title="Concentration risk percentage">3</span>% from EW (see Note 2).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2022 and 2021, <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20210701__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--EWMember_zq0G50JEHHsd" title="Concentration risk percentage"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_c20200701__20210630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--EWMember_zCtQiXGXho4l">100</span></span>% of accounts receivable were due from EW.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 0.97 0.03 0.96 0.03 1 1 <p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zkPv4NH1BVL2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_865_z2z3d2jrBqBb">Segment</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, the Company operated one reportable business segment. In accordance with the “Segment Reporting” Topic of the ASC, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_843_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zlp8FK26HIn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_867_zpL8QwEEcPhk">Recent Accounting Pronouncements</span> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the Financial Accounting Standards Board (the "FASB") issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is effective for the Company beginning July 1, 2023, and early adoption is permitted. The Company does not believe the potential impact of the new guidance and related codification improvements will be material to its financial position, results of operations and cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p id="xdx_802_eus-gaap--RevenueFromContractWithCustomerTextBlock_zicl9Yg61n0j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 2 – <span id="xdx_82C_zq1vtnJ98GNk">Contracts with Desmet Ballestra</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has the following agreements with Desmet Ballestra (Desmet), a company located in Europe:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"/><td style="width: 0.25in">a.</td><td style="text-align: justify">October 2021 Agreement – In October 2021, the Company executed a three-year agreement with Desmet that is a continuation of the October 2018 agreement (See B below). In accordance with ASC 606, the Company recognizes revenue from the sale of reactors at the time of shipment of the Nano reactor hardware as shipment is deemed to be the Company’s only performance obligation and the Company had no more continuing obligation other than the reactor’s two-year standard warranty. Desmet pays for such reactors on credit terms and the amount of a sale is recorded as a receivable upon acceptance by Desmet. In addition, Desmet agreed to provide the Company monthly advances of $40,000 through October 1, 2024 to be applied against future sales of reactors.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.25in"/><td style="width: 0.25in">b.</td><td style="text-align: justify">October 2018 Agreement (expired in October 2021, see “A” above) - In October 2018, the Company signed a three-year global Research and Development (R&amp;D), Marketing and Technology License Agreement with Desmet for the sale and licensing of the Company’s reactors. This agreement was a continuation of an original agreement the Company signed with Desmet in fiscal 2012 and amended in fiscal 2016.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As part of the October 2018 agreement, Desmet provided the Company monthly advances of $50,000 through October 1, 2021, to be applied against the Company’s gross profit share from future sales. In accordance with ASC 606, the Company determined that the gross profit to be earned from Desmet was a variable consideration and evaluated the amount of the potential payments and the likelihood that the payments would be received using the most likely amount approach (subject to the variable consideration constraint). Estimates were available from our distributor which were considered in the determination of the most likely amount. However, given the lack of control over the sale to the end customer and the lack of history of prior sales, the Company considered these as variable revenue constraints, and as such, the amount of gross profit share revenue recognized was limited to the actual amount of cash received under the contract which the Company had determined was not refundable and probable that a significant revenue reversal would not occur. Further, the Company had not been able to develop an expectation of the actual collection based on its historical experience. The Company also had no control with regards to the sale and installation of Nano Reactor® and CTi Nano Neutralization® System, between Desmet and the end customer. Under the October 2021 agreement (See “A” above), the Company is no longer entitled to revenue from a share of gross profit to be earned from distributors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2022, the Company recorded sales of $<span id="xdx_908_eus-gaap--Revenues_pp0p0_c20210701__20220630__srt--MajorCustomersAxis__custom--DesmetBallestraMember__srt--ProductOrServiceAxis__custom--NanoReactorSalesMember_zcHSpgKq3aa4" title="Revenues">592,000</span> from <i>Nano Reactor®</i> sales from Desmet, and $<span id="xdx_90E_eus-gaap--Revenues_c20210701__20220630__srt--MajorCustomersAxis__custom--DesmetBallestraMember__srt--ProductOrServiceAxis__custom--GrossProfitShareMember_pp0p0" title="Revenues">1,027,000</span> from gross profit share for a total revenue of $<span id="xdx_90F_eus-gaap--Revenues_c20210701__20220630__srt--MajorCustomersAxis__custom--DesmetBallestraMember_pp0p0" title="Revenues">1,619,000</span> from Desmet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2021, the Company recorded sales of $<span id="xdx_90E_eus-gaap--Revenues_pp0p0_c20200701__20210630__srt--MajorCustomersAxis__custom--DesmetBallestraMember__srt--ProductOrServiceAxis__custom--NanoReactorSalesMember_zJsyeUzz1Jg8" title="Revenues">346,000</span> from <i>Nano Reactor®</i> sales and $<span id="xdx_90C_eus-gaap--Revenues_c20200701__20210630__srt--MajorCustomersAxis__custom--DesmetBallestraMember__srt--ProductOrServiceAxis__custom--GrossProfitShareMember_pp0p0" title="Revenues">191,000</span> from gross profit share for a total revenue of $<span id="xdx_901_eus-gaap--Revenues_c20200701__20210630__srt--MajorCustomersAxis__custom--DesmetBallestraMember_pp0p0" title="Revenues">537,000</span> from Desmet.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, advances received from Desmet related to future sales of reactors amounted to $<span id="xdx_907_eus-gaap--ContractWithCustomerLiability_iI_pp0p0_c20220630__srt--MajorCustomersAxis__custom--DesmetBallestraMember_zTHC6CKQUvNl">80,000</span>. At June 30, 2022, there were no advances received from Desmet related to the Company’s future gross profit share. At June 30, 2021, advances received from Desmet related to the Company’s future gross profit share amounted to $<span id="xdx_907_eus-gaap--ContractWithCustomerLiability_iI_c20210630__srt--CounterpartyNameAxis__custom--DesmetMember_z5nTQHPSq7We">727,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 592000 1027000 1619000 346000 191000 537000 80000 727000 <p id="xdx_808_eus-gaap--EquityMethodInvestmentsDisclosureTextBlock_zhhAHcwbgvVg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 3 - <span id="xdx_825_z5zeMt1CN9Ah">Investment in equity method investment</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2019, the Company and Delaware Water Company, LLC (Delaware) formed a limited liability company called Enviro WaterTek LLC (“Enviro”). Enviro is owned 50% by the Company and 50% by Delaware, and the Company accounts for its investment in Enviro under the equity method. From 2019 to 2021, Enviro had no operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2021, the Company and Delaware entered into a separate agreement under Enviro for a specific project (referred to as “Ameredev”). Delaware has certain contracts in place to provide recycled water to operators of certain active oil and gas wells. Under the agreement, the Company contributed $1.2 million that was used by Ameredev to increase the capacity of certain pipelines and water treatment facilities operated by Delaware. Pursuant to the agreement, for each barrel of recycled water that Ameredev sells, Delaware will receive $0.10 per barrel, and the Company will receive $0.05 per barrel (referred to as usage fees), with the balance of net income (loss) from Ameredev being allocated 70% to Delaware and 30% to the Company. The Ameredev agreement will terminate the earlier of three years (unless extended by unanimous agreement of the Board and Members of Ameredev) from the date of the agreement or by unanimous agreement of the Board and Members of Ameredev.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2022, the Company recorded total revenues from Ameredev of $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210701__20220630__srt--MajorCustomersAxis__custom--AmeredevMember_pp0p0">46,000</span>, made up of $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210701__20220630__srt--MajorCustomersAxis__custom--AmeredevMember__srt--ProductOrServiceAxis__custom--ReactorSalesMember_pp0p0">32,000 from the sale of reactors, and $</span><span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210701__20220630__srt--MajorCustomersAxis__custom--AmeredevMember__srt--ProductOrServiceAxis__custom--UsageFeesMember_pp0p0">13,000</span> from usage fees. During the year ended June 30, 2022, the Company recognized a loss of $<span id="xdx_903_eus-gaap--IncomeLossFromEquityMethodInvestments_iN_pp0p0_di_c20210701__20220630__srt--MajorCustomersAxis__custom--AmeredevMember_zQ4az0wDmhJ8">48,000</span> related to the equity method investment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2021, the Company recorded revenues of $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20200701__20210630__srt--ProductOrServiceAxis__custom--UsageFeesMember_zqwFNVPmCEWf">21,000 </span>from the usage fee. During the year ended June 30, 2021, there was no income or loss recognized for the equity method investment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the activity of the Company’s equity method investment:<span style="font-family: Times New Roman, Times, Serif">  </span></p> <table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--EquityMethodInvestmentsRollforwardTextBlock_zicolXhjuJOe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Investment in equity method investment (Details - Rollforward)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8BF_zkWfnDdQMR25" style="display: none">Schedule of equity method investment</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20210701__20220630_zxEHoUUBIril" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold">Balance at beginning of period</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--EquityMethodInvestments_iS_d0_c20210701__20220630__us-gaap--InvestmentTypeAxis__us-gaap--EquityMethodInvestmentsMember_zEZKt6OBPsyi" style="text-align: right" title="Balance at beginning of period">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 83%; text-align: left">Contributions to equity method investment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--PaymentsToAcquireEquityMethodInvestments_c20210701__20220630__us-gaap--InvestmentTypeAxis__us-gaap--EquityMethodInvestmentsMember_zOp2GAth6E97" style="width: 14%; text-align: right" title="Contributions to equity method investment">1,223,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loss from equity method investment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--IncomeLossFromEquityMethodInvestments_c20210701__20220630__us-gaap--InvestmentTypeAxis__us-gaap--EquityMethodInvestmentsMember_zAQSw4Bobmjd" style="text-align: right" title="Equity in earnings of equity method investment">(48,000</td><td style="text-align: left">) </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Distribution from equity method investment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--EquityMethodInvestmentDividendsOrDistributions_iN_di_c20210701__20220630__us-gaap--InvestmentTypeAxis__us-gaap--EquityMethodInvestmentsMember_zWDiN70ojaK8" style="border-bottom: Black 1pt solid; text-align: right">(26,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--EquityMethodInvestments_iE_c20210701__20220630__us-gaap--InvestmentTypeAxis__us-gaap--EquityMethodInvestmentsMember_zxSZBPXSUBC6" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of period">1,149,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_z07bTisEKlR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summarized balance sheet as of June 30, 2022, for Ameredev, and a summarized statement of operations for the year ended June 30, 2022, for Ameredev is presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Balance Sheet: </span></p> <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--EquityMethodInvestmentsTextBlock_zL5I7NAPyS7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Investment in equity method investment (Details - Ameredev)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B9_zeR7oaRPRi3" style="display: none">Statement of operations for Ameredev</span></td><td> </td> <td colspan="2" id="xdx_49E_20220630__us-gaap--EquityMethodInvestmentNonconsolidatedInvesteeAxis__custom--AmeredevMember_zFsTrLBQEw8h" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_eus-gaap--Cash_iI_z94yBWBRBN5j" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify">Cash</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="width: 83%; text-align: justify; padding-bottom: 1pt">Property and equipment</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">1,223,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--Assets_iI_pp0p0_zkH6YR9bICLa" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,234,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccountsPayableCurrent_iI_zk5xhINlnM6g" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify">Accounts payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">43,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PartnersCapital_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Partners equity</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,191,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquity_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total liabilities and equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,234,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Income Statement</span>: </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%; text-align: justify">Revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--RevenueFromJointVenture_pp0p0_c20210701__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AmeredevMember_zroKwCAOMGJ7" style="width: 14%; text-align: right" title="Revenue">165,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Usage fees paid to Cavitation and Delaware</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--UsageFees_iN_pp0p0_di_c20210701__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AmeredevMember_zEDvxLSN6Zt5" style="text-align: right" title="Usage fees paid to Cavitation and Delaware">(41,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 1pt">Operating expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingExpenses_iN_pp0p0_di_c20210701__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AmeredevMember_z1Qsd7PLT4Vi" style="border-bottom: Black 1pt solid; text-align: right">(282,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--IncomeLossFromJointVenture_pp0p0_c20210701__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AmeredevMember_ziCoeQEVmam5" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income">(158,000</td><td style="padding-bottom: 2.5pt; text-align: left">) </td></tr> </table> <p id="xdx_8A4_zD5m5m9Qybq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 46000 32000 13000 -48000 21000 <table cellpadding="0" cellspacing="0" id="xdx_895_ecustom--EquityMethodInvestmentsRollforwardTextBlock_zicolXhjuJOe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Investment in equity method investment (Details - Rollforward)"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span id="xdx_8BF_zkWfnDdQMR25" style="display: none">Schedule of equity method investment</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_491_20210701__20220630_zxEHoUUBIril" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold">Balance at beginning of period</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--EquityMethodInvestments_iS_d0_c20210701__20220630__us-gaap--InvestmentTypeAxis__us-gaap--EquityMethodInvestmentsMember_zEZKt6OBPsyi" style="text-align: right" title="Balance at beginning of period">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 83%; text-align: left">Contributions to equity method investment</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--PaymentsToAcquireEquityMethodInvestments_c20210701__20220630__us-gaap--InvestmentTypeAxis__us-gaap--EquityMethodInvestmentsMember_zOp2GAth6E97" style="width: 14%; text-align: right" title="Contributions to equity method investment">1,223,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loss from equity method investment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--IncomeLossFromEquityMethodInvestments_c20210701__20220630__us-gaap--InvestmentTypeAxis__us-gaap--EquityMethodInvestmentsMember_zAQSw4Bobmjd" style="text-align: right" title="Equity in earnings of equity method investment">(48,000</td><td style="text-align: left">) </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Distribution from equity method investment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--EquityMethodInvestmentDividendsOrDistributions_iN_di_c20210701__20220630__us-gaap--InvestmentTypeAxis__us-gaap--EquityMethodInvestmentsMember_zWDiN70ojaK8" style="border-bottom: Black 1pt solid; text-align: right">(26,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance at end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--EquityMethodInvestments_iE_c20210701__20220630__us-gaap--InvestmentTypeAxis__us-gaap--EquityMethodInvestmentsMember_zxSZBPXSUBC6" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance at end of period">1,149,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0 1223000 -48000 26000 1149000 <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--EquityMethodInvestmentsTextBlock_zL5I7NAPyS7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Investment in equity method investment (Details - Ameredev)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B9_zeR7oaRPRi3" style="display: none">Statement of operations for Ameredev</span></td><td> </td> <td colspan="2" id="xdx_49E_20220630__us-gaap--EquityMethodInvestmentNonconsolidatedInvesteeAxis__custom--AmeredevMember_zFsTrLBQEw8h" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_eus-gaap--Cash_iI_z94yBWBRBN5j" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify">Cash</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="width: 83%; text-align: justify; padding-bottom: 1pt">Property and equipment</td><td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">1,223,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--Assets_iI_pp0p0_zkH6YR9bICLa" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,234,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--AccountsPayableCurrent_iI_zk5xhINlnM6g" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify">Accounts payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">43,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PartnersCapital_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Partners equity</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,191,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquity_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 2.5pt">Total liabilities and equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,234,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Income Statement</span>: </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%; text-align: justify">Revenue</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--RevenueFromJointVenture_pp0p0_c20210701__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AmeredevMember_zroKwCAOMGJ7" style="width: 14%; text-align: right" title="Revenue">165,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Usage fees paid to Cavitation and Delaware</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--UsageFees_iN_pp0p0_di_c20210701__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AmeredevMember_zEDvxLSN6Zt5" style="text-align: right" title="Usage fees paid to Cavitation and Delaware">(41,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 1pt">Operating expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--OperatingExpenses_iN_pp0p0_di_c20210701__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AmeredevMember_z1Qsd7PLT4Vi" style="border-bottom: Black 1pt solid; text-align: right">(282,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--IncomeLossFromJointVenture_pp0p0_c20210701__20220630__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--AmeredevMember_ziCoeQEVmam5" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income">(158,000</td><td style="padding-bottom: 2.5pt; text-align: left">) </td></tr> </table> 11000 1223000 1234000 43000 1191000 1234000 165000 41000 282000 -158000 <p id="xdx_80B_eus-gaap--LesseeOperatingLeasesTextBlock_zhatiO3BJ5A6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 4 – <span id="xdx_82F_ztMURvFxeXk6">Operating Lease</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company leases certain warehouse and corporate office space under an operating lease agreement. We determine if an arrangement is a lease at inception. Lease assets are presented as operating lease right-of-use assets and the related liabilities are presented as lease liabilities in our consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating lease right-of-use (“ROU”) assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in lease arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The Company’s incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The components of lease expense and supplemental cash flow information related to leases for the period are as follows: </p> <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--LeaseCostTableTextBlock_z3FQNBqlqQq8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Lease (Details - Lease Cost)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span id="xdx_8BE_zLbMeflO5nsc" style="display: none">Lease cost table</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Lease costs:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt; width: 66%; text-align: left">Operating lease (included in general and administrative in the Company’s consolidated statement of operations)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseCost_c20210701__20220630_pp0p0" style="width: 14%; text-align: right" title="Operating lease cost">78,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseCost_c20200701__20210630_pp0p0" style="width: 14%; text-align: right" title="Operating lease cost">74,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLeasePaymentsUse_c20210701__20220630_pp0p0" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities">72,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeasePaymentsUse_c20200701__20210630_pp0p0" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities">71,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Weighted average remaining lease term – operating leases (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630_z4NLKx3FVNk6" title="Weighted average remaining lease term - operating leases (in years)">2.6</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20210630_zu8AtIBycK2a" title="Weighted average remaining lease term - operating leases (in years)">3.6</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Average discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220630_zM1vLH5W49Xc" title="Average discount rate - operating leases">4</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20210630_zKfmWEpZ0xeb" title="Average discount rate - operating leases">4</span>%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; text-indent: -10pt; padding-left: 10pt; text-align: left">The supplemental balance sheet information related to leases for the period is as follows:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Long-term right-of-use assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAsset_c20220630_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Long-term right-of-use assets">180,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_c20210630_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Long-term right-of-use assets">245,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Short-term operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLeaseLiabilityCurrent_c20220630_pp0p0" style="text-align: right" title="Short-term operating lease liabilities">63,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityCurrent_c20210630_pp0p0" style="text-align: right" title="Short-term operating lease liabilities">58,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Long-term operating lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20220630_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Long-term operating lease liabilities">127,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20210630_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Long-term operating lease liabilities">193,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseLiability_c20220630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total operating lease liabilities">190,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeaseLiability_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total operating lease liabilities">251,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zdohtbWWR1u1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Supplemental cash flow information related to the lease liabilities are as follows: </p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zE0LgmpxHs55" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Lease (Details - Operating Lease Minimum payments)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B9_z4LUtxCx0oj4" style="display: none">Schedule of lease liability maturities</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20220630_zr1eKVmM1Z2" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Operating</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: left">Year Ending June 30:</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Lease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzqdD_zzCArCgQhI7f" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%; text-align: left">2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">75,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzqdD_zNsP7f43coAb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzqdD_z4HHBkFHDlhc" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">47,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzqdD_zGkFgufKEkt7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zeTR6L9FaByf" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Less: Imputed interest/present value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zW5ojWzJs5w7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">190,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_z7y1gAvOEO3a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--LeaseCostTableTextBlock_z3FQNBqlqQq8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Lease (Details - Lease Cost)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span id="xdx_8BE_zLbMeflO5nsc" style="display: none">Lease cost table</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Lease costs:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt; width: 66%; text-align: left">Operating lease (included in general and administrative in the Company’s consolidated statement of operations)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--OperatingLeaseCost_c20210701__20220630_pp0p0" style="width: 14%; text-align: right" title="Operating lease cost">78,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseCost_c20200701__20210630_pp0p0" style="width: 14%; text-align: right" title="Operating lease cost">74,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLeasePaymentsUse_c20210701__20220630_pp0p0" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities">72,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeasePaymentsUse_c20200701__20210630_pp0p0" style="text-align: right" title="Cash paid for amounts included in the measurement of lease liabilities">71,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Weighted average remaining lease term – operating leases (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20220630_z4NLKx3FVNk6" title="Weighted average remaining lease term - operating leases (in years)">2.6</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20210630_zu8AtIBycK2a" title="Weighted average remaining lease term - operating leases (in years)">3.6</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Average discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20220630_zM1vLH5W49Xc" title="Average discount rate - operating leases">4</span>%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20210630_zKfmWEpZ0xeb" title="Average discount rate - operating leases">4</span>%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; text-indent: -10pt; padding-left: 10pt; text-align: left">The supplemental balance sheet information related to leases for the period is as follows:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Long-term right-of-use assets</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--OperatingLeaseRightOfUseAsset_c20220630_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Long-term right-of-use assets">180,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_c20210630_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Long-term right-of-use assets">245,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Short-term operating lease liabilities</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--OperatingLeaseLiabilityCurrent_c20220630_pp0p0" style="text-align: right" title="Short-term operating lease liabilities">63,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityCurrent_c20210630_pp0p0" style="text-align: right" title="Short-term operating lease liabilities">58,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Long-term operating lease liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20220630_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Long-term operating lease liabilities">127,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20210630_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Long-term operating lease liabilities">193,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--OperatingLeaseLiability_c20220630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total operating lease liabilities">190,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeaseLiability_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total operating lease liabilities">251,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 78000 74000 72000 71000 P2Y7M6D P3Y7M6D 0.04 0.04 180000 245000 63000 58000 127000 193000 190000 251000 <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zE0LgmpxHs55" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Operating Lease (Details - Operating Lease Minimum payments)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B9_z4LUtxCx0oj4" style="display: none">Schedule of lease liability maturities</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20220630_zr1eKVmM1Z2" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Operating</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: left">Year Ending June 30:</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Lease</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzqdD_zzCArCgQhI7f" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%; text-align: left">2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">75,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzqdD_zNsP7f43coAb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzqdD_z4HHBkFHDlhc" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">2025</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">47,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzqdD_zGkFgufKEkt7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zeTR6L9FaByf" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Less: Imputed interest/present value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zW5ojWzJs5w7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">190,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 75000 78000 47000 200000 10000 190000 <p id="xdx_80A_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zft4B9ygKRP" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 5 - <span id="xdx_823_zTDr9nB40lS4">Property and Equipment</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment consist of the following as of June 30, 2022 and 2021: </p> <table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--PropertyPlantAndEquipmentTextBlock_z4G3b0u1msah" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8B2_zHI0GN2ZR117" style="display: none">Schedule Property and Equipment</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Leasehold improvement</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_c20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="width: 14%; text-align: right" title="Property and Equipment">2,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="width: 14%; text-align: right" title="Property and Equipment">2,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Furniture</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="text-align: right" title="Property and Equipment">27,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="text-align: right" title="Property and Equipment">27,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Office equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_c20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_pp0p0" style="text-align: right" title="Property and Equipment">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_pp0p0" style="text-align: right" title="Property and Equipment">2,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_c20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_pp0p0" style="text-align: right" title="Property and Equipment">306,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_pp0p0" style="text-align: right" title="Property and Equipment">484,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Systems</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_c20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherMachineryAndEquipmentMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Property and Equipment">187,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherMachineryAndEquipmentMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Property and Equipment">187,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_c20220630_pp0p0" style="text-align: right" title="Property and Equipment">524,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_c20210630_pp0p0" style="text-align: right" title="Property and Equipment">702,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220630_zWEclLc7Tv42" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization">(520,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20210630_zyyLg1wGxqV7" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization">(520,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_c20220630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">4,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">182,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense for the years ended June 30, 2022 and 2021 amounted to $<span id="xdx_906_eus-gaap--Depreciation_c20210701__20220630_pp0p0" title="Depreciation expense">0</span> and $<span id="xdx_908_eus-gaap--Depreciation_c20200701__20210630_pp0p0" title="Depreciation expense">22,000</span>, respectively and was recorded as part of General and Administrative expenses in the accompanying Consolidated Statements of Operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2022, the Company determined to cease further development and construction of certain testing equipment and a result, the Company write-down certain capitalized equipment costs of $<span id="xdx_908_eus-gaap--EquipmentExpense_c20210701__20220630_z5LqVMkKu8L2">178,000</span> that we considered abandoned. For the year ended June 30, 2021, the Company did not recognize any impairment for its property and equipment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--PropertyPlantAndEquipmentTextBlock_z4G3b0u1msah" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8B2_zHI0GN2ZR117" style="display: none">Schedule Property and Equipment</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Leasehold improvement</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_c20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="width: 14%; text-align: right" title="Property and Equipment">2,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="width: 14%; text-align: right" title="Property and Equipment">2,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Furniture</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="text-align: right" title="Property and Equipment">27,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_pp0p0" style="text-align: right" title="Property and Equipment">27,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Office equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_c20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_pp0p0" style="text-align: right" title="Property and Equipment">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_pp0p0" style="text-align: right" title="Property and Equipment">2,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_c20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_pp0p0" style="text-align: right" title="Property and Equipment">306,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_pp0p0" style="text-align: right" title="Property and Equipment">484,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt">Systems</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_c20220630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherMachineryAndEquipmentMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Property and Equipment">187,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_c20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OtherMachineryAndEquipmentMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Property and Equipment">187,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentGross_c20220630_pp0p0" style="text-align: right" title="Property and Equipment">524,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_c20210630_pp0p0" style="text-align: right" title="Property and Equipment">702,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation and amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20220630_zWEclLc7Tv42" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization">(520,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20210630_zyyLg1wGxqV7" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization">(520,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_c20220630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">4,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentNet_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">182,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2000 2000 27000 27000 2000 2000 306000 484000 187000 187000 524000 702000 520000 520000 4000 182000 0 22000 178000 <p id="xdx_803_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zE86YAmphPO9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 6 – <span id="xdx_822_zYUOnFFAsdCa">Related Party Transactions</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2021, accrued salaries and estimated payroll taxes due to current and former officers of the Company totaled $<span id="xdx_902_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_c20210630_zYuuBrgsFCD1">667,000</span>. During the year ended June 30, 2022, the Company paid $27,000 of accrued payroll expenses, reduced estimated payroll taxes by $44,000, and transferred $316,000 to an unrelated party, which was subsequently settled through the issuance of 6,855,700 shares of common stock (see Note 8). As of June 30, 2022, outstanding balance of accrued payroll and payroll taxes-related parties totaled $<span id="xdx_903_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_c20220630_zBPKLxbUYPbl">280,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> 667000 280000 <p id="xdx_808_eus-gaap--DebtDisclosureTextBlock_zJRuCrmnwkpd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 7 – <span id="xdx_825_zhYRs7Y1ASCj">Notes Payable </span></b></p> <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfDebtTableTextBlock_zRKPG8auV1Fi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B8_zYlKmh7HNhGf" style="display: none">Schedule of notes payable</span></td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">A.      Note Payable - PPP#1</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--LongTermNotesPayable_iI_pp0p0_d0_c20220630__us-gaap--LongtermDebtTypeAxis__custom--PPPMember_zG6fH9Fxbbkf" style="text-align: right" title="Notes Payable">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--LongTermNotesPayable_iI_pp0p0_d0_c20210630__us-gaap--LongtermDebtTypeAxis__custom--PPPMember_z9Rq7uaTa1M2" style="text-align: right" title="Notes Payable">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left">B.      Note Payable - PPP#2</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--LongTermNotesPayable_iI_pp0p0_d0_c20220630__us-gaap--LongtermDebtTypeAxis__custom--PPP2Member_z9C0qx3Bdnb3" style="width: 14%; text-align: right" title="Notes Payable">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--LongTermNotesPayable_iI_pp0p0_c20210630__us-gaap--LongtermDebtTypeAxis__custom--PPP2Member_zd9kfaDSTaY4" style="width: 14%; text-align: right" title="Notes Payable">104,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">C.      Note Payable - EIDL</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--LongTermNotesPayable_c20220630__us-gaap--LongtermDebtTypeAxis__custom--EIDLMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Notes Payable">150,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--LongTermNotesPayable_c20210630__us-gaap--LongtermDebtTypeAxis__custom--EIDLMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Notes Payable">150,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--LongTermNotesPayable_c20220630_pp0p0" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Notes Payable">150,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--LongTermNotesPayable_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Notes Payable">254,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zAsIJdIl94rb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 16, 2020, the Company was granted a loan for $<span id="xdx_90A_eus-gaap--ProceedsFromLoans_pp0p0_c20200401__20200416__us-gaap--LongtermDebtTypeAxis__custom--PPPMember_zdQFZpV0z47">104,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(PPP #1) pursuant to the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief and Economic Security Act (the “Cares Act”). PPP #1 loan was scheduled to mature in April 2022 had a <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200401__20200416__us-gaap--LongtermDebtTypeAxis__custom--PPPMember_zAgKaFuib4Uj">1</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% per annum interest rate, and was subject to the terms and conditions applicable to loans administered by the Small Business Administration (“SBA”) under the CARES Act. The Company applied ASC 470, Debt, to account for PPP #1 loan. In May, 2021, the SBA approved the forgiveness of PPP #1 loan of $<span id="xdx_908_eus-gaap--DebtInstrumentDecreaseForgiveness_pp0p0_c20210501__20210531__us-gaap--LongtermDebtTypeAxis__custom--PPPMember_z2X0m95jWYh2">104,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, and we recognized a gain on extinguishment of PPP #1 loan of $<span id="xdx_905_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_c20200701__20210630__us-gaap--LongtermDebtTypeAxis__custom--PPPMember_zk7dn4kcF6j5">104,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">during the year ended June 30, 2021.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 26, 2021, the Company was granted a of $<span id="xdx_906_eus-gaap--ProceedsFromLoans_pp0p0_c20200501__20210326__us-gaap--LongtermDebtTypeAxis__custom--PPP2Member_zTRSQghq3yg" title="Proceeds from loan">104,000</span> (PPP #2) pursuant to the PPP that was scheduled to mature in March 2026. PPP #2 loan had an interest rate of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200501__20210326__us-gaap--LongtermDebtTypeAxis__custom--PPP2Member_zVJ60qIgTF0b" title="Interest rate">1</span>% per annum, was unsecured, and guaranteed by the Small Business Administration (the “SBA”). In July 2021, the SBA approved the forgiveness of PPP #2 loan of $<span id="xdx_90C_eus-gaap--DebtInstrumentDecreaseForgiveness_pp0p0_c20210701__20210731__us-gaap--LongtermDebtTypeAxis__custom--PPPMember_zd9rrquTiHxk">104,000</span>, and we recognized a gain on extinguishment of PPP #2 loan of $<span id="xdx_90F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pp0p0_c20210701__20220630__us-gaap--LongtermDebtTypeAxis__custom--PPP2Member_z1AHzyYNuUFl" title="Gain on forgiveness of note payable">104,000</span> during the year ended June 30, 2022.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2020, the Company received a loan of $<span id="xdx_90B_eus-gaap--ProceedsFromLoans_c20200701__20200731__us-gaap--LongtermDebtTypeAxis__custom--EIDLMember_pp0p0" title="Proceeds from loan">150,000</span> from the SBA under its Economic Injury Disaster Loan (EIDL) assistance program. The EIDL loan is payable over 30 years, bears interest at a rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200701__20200731__us-gaap--LongtermDebtTypeAxis__custom--EIDLMember_zuqPKEKTCxI9" title="Interest rate">3.75</span>% per annum and secured by all tangible and intangible property of the Company. The Company was in compliance with the terms of the EIDL loan as of June 30, 2021. As of June 30, 2022 and 2021, the outstanding balance of the note payable was $<span id="xdx_90F_eus-gaap--LongTermNotesPayable_c20220630__us-gaap--LongtermDebtTypeAxis__custom--EIDLMember_pp0p0" title="Note payable"><span id="xdx_90F_eus-gaap--LongTermNotesPayable_iI_pp0p0_c20210630__us-gaap--LongtermDebtTypeAxis__custom--EIDLMember_za3QAazgnZ36" title="Note payable">150,000</span></span>, respectively.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfDebtTableTextBlock_zRKPG8auV1Fi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B8_zYlKmh7HNhGf" style="display: none">Schedule of notes payable</span></td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">A.      Note Payable - PPP#1</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--LongTermNotesPayable_iI_pp0p0_d0_c20220630__us-gaap--LongtermDebtTypeAxis__custom--PPPMember_zG6fH9Fxbbkf" style="text-align: right" title="Notes Payable">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--LongTermNotesPayable_iI_pp0p0_d0_c20210630__us-gaap--LongtermDebtTypeAxis__custom--PPPMember_z9Rq7uaTa1M2" style="text-align: right" title="Notes Payable">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left">B.      Note Payable - PPP#2</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--LongTermNotesPayable_iI_pp0p0_d0_c20220630__us-gaap--LongtermDebtTypeAxis__custom--PPP2Member_z9C0qx3Bdnb3" style="width: 14%; text-align: right" title="Notes Payable">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--LongTermNotesPayable_iI_pp0p0_c20210630__us-gaap--LongtermDebtTypeAxis__custom--PPP2Member_zd9kfaDSTaY4" style="width: 14%; text-align: right" title="Notes Payable">104,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">C.      Note Payable - EIDL</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--LongTermNotesPayable_c20220630__us-gaap--LongtermDebtTypeAxis__custom--EIDLMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Notes Payable">150,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--LongTermNotesPayable_c20210630__us-gaap--LongtermDebtTypeAxis__custom--EIDLMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Notes Payable">150,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-weight: bold; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--LongTermNotesPayable_c20220630_pp0p0" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Notes Payable">150,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_984_eus-gaap--LongTermNotesPayable_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Notes Payable">254,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 0 0 0 104000 150000 150000 150000 254000 104000 0.01 104000 104000 104000 0.01 104000 104000 150000 0.0375 150000 150000 <p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zualNx2Uq8gk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 8 - <span id="xdx_82E_z2CD3DSVyuF2">Stockholders’ Deficit</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Preferred Stock</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 17, 2009, the Company filed an Amended and Restated Articles of Incorporation and created two new series of preferred stock, the first of which is designated Series A Preferred Stock and the second of which is designated as Series B Preferred Stock. The total number of shares of Common Stock which this corporation has authority to issue is 1,000,000,000 shares of Common Stock and 10,000,000 shares of Preferred Stock of which 5,000,000 shares are designated as Series A Preferred Stock, and 5,000,000 shares are designated as Series B Preferred Stock, with the rights, preferences and privileges of the Series B Preferred Stock to be designated by the Board of Directors. Each share of Common Stock and Preferred Stock has a par value of $0.001. As of June 30, 2022, and 2021, there are no shares of Series A or Series B Preferred Stock issued and outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Common Stock</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Year Ending June 30, 2022</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2022, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210701__20220630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zpf4mpS5L6l4" title="Stock issued new, shares">12,071,785</span> shares of common stock and <span id="xdx_901_ecustom--WarrantsIssuedNewShares_c20210701__20220630__us-gaap--StatementClassOfStockAxis__custom--WarrantsMember_zbOEsGdZp8oh">12,071,785</span> fully vested warrant to purchase common stock over a period of 5 years with an exercise price of $0.09 per share in exchange for net cash proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20210701__20220630__us-gaap--StatementClassOfStockAxis__custom--CommonStockAndWarrantsMember_zQtLJcL60H5">785,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2022, the Company issued <span id="xdx_90D_eus-gaap--ConversionOfStockSharesIssued1_c20210701__20220630__us-gaap--AwardTypeAxis__custom--CashlessExerciseOfWarrantsMember_zPdKITiDFru7">34,407,709 </span>shares of common stock to warrant holders who exercised their <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_c20210701__20220630__us-gaap--AwardTypeAxis__custom--CashlessExerciseOfWarrantsMember_zgI7qe8hPEP5">50,110,000</span> warrants on a cashless basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2022, the Company issued <span id="xdx_90D_eus-gaap--ConversionOfStockSharesIssued1_c20210701__20220630__us-gaap--AwardTypeAxis__custom--CashlessExerciseOfOptionsMember_zBhE7PdmOZ43">6,267,946</span> shares of common stock to option holders who exercised their <span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_c20210701__20220630__us-gaap--AwardTypeAxis__custom--CashlessExerciseOfOptionsMember_z6LCXR7xB7eb">8,500,000</span> options on a cashless basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company issued an additional <span id="xdx_90F_ecustom--StockIssuedToWarrantAndOptionHoldersShares_c20210701__20220630_zoQJpWYr497k">778,609</span> with a fair value of $<span id="xdx_902_ecustom--StockIssuedToWarrantAndOptionHoldersValue_c20210701__20220630_zYm8DR5nwoz4">87,000</span> to the warrant and option holders who exercised their cashless exercise options above. These shares of common stock were valued based on the closing price of the Company’s common stock on the date the shares were issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2022, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210701__20220630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zPtNEzTUQlC7" title="Number of shares issued for service">500,000</span> shares of common stock valued at $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210701__20220630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zkCgonIUtYHd">25,000</span> for services rendered. These shares of common stock were valued based on the closing price of the Company’s common stock on the date the Company entered into the agreement related to the issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 16, 2022, the company granted an executive officer <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationGross_c20220601__20220616__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ExecutiveOfficerMember_zPBC4oAfMw6l" title="Shares issued for compensation, shares">4,000,000</span> shares of common stock as part of the officer's compensation valued at $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_c20220601__20220616__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--ExecutiveOfficerMember_zA2m71J68b5j">200,000</span>. These shares of common stock were valued based on the closing price of the Company’s common stock on the date the Company entered into the agreement related to the issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2022, the Company issued <span id="xdx_907_ecustom--StockIssuedForLiabilitiesShares_c20210701__20220630__us-gaap--TransactionTypeAxis__custom--FormerAccruedPayrollMember_zbex2zz44O05">6,855,700 </span>shares of common stock with a fair value of $<span id="xdx_903_ecustom--StockIssuedForLiabilitiesValue_c20210701__20220630__us-gaap--TransactionTypeAxis__custom--FormerAccruedPayrollMember_zdsFVAfAOrai">718,000 </span>to settle $316,000 of liabilities related to former accrued payroll (see Note 6) and $31,000 of additional liabilities. A loss on settlement of $<span id="xdx_909_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20210701__20220630__us-gaap--TransactionTypeAxis__custom--FormerAccruedPayrollMember_zNdxsWdr9Mb4">371,000 </span>was recognized. In addition, during the year ended June 30, 2022, the Company issued <span id="xdx_903_ecustom--StockIssuedForLiabilitiesShares_c20210701__20220630__us-gaap--TransactionTypeAxis__us-gaap--OtherLiabilitiesMember_zWbBO5B1u1vk">4,331,260 </span>shares of common stock with a fair value of valued at $<span id="xdx_908_ecustom--StockIssuedForLiabilitiesValue_c20210701__20220630__us-gaap--TransactionTypeAxis__us-gaap--OtherLiabilitiesMember_zPsIOrCNpM4l">211,000 </span>to settle outstanding liabilities of $211,000, with no gain or recognized. These shares of common stock were valued based on the closing price of the Company’s common stock on the date the Company entered into the agreements related to such issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Year Ending June 30, 2021</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2021, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200701__20210630_zACammuN5zK9" title="Stock issued new, shares">11,269,538</span> shares of common stock and <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200701__20210630_zEpHo8jaAke9" title="Warrants granted to purchase common stock">11,269,538</span> fully vested warrants to purchase common stock over a period of five years with an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210630_zFbm1HaBj2xj" title="Warrant exercisable price per share">0.09</span> per share in exchange for net cash proceeds of $<span id="xdx_909_eus-gaap--SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions_pp0p0_c20200701__20210630_zlKxArcNlmB6" title="Net cash proceeds">728,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Stock Options</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has not adopted a formal stock option plan. However, it has assumed outstanding stock options resulting from the acquisition of its wholly owned subsidiary, Hydrodynamic Technology, Inc. In addition, the Company has made periodic non-plan grants. A summary of the stock option activity from June 30, 2022 and 2021 is as follows: </p> <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zHUiAEJsphU8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Deficit (Details - Option activity)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt"><span id="xdx_8B2_zAAKTm12BI5h" style="display: none">Stock Option activity table</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 49%">Outstanding at June 30, 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zGlv05JteFn7" style="width: 14%; text-align: right" title="Options outstanding, beginning balance">11,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHgVXzIfhWC6" style="width: 14%; text-align: right" title="Weighted average exercise price, options outstanding, beginning price">0.03</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190701__20200630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4V2vM2BBqUk" title="Weighted average remaining contractual life, options outstanding">6.07</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">- Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZpBasm8QlMa" style="text-align: right" title="Options granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zzMqBGNbhdMf" style="text-align: right" title="Weighted average exercise price, options granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt">- Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPQvRn5FNGa5" style="text-align: right" title="Options forfeited">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zon9y3Y0O9Kh" style="text-align: right" title="Weighted average exercise price, options forfeited">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">- Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxAxgvjgpxH8" style="text-align: right" title="Options exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkRZNiOpp3ol" style="text-align: right" title="Weighted average exercise price, options exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; padding-bottom: 1pt">- Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zgO3f9jABMq6" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zvvq8SxSR0tb" style="text-align: right" title="Weighted average exercise price, options expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding at June 30, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zRpgmeqjJrbf" style="text-align: right" title="Options outstanding, beginning balance">11,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z94ZlfTSnl11" style="text-align: right" title="Weighted average exercise price, options outstanding, beginning price">0.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxpPRIG4vPG9" title="Weighted average remaining contractual life, options outstanding">6.07</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt">- Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTrOlMmXAvwb" style="text-align: right" title="Options granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zzIq4dc6efFi" style="text-align: right" title="Weighted average exercise price, options granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">- Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di0_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zstZx2uC57Ib" style="text-align: right" title="Options forfeited">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWtxAPUM0Dr5" style="text-align: right" title="Weighted average exercise price, options forfeited">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt">- Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zjDwFcCkL59l" style="text-align: right" title="Options exercised">(8,500,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted average exercise price, options exercised">0.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Exercised_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zjOFx7Gb8jFl" title="Weighted-Average Remaining Contractual Life Exercised">6.07</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">- Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZzbiVIxV3hi" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired">(1,250,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted average exercise price, options expired">0.03</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Expired_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfC58XOFIVo3" title="Weighted-Average Remaining Contractual Life Expired">0.67</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zAGxu1Z5WGPf" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending balance">1,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTXXEidchmNg" style="text-align: right" title="Weighted average exercise price, options outstanding, ending price">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zm2868wpim69" title="Weighted average remaining contractual life, options outstanding">0.43</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zWBpWuO2q5Dj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, all outstanding options were fully vested and exercisable. The intrinsic value of the outstanding options as of June 30, 2022 was $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20220630_zG49W6vESsz4">25,000</span>. The following table summarizes additional information concerning options outstanding and exercisable at June 30, 2022.</p> <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zXK31wIRxFm1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Stockholders' Deficit (Details - Options by exercise price)"> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center"><span id="xdx_8BC_zY1P5AgE2Dv4" style="display: none">Schedule of options outstanding and exercisable</span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="10" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options Outstanding</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="6" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options Exercisable</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Shares</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Shares</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price1Member_pdd" style="width: 13%; text-align: right" title="Weighted average exercise price options outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 1%"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price1Member_pdd" style="border-bottom: black 1pt solid; width: 14%; text-align: right" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,250,000</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price1Member_zWkvahkMivvg" title="Weighted average remaining life options outstanding">0.87</span></span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="width: 14%; text-align: right" title="Weighted average exercise price options outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 1%"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price1Member_pdd" style="border-bottom: black 1pt solid; width: 14%; text-align: right" title="Number of shares exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,250,000</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210701__20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price1Member_zSaGP0HHp6ji" title="Weighted average remaining life options exercisable">0.87</span></span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,250,000</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Number of shares exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,250,000</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> </table> <p id="xdx_8AD_zpwuopevjVei" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Warrants</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of the Company’s warrant activity and related information from as of June 30, 2022 and 2021 is as follows.  </p> <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zZfL3ylUTMPe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Deficit (Details - Warrant activity)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8B0_zPN4XbNjYYTf" style="display: none">Schedule of warrant activity</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 52%">Outstanding at June 30, 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeyisvvo5oG9" style="width: 13%; text-align: right" title="Warrants outstanding, beginning balance">87,696,511</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20200701__20210730__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zpsiYTcA0rz6" style="width: 13%; text-align: right" title="Weighted average exercise price, warrants outstanding, beginning price">0.07</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20190701__20200630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zP3GWtADktL3" title="Weighted average remaining contractual life">5.64</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Warrants granted">11,269,538</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Weighted average exercise price, warrants granted">0.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_ecustom--WeightedAverageRemaingContractualLifeWarrantsGranted_dtY_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zoYGkriWsoOb" title="Weighted average remaing contractual life, warrants granted">5.00</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zakGGyS6VTrj" style="text-align: right" title="Warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8gA22ohxOM6" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Outstanding at June 30, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zpzX48myGrki" style="text-align: right" title="Warrants outstanding, beginning balance">98,966,049</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8pPbEc5CMMh" style="text-align: right" title="Weighted average exercise price, warrants outstanding, beginning price">0.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztK4BRsYdqcc" title="Weighted average remaining contractual life">4.49</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Warrants granted">12,571,785</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Weighted average exercise price, warrants granted">0.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--WeightedAverageRemaingContractualLifeWarrantsGranted_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGQhweETQEOk" title="Weighted average remaing contractual life, warrants granted">5.00</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zY1NJ1qazVqg" style="text-align: right" title="Warrants exercised">(50,110,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwDbcNtj4J46" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zBK9zLicKr95" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance">61,427,834</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zTc0UT3cdwW4" style="text-align: right" title="Weighted average exercise price, warrants outstanding, ending price">0.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zAzMzpxhNra2" title="Weighted average remaining contractual life">2.81</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zwx0mWOUSxi2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2022, all outstanding warrants were fully vested and exercisable. The intrinsic value of the outstanding warrants as of June 30, 2022 was $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pp0p0_c20220630_zGhOtbTQTgH6">216,000</span>. The following table summarizes additional information concerning warrants outstanding and exercisable at June 30, 2022.</p> <table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zJHbfWe2jda9" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Stockholders' Deficit (Details - Warrants by exercise price)"> <tr style="background-color: White"> <td style="vertical-align: bottom; text-align: center"><span id="xdx_8B4_zR5pO2aRRP9b" style="display: none">Schedule of warrants outstanding and exercisable</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td colspan="10" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants Outstanding</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="6" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants Exercisable</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Shares</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Shares</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td></tr> <tr style="background-color: rgb(238,238,238)"> <td style="vertical-align: bottom; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.03 - $0.05</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_pdd" style="vertical-align: top; width: 13%; text-align: right" title="Number of warrant shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,626,518</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210701__20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_zdX53I4iIz3k" title="Weighted average remaining life warrants outstanding">2.63</span></span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_pdd" style="vertical-align: bottom; width: 14%; text-align: right" title="Weighted average exercise price warrants outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_pdd" style="vertical-align: top; width: 14%; text-align: right" title="Number of warrant shares exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,626,518</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98A_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1Exercisable_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_pdd" style="vertical-align: bottom; width: 13%; text-align: right" title="Weighted average exercise price warrants exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: White"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.08 - $0.12</span></td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_pdd" style="border-bottom: black 1pt solid; vertical-align: top; text-align: right" title="Number of warrant shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,801,316</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210701__20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_zrQZMIlcLkBl" title="Weighted average remaining life warrants outstanding">2.89</span></span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_pdd" style="vertical-align: bottom; text-align: right" title="Weighted average exercise price warrants outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.10</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_pdd" style="border-bottom: black 1pt solid; vertical-align: top; text-align: right" title="Number of warrant shares exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,801,316</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98B_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1Exercisable_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_pdd" style="vertical-align: bottom; text-align: right" title="Weighted average exercise price warrants exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.10</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: center"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Number of warrant shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61,427,834</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Number of warrant shares exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61,427,834</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> </table> <p id="xdx_8AC_zuDHHnHtKDRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Year Ending June 30, 2022</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2022, the Company granted warrants to purchase <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210701__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdPhYTcUFpel">12,071,785</span> shares of common stock in relation to the issuance of common stock (see Common Stock above).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 1, 2021, the Company granted a service provider a warrant exercisable for <span id="xdx_90C_ecustom--WarrantsIssuedForServicesShares_c20210701__20220331__srt--CounterpartyNameAxis__custom--ConsultantMember_zn3fS1J2EYhf" title="Warrants issued for services shares">500,000</span> shares of common stock at an exercise price of $<span id="xdx_907_eus-gaap--WarrantExercisePriceIncrease_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4sndqeZ1DKd" title="Exercise price">0.09</span> per share, these warrants were valued at $<span id="xdx_909_ecustom--WarrantsIssuedForServicesValue_c20210701__20220331__srt--CounterpartyNameAxis__custom--ConsultantMember_z0T2alhOh5hf" title="Warrants issued for services value">40,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the warrant awards was estimated using the Black-Scholes method based on the following weighted-average assumptions:<b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zPTyD6IsrzG2" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Stockholders' Deficit (Details - Assumptions)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8B3_zIvOELMQAGi9" style="display: none">Assumptions</span></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30,</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 75%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td style="width: 3%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zBBcYoBKzg3k" title="Risk free interest rate">0.66</span>%</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual terms (years)</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z0P3ytjr4RG1" title="Expected term (years)">5</span> years</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9M4JeDPVDLc" title="Expected volatility">258</span>%</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zB628WMje7O" title="Expected dividend yield">0</span>%</span></td> <td> </td></tr> </table> <p id="xdx_8AD_zsuKDNVfc4L4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of measurement corresponding with the expected term of the warrants; the contractual terms represents full contractual term the warrants; expected volatility is based upon historical volatility of the Company’s common stock; and the expected dividend yield is based on the fact that the Company has not paid dividends in the past and does not expect to pay dividends in the future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Year Ending June 30, 2021</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2021, the Company granted warrants to purchase <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200701__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z48noMAHd8Ae">11,269,538</span> shares of common stock in relation to the issuance of common stock (see Common Stock above).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 12071785 12071785 785000 34407709 50110000 6267946 8500000 778609 87000 500000 25000 4000000 200000 6855700 718000 -371000 4331260 211000 11269538 11269538 0.09 728000 <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zHUiAEJsphU8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Deficit (Details - Option activity)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt"><span id="xdx_8B2_zAAKTm12BI5h" style="display: none">Stock Option activity table</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 49%">Outstanding at June 30, 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zGlv05JteFn7" style="width: 14%; text-align: right" title="Options outstanding, beginning balance">11,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHgVXzIfhWC6" style="width: 14%; text-align: right" title="Weighted average exercise price, options outstanding, beginning price">0.03</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20190701__20200630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4V2vM2BBqUk" title="Weighted average remaining contractual life, options outstanding">6.07</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">- Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZpBasm8QlMa" style="text-align: right" title="Options granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zzMqBGNbhdMf" style="text-align: right" title="Weighted average exercise price, options granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt">- Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPQvRn5FNGa5" style="text-align: right" title="Options forfeited">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zon9y3Y0O9Kh" style="text-align: right" title="Weighted average exercise price, options forfeited">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">- Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxAxgvjgpxH8" style="text-align: right" title="Options exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkRZNiOpp3ol" style="text-align: right" title="Weighted average exercise price, options exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; padding-bottom: 1pt">- Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zgO3f9jABMq6" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zvvq8SxSR0tb" style="text-align: right" title="Weighted average exercise price, options expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding at June 30, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zRpgmeqjJrbf" style="text-align: right" title="Options outstanding, beginning balance">11,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z94ZlfTSnl11" style="text-align: right" title="Weighted average exercise price, options outstanding, beginning price">0.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zxpPRIG4vPG9" title="Weighted average remaining contractual life, options outstanding">6.07</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt">- Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d0_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTrOlMmXAvwb" style="text-align: right" title="Options granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d0_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zzIq4dc6efFi" style="text-align: right" title="Weighted average exercise price, options granted">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">- Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di0_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zstZx2uC57Ib" style="text-align: right" title="Options forfeited">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d0_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWtxAPUM0Dr5" style="text-align: right" title="Weighted average exercise price, options forfeited">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt">- Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_di_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zjDwFcCkL59l" style="text-align: right" title="Options exercised">(8,500,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted average exercise price, options exercised">0.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Exercised_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zjOFx7Gb8jFl" title="Weighted-Average Remaining Contractual Life Exercised">6.07</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">- Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_di_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZzbiVIxV3hi" style="border-bottom: Black 1pt solid; text-align: right" title="Options expired">(1,250,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="text-align: right" title="Weighted average exercise price, options expired">0.03</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Expired_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfC58XOFIVo3" title="Weighted-Average Remaining Contractual Life Expired">0.67</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zAGxu1Z5WGPf" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding, ending balance">1,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTXXEidchmNg" style="text-align: right" title="Weighted average exercise price, options outstanding, ending price">0.03</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zm2868wpim69" title="Weighted average remaining contractual life, options outstanding">0.43</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 11000000 0.03 P6Y25D 0 0 -0 0 -0 0 -0 0 11000000 0.03 P6Y25D 0 0 -0 0 8500000 0.03 P6Y25D 1250000 0.03 P0Y8M1D 1250000 0.03 P0Y5M4D 25000 <table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zXK31wIRxFm1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Stockholders' Deficit (Details - Options by exercise price)"> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center"><span id="xdx_8BC_zY1P5AgE2Dv4" style="display: none">Schedule of options outstanding and exercisable</span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="10" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options Outstanding</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="6" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options Exercisable</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Shares</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Shares</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price1Member_pdd" style="width: 13%; text-align: right" title="Weighted average exercise price options outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 1%"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price1Member_pdd" style="border-bottom: black 1pt solid; width: 14%; text-align: right" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,250,000</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price1Member_zWkvahkMivvg" title="Weighted average remaining life options outstanding">0.87</span></span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="width: 14%; text-align: right" title="Weighted average exercise price options outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="border-bottom: black 1pt solid; width: 1%"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price1Member_pdd" style="border-bottom: black 1pt solid; width: 14%; text-align: right" title="Number of shares exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,250,000</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20210701__20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Price1Member_zSaGP0HHp6ji" title="Weighted average remaining life options exercisable">0.87</span></span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Number of shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,250,000</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Number of shares exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,250,000</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> </table> 0.03 1250000 P0Y10M13D 0.03 1250000 P0Y10M13D 1250000 1250000 <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zZfL3ylUTMPe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stockholders' Deficit (Details - Warrant activity)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8B0_zPN4XbNjYYTf" style="display: none">Schedule of warrant activity</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">(Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 52%">Outstanding at June 30, 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zeyisvvo5oG9" style="width: 13%; text-align: right" title="Warrants outstanding, beginning balance">87,696,511</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20200701__20210730__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zpsiYTcA0rz6" style="width: 13%; text-align: right" title="Weighted average exercise price, warrants outstanding, beginning price">0.07</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20190701__20200630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zP3GWtADktL3" title="Weighted average remaining contractual life">5.64</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Warrants granted">11,269,538</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Weighted average exercise price, warrants granted">0.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_ecustom--WeightedAverageRemaingContractualLifeWarrantsGranted_dtY_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zoYGkriWsoOb" title="Weighted average remaing contractual life, warrants granted">5.00</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zakGGyS6VTrj" style="text-align: right" title="Warrants exercised">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8gA22ohxOM6" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Outstanding at June 30, 2021</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zpzX48myGrki" style="text-align: right" title="Warrants outstanding, beginning balance">98,966,049</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z8pPbEc5CMMh" style="text-align: right" title="Weighted average exercise price, warrants outstanding, beginning price">0.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_ztK4BRsYdqcc" title="Weighted average remaining contractual life">4.49</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Warrants granted">12,571,785</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Weighted average exercise price, warrants granted">0.09</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_ecustom--WeightedAverageRemaingContractualLifeWarrantsGranted_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zGQhweETQEOk" title="Weighted average remaing contractual life, warrants granted">5.00</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zY1NJ1qazVqg" style="text-align: right" title="Warrants exercised">(50,110,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di0_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zwDbcNtj4J46" style="border-bottom: Black 1pt solid; text-align: right" title="Warrants expired">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Outstanding at June 30, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zBK9zLicKr95" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance">61,427,834</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zTc0UT3cdwW4" style="text-align: right" title="Weighted average exercise price, warrants outstanding, ending price">0.09</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zAzMzpxhNra2" title="Weighted average remaining contractual life">2.81</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 87696511 0.07 P5Y7M20D 11269538 0.09 P5Y -0 -0 98966049 0.07 P4Y5M26D 12571785 0.09 P5Y 50110000 -0 61427834 0.09 P2Y9M21D 216000 <table cellpadding="0" cellspacing="0" id="xdx_890_ecustom--ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock_zJHbfWe2jda9" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Stockholders' Deficit (Details - Warrants by exercise price)"> <tr style="background-color: White"> <td style="vertical-align: bottom; text-align: center"><span id="xdx_8B4_zR5pO2aRRP9b" style="display: none">Schedule of warrants outstanding and exercisable</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td colspan="10" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants Outstanding</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="6" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants Exercisable</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Shares</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life (Years)</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Shares</b></span></td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td> <td> </td> <td colspan="2" style="white-space: nowrap; text-align: right"> </td> <td> </td></tr> <tr style="background-color: rgb(238,238,238)"> <td style="vertical-align: bottom; width: 17%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.03 - $0.05</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_pdd" style="vertical-align: top; width: 13%; text-align: right" title="Number of warrant shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,626,518</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210701__20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_zdX53I4iIz3k" title="Weighted average remaining life warrants outstanding">2.63</span></span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_pdd" style="vertical-align: bottom; width: 14%; text-align: right" title="Weighted average exercise price warrants outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_pdd" style="vertical-align: top; width: 14%; text-align: right" title="Number of warrant shares exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,626,518</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98A_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1Exercisable_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice1Member_pdd" style="vertical-align: bottom; width: 13%; text-align: right" title="Weighted average exercise price warrants exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.04</span></td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: White"> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.08 - $0.12</span></td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_pdd" style="border-bottom: black 1pt solid; vertical-align: top; text-align: right" title="Number of warrant shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,801,316</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210701__20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_zrQZMIlcLkBl" title="Weighted average remaining life warrants outstanding">2.89</span></span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_pdd" style="vertical-align: bottom; text-align: right" title="Weighted average exercise price warrants outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.10</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_pdd" style="border-bottom: black 1pt solid; vertical-align: top; text-align: right" title="Number of warrant shares exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,801,316</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98B_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1Exercisable_c20220630__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantPrice2Member_pdd" style="vertical-align: bottom; text-align: right" title="Weighted average exercise price warrants exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.10</span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: center"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_c20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Number of warrant shares outstanding"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61,427,834</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_c20220630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_pdd" style="border-bottom: black 2.25pt double; text-align: right" title="Number of warrant shares exercisable"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61,427,834</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> </table> 18626518 P2Y7M17D 0.04 18626518 0.04 42801316 P2Y10M20D 0.10 42801316 0.10 61427834 61427834 12071785 500000 0.09 40000 <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zPTyD6IsrzG2" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Stockholders' Deficit (Details - Assumptions)"> <tr style="vertical-align: bottom; background-color: White"> <td><span id="xdx_8B3_zIvOELMQAGi9" style="display: none">Assumptions</span></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30,</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 75%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td style="width: 3%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zBBcYoBKzg3k" title="Risk free interest rate">0.66</span>%</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual terms (years)</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z0P3ytjr4RG1" title="Expected term (years)">5</span> years</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z9M4JeDPVDLc" title="Expected volatility">258</span>%</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20200701__20210630__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zB628WMje7O" title="Expected dividend yield">0</span>%</span></td> <td> </td></tr> </table> 0.0066 P5Y 2.58 0 11269538 <p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zqIkYWgVM6Lk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 9 - <span id="xdx_824_zjCxYhtKjwn2">Income Taxes</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the year ended June 30, 2022, the Company recorded no provision for income taxes due to the Company’s taxable net loss position. For the year ended June 30, 2021, the Company recorded no provision for income taxes due to available Federal and State net operating loss (NOL) carryforwards that are available to reduce taxable income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A reconciliation of the effective income tax to statutory US federal income tax is as follows: </p> <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zdPfByZA87Wf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details- Tax Reconciliation)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B1_zOQ2QnbmKis7" style="display: none">Income Tax Provision</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Federal statutory rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_c20210701__20220630_zcS6ZX2yHjNb" title="Federal statutory rate">(21</span>)%</td><td style="width: 1%; text-align: left"/><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_c20200701__20210630_zBKy20cOsnUi" title="Federal statutory rate">(21</span>)%</td><td style="width: 1%; text-align: left"/></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income taxes, net of Federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_dpi_c20210701__20220630_z3pAz3N4TtA7" title="State income taxes, net of Federal benefit">(7</span>)%</td><td style="text-align: left"/><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_dpi_c20200701__20210630_zbcCG74K550e" title="State income taxes, net of Federal benefit">(7</span>)%</td><td style="text-align: left"/></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_c20210701__20220630_zyrkK0g8f5nk" title="Net operating loss/carryforward">28</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_c20200701__20210630_zwfQRyaVslql" title="Net operating loss/carryforward">28</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income tax provision</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_c20210701__20220630_zF8SkPN191kc" title="Income tax provision">–</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_c20200701__20210630_zqf3KrDeI3Mh" title="Income tax provision">–</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zwglmr7d6hJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred income taxes result from temporary differences in the recognition of income and expenses for the financial reporting purposes and for tax purposes. The components of deferred tax assets are presented below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At June 30, 2022, the Company had available Federal NOL carryforwards of approximately $<span id="xdx_90C_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_dm_c20220630_zUKXHvvcbKC1" title="Net operating loss">10.5</span> million that are available to reduce future taxable income. The Federal NOL carry forward expires through 2037. The NOLs are subject to statutory limitations under Internal Revenue Code Section 382 regarding substantial changes in ownership of companies with loss carry forwards.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended June 30, 2022 and 2021, management has determined that it is more likely than not that the Company will not be able to realize the tax benefit of the carryforwards due to recurring operating losses. Based on their valuation, the Company determined that the net deferred tax assets, do not meet the requirements to realize, and as such, the Company has provided a full valuation allowance against them.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At June 30, 2022 and 2021, significant component of the Company’s deferred tax assets and liabilities are as follows: </p> <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zyiFt5PokTbj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details- Deferred Tax Assets and Liabilities)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8BF_zgWO6L6Xwjv2" style="display: none">Schedule of Deferred Tax Assets</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20220630_zLH8YHs0GQ3f" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20210630_zu2G2RAJMUYg" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_d0_maDTAGziNM_zz3KUf4kljEb" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Operating loss carryforwards <b> </b></span></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3,063,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,758,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGziNM_zxcD4RzLKBna" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock compensation expense <b> </b></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">938,000 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">840,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGziNM_maDTANzXUP_zP4gtzNJI0Bd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total net deferred tax assets <b> </b></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,001,000 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,598,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzXUP_z9ejS22VhR84" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less valuation discount <b> </b></span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,001,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,598,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_d0_mtDTANzXUP_zag2jwxXaSz5" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_ztxkdXYcC3Y1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">   </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounting rules prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. The Company classifies interest and penalties as a component of interest and other expenses. To date, there have been no interest or penalties assessed or paid.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures and records uncertain tax positions by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zdPfByZA87Wf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details- Tax Reconciliation)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8B1_zOQ2QnbmKis7" style="display: none">Income Tax Provision</span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Federal statutory rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_c20210701__20220630_zcS6ZX2yHjNb" title="Federal statutory rate">(21</span>)%</td><td style="width: 1%; text-align: left"/><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_c20200701__20210630_zBKy20cOsnUi" title="Federal statutory rate">(21</span>)%</td><td style="width: 1%; text-align: left"/></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income taxes, net of Federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_dpi_c20210701__20220630_z3pAz3N4TtA7" title="State income taxes, net of Federal benefit">(7</span>)%</td><td style="text-align: left"/><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_dpi_c20200701__20210630_zbcCG74K550e" title="State income taxes, net of Federal benefit">(7</span>)%</td><td style="text-align: left"/></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_c20210701__20220630_zyrkK0g8f5nk" title="Net operating loss/carryforward">28</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_dp_c20200701__20210630_zwfQRyaVslql" title="Net operating loss/carryforward">28</span>%</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Income tax provision</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_c20210701__20220630_zF8SkPN191kc" title="Income tax provision">–</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp0_c20200701__20210630_zqf3KrDeI3Mh" title="Income tax provision">–</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0.21 0.21 0.07 0.07 0.28 0.28 0 0 10500000 <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zyiFt5PokTbj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details- Deferred Tax Assets and Liabilities)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span id="xdx_8BF_zgWO6L6Xwjv2" style="display: none">Schedule of Deferred Tax Assets</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_494_20220630_zLH8YHs0GQ3f" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_497_20210630_zu2G2RAJMUYg" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_d0_maDTAGziNM_zz3KUf4kljEb" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Operating loss carryforwards <b> </b></span></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3,063,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,758,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0_maDTAGziNM_zxcD4RzLKBna" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock compensation expense <b> </b></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">938,000 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">840,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsGross_iTI_pp0p0_mtDTAGziNM_maDTANzXUP_zP4gtzNJI0Bd" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total net deferred tax assets <b> </b></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,001,000 </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,598,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzXUP_z9ejS22VhR84" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less valuation discount <b> </b></span></td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,001,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,598,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_d0_mtDTANzXUP_zag2jwxXaSz5" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3063000 2758000 938000 840000 4001000 3598000 4001000 3598000 0 0 <p id="xdx_800_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zP6BO3dQZZF" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 10 – <span id="xdx_82B_z1rFW9aGBlx7">Commitments and Contingencies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Royalty Agreements</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 1, 2008, the Company’s wholly owned subsidiary entered into Patent Assignment Agreements with two parties, its President as well as its former Chief Executive Officer (CEO) and current Technology Senior Manager, where certain devices and methods involved in the hydrodynamic cavitation processes invented by the President and former CEO/ current Technology Senior Manager have been assigned to the Company. In exchange, the Company agreed to pay a royalty of 5% of gross revenues to each of the President and former CEO/ current Technology Senior Manager for licensing of the technology and leasing of the related equipment embodying the technology. These agreements were subsequently assigned to Cavitation Technologies on May 13, 2010. The Company’s former CEO/ current Technology Senior Manager and President both waived their rights to receive royalty payments that have accrued, or that may accrue, on any gross revenue generated through June 30, 2022 and 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 30, 2008 (as amended November 22, 2010), the Company’s wholly owned subsidiary entered into an employment agreement with the Director of Chemical and Analytical Department (the “Inventor”) providing that the Inventor shall receive an amount equal to 5% of actual gross royalties received from the royalty stream in the first year in which the Company receives royalty payments from the patent which the Inventor was the legally named inventor, and 3% of actual gross royalties received by the Company resulting from the patent in each subsequent year. As of June 30, 2022, and 2022 no patents have been granted in which this person is the legally named inventor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�[^P<'_WB%H<.@>'+IYH@59GM8-TVPRDF)/ MI+'&:.8FGYO<&[.)N?F,"RWQWQC]]&3Z^+!XO)O=7#W?WI#%,U[N;Q^>%^3Q M$WF!K@N!O ;!J ^N1=<;Q2YY1%$ MYP%SF\;H-\69\*5(@ M"\TTX/K6Y-^K%Z4EKL__;+-5! OLPB58[V? <-%*2/"C1"1C4K_90(M X0E $-8QZU8^;:0,2\JPE7(JE"9BA8R- MTQC6QNT$M(YG,<,BWL37+_GZK7R?I5"*9%*L8FV#Z]=&I:$?U.GJ=KWNH)%N M4-(-VNF @V0)83PB+,*Z&)LM9Q2!P"M*G )E@Q[4H?O^H YML?/#H)%Z6%(/ M6ZEG:<9BF1<)_/+P;1MGYL%&.K206D#K9@V(U*L$P?O!]E' Y'*3SVV$JS,1 M.67KQ!YBGO/6<2UF+5N)GH@8;65^%AH7 YYMS!K@ZW946D<=^ET+K,70'_2: MD06W([J6[;VT%)(;8;]H+F4TDK<:+NZ/>H-2'+0N ^W MQ;S:CP'OJFSO%>T\[4K;:+NX?<8#,,%3)IZ3UUA4.. 'PRT[G\_)G6#I2#^V.Z1E4RDC;I3'?L1\)!_ODU:6MTST_+ASPZH;#9MVFE032 M=@U\P-8TP>]NA1O6#H0=Z\'1:A@,ZWCN26>4@ESG#:,B2['ENN@XRK=E4WJ5 MMV+?O;\VS6K><55ABD[WGF&)X(HDL,*0WD4?J631/!8/6F1Y__4B-'9S^>T& M&VZ0Q@#_7PFACP]F@+*%G_P/4$L#!!0 ( /:)357+O]$?T ( .8' 8 M >&PO=V]R:W-H965T&ULK55=;]HP%/TK5C9-F]0UP4!" M.XC$5S6FM:#"UH=I#R:Y$*N)S6P'NG\_VX$,*&2=U)?X(_><>X[CW-O>JY0RF @D\RPCXG[/=^PWUKOV,B<2^CQ]H+%*.D[+03$L2)ZJ>[[Y M#%L_3<,7\53:)]H4L7[@H"B7BF=;L%:045:,Y&E[#GN FG\&@+< ? QHG '4 MMX"Z-5HHL[8&1)&P+?@&"1.MV4F:\X54*_I1JGPO[X;CK^.AIT M9\,!FL[T<#N\FTW1^ :-)\/[[FRD ]#["1' 5 **1B3]@#ZBM\A%,M&[LNTJ MK<.PN=$V9Z_(B<_DK&%TRS6;1$,60WQ(X&H#I0N\<]'#E8Q?Y]..7TEL@/?C=)WHXH]'!+!*%M*- &!IN9V M7* >D30ZY;J@:EHJ4VO6H==VU_M6JB(.]#5+?@::Z.+V&AL/E/A541 M!PK]4J%?J?#!EAV(47<-0E=1=)=GT4O$=@A>;>1YYSHR[5S(S$$O;222* M>,Y447?*W;)9=6V-/MKOZ296])R_-$4'O"5B29E$*2PTI7<9Z'LBBJY2+!1? MV<(\YTJ7>3M-=",&80+T^P7G:KYO11 M- 8 *\D 8 >&PO=V]R:W-H965T&ULM5I_<^(V$/TJ M&MII>S/'8G2Z)"M,WV5KDO)?YEF^ MPHSOYHL>7><$SPJG5=)#EN7V5CA..X/SXKO;?'">;5@2I^0V!W2S6N'\WRN2 M9-N+#NP\?W$7+Y9,?-$;G*_Q@DP(>UC?YGROMT>9Q2N2TCA+04[F%YU+>!:A MOG H+#[%9$L/MH$XE,%XN/V,?ET2B ,'A!H<4.F CAQLM\'!+AWLXQ6\!@>G M='".'*#=X- O'8I#[^V.O2 NQ P/SO-L"W)AS='$1L%^X1R&8W/./C]'-_02,K\'P_>7-;]$$C&[X#^/A'^_''\+H M;O(SB/Y\&-W_!7X)H^O1<'3_!G3!PR0$O_SXYKS'>$P"N31_*V"&>IC+V2P6A8<3<(OC63=.P1"O8\;W-:"A'O2. M,'ZFD1F(<)[&Z8+JL"(]UGW&8ZF[]7BJ]OE"^WRA L=IP+DBBS@5P?#3(\'I ME+P%3SC9$( 9^'V3O@.V]18@"UFJ5.R@^P6TZ"!/ QAXEL5MGPZIELV0C0(H M&8:R81?9@>=+EI'"T@FL0[L:&_:>#;LM&W2)[& ME&[XJ<)'%YABNE3Q[ M,$-#.*$KI;KK%CWQJ'6ZVI\K147>,X+T='-@=31;UB*K[F5Z04 MB]&J*UOM4BT+:&@2+#0)%GFGS\Y:+OQ]+GQM+J)T=GJB0Q7QOCRJ+7G\#GTI M<.18"L-0-NPBQT5R_XWDE;M.O9W7J CV5 2MJ%"/@GKUHGBUS5^_Y@K;0!M:],H6F0*K4Y^I7R@7OH,.M<4% MDBF@$,H"K>M"Q272"PSKA%4*!YZ0.*J:R];B>DA-HJQQ7$7%R:*C*YN%^MC: M%-SW ]7YJV00U.N@+[M;6&?B:O.3N*H9SW<]M+CA,RHZZ,,Z2Z.2WO'\QYM8"$^RBL-L6@\;4C! M*\2.NH/+0L>Q%/W)T'K1R?7J?%:R"NIUU8MJ^YEF;7'+NLBV/=A'2*IN;42M MJ]LD6F0*K9Z-2ME!O;0[?<>A,3< IS/MV UD(:(8N[)"]%5CUZBB4RWJ-=8V MJK0:TFNUTVR>:A=(5F]]Q<, 64LAI&@&^G!;- /E@LWB#57B#>G%F]$[7DA6 M=(X(4N;/J* SBA:90JLGY.!1EE[0G4X(RW@%,Y80D,3X,4YB%C>D0_%H2]$! MD"SU JBX#:8/O$TQ*Q9$S<($54H.Z97<*[G3EK3B>1B$OATXWC&-1I^'&46+ M3*'5\U()1J07C"^ZE8N4],O2$7FJI[,*.S[%Y-8=*BR[J(\<>>9%"E-HV6YS MH58*$.D5X,MNZ*H9D=4=\EPW\'T;'I-B5. 918M,H>T2T#MXUT.\RO,1YXLX MI2 AL?CQGC2KS87!(\([DPX+_/LXP][X@W2O;O M* W^ U!+ P04 " #VB4U5Y3)B#B4' #M( & 'AL+W=OD"3,YP@B-8*:?,F&+-:_]>2][JB]ZQ;DAW]9%J<\[ M*V.JTUY/YRN^9OJ-K'@)ORRD6C,#7]6RIRO%V=P-6A<]FB3#WIJ)LC,Y<^=N MU>1,;DPA2GZKB-ZLUTP]O.6%O#_OI)W'$Y_$ MSLM[UW3&PH=U)^L5^NY^>=Q"KB!<^- M=<'@8\NGO"BL)]#QM7':V5W3#MP_?O1^Y8*'8.Z8YE-9_"7F9G7>&7?(G"_8 MIC"?Y/UOO EH8/WELM#N+[EO;),.R3?:R'4S&!2L15E_LF_-C=@;D Y;!M!F M 'TZH-\R(&L&9"[06ID+ZY(9-CE3\IXH:PW>[(&[-VXT1"-*.XTSH^!7 >/, M9'KS<7;S_OKRXO.[2S+[#!\?WGW\/",W5V1Z,?N-7+V_^6M&NN2/V27Y\?N? MSGH&+FJ']O+F F_K"]"6"Z24?)"E66GRKISS^:&#'JC=2::/DM_2J,??-^4; MDB4_$YI0B@B:'C\\CGV'VJW?1Q-_9Q M/=45R_EY!YY'S=66=R8_?)<.DU^P&%_)V4'$_5W$_9CWR4?(+H74&@NR'CEP M(VT*V4ZZP_0D29*SWG9?/V;7/[ [D#;821M$)^-B_C<\,Y!FC"9&0I[)99F+ M@I.RT6S/VN.O.:&OY.S@K@UW=VT8 MG=!+#DYSP>K$6LX)6TMEQ#_N!!9Y[6ZX-WM/YS>TH+1U=D<[G:.HSBLF%-FR M8L.)7)!@%U)D_H4(K3 M\2A0Q"Y:%9B_(T\;Q+HMI_A=*&@%Q0N(0"HN20$R"(V]M;4DK#2<4> MV%W!4= E@9QNFO1#V4<8'JK?HW4:5?_>IC![L[DQ!;=YSHHO!+L3A4M4J.XT MD).-4D1V:-EW!8GD4RK]N1&6_H#)I 3N.$?K=80 7O\L:*E4NN02I*U_15\?I:W@ZC]H!-XX2] MR'.YL9D=.,O%MC7#A-A$LB)B=3)N3RZ>KFDP9DHCU0,J+61?EV:(N- N M0O[4@S*-D_)6<<@D&?8.L\L-W8YJFO\ #5S#C+%4;'VG( MO6Z&!8/8Q:+QD*1Q2'[:T_@0JT!HB+XN G+$K$VC)R2-$W+J]B*X(FR^965+ M64=#TD%;AQ32B&$V:&__J.H][O0HO4W@",13VE[?4(]H&D?T=/\Y$\CB1>,*R=LV8ZAE MN_#,4SI+H@_:E2@AY1ZSQ1BE_8OW&%_)VV'4GO%9G/&W2N:[/Y(XO15G:*;!YFBLA MYV@,(?[3;(BD+\1P%"G),E\F9/'>-Q(#MYNR4?5AJ]OO(_498O3N\ M);Y R.(%@IM0UXS;;5Y1&@Y708N"+-9H-[$!T/C=?W0/U"=G=V]\[^PKVI?G+^;7HZK=^\>S?U/P)\8 KRE(9V; $N MDS&PO=V]R:W-H965T&ULM5Q;C]M&LG[GKVC,!@L;T,@C>7R+$P/VV#[K1>(8'GN#@X/S0)$M MB6N*5-CDR,JO/_5555^HD<8.L./Q@DU?- MV8N?^-J'[L5/[=#756,_=,8-FTW>[5_9NMW]?#8[\Q<^5JMUCPL/7ORTS5?V MVO:?MQ\Z^O4@C%)6&]NXJFU,9Y<_G[V<_?CJ$L_S _^J[,XE?QNL9-&V7_#C M7?GSV04(LK4M>HR0TS\W]LK6-08B,O[0,<_"E'@Q_=N/_I;73FM9Y,Y>M?7O M5=FO?SY[>F9*N\R'NO_8[OYA=3V/,%[1UH[_;W;Z[,69*0;7MQM]F2C85(W\ MFW]5/GS/"W-]8N\SU_\U+4[T^%I&@U_\%+Y;2*N:K IUWU'=RMZ MKW_Q6[?*F^K/7%C4E.9:=L>T2W-=K9IJ615YTYN71=$.35\U*_.AK:NBLNZG M!ST1@&$>%#K9*YEL?F*RV=S\VC;]VIDW36G+\0 /B/) _MR3_VI^YXC_')JI M>7@Q,?.+^?R.\1X&=CSD\1Y^!SLFYJIM'"VVC-SYT%EGFUXN$(O>5DW>%%5> MFVNZ:$E:>V?^Y^7"]1W)V_\>8Y$0<'F< .C@CVZ;%_;GLRWFZF[LV8N__VWV M^.+Y'F[].4.8),E?Y3:4[ M\T\HNG\Z?F_]J(0"D!(7M&B8CIVU@0G"C"-I! RZ](F0N*L(ZO[%F M86U#M-AMWM%SV&:S:O5]'IA M:)=VZVK8HV+]/:VIC$<\X0L3>T%A(0B=\[2 MR%@N[M*/ON;9Z&965_FBJJL>TN$94O5""ZV860PHK^G.T#F+ 1>#([EU;FI> M.E@9F MAT'6TD:5=]&#C@Y;6\L=0]7N_<.('O; DP34D MAR+NNB'CD:U1'G>DW= 4A#GV55U MG2UHM)N\JO-%;?U&+H=^H#&(MG;1D_,A>^:&Y1+H0(L7'M 4MJ#M925HS09^ M3L(YQJ$GS_&4+=U$2$@YB_D-YJ>I,QH@+]85Z1]6N:2U@*"$!6UW]PB!A(H( MTQ5 XF$L!F)4NZBKE8PU-=?K=JA+VJN&O",6\27Q@(;(9,4'K!I+!':8I*O' M&Y@L$CFE9VB#SF?/S&N66/,=$OO;O]Z]ICJ V-T9IJ'C #Y2NXVHF&@=L$6@I0!FD'WJDX4EX08"U#%)P[G MF4LL0['.FU64"GK-W.3U8 _>*P=F?KH8XQ=#JH\M(W'LR=^O2E%[2EX17!"'G55!NR0L9^)1Y"S+O*?6$V M\E()X=N]A;$F$*R'$N)!HH1_PCV IX0RY#O<_ IJ$G>/^3GP).=VU#HNB& MQ:9R3@U$U=RT5:$&8)OO68BFY+C11-6VMDSZV+&#.'X3WY50R]S(Q1V1L>YT M0_SF[M8M'(%V!Z BBAWM!S#I'_NR:\L]67Y:27C?F_YW9 R[PLL0D@( MJ["K( #19=Q&7J\L>3+L M%]NU6Z,,GGZ37M+_ L)3J 22X61 M(#O%2V>$S5E9U$,@SPHC>\0?NPF)4T VNG)%+0))3P%ZB6"V%D=?,(KE1P0B M WO$[SI&0$=&HB',P7W2 8IBK5,/(2&:N47 V9;3D;L;%Z]2EUQ9BOX#+/E' M1A)/]+1PFA>T;]85EJ1BPC 8]A5(K$9\8TE5L0\T0*^^2\+?X"#B?1"(5RD. M+;X0U@C0Z,]=WI%("M()T(FWN2*<9*K2V"Y+PB$*\P@#N]*95RW]$\*,MR^O7X6(X.CS5VW) MV\OS^]=>7E^%MQY?/)X$8K$4P!2[!HY5++OB= #9DO1UO.:'(.[(!5.096'= M(=&]L>>NMUNS:4M;BW\2%(]V/V"V_8K@@7CW[Z%>UAZKSOKK)*Y,TH*BHQ]G+O!3X\S29\U5F%$@$/3778;F+NS<1 GE@.G Y'?[EE9,XLF_170&W'[EQ&(S)X$2B>XGD(OETJHMC$G16[2B2* MG1 PC*^J2'C)'>\81U=A.2[K4AZ .VZ=BQ%:=8C[))[ F!0JD"_>^(62Q>J[ M:C& 1!&BI1O6D=19_7%0K@D M8A3;,$U\!% 9@Z_ ^X0L)23OXKS1S'O]&SD8F#@;33PU_VAWQ"+2_Q6)MKQ; MY[ Y"C0M14#?)"$0P[B$&L,:T9M.'%Z9.#O< ;]1 MB2B2&,&MZD4/Q/]C(Q3#; Z^Z15;(82)&9V 3,*C0T?;<\>6F48S^X'(@@!5/NK =QZ*=:C&\S' _[T9\1/9<,D#"/AEIL3]0HROP$HOG/]Z0 MI2*W@6U%JF!>U,C[K59K$B0)3!OGY?AP%#(Q>?3'[#!V0E!\D&FI&C#("21B9*&*1BMIO:1G11*WT8.$ MN(/XZV_!;H2D+'8]G'2/!\0/1G>8+A_Z$U!8(8DMUOVG@ 6K)@NQ\ MDJ;TW'\K#V:OR2UUI 7O&I^4N4HRFL'9>?TNNBW$RV$+"G^8/[I INE$D!E9 MEK*KE G9E(-H28&=H#NR#@L= ^Z"0A][P^:15(9V890D0*H1:N!1J$#PWDM0 M:K\22JB+13[1E@UB*YP=\WMABWQPH]2"BX^[>:&2Q ME^=I_!,[_]+'EQ\94A@.PK4N7H."Q1 +JM9A4W/)2F@H7":I,*8T/W2_$:!P MUA,I2'N0H+'BM*OCH1Y#L@Y8 ^)LF43%D<(LZKQIALV", G;Z[&"(*BH.H(O M"JN8PSM)#/9@-83:Y#LUDP2"1"0V-$!%2(T0$Y6>47XM\#9U&>F) 88T#J?! M%'-BP2*YZ-D;\3%$&2PH@G'9Z*$*..F!0,51Q%Q 0+,DX@V2RP!- M40T_7N\9BH3=\ <3N,;0M[CAG68?8L#FM2@/@ -A79/P)S)GW8I<$X_2O+BP M7]A6,9\5TCPB&1*+-VR)280.-&";DS_!B;93XH"D%[8:^9[;J)K=B:I^FP*I MV*^A40YQEN[(C.";#X_C7_"T>]D3<7Y)&T0T"_A$-#"I2J:E!XS,*45D3AW[ MQ=%NBVB'S4"0*@6-Z7@Z)'%:9NT2@EFY-?V]:MO2^12"5!8=4^!B;8 \^^CG MVJ.9P=2-CE4<\Z%#;I"4 A/ C&YYHT:7;;@\8@EHF)K7((H4".*458G1B"XD MZIRH>Y^C^.5)Q1J39 +9]K#D%'X+'9,MN&05!5@5_3 M; UR3F$7IIHC=+WN%NI394;R)IZ794,6F"6A6N%1H+-]Q66>2!NRFC?>Q3^V MIUZ4)\&G7<'-@J/"9:(&'CB;3DG]5H#U_>0@B(KQ<4SH)6F\4?IX>DHR1OB@ MPL$IG[#DOR 2(:M\0CBFV0DJPD-+F_UB":76;5VB4$!"JVNM1LO%2$OO#N#?QN29A(W"V)UY'!K A+ M"R0D0H!_, V\03C]"]E$ +? (C-&JG Z"-0\8S;2, M!4]IR8FTX$ZP["-/%^5X)Z'Z@;4B*DCD>IH)E6XT/.11O'5BRGC),2 + M$T"!DB6)^HRUA,C<46 AWS7)*1I'B,(:A:K2U,&5!+27T6^WX6H8YP%\ :) M"Q\Q,N%DBJ;>X/D>CPY3#[9JEC0M)R\"NF* B!C1WV7(,L_D'EN MK02:&E1/1'/97QSGA^%SA3RF .#)!#+O287Q;'!+3*\IJ-P@FN_TIK=S09G*\-V)F# R1@#ZB[1@L MSLD:,M)CMJ[:)]*Q&L2)B!YG7^5 %HCX[P7P/ N MFRH7[T&LKB8V@TQEGN;=V.)B3+@>&3=D Q>^QPH2^?H[-HLSPN6_*>Q4V.4MD]W) M?"(D0A)&JO.=QCF<2/!4J0=!3GC!0CPU[-FY.VPH_5O+,]JAU7&]3E)]MRIX M+Z]?<4GLZ>5\HF,?:)V'-TX],%#E,6.*MC3@:RLI/&0-Q'_,V538K61KN)/Y MO%V>DW.3*=-"0'?4&G1XPW J M@@V=I:0(UW)ZD41X]53)[\3C?DSKFR<<6" M:^LRA&^.H VMV'L/]H[OC]HD]\HSTC!12,!=\';8>U(.2>^H# MT T-X5AY2&9P?")'QILYL%A(\-SQG,A\M%TG 0?7[9B(3$D8(7; \:/40]P. M:XG?2?<]9ZWAOM>']Z?F+2S1O_B-7\78\?!15.<7Y[.+XQ5:[5Z0'I1QJ],X MD=@-&DXO6E17C^MQNF%-J=6'!.!XC9K[-')"8!FJ/8Q"V19J$@/=$!:DYC99 ME)2NW)%.K?SH J20YU$:&Q,=Y?A4)CT "QOJD]*^&>QX6LU=V'X'* ?\L2W/ M.S#C5GJ-296RHJ=SHN&M%/0SBG+H+R$P:2O1C?.:U:)),EDK1WH.=@8I("[0 MQYOKBOROKECOF='16E3-=O!]<_$9KF@1P2@O"D?P%-R55JL;-3J%W:$OU6N; MC2_:\UN^Z4,^B Q_1FR,J$FV"' MEZ0X[C=+@K<35UE27 XNH!?E(XG^B0E]<)-XGXRPW*0K'5K20B\>QVYZD9[J M6I0SMMNN_:J[1"01E"0HF+00.V0:SUF2FKS7;D(F+M$>='#3+IR_8B;#2:&9 M13M^MQI$JMAPO]QADYUOK\O\48;07@=3&[IDQ78WY_'*K;8[GQ=!BS_+4-)) M.@4QRB]YDXD6R0@^##NHV4G_^LGLZ234Q=1Q8?5-(#CI0@E5V)0GNC-, P/% M;3JX&EBZ;(/R4LH$!'I(W'8LGC2+=LLPXQID('-VAV*SL7_UD.G!5A[+'0BS M_)TC7E@ZF#01R1XJX;519^2RH+"=>..'](A]'" MI#@!!GZ;6TD3DP(G=^E).7K\( MQ++OC6ULJ*S=E]S/=B"7-I=@6%-*U M(*N6(;+1AIC;PI=D+U//)Y(4:L0)E1 FLFG-?IR:3!]1@0QUK^B7ZK.G9@LK M'DM4;39G/_Y2'XXXAD6SM=RM)&Q7I8QNETFM\/HDD # MOVE5%=)AK>:\PL-D%"S\3A(9P!#:.)>VE6_WX*J38'Q)\Y?A ECMV(BMX38=\?<+\G,MIO]_%\.SE M_.Y^E"?1.CZ"3]_7N/./.>1\)H'( \> MC_SEIQKWIN8]+>_>+USH^4!DL*^6KB(X[I"!(1[YYE(%K4L&2%"S5=]0!&TV-3\XHOTY^CDHU^6C&J7'TS42\%E:(:(;1@TS+ M(*EAHRLE SU/*?D9[CJ%T7&V"'V8WF+$UFL47=D;'AGQG64-DP,*I29E 35, M]@&'Z'8F=><(9QC3NZUC7UK-AG(JOB#,:,=&,IA-L9=<%8B4J*%8V%75('GD ML^%:,/()0S1O(_KV),E)(AH70":-N2)S8&YY8G,F([:;E.T27?IH+MGYK/7! M=G1-W2%OO6=$* &3*6C/Z2$<>O3F;<1#;WA5\D8N60)I*F_9;\>H0"52#Y.* M?-WXHD+2RWQ\N7PZ@FLC)ZD()]LBU=DMRM1)<.I5Z&F8T0#'&#@EC/6J,5:Z M6#Y"RR4]<7ZXM'O5U$XG%$FTSH;@FRO:M[6Q[4*Y^P"$[JL!TN1/R./[2IDB MUPB#/HV:<:3PQ/KO[?).:##L^ 4)6'%A^SY,>&C1VABQ,74LT3_^L1= M/*S$L(V0#!L8SR?Q!,V!]*/2\=6 MEBF/3$/ MO^.M&=[*@F/Z[#&]=SV@-UU9.#7[SB+E$$IQFP12(NAE^P@EW)R-)42;4 M>$VH\:K+Y2?\Z,_2^@^U?&K)1_6031'K:/KHUZTKNXR-4N1D$MY#6% C[>)! M>-]7'5VT*W[SS5>29=YRZ1KL(,"M-NZXV]\]".57/Q$ARX)T(SU\2(]2P%58 M2?I)^Z"VG(33:Z'DSL4,OZPIT5-)<.-3=.%<9E("RM.6/LYWHGJ#?G)E9CB8 M/$GK5-FHK"4A.SUFY/-:G-98::$EEE3_&'+T8]9[_VD0?2EOFH$C".E@.]_A M3IC9@T]8 M=<2\00OY#J#"X#2_F#T69(A?\3IVBA*CWIX(J[>7/WB9\_2(O_X<0RHY1I)HYQN M2HAY*#DH$HLXG$>H)!C0SF&5 K)2=<4=_"$=R@UIOH]*JA[^_%+*H\I_6:6Z MN?T=EQ"JD4@0(,W87#W4PPIZ?R*O85-U?<'K7O9D=:]-%SVG\,1<]38 M7:RA)(<)2+23[P.,^MK]%X0")FEC9$>_#*-%(-]!/36_]7(:@C5E M].6.D::(E&?^C"")?KIY(.$-P=8*/][A46<^Y>Z+>=MVA<:G+^D^ MQDAUA1PA&]0/ QF8PJM=/CKP7+4FE_L $X=N?+_X/4$L#!!0 ( /:)357O82BQ]08 &,1 8 M >&PO=V]R:W-H965T&ULG5A9<]M&$G['KYAB7"ZYBN$E MZK!U5.EP*MG:>%V2DSRD]F$(#(%9 1CLS( T\^OWZQX !&1*WLJ+A*./K[N_ M[A[PUS7:K/5KBZ**3=W:K<;*]&\U'[X$&GF:<' MT^O+2J;J4?G?JL\6=]/.2J(+53IM2F'5^FIT,_]PNR1Y%OA=JZWK70N*9&7, M$]W\DER-9@1(Y2KV9$'BWT;=J3PG0X#QW\;FJ'-)BOWKUOI/'#MB64FG[DS^ MATY\=C4Z'XE$K66=^P>S_5DU\9R0O=CDCO^*;9!=GHU$7#MOBD89" I=AO_R M:Y.'GL+Y[ 6%1:.P8-S!$:.\EUY>7UJS%9:D88TN.%36!CA=4E$>O<5;#3U_ M?6=*;Y$:![\^$_?*%6#"KC<5BMEB\8N^X"_F8[1V_8.]!;519*[&V MIA!M_"'\.TZXLN+/FY7CY_\^E(%@?WG8/K71!U?)6%V-T"=.V8T:7;_]87XZ MNW@%_;)#OWS-^M\IV*L&#\/]9+P2"_'VA_/%?'XAON-4?,D49(I*ECN122<\ M[MUY!EBUFQQ[V-^WC-P]*B4N!4KFG3O)@1&QK&QB2QC%:S?/-Z)T]GI$)=5 ML4E+_9=RN.Q1$S*1D[DBKYBW\&D!R+.NQV"DYR[3%?MND'V2I6F%40F;;*55 M A7I!!%40G@3X0V@]I%P%L\NG#!EOA.5LCSS 3XRJURG(06R3 ;H,YD(^"P, M_#2YHIKW- S$+71DR8H-NLZ9WYI0">=A&Y %,%M9^MVD)5HE=PY\LI&KXVR? M"]B.K4HT4J)LX3IHLC!U2(D4G$#M.,DVH>)347&G]$:N\*ZN>#?$JO)+.S&7'.U&G6 MD6?. VW9E$%65:X)7HI%ZKQ8U[Y&1@F^ZQ-@$JTF0_[MN^!(?:VT#3TS; ,' M8E+"%[.+&_Z/7I$KLU'OQ(_#IIF?#\@9.9V6SULFS3L*%2\GTNG;S&)9IW!\ET*&&I-\"H:]37<5UA0*B[1C1(0-TPZ!7#^I7&?&]!!U0EM3YPD!"H, MFLF M%PD5QOF(M7>M-^33&@FF'[EZ]1^<)RDTZ7'&OCH,*R!'UX5 MS>*-U#GK*8B>;O]5@3#\C<'#KQLLMDHXF^ L)=A,O*:F!EC@QY ML,=,CQVOGBY)[7;;IP?:W$783YCLXV<5'A H4+0UT>W,)"("Y;K0/JPT-A'[ MFAJ[LQ1+E_5JC98-LX%?.6.29Y:NBU MCK&^>EB1:N2J81U9,7%9C)Z(/E806I ;;0^$T32=2MEJAF2>#0YO,G6E7>=\ZK8HQ0_9:B M;7=L0[P^&R?BMZYJ@T/@L^/7X2TWCOH9UE1*'##+%$9H?O@\<&=P_)(-Y9X3 M\=M)UNM?C,S[VK:CA+=E6!#XB%'=1PP7/.J?__AHTBW[-^+D_8('_8&TSL>S MQ1F_G(]/Y^_YZOL^AV?AZ)#/X^7IBS[?S_G5R7'P?,,JSV+J%E77:+TY#X^Y M;%KTI;--T[!!Z(TX#[ONK(GVT+?3M/?A"Y*D_'GOP&"8"=_ W=/N%X2;\.&\ M%P\_/^"D@N, 1HE:0W4V.3L9"1L^Z<.--Q5_1J^,!R/Y,E,2G"0!O%\;+*/F MAAQTOZM<_P]02P,$% @ ]HE-50UZO*T!!@ PPX !D !X;"]W;W)K M&ULI5=M;]LV$/ZN7W%PL\$!/-N2G33-&Y"D+=:B MZ8*F+Q^&?:"EL\55(E62BI/]^MV1DB*WL3M@7RQ3O'ONN3>>>+K6YJO-$1W< MEX6R9X/IX,K%ICJ6P8UVAHIVE-J5PM#2KB:T,BLPKE<4DF4X/)Z60:G!^ MZM_=F/-37;M"*KPQ8.NR%.;A$@N]/AO$@_;%![G*';^8G)]68H6WZ#Y5-X96 MDPXEDR4J*[4"@\NSP45\?#EG>2_P6>+:]OX#>[+0^BLOWF1G@RD3P@)3QPB" M'G=XA47!0$3C6X,YZ$RR8O]_B_[:^TZ^+(3%*UU\D9G+SP9' \AP*>K"?=#K MW['QYX#Q4EU8_POK('MP.("TMDZ7C3(Q**4*3W'?Q*&G<#3=HI T"HGG'0QY MEB^%$^>G1J_!L#2A\1_OJMN[\C;I#ZRC*#J0"_%9+]P E MNEQG]*+=.YTXLL4:D[3!O0RXR1;<.(%KK5QNX97*,-L$F!#)CFG2,KU,=B*^ MK=489M,1)-,DV8$WZSR?>;S9%KQ7P=?KX.MC'"P(E<%;+2DDGVE=&[3PY\7" M.D,E]-=3H0B&YD\;XK8ZMI5(\6Q ?6/1W.'@_-=G\>'T9(<;\\Z-^2[T_Y' MG;A/LWZO'<(,?H/_9I7$*%OQBQ&X'.%*EY50#SZ\+[$0:V$0O@B'IMT:1>_> M7<&PW=P'/G0P P&%+*6C?X44"UFPL;1!2T51T,8K=2>-#G ?\2MXH%^?'27) M]"3L^45\LC]N9:4%O5:D>S#]!18/?8X1MVQ&GOB&(VFJ:RX8H@F2GG(C M*HV9FNK?>+V-,(WAM=&E#P\XS44=CUJ57&2@--#):P2?77;,D;S%RF&Y(+ @ MO#6F9!\-9A%5L*;86:P$X2"(E4'T[ *GQAJS)ZD*4[F4*51&_TU')@SI>$1# M.$Q/6&B">5$R-MX]AK.SFY-4BL;1**#T*-\OEEA 55 =,0QAW\D,Z31/'U). MV]JGW[6^:D,Y678@X<@&+0OOX(KPUW1^4S@^=4'MG-H,B+>I)A&&AK:76Y>KNV"Y0JA50J^K41^4Y]19!M^Q]O\W"NQ[+,7RD M10?R6+_>68H)#40N;-]* W%H:U*M!:P'N'/(@X'[422I:Z MMCU$KX;1I18F\\&Z]JWFR[$ET#C%UC(V&W3Z(&8W/.R$ITZJ#8>))9D]!,8T M^+ ;?+[*HS:+E$!M,I\F)SC]=ZAJJK[-X).-/9@?CJ;3*1(DQG"1?"I$S\_L5M'SG%T2]^M61V\VB85;<0TNFP*F?IK@2NI%-,B=>H( MJ3D:WFQ\0NXUIPH?RERL6R=?/$H2'\+H';5#2,A6X6$3YOWHI;2=@9\I)8>- M4H\^)6:#>#R*YR^\V,5CA+.N<\-WO_#9V2RSB,^CMH)"48@^@G74 6UI/PXJ M?XSMKM\^,,]@_W6A_%')5X1C:-VY97*4SQV66ISHHN1)'%T)F[/7OLRB&\/B M+DQ'CF/E8?9ZR?GH^T98BS2^_<9L[CB0=?G]1!0>5&&*>X=9O,^""_ MB'MP[4>*;,9$3["!IW'NS\K.M]:!#Z%=6/;PP$-^ZHY>HB+]@7PEJ#-$N-3T MY_YP'C<5\4<($U4QWM/US9+R,#E*FMWWE',^I,G*,#YH2@^>^A:=]"X6%.J5 MOS[1D&>NX8[1O>UN:!?A8O(H'JYWU\)09UDH<$FJT_'S@P&8<&4*"Z7'O\WIULF&A:@_:6FC\]FP0:Z>^OYOU!+ P04 " #VB4U5\V]6#50% M "/#0 &0 'AL+W=O[=F?J$;)X6"6\-L4U7<;*Y ZO5EG,;=Q@>Q*AUM MC.<7-5_!';A/]:W!IW&/4H@*E!5:,0/+R_AM.KN:DKP7^$O V@[6C#Q9:/V% M'MX5EW%"A$!"[@B!X]\]7(.4!(0TOK:8<6^2%(?K#OT7[SOZLN 6KK7\+ I7 M7L9G,2M@R1OI/NCU;]#Z_J<%P M)]2*_0'HW,78(2B]&N)/>Q8G'F_Q_%P/ =#\ ]<7,UCR'RQ@+WX*YAWC^XEEZ MDIP?H#?MZ4T/H?\(O8, ^^G]J1VP*7OQ["Q+TW.V8X1]+(%=ZZKF:L,D[5B6 M@W'8Q&S-#92Z02&N"I9K4VM4A4@OER('YBVQ!G-M4(#I'MC#,+XR -BT;L0^ M [:' X-5"TPL29H;P]7*OV?",MXIX9/*H:8^';4,N;7@4,0 \UXI!P5N1KL& M#;7=D5X>-0,E).[00P.2DYH4?"&D< *> K8P0Q$,@FX,NJZLEJ+P$ LNN2+W MJ=/L:!#0/31>4MBSY/S#S2>_2L]?10-JNW0,Y'JEQ#?BX]!LA?')0Y#(N)\Z M!<,11CZUW-D]EPTPO6SMUWQ#"I;I>TP,"89]BO^((9$V-I&!#H%\]+29TRSD M.^15;L@O+\]P[.^@!1>>!&T;5R^D6'$_=Q&\XE]@AV?$C;!D9FET]6AAQ'X% MA9&5S^0A=&PP7P/GIX?-H&5$)6; M6B.X$SD*F*W,$T.?&^O0"U)#F^N2&@??(&P10D1OUKJ16+ 02.SV2U\*1$LU/Q(L0+'EJA($!MJN@<;5W$8JVU"H77!0$>\,;0C@_;U+5L?8YR M;DNVQ&L PH3K1#C90Y-BG;23J*LY9"YTX5N$TZY$53N+PGS(-=: H[Q&>&" M/S"Z140G!QT?Z4 8-7>;]F4;@H)2O J%YVGS@G)M'4G?^P)P>_*Y-2 P,2[T M+ :B#3J^?\6>L].SUTF2T&)*B^@&P'!)KL"L_*< -3'6<+@O][O]U\;;<,E^% ^? M*N^Y60E%,W&)JLGH]#@.Y=<].%W[*_=".[S ^V6))Q(8$L#W2XW7L_:!#/3? M8/-_ %!+ P04 " #VB4U51J"XNS7 OED21'_F1)K7<:?/=5@#([FNI["JN M$)M%DMB\@IK;,]V HIM2FYHC'S,71*>I1"U*"LT(H9 M*%?QY7AQ-77Z7N$? 3L[V#/'Y%;K[^[PKEC%J0L().3H$#@M=W -4CH@"N-' MAQGW+IWA<'] ?^.Y$Y=;;N%:RW]%@=4JGL>L@)*W$K_HW5OH^,P<7JZE]5^V M"[I3\IBW%G7=&=.Y%BJL_+[+P\!@GCYBD'4&F8\[./)1ON+(UTNC=\PX;4)S M&T_56U-P0KFBW*"A6T%VN-X8JJ_!/>.J8*]_M**AC.,R0<)V&DG>X5P%G.P1 MG''&/FJ%E66O50'%0X"$@NHCRPZ1764G$=^WZHQ-TA'+TBP[@3?IF4X\WN0/ M3$=L([G"AX39U\M;BX;^D6_'N ?DZ7%DUS<+V_ <5C$UA@5S!_'ZV9/Q>?KR M1-S3/N[I*?3_4:&3.,>C_*01V(R]8,>]/!1#+\XU=:5%IDN&%;!22VINH;81 MMTY&I8.^=-Z4-N-%=$,CI6@E/.(MZNT.F\@#../H U#O55H63-2-T7?@ WG* MLE&:IHM,:); UP+(+?Q&6Z'-9BAP&#()9,/I-=Y*>>_ET/O4W-WN+4%LV MG@>T;HUFF;]G%VE ^ #6+FC"Y&W=2HY0T&"@).>"A]%#+'FM#8J?0?#7+$L] MP//!-CJ>[!%3X(A..Z+C>8C]U= #W-.4MJX2QE=D#]Q8!JX5?3*C_U3#!=0J M%RIJ0J5-$+P1 LTG\R*(3/#8UW2V/TH;^=$0@O"KU3O7G.&X%1F M*Y1E$DHR3<\N9C$S8?Z' ^K&S]Q;C33!_;:B)Q.,4Z#[4E/C=0?GH'^$U[\ M4$L#!!0 ( /:)357R"5YG8 ( '(% 9 >&PO=V]R:W-H965T@W<=AV$&Q MZ=BH+'D2W33_?I3L>!F0!N@E%J67CUY*H69;;1YMB4CP7$MEYT%)U%R'H[,R'(4#):]J5+;2"@P6\V 17R_' M3N\%/RK#C> MTS_ZVKF6M;!XJ^7/*J=R'DP#R+$0K:1[O?V$?3WO'"_3TOI?V';:$8NSUI*N M^V1V4%>J^XKG_AP.$J;1"PE)GY!XW]U&WN5[02*=&;T%X]1,=A82\YTJS'K6LF,E+[#B!.ZTHM+" M!Y5C_C\@9&.#NV3O;IF<)'YIU26,H@M(HB0YP1L-U8X\;_3J:N'78FW)TE$#B MF=?R%H$T_ZV-045>ZIX5-*"+HLK06!X E0BWNFZ$VK&:A&3\6YA,KBZB*()D M&OGOL8,-#_J J1O?[18RW2KJ6F*8'1Z41=='_^3=:W0GS*;BBB46G!I=7KT+ MP'0=W@6D&]]5:TWV?0O4$L#!!0 ( /:) M357H<(8L!00 .4( 9 >&PO=V]R:W-H965TQV07/;/@S[H-B,K=66?)+<-/OU MH^27IEB:?4DHB7SXD!1%3W92/>D!F4C M_-G%[*S6;R-H47.!*@:[+DJG] @NYF_J1 MWVT\\BPW=B.832J6X1K-;]5*T2KH45)>HM!<"E"XG?KSZ&8QMOI.X7>..WT@ M@XUD(^6373RD4S^TA+# Q%@$1G_/N,2BL$!$XWN+Z?&AW*'_Y&*G6#9, MXU(6?_#4Y%/_VH<4MZPNS*/<_8QM/!<6+Y&%=K^P:W3C*Q^26AM9ML;$H.2B M^6'>X,7#'=5)(72N$/^<;;11=AK^. M1=M@C8]CV0:YT15+<.I3!VA4S^C//IY%E^'M":;CGNGX%/K_E^*D^7%R%M.[ M@H]GUW$4W<(;%]Z:.CRM"P2Y!>%.JO:$BH"N")W@V6K8DD3>?.A@.A3X$5:K MU5D$'WHOO>0MCNK&O684C@=A&'K+_^C=/]S] M%%:(^[?^^;-*P@^&[_ \07 M#0"1^BI@7BE>0'3I+@^Q-SEZ2UE63.QAQS1DB@F#*3 H)!- 3YH%:SF<$S4X MBSY!52M=DR(8:1$L*4I4\@0K11S=8^*12& EG-M(XO"6;)T4W7Z"FCI!.#N 1"XY;8"*%^T0*6?($UIC4BIL]S!,#Y]:LQ5PR*J/=[9"' MT%!LV%- GFXKF%JN]$39"\Z[/+B2YI>XMI@I;/;.>%VRHH!% MK>F2:@JB52&'-GM=UM:+^;&LS1_OUS;N(7QS26P*Z%R3A_EZ">,KJJ[M[(&E MP9)$UE0O6\^## WA0< 7MG>W(1HTO!9S"Z3D,Z:>W2";C,:"8TEM<)A@6O:W M P:>2Q/2($ID)O@_[AIE-/6 9@N^&"ZRFNN2E5&R1.3)[9 K0OIM] MGSFJ0]LW7RUWE>007QX$\,YU?D,U>I5>VXM2\;DN]J^-T>>5 D+*0-\5#5;; M8:/AU46_./;&!0>CIT25N0&KP16DF4+];C_#Y\WH>E5O/@ HW(S3?2IP2Z8A M>?9!-4.U61A9N4&VD8;&HA-S^@Y!917H?"NI/]N%==!_V()!"RBV),NWW "GS6QGL9T)FLX6B\4^,!)E$Y%$#4G9 M]=_O.:1N=FVC[13S$(NBSOU.YF8KU8M>,USIH>R MY 5\2:7*F8%7M1KI4G&66*0\&X6^/QWE3!2#NQN[]ZCN;F1E,E'P1T5UE>=, M[>YY)K>W@V#0;'P0J[7!C='=3'H[6 97 M]Q'"6X!_"[[5O35%39ZE?,&77Y/;@8\"\8S'!BDP>&SX&YYE2 C$^+.F.6A9 M(F)_W5#_Q>H.NCPSS=_([)-(S/IV,!_0A*>LRLP'N7W':WTF2"^6F;:_=.M@ MPW! XTH;F=?(($$N"O=DGVL[]!#F_@F$L$8(K=R.D97R+3/L[D;)+54(#=1P M856UV""<*- I3T;!5P%XYN[)R/AE+;.$*_WS3_,PF%W3MSP5L3 W(P,,$&P4 MU\3N';'P!+$@I.]E8=::/A0)3_8)C$"R5KRP$>\^/$OQGU4QI&/?HZ$?AF?H MC5MUQY;>^ 2]AS\K87;TO\MG;11$Q/^.*>E(1,=)8)9DG/L**/D!M<*9XX*/I[0=\S M%:]I,$-?^ N/FC6G;V1>LF)'4Y$!*"OH$O(5/$]8D= /7!MF8'^IC(@SKJE, MZ:]%+%4I%7,Y"6 QU!*$,EM)"\AB$%,XV+(50J,0CF4JE#;X=;L6((_0D(-: MK I+X\GA+COYB9,?&2&VYK&$Y0ETIAL*]X<6&-*/@&ZD81DMJOR9*R2BUTPY M6<$2.2CDN#G:9@W4>]J2-=!GE5E+A3%H)'#7%4<9 L_W_>;O%%74(3@&=>BL M5KO)(3#\D*/Z+@^)>);=,0)?:3 /"IE96Z,KK(S:J_W)BYAK&R"E$AL(G)73 M B%/$4-C/>]Q?MY9A'O)E'7G6Z&@SDNEA_2!@>I6WJ,F/"#MO$)+INB&997% MN?"'OA\,Z=(*!C6(MS7(V056@0U'X(%\"MES1VM2J4XK9%V?6&+0*B%1BD04 MJ^&^N/_A(-6#_;(O!7U;*=Q$$^P0R&;=H:2]#"4UOR#T_%G@S>:3_A+^K)._ ME^HX\B)_YLW\!9GX7N""]+NI3;UP.O,6T93.O4D=?A][Q:8U'65)(C"S("=G ML[DW]1=T/OM+O!M^H3,(E#V+$TS[.'$MR$JQPCA)^&<>5SA?$)E"!87J$+6I M$_I_U1[SR02,ZY-9,$=*9#RS!8-$WG@<@+5\$@9NYU3$!%_!/3@>,A;#E+."TA MMV4"N(4L+E$'%Q!0@9;-C-O4M;[<;A#%#F"EWL_KIKA D!/@DX+H79 GV@TFZVX$>C(,YF*CY!FH4=O*I6$8>/G,5"\WIOT3* M2>/ 1P4!3%]A*.G7Y/>>^9G9$]>G0=NXZ 7&Q)A.A_Z,7-)_U*EAYXK@^O ) M$#!3IUR8]2(_PIR:[('X ^GLW/2A[1# MN6A0HO&)II5E>XE4IQ#98@=+*TR0#8QK=4?B3FZ,+C?W"(@9 0>QN.N1&-9' M*.)(<,B>;F'SHJZIY G.E4F562(-4I_0@0!M6/9-T>P]].":H*=?+-K8/WAV M\?^;F^C:;*$GOQ"7'=CF7"AY#K(K%&A3Q3,[.8G"'>6Q\MH*=,QCO3I$NSHTW'/>(9GZT M< RC8;3H&(;>I)ZNCC%\U9N37G\+VY!. R\*9]Y\'#E-%S0^?*&!P7E:K"D[JP9'9LIN<\;2_03N52FY$ L9F;5WI10*. MC>UL;F,^ZLX%*1-J/S[;R@2+1-LHA" 7.=8_4NE&Y?N,Q2^7$)42+R=R#B?S MQ%[QP=!9N,L&6_=LF#>5C-5A9,=3UX:NR+)[(8WU"*I-/@C]R(;*'#A#7]=GIP.5B>+V;@J#"0O2%Q '1/@1N[3:52 2 M70L8MR'Y +\'I=-N=R5 M.AJR*HR[=VYWVUO[I;NL[L#=E?][IE;07FC&4T#UA[/)P%T6-2]&EO;J^ED: M(W.[7',X>RD$@.^IE*9Y00;M_S+N_@]02P,$% @ ]HE-56!2UY\5!@ MW0X !D !X;"]W;W)K&ULE5?;;MLX$'W75PS< MHD@!QQ&U#5U72P0Q[(X M')Z9.7-(GF^TN;,YHH.'LE#V8I0[MSZ;3FV28RGL1*]1T4BF32D<_32KJ5T; M%*F?5!;3>#9[,2V%5*/+<__NQER>Z\H54N&- 5N5I3#;:RSTYF(T'S4O/LM5 M[OC%]/)\+59XB^[K^L;0KVGK)94E*BNU H/9Q>AJ?G9]Q/;>X)O$C>T] T>R MU/J.?[Q++T8S!H0%)HX]"/JZQ]=8%.R(8'RO?8[:)7EB_[GQ_M;'3K$LA<77 MNOA;IBZ_&)V.(,5,5(7[K#=_8AW/,?M+=&']?]@$V\5B!$EEG2[KR82@E"I\ MBXK9UV%V_(O9\Q@^:.5R"W^H%-.A@RE!:?'$ M#9[K>*_'ORHU@<5L#/$LCO?X6[3Q+;R_Q6_C@S?2)H6VE4'XYVIIG2%&_+LK MYN#Q:+='[I(SNQ8)7HRH#2R:>QQ=/GLR?S%[M0?O48OW:)_WW]9C[^S=V#YJ MA]%+.(2^;R!.@\L1MB@,(%^J8D M30 9G#KO-*WH27N_];)O:HK5L_:S%7<1XU47?K& []()[S)PJ) MZ"=N'-*2M?E:HL),.C@XH;_HFRBJ$)A@2$)1#N)3^FN@,>BN++[\\U?M]QO, MT%#JAK4BJI*(0F9T"0[+M3:T/T J*6<&:04;2>6SR+E=*=DDMG;"%<4'VJ8L M6D\$-LVD(G"2 C!(#GV)UY4AUI$1S_"&#+9^.8$O-(T5(;A[VM7'Y)OEJ@4BK93VC@=+4R-@ X-[1P M*^HF%\;[P#>R*/S(DK+<$E\4\@=Z.TY+PX^:Z,/>J;N0ZE89'\.PWSCKU[2G MIJ!]@:6!^X9@PQ0^CH+'F*@[*C2&5'O0)1]J6,4,?J^D\2FQO1#&/FF4(ELE M^>.*V+KP)G![-O.D7[:@7?U$R."*; MN;=?C(]?!N?OD7!T24]I^]85)>V@,WX.!ZT]//=Q[/+^M-6?[NDJ\=XX8$-I ML[ZG$R.7G-N!T+B<1G)=I/5.$%2CWKVXEVIZI4PMS[DE9MQ>2_3>@ZL?7O0> M21.K7_[DVT(9DWO!!QB>,HZ2@N+SI J#DA2)H+K@"Y4H MF"G$\BY40N"M9$D&1NJ4NZ4[%_%$.A>I-C9;-<+8=$:S**%LUHL&ZS$KQ9#C M V":4F!:O2;G&E+*@N\_@I"+>\X:K@];%O2.F!%!HT,+K1#D>C X@5W'VFGORE&B6?F+%5_4$L#!!0 ( /:)3578LM+NX@0 )\+ 9 M>&PO=V]R:W-H965T[1';)#[JXL1QFO9%(H/Q MJU&EM.E/SZ/LSDW/;1-*;?C.D6^J2KG-)9=V?=&?]+>"#SHO@@A&T_-:Y?R1 MP^_UG<-NM$/)=,7&:VO(\?*B/YN\N3P6_:CPA^:U/UB3,%E8^UDV;[.+_E@< MXI+3( @*?RN>*X>%ZB_YKY XN"^5Y;LL_=1:*B_YIGS)> MJJ8,'^SZ-^[XG A>:DL??VG=ZIXD?4H;'VS5&<.#2IOV7]UW<3@P.!U_QR#I M#)+H=WM1]/)*!34]=W9-3K2!)HM(-5K#.6TD*1^#PZF&79C.;57I@"@'3\ID M-+KDW&V4. $7S;.9AL';Q, MGD1\UY@A'8T'E(R3Y F\HQWAHXAW]%\(TY7V:6E]XYC^FBU\<*B:OQ\+0WO) M\>.72">]\;5*^:*/5O'L5MR?/G\V>34^>X+"\8["\5/H/Y^S)^$>=_:]#4R3 M,3U_=II,)F?T=-@^V(TJPX9FN6-NE6X-O6O*#4TD<^/3 86"!:569A-!7Y]Y M6A>VA(Y=&\YZOEEXG6F,!@(".\Y(FV#I3@7L:>:]SDT5E_MKUCH4%-:6:N4" M7!F0AO0./'0FJ@HJ:'GYEP.98NQH7FA>TO4]IXT,!;I=+G4*^8OY]>W+GO!+ M&^?$_A.GA;&ES3?TD8VVCFZ4P;1R S@/'PEF ;,/DV %B#8X%8?"9KC1K&RY MBCPB_6*3.9MMC*IT2JE:Z:#B:*J=A:GG:"'<,UIL>F)Q0 2X6^^O;T<_=I * M!68+9HR^&#J@(IH':1C26T-\GQ8*B7R0(%(28='OU0H[3D_[H-;2H12LQ]DW> O;!7%\22U<$IW"B5!(V_-+J.%<+5 M H$6%3G?6P_I4X$2;_EU%219E-J#-00HQ\-PS?=9VKF,,NMA?X/(3(ZDO"?C MB/M->?\<<2&V#]S"HK#72DOY@(-VY.0#$T/M.&4<]+9908Y:+J%0H0Q"B%#22#)#W)(Z&5V,8RA<+;)"_2OX=WHC>YA,1E*:\]JI\ON M;'Q*+]!>"BY@Y--[NT+TP2=)VMB\'/1^U/OTO=Y7*-"J+FWDM\]:U_9 O=(( M1@!)E,(<#Q:=JC*Z.C.JW(2XO6(9#F+7>R$VXD(R/GL;>\VZN)V1C>F1^=C9H16KJ[G@0HW;TKU@L-E]YY?$&DKA][05(Q+&P;Z](;HAA+O<\*+!!KZNP MA(SM /S!$,N=BI/Q(##:4\W.HYSU(]1H2VU(CWUT1P>/)G1I'I^&GE)):_M^ MVDEWK\]9^^C:J[=/UQOE 9 M>&PO=V]R:W-H965TYYSYD:98OP&NQ\22R)GYLRY MWV9^WM7-%[/6NE5?-V5E?CE9M^WVQ:-')EOK36JF]597]&19-YNTI:_-ZI'9 M-CK->="F?#0_.[MXM$F+ZN35S_S;A^;5SW77ED6E/S3*=)M-VNQ?Z[+>_7(R M.W$_?"Q6ZQ8_/'KU\S9=Z1O=?MY^:.C;(S]+7FQT98JZ4HU>_G)R.7OQ>GZ. M ?S&GX7>F>BSPE86=?T%7Z[S7T[. )$N==9BBI3^W.HK79:8B>#XVTYZXM?$ MP/BSF_T=;YXVLTB-OJK+OXJ\7?]R\NQ$Y7J9=F7[L=[]JNV&GF"^K"X-_Z]V M]MVS$Y5UIJTW=C!!L"DJ^9M^M8BXSX"Y'3!GN&4AAO)-VJ:O?F[JG6KP-LV& M#[Q5'DW %16HVK]\TJK8I_4D%1E:L;(8^JE^JF6%7%LLC2JE67 M659W55M4*_6A+HNLT$8]<)\>_ORH)5@PXZ/,KOM:UIT?678!41\:;735R@^$K7=%E599D9;JAG[4Q+FM4?]]N3!M0ZSW/T,H$@#.AP& M/+XPVS33OYQLL59SJT]>_?3#[.+LYG.K36I/09?5FFU9[/,@\#G6NE@Y=B0GH6J>W6BVTKA1-NDT;>@_85JO: MCN>)20H+,U&[=9&M\2.-WI8TAU$M+4FZJ70,361)C=$T,RB&I_2E+7DU>IB4 M1;HHRJ(%-^,- G93M )+4?& "K)?TI.N,1H3+CI#N#!FJBX-]!+T"\%95/?9 MK J;G:B\:^C-!*OL==HH#4E0Q,?:\_&$8;B2:6F-K&N E%15I+#+VAA ]*.Z MF#V?G)V=J?-GY_SWDG\?F6F=&I6E9FUWF:0;2+=,=GX^XTD^1>]OTKU*2U.K MM 6V6]76JDD+PDB:YP5P383,]:(%&A_5M)>_NZ+=NXT3/FC LB,4DSUIF#B6 M)C61NKXM\G@FUN2,Q'1;M&DY!2R-5H4A$!>$=79%628+ MFNTV+!98PP M]],/S^:SIR_QEL[-1$"(,8OU%=:GI1.:(,W6A2:NIETN:2\ *$(!03,Z@P>A M(,#L#L#Q4"D=(:I>E,5*YIJJFW7=E3G1JB)[RBR^)!S0%(GL^ !5?8X A8F[ M6HS 8@'(J1I1-T^\NGDRJFZN0./3V?,A33,ZO_G]1L: MD=!N<[TI,I47.;%3*THG)02TNH&(0K0*0DK60OF0W#M3HOLI8U$"DCJS,;0@4! MUW8Y0X"':7ZKH?[L]MW/Y.4M2-U^84D&I'JY)&UH@+:= "IY;++P1[$2OCC MG[$BHX4W=:O+?0(T=2T9G'_X+5B.IJZ(%4VWV!3&6)-55+=UD5F3M$WWS$2C M4GCAI?!B5 H_D+!DQ;;4O/N>3S,DF*.3#0OFR HL,]\TBQ:;FDF6BME3"2X@*8>9W!>0GA C;P 4K M79%T@R;T7&\MQK#(Y^D-B0:)-8$7&RW(7OJ%Y,Y#"2+ ZI/CP41ADYFRKK$N MW[9N,+,SX7V_+_+RR.DJ3%:*/--;L*4$,)O_P0'*&N2L/T2]+49\@*7])2&$0/#6BM@71 M39M,$[].V(IXNL*06:]LHTG3@0XT06N=T0B_JC-")8P'@!A*D6CVA52UZ&G[ M=9S&X24L0<&T9O>V3;\*.29 M* @A$'MZ@W<;G%]G ')V.G)"V*'1BV;>@/-82)\C0KD,R^0ST8%\J.EYDR>-_FUVSU:- MMGI.-)O-Q.AFHA[,^X/!N"3 G!]CR@2//+&*SLW=FYIF>OR06![PDJ=AP8AL M#Y0HA/C!^4.6E4P\T,&WG%]H1)/K&*(D@DBTU8,G#]D9(F[[1YQ:JZD(X12N M'-D.'$I#G\RRT'G? :XKJ/?MMBQL#'Z'JG42$,QD$P>5@J*%A#F#05!&K.]T MO*.SA86',WN4FJ-(PK7^:CUIY^IZS4.O,\Y(11@$9? 4LK(0OZK'TR8MM=.6 M?Z04;7XDE)!J-5C/(8U6Y$T0^'F'+:5D3_%Q"P*(NZTN",$HA@QT=1AJ&4)Q[E]BG$L[[=C MDB;& ;!CUJE8R%6#+(-$KYB3 E.*LRJW43*G;5,L.J (1@1*'+&U$[H=N%7# M7!O2_11?@=I]6HH!M: D"!&$RS>U:*I^K7>$(I+_%;&VC"U3&$2K:&J*Q6^U9;NT]!*I MD56R)/!)*#>2F$"L]A)B#%-)(XT$,[)P)0>\Z^8T0OW.I- 6@*03#><^6BL M%$_5Y_ \;7IX1')?\HV"/IEIL3\0HQ%GXKEW)IZ/)T- #N"//[PE8T=N$931 MD$LQ.M61[,BQ^7LZP$D#Q37%:DV\+C%V[!8F;/XH*%X52,N1R'4V0&91(5-& MPL)9?(3HB.Q%0S"_Z; NIR=Z$3N#1Q]FAZ$[B @V-:&W,+%#1;#F1 MA%1!%J4-Z$4R"IU$8N_ $QL 6G+"1^ .J,-&^S9A04&MOF4+3E)-5.CE MJ)![AZ0Z19DA=]1*3D1_)45FO4!BPBW;[%HPV\?W0F=I9WJ9+6-L-E[DC*?= M462TEE01-AVH>VLCL[V\3_,?H?R(E,[.0FWL;%1.+UWZX2.K3JB]P4K7Z"S# M(CHPM?*_->$WZ*@00D-;-6"Z5))V-E.41[EKQF1Z&%XA .4R!6H&^B!_J24H ML[Z;=;HB/,.@$N7S*!\3($R"VE15MUF06@?[.75+6CPK&K( %#8S!^PDD]^" M%2!T*MU93X/L" $)AO/:UF<.B<@6GEY"W-,^]KKIC0Z^2)C.8ITQL6"16;3L MT+D8,?=."&-7K"%Q8I?YHI(W$Q%QG(T/LXC%A0 E44;#2Q;;.(I:^?5RSZI2 MT V7.K)XF/H.-ES5F1=Z=,W2\.4\OD%4\D )9 M4.$,R;54[,P0"QU(Z#8EEXSST,?8 3EAD!KIT+M:/QG5^HY,'E30JZLLACB) M/;#BN*Q'=?#9J*Q?NQS*H(2/CAV6<#^A"I\00K7"*1+5D(R*P&1P=FF[),") MK6!BOUP'F!*B# <\P2$3@?,L@M2(U$6G_>60U*R9X$N(2V'6]'E5U[EQB2LI M8QN&P(02(X5L(8#1@^G\.#[ZZ8?9T_.7ZK'*3-Z$3'LM1#LZO>S]K_W*,:T#15;X WTCR0PZ2(O($0OJ#NCY:04T#D M4FX^1@@Z@\SALB/Q*VZU+ZQ(+G*J7NL6!)<,74-F8$?.[\2F%&E^$A-2@0T, M ZI--C-*C[2+-(JE[D\J@9#45:'/7MKDFIV!YV:72U=L/:P.X6$VC8EDK&>4 MJ4WKF]8R%"KQ>4*"*EZ_9@_%(TO2!)E3GXUN"RYH!]A0+;EUX>40VSD=,/'Q MU HN/CQ0+HA7B/[8)Y*24@%[N)\6FA[CC)YBMG&L<(=MA#_G88J M\%ORKFM0 *3=/3E]JOZ+ GZ3O$>A7$?+/K$/?DL7T:_G]M>;+Q1*F+U!SM;] MJ'X/-E$,B_,YTJ;A;)JO>V[M5I/^5I%V062I$/-)LDYR/E*1Z'D:!1FA#,DP MGUPZ6 9N/@+.A1 1%H_MR34C1OH-["00<_BLOJ@[B2L6MED%PN-IQPK7%NSA M B\YB>O],.9])+ #GUN_.-#$5U6Q5T2D$5]/$X'2]*8'/TH81DCI;SDD _P" M$*!H2R(^?2DA,'<4\2'2VE41:#:'YADU"57K<7L)W$9)K M'Y,.FH#O:*0Z-G\_3>;<#:[ZAKB8LXTV-XVX:SA]$L=/1;4DW'!VSYL 3!#4 M6G!FT] F@^J0;;(COZXCYZO6DHFQ6:>)J!>.!OK5'7C4/M$O6OIH^8<9IT#Q MX3#,8)4FFA;55)J!WN>H$CE\8YTT:T\DR8NTF^_O<9EK6W#GWHH*CK_,F>N! M:4+V;FP:<.M463(2#<+4R0,\>Q@DZ]B^P>QVYM@Q'C(ZA)&J1NT8EI&8J/5+ M'\%FHV\+O8-D@'6"D/T?:3"7$#VNPHH#C]%63:V45T'5?@M#XA^(1M$;I#*: M_3'5L2%BT8K74$PBZ'>2IX!LYE=^B)2Q%!BFC'4-BU- MB#'+S+JLD!0")RNVAV^CO$9,%:Q[CC2!1*O%A:B\N0>QN):3_ZLSK;4'3#*A3N+R@T%7 M8J8RW=E EO-7#BKK?U$(D[%TC0M/Z&&:N)I:-/(@Q:S@8C%"?EH$>E]%.* 6"&B7IB0@@B M[H%\CWED=*VD7_[D+B*9PG71$8\5'(YYWX"?]_?5X\\[$!Q4C0@]\HXT%V;2 M&B2VJ-LZ ^CUCH/>&X6N(IV?'X+IG<2 D3XQ.V8+2=@TO"9R@'732 3)30 , M1&)!Z%DW;_,&H0>['38FW!/N!T9K]4=-BS]^."YTH65Q-MZS^ ZF_T]>]G?Q M+HZ& =_1KS@\>R1-\[/3V=EP1XIM)9-6Q7[;;K\JT70VA;.HT4TRK/UBGJIR M6VV-S *3P192E)S86OKJ-NON9 M)#LD5'XK&WE.T*2G5FX&NXW1P ]*XX&P; M>"?$/>&M1!JR%MKW8\CA".^6Q=TK"]WN8 !A--@U2QL@XTXNG$&5-@H'Y\2F M5*2!*:'(FCX)@%&/GR6<$_X:1Q"BO7)VP< Z(S/*#4GAX;H@=[K)UGM&=+"Q M1;7M7 ]X>(UY=$U*/,IUX(D_W=\X M:R#I-8_/-VS2YHM&6((6'KR=V"Q'Q-9L\VVK(E)FE0\ >A"&CHDHX6SKG,A8 MHR\#;PJTXAT4_7C7ED:.P5&),UPA^X>>[D^GHIK+[AUQ=".A]"Y$T"_N=,V8M\*R.$ 1P*R#K-?@'A;3=.=L8,J@NLF&&CG)B M C(G%9=U7ZPD.QQ3+:*52)9M );>6[\R#[$-S=#'--)G OU#H,-Q4ICWF_T% M=Y.E2=1,X[U4Q\H#5;F)\DW)D_"<_ 1Y2+\TZ _VC=$<7GYB?*IAA^38_.HO;1,7EK>YP_JP+=LU9"?N-*-OR(8_X(^EB(-1G89? M[C1JNUP<3ODQHT>G(J8 QA)51C+0PK[>%V1'/SD:ISR=/9OX2KOUKEC'1'8B M:@WT?2["P?T%N4DV*%C'2$ ,CXI&PS)$J]@61D9_K"U\R27OKO(*KGE;U9C_H5XO(%,E<'U8+4>(KX ,;2-G?<99F8W8^N26YZ M);?W4Q%7666NW.K=/2X-(_O3"$V%!N_/]%77)/ MU*GCJ/MX3Y'IJX"09C+I1B=V,:D'5Q6R!?3"\D[C!H>!8GD.VJZGZC.W>7II MCX('UY2*HQ^2BF#;G[@V;6S[0=\1\"7GAY+6VW;D=Z>25+!I5<$^:0$Y02NU M:T:YO##Q+3O6[78Y6@L5[P69W 3AEVT!O,M\4<8\=L\"2+Z_(X(2S$2&M]KW MT^'Q*Y8A?4$X.,_VW6.K^1WW.2HZ4=WC >EA&#.'X5C,;/QR'#O)'Q]%/]K=$*\:O)6-];C0 MM*EF9Q=\8'XVYS]C> T=PK/Q%N&/A ?$E2Q_;^ UU(!/X[D[V@4'E]%]1[G MT6./"$DR@W&) 52QK7-"_N7R;IJ1!DD>]#G.*2PY!J*')X0E[9N:_+:K)D293UU./ RPY4=='77/@Y(D@P5>VU>T%;M0G:YK7LQ".JO.&Z0%W'G?++C MFY,P##T&! M'@Q[AXCPUZVK6D;'G(:WRPS%QIB-A MTP&SD?SA+F3Z43UPUS$]Y"_G]DORU[BB8[4]>VFAG9\_FSQ]?#&97\S5[/G3 MR7Q^/GG^[%GRYH .'+X&#=E+3?3YU,UO_]X%YP .AX)CD/@='Z+G181'IZ$) M$6=3AQ+[Z1,W6;(0PWAS.M]FZNNHG4M).U?BPV%8 1)G]+4;%]_V50Y.J-+W MB-'N?0+-\R(+38Q9K_P3N<)0#@WB7D.7Q[+GD7FH,W:<](4,PCWA#7C#UM?G MDW#X]H#[\=/0SA*K3E.;'74L(8GJT%W2D]]I%[5&H76K^3YT_5XWN,FF%4X@..YQ7/56SZXP>M"+T-'+04-9!XA6V@0:<)U M4>YX5?!HKWCDVZ\D^BPAT@/?0-YKV^%I[MX.YGM/W$*DB!>D2N)K'.C5FCP2 M+9EZ:8:WO8G^'@#? L5E4K>M*<%32"#M\NK^AHNHN)S&#>I<24%=&,?*+#+] M_3.3N *>] KFDF>CUY3JV M$*C\@7$R"6497@QD["IH7-I462SWW+^;KE:-[EW)\"W.#-6I(M1R_4&^A:0M M<_?$Y3=?A#YCY"XIK"#8<"[9O$Q"96L07R_EMC!R?6WQ9')P 85X-:&Q6MQD M.0UZ4\AUBG=$U[@V 4OV28)$8]P<$KC VV>*Z[Z%'EL^7G(_AHU;_KWK,\?C M]- /.Q_OA\7QVX/K;1NB0&=;H88MS'?TR'YK'6A UJ3SL]F%J+%PH>S0A3V) MO> ';YZ@J';RT%VZ='GS6?U13WFJT]GCB;J2L]J_R0G/TUZG$VY6ZSTF2H:5 MKZ.$<[C5YW-BIXYO]OGLUAMNEN*^.J@TI.A/R[KF"SZ]8KK3O.WK)?:@N3V> MZH"X>GOUFUL]B7N=^J]C0ENUEOSB\=ZLD$N6PZVAELU)K$("/7MHQ[(LF?FR MX,-SON#"WO9K1A^'$$J0]9VQ;']MS?RGKV=P6 M# OV!#=%VQXTI"<##>EQ*L3=<"FVL]*[4*6-SO&1'$;70O6.E+EK2KT"M6>" M GK=6:5),GC9HRTSN\-+4_6^E8.(+"F]V^1ZDB)D8U?X MV<-;T(. M",T5;]V=0U>X.EBN<'07B\)P2(>.HP'KQOY5=X>WCX:;1X=<&=>&25.'VV"] MHDSNKR@?15>& UM\,;H1TRJWA_M?_>7KEW+E>'A=;F[_/06RT:N\I*%GTZ=/ M3J3IUWUIZRU?0+ZH6S)__'&M2<0:O$#/ES5QI?V"!?R5]*_^%U!+ P04 M" #VB4U5OLBI8Z@# #N" &0 'AL+W=OIMP3#L RV=+"(4J9)4 MW.S7[TB]Q.UM#A(]:!+ $,^55SHI5\:4U^&H MUL#E8>G'?G_P@>U+8P_"U:*F>]B"^;7>*-R% TK.*A":24$4%$O_*KY M"?S&X*"/UL1&LI/RP6Y^S)=^9!T"#IFQ"!0?CW -G%L@=.-CA^D/)JWB\;I' MOW6Q8RP[JN%:\GN6FW+ISWR20T$;;C[(PP_0Q3.Q>)GDVOV30R<;^21KM)%5 MIXP>5$RT3_JIX^%;%)).(7%^MX:A 8]L7AAUEE=MU:3KUB-$_)>"E-J\E;DD'\.$&((0QQ)'\ODB3J,W9\(; M#^&-SZ&O-@K+6IDG%PM\;%AM/2:-AJ+AA+,"3GG\7S&]=X %5$J>$U;52CYV M/&U+J0PHRZ,IP8GV:ZHU=B:I"+>J!*4J[[91@IE& 9E\/R6_ U7:NRLP4>'( M[*1[\8[NCD['W>GV@>5$/VF\*=T?GJ%U,M Z.4O!FFJ6N?ASQAL#.>%2:X*T MD$Q6%::*+JDZR>W_ NQA&8 M \^6@:V%V/L9^7/"WY%7:3P/HB@BK]UFW&V\ M>]>[$)0^@L)6_!FF)B]?S)(X?F.['SJ1C&?!=)0&29J0>#X-DF0-.!(!'114])NSJ3".F0".G9^]KB\,P;[M(88V1Y3TX;RJD$ M. MXNAW\BY4A&UQ3),>[V+OK;B(.DDGD\B".[&ULC599;]LX$'[WKR#4H$B!(#I\U$UM [;3Q;;8M$;2XV&Q#[0TMHA2I,JA M[.3?[Y"2%1>PU;Q8/.;[YN9XLM?F)^8 ECT64N$TR*TM;\(0TQP*CM>Z!$4W M&VT*;FEKMB&6!GCF084,DR@:A047*IA-_-G*S":ZLE(H6!F&55%P\[0 J??3 M( X.!_=BFUMW$,XF)=_" ]AOY+P^L/_E?2=? MUAQAJ>4/D=E\&HP#EL&&5]+>Z_W?T/CC#4RU1/_+]K7L&2=-;&[A7?5H,DXHEY0':^A6 M$,[./JH=H*4H6R84@U^5L$^L )OKC [:N\NO?"T!WTQ"2TH=-$P;!8M:07)& M09RP.ZULCNR#RB#[G2 D:UN3DX/)BZ23\5.EKED_NF))E"0=?/TV!'W/US_# M]Z%V^JYV^CD@R+C*V"G-V3R>LKF3];3-+U'5HS1! MFZ;>@DNN4F#OQHG'Q53QXY\4Z MDCALDSCL3J+E%KQN4D$OK^%U'.CU9?,"#&2P.Y7$3M8S27R!JMZ\T!7EE@0_2U(ON<&J';BI@R^U&&BTH5'&HM(X,MD MG#2WGVF&2E>*%^PR'C;U=K(JPJ,'FT*]]6,)F0]-_7:WI^WDF]2F7G\=:Y:IHD M=K6%DMN>KD#ASEJ;DCNS/S:HUG,=.VD4/!H MF*W+DIO#/4B]G\=9W"Y\$9NMHX5D,:OX!I[ _54]&IPE'4HA2E!6:,4,K.?Q M73:]'Y*]-_A;P-Z>C!EELM3Z&TT^%/,X)4(@8>4(@>/?#AY 2@)"&O\VF'$7 MDAQ/QRWZ[SYWS&7)+3QH^544;CN/)S$K8,UKZ;[H_1_0Y.,)KK2T_I?M@VW_ M)F:KVCI=-L[(H!0J_//OC0XG#I/T%8>\<<@][Q#(L_R-.[Z8&;UGAJP1C08^ M5>^-Y(2BHCPY@[L"_=SB^Q^O_ M7*[G4@P @_, U"!36_$5S&/L MF!_'B[9MLE-Y>H#?HZ TNH2]" 5;:.N:H M".?X740XS^\E;(2R@I>U'42D+XF<14=C.XV.>LEP-H1:R1IKRX1B&U"X*QE7 M!>,%GDQA'5GO@';=%MB#+BNN#F_?3/)L?&L155DM1<$=(EB'?]C"]0S?;40,'IF0^I>RVY=UN M6E*('8 ;S"/OC5B_-XKN&J!"V!719.@!KR,,V"!Z1NZVKBKIJ:/&2RZY6N&B MOZ9/E$!ZTLOI= M @E#R""PT2F$9IT6)MR^6]*-6FVN?@Z%$K_7ZNL:LN+7@ M2(]LDC:"Y(.A5^1IJXT++B_(OI!RU&\\A[Y^)Z$N^67YV+ME-]X]>M:4\.5( MV4U'1%W/,]^7/!C@T8 M_8.'BNY5DJ1IVVFXQ:AY^W2 0[EP-F@ZB,9#-AB?Z!IB5?Q !\MBRZ>A5&#M ME'THJ]KY[L&J@76)YXLG=L=EC=V?!=6OHLBDKW6G @ %P8 M !D !X;"]W;W)K&ULA55;;]HP%'[G5UC9-+42 M:D((+>H@4NDZ;5.KH;++P[0'DQR(55]2VRGM?OV.[9!2B=(7;)_+Y^_SX9Q, M-DK?F0K DD?!I9E&E;7U>1R;H@)!S8FJ0:)GI;2@%H]Z'9M: RU]DN!QFB2G ML:!,1OG$V^8ZGZC&!\EKEX'_"+P<;L[(E3LE3JSAV^EM,H<82 0V$= M L7E 2Z!

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 104 259 1 false 41 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://ctinanotech.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://ctinanotech.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://ctinanotech.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://ctinanotech.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Sheet http://ctinanotech.com/role/ConsolidatedStatementsOfOperationsParenthetical CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) Statements 6 false false R7.htm 00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 00000008 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Contracts with Desmet Ballestra Sheet http://ctinanotech.com/role/ContractsWithDesmetBallestra Contracts with Desmet Ballestra Notes 9 false false R10.htm 00000010 - Disclosure - Investment in equity method investment Sheet http://ctinanotech.com/role/InvestmentInEquityMethodInvestment Investment in equity method investment Notes 10 false false R11.htm 00000011 - Disclosure - Operating Lease Sheet http://ctinanotech.com/role/OperatingLease Operating Lease Notes 11 false false R12.htm 00000012 - Disclosure - Property and Equipment Sheet http://ctinanotech.com/role/PropertyAndEquipment Property and Equipment Notes 12 false false R13.htm 00000013 - Disclosure - Related Party Transactions Sheet http://ctinanotech.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 00000014 - Disclosure - Notes Payable Notes http://ctinanotech.com/role/NotesPayable Notes Payable Notes 14 false false R15.htm 00000015 - Disclosure - Stockholders??? Deficit Sheet http://ctinanotech.com/role/StockholdersDeficit Stockholders??? Deficit Notes 15 false false R16.htm 00000016 - Disclosure - Income Taxes Sheet http://ctinanotech.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 00000017 - Disclosure - Commitments and Contingencies Sheet http://ctinanotech.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 00000018 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables) Sheet http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables Organization and Summary of Significant Accounting Policies (Tables) Tables http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - Investment in equity method investment (Tables) Sheet http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentTables Investment in equity method investment (Tables) Tables http://ctinanotech.com/role/InvestmentInEquityMethodInvestment 20 false false R21.htm 00000021 - Disclosure - Operating Lease (Tables) Sheet http://ctinanotech.com/role/OperatingLeaseTables Operating Lease (Tables) Tables http://ctinanotech.com/role/OperatingLease 21 false false R22.htm 00000022 - Disclosure - Property and Equipment (Tables) Sheet http://ctinanotech.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://ctinanotech.com/role/PropertyAndEquipment 22 false false R23.htm 00000023 - Disclosure - Notes Payable (Tables) Notes http://ctinanotech.com/role/NotesPayableTables Notes Payable (Tables) Tables http://ctinanotech.com/role/NotesPayable 23 false false R24.htm 00000024 - Disclosure - Stockholders??? Deficit (Tables) Sheet http://ctinanotech.com/role/StockholdersDeficitTables Stockholders??? Deficit (Tables) Tables http://ctinanotech.com/role/StockholdersDeficit 24 false false R25.htm 00000025 - Disclosure - Income Taxes (Tables) Sheet http://ctinanotech.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://ctinanotech.com/role/IncomeTaxes 25 false false R26.htm 00000026 - Disclosure - Organization and Summary of Significant Accounting Policies (Details- Property and Equipment) Sheet http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-PropertyAndEquipment Organization and Summary of Significant Accounting Policies (Details- Property and Equipment) Details http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 26 false false R27.htm 00000027 - Disclosure - Organization and Summary of Significant Accounting Policies (Details- Net Loss Per Share) Sheet http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-NetLossPerShare Organization and Summary of Significant Accounting Policies (Details- Net Loss Per Share) Details http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 27 false false R28.htm 00000028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details - Antidilutive shares) Sheet http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares Organization and Summary of Significant Accounting Policies (Details - Antidilutive shares) Details http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 28 false false R29.htm 00000029 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) Sheet http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Organization and Summary of Significant Accounting Policies (Details Narrative) Details http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables 29 false false R30.htm 00000030 - Disclosure - Contracts with Desmet Ballestra (Details Narrative) Sheet http://ctinanotech.com/role/ContractsWithDesmetBallestraDetailsNarrative Contracts with Desmet Ballestra (Details Narrative) Details http://ctinanotech.com/role/ContractsWithDesmetBallestra 30 false false R31.htm 00000031 - Disclosure - Investment in equity method investment (Details - Rollforward) Sheet http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Rollforward Investment in equity method investment (Details - Rollforward) Details http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentTables 31 false false R32.htm 00000032 - Disclosure - Investment in equity method investment (Details - Ameredev) Sheet http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Ameredev Investment in equity method investment (Details - Ameredev) Details http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentTables 32 false false R33.htm 00000033 - Disclosure - Investment in equity method investment (Details Narrative) Sheet http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative Investment in equity method investment (Details Narrative) Details http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentTables 33 false false R34.htm 00000034 - Disclosure - Operating Lease (Details - Lease Cost) Sheet http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost Operating Lease (Details - Lease Cost) Details http://ctinanotech.com/role/OperatingLeaseTables 34 false false R35.htm 00000035 - Disclosure - Operating Lease (Details - Operating Lease Minimum payments) Sheet http://ctinanotech.com/role/OperatingLeaseDetails-OperatingLeaseMinimumPayments Operating Lease (Details - Operating Lease Minimum payments) Details http://ctinanotech.com/role/OperatingLeaseTables 35 false false R36.htm 00000036 - Disclosure - Property and Equipment (Details) Sheet http://ctinanotech.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://ctinanotech.com/role/PropertyAndEquipmentTables 36 false false R37.htm 00000037 - Disclosure - Property and Equipment (Details Narrative) Sheet http://ctinanotech.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://ctinanotech.com/role/PropertyAndEquipmentTables 37 false false R38.htm 00000038 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://ctinanotech.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://ctinanotech.com/role/RelatedPartyTransactions 38 false false R39.htm 00000039 - Disclosure - Notes Payable (Details) Notes http://ctinanotech.com/role/NotesPayableDetails Notes Payable (Details) Details http://ctinanotech.com/role/NotesPayableTables 39 false false R40.htm 00000040 - Disclosure - Notes Payable (Details Narrative) Notes http://ctinanotech.com/role/NotesPayableDetailsNarrative Notes Payable (Details Narrative) Details http://ctinanotech.com/role/NotesPayableTables 40 false false R41.htm 00000041 - Disclosure - Stockholders' Deficit (Details - Option activity) Sheet http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity Stockholders' Deficit (Details - Option activity) Details 41 false false R42.htm 00000042 - Disclosure - Stockholders' Deficit (Details - Options by exercise price) Sheet http://ctinanotech.com/role/StockholdersDeficitDetails-OptionsByExercisePrice Stockholders' Deficit (Details - Options by exercise price) Details 42 false false R43.htm 00000043 - Disclosure - Stockholders' Deficit (Details - Warrant activity) Sheet http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantActivity Stockholders' Deficit (Details - Warrant activity) Details 43 false false R44.htm 00000044 - Disclosure - Stockholders' Deficit (Details - Warrants by exercise price) Sheet http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantsByExercisePrice Stockholders' Deficit (Details - Warrants by exercise price) Details 44 false false R45.htm 00000045 - Disclosure - Stockholders' Deficit (Details - Assumptions) Sheet http://ctinanotech.com/role/StockholdersDeficitDetails-Assumptions Stockholders' Deficit (Details - Assumptions) Details 45 false false R46.htm 00000046 - Disclosure - Stockholders??? Deficit (Details Narrative) Sheet http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative Stockholders??? Deficit (Details Narrative) Details http://ctinanotech.com/role/StockholdersDeficitTables 46 false false R47.htm 00000047 - Disclosure - Income Taxes (Details- Tax Reconciliation) Sheet http://ctinanotech.com/role/IncomeTaxesDetails-TaxReconciliation Income Taxes (Details- Tax Reconciliation) Details http://ctinanotech.com/role/IncomeTaxesTables 47 false false R48.htm 00000048 - Disclosure - Income Taxes (Details- Deferred Tax Assets and Liabilities) Sheet http://ctinanotech.com/role/IncomeTaxesDetails-DeferredTaxAssetsAndLiabilities Income Taxes (Details- Deferred Tax Assets and Liabilities) Details http://ctinanotech.com/role/IncomeTaxesTables 48 false false R49.htm 00000049 - Disclosure - Income Taxes (Details Narrative) Sheet http://ctinanotech.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://ctinanotech.com/role/IncomeTaxesTables 49 false false All Reports Book All Reports cavitation_i10k-063022.htm cavitation_ex3101.htm cavitation_ex3102.htm cavitation_ex3201.htm cavitation_ex3202.htm cvat-20220630.xsd cvat-20220630_cal.xml cvat-20220630_def.xml cvat-20220630_lab.xml cvat-20220630_pre.xml image_001.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cavitation_i10k-063022.htm": { "axisCustom": 0, "axisStandard": 17, "contextCount": 104, "dts": { "calculationLink": { "local": [ "cvat-20220630_cal.xml" ] }, "definitionLink": { "local": [ "cvat-20220630_def.xml" ] }, "inline": { "local": [ "cavitation_i10k-063022.htm" ] }, "labelLink": { "local": [ "cvat-20220630_lab.xml" ] }, "presentationLink": { "local": [ "cvat-20220630_pre.xml" ] }, "schema": { "local": [ "cvat-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 415, "entityCount": 1, "hidden": { "http://ctinanotech.com/20220630": 3, "http://fasb.org/us-gaap/2022": 16, "http://xbrl.sec.gov/dei/2022": 8, "total": 27 }, "keyCustom": 30, "keyStandard": 229, "memberCustom": 20, "memberStandard": 16, "nsprefix": "CVAT", "nsuri": "http://ctinanotech.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://ctinanotech.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Investment in equity method investment", "role": "http://ctinanotech.com/role/InvestmentInEquityMethodInvestment", "shortName": "Investment in equity method investment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Operating Lease", "role": "http://ctinanotech.com/role/OperatingLease", "shortName": "Operating Lease", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Property and Equipment", "role": "http://ctinanotech.com/role/PropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Related Party Transactions", "role": "http://ctinanotech.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Notes Payable", "role": "http://ctinanotech.com/role/NotesPayable", "shortName": "Notes Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Stockholders\u2019 Deficit", "role": "http://ctinanotech.com/role/StockholdersDeficit", "shortName": "Stockholders\u2019 Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Income Taxes", "role": "http://ctinanotech.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Commitments and Contingencies", "role": "http://ctinanotech.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)", "role": "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Organization and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "CVAT:PropertyAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)", "role": "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables", "shortName": "Organization and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "CVAT:PropertyAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://ctinanotech.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "CVAT:EquityMethodInvestmentsRollforwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Investment in equity method investment (Tables)", "role": "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentTables", "shortName": "Investment in equity method investment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "CVAT:EquityMethodInvestmentsRollforwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Operating Lease (Tables)", "role": "http://ctinanotech.com/role/OperatingLeaseTables", "shortName": "Operating Lease (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Property and Equipment (Tables)", "role": "http://ctinanotech.com/role/PropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Notes Payable (Tables)", "role": "http://ctinanotech.com/role/NotesPayableTables", "shortName": "Notes Payable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Stockholders\u2019 Deficit (Tables)", "role": "http://ctinanotech.com/role/StockholdersDeficitTables", "shortName": "Stockholders\u2019 Deficit (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Income Taxes (Tables)", "role": "http://ctinanotech.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "CVAT:PropertyAndEquipmentUsefulLife", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-012022-06-30_us-gaap_LeaseholdImprovementsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Organization and Summary of Significant Accounting Policies (Details- Property and Equipment)", "role": "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-PropertyAndEquipment", "shortName": "Organization and Summary of Significant Accounting Policies (Details- Property and Equipment)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "CVAT:PropertyAndEquipmentUsefulLife", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-012022-06-30_us-gaap_LeaseholdImprovementsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Organization and Summary of Significant Accounting Policies (Details- Net Loss Per Share)", "role": "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-NetLossPerShare", "shortName": "Organization and Summary of Significant Accounting Policies (Details- Net Loss Per Share)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "INF", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-012022-06-30_us-gaap_StockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Organization and Summary of Significant Accounting Policies (Details - Antidilutive shares)", "role": "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares", "shortName": "Organization and Summary of Significant Accounting Policies (Details - Antidilutive shares)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-012022-06-30_us-gaap_StockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative)", "role": "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Organization and Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://ctinanotech.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2021-06-30_custom_DesmetMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Contracts with Desmet Ballestra (Details Narrative)", "role": "http://ctinanotech.com/role/ContractsWithDesmetBallestraDetailsNarrative", "shortName": "Contracts with Desmet Ballestra (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2021-06-30_custom_DesmetMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Investment in equity method investment (Details - Rollforward)", "role": "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Rollforward", "shortName": "Investment in equity method investment (Details - Rollforward)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "CVAT:EquityMethodInvestmentsRollforwardTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-012022-06-30_us-gaap_EquityMethodInvestmentsMember", "decimals": "0", "lang": null, "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Investment in equity method investment (Details - Ameredev)", "role": "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Ameredev", "shortName": "Investment in equity method investment (Details - Ameredev)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:EquityMethodInvestmentsTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-012022-06-30_custom_AmeredevMember1836808843", "decimals": "0", "lang": null, "name": "CVAT:RevenueFromJointVenture", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Investment in equity method investment (Details Narrative)", "role": "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative", "shortName": "Investment in equity method investment (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2020-07-012021-06-30_custom_UsageFeesMember", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Operating Lease (Details - Lease Cost)", "role": "http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost", "shortName": "Operating Lease (Details - Lease Cost)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Operating Lease (Details - Operating Lease Minimum payments)", "role": "http://ctinanotech.com/role/OperatingLeaseDetails-OperatingLeaseMinimumPayments", "shortName": "Operating Lease (Details - Operating Lease Minimum payments)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Property and Equipment (Details)", "role": "http://ctinanotech.com/role/PropertyAndEquipmentDetails", "shortName": "Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Property and Equipment (Details Narrative)", "role": "http://ctinanotech.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "Property and Equipment (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Related Party Transactions (Details Narrative)", "role": "http://ctinanotech.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LongTermNotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Notes Payable (Details)", "role": "http://ctinanotech.com/role/NotesPayableDetails", "shortName": "Notes Payable (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromRelatedParties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Notes Payable (Details Narrative)", "role": "http://ctinanotech.com/role/NotesPayableDetailsNarrative", "shortName": "Notes Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2020-04-012020-04-16_custom_PPPMember", "decimals": "0", "lang": null, "name": "us-gaap:ProceedsFromLoans", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2021-06-30_us-gaap_StockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Stockholders' Deficit (Details - Option activity)", "role": "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity", "shortName": "Stockholders' Deficit (Details - Option activity)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-012022-06-30_us-gaap_StockOptionMember1836811921", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30_us-gaap_StockOptionMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Stockholders' Deficit (Details - Options by exercise price)", "role": "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionsByExercisePrice", "shortName": "Stockholders' Deficit (Details - Options by exercise price)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30_us-gaap_StockOptionMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Stockholders' Deficit (Details - Warrant activity)", "role": "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantActivity", "shortName": "Stockholders' Deficit (Details - Warrant activity)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-012022-06-30_us-gaap_WarrantMember1836811562", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2021-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Stockholders' Deficit (Details - Warrants by exercise price)", "role": "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantsByExercisePrice", "shortName": "Stockholders' Deficit (Details - Warrants by exercise price)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "CVAT:ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30_us-gaap_WarrantMember", "decimals": "INF", "lang": null, "name": "CVAT:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2020-07-012021-06-30_us-gaap_WarrantMember1836812265", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - Stockholders' Deficit (Details - Assumptions)", "role": "http://ctinanotech.com/role/StockholdersDeficitDetails-Assumptions", "shortName": "Stockholders' Deficit (Details - Assumptions)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2020-07-012021-06-30_us-gaap_WarrantMember1836812265", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "CVAT:StockIssuedToWarrantAndOptionHoldersShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - Stockholders\u2019 Deficit (Details Narrative)", "role": "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative", "shortName": "Stockholders\u2019 Deficit (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "CVAT:StockIssuedToWarrantAndOptionHoldersShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - Income Taxes (Details- Tax Reconciliation)", "role": "http://ctinanotech.com/role/IncomeTaxesDetails-TaxReconciliation", "shortName": "Income Taxes (Details- Tax Reconciliation)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - Income Taxes (Details- Deferred Tax Assets and Liabilities)", "role": "http://ctinanotech.com/role/IncomeTaxesDetails-DeferredTaxAssetsAndLiabilities", "shortName": "Income Taxes (Details- Deferred Tax Assets and Liabilities)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - Income Taxes (Details Narrative)", "role": "http://ctinanotech.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2022-06-30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EarningsPerShareBasic", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)", "role": "http://ctinanotech.com/role/ConsolidatedStatementsOfOperationsParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2020-06-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)", "role": "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "AsOf2020-06-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Organization and Summary of Significant Accounting Policies", "role": "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies", "shortName": "Organization and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Contracts with Desmet Ballestra", "role": "http://ctinanotech.com/role/ContractsWithDesmetBallestra", "shortName": "Contracts with Desmet Ballestra", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "cavitation_i10k-063022.htm", "contextRef": "From2021-07-01to2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 41, "tag": { "CVAT_AmeredevMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ameredev [Member]" } } }, "localname": "AmeredevMember", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Ameredev", "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "CVAT_CashlessExerciseOfOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cashless Exercise Of Options [Member]" } } }, "localname": "CashlessExerciseOfOptionsMember", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "CVAT_CashlessExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Cashless exercise of warrants" } } }, "localname": "CashlessExerciseOfWarrants", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "CVAT_CashlessExerciseOfWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cashless Exercise Of Warrants [Member]" } } }, "localname": "CashlessExerciseOfWarrantsMember", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "CVAT_CashlessExerciseOfWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued upon exercise of warrants, shares" } } }, "localname": "CashlessExerciseOfWarrantsShares", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "CVAT_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1Exercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price warrants exercisable", "label": "Weighted average exercise price warrants exercisable" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1Exercisable", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantsByExercisePrice" ], "xbrltype": "perShareItemType" }, "CVAT_CommonStockAndWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock And Warrants [Member]" } } }, "localname": "CommonStockAndWarrantsMember", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "CVAT_CommonStockIssuedUponExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[custom:CommonStockIssuedUponExerciseOfWarrants]" } } }, "localname": "CommonStockIssuedUponExerciseOfWarrants", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "CVAT_CommonStockIssuedUponExerciseOfWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:CommonStockIssuedUponExerciseOfWarrantsShares]" } } }, "localname": "CommonStockIssuedUponExerciseOfWarrantsShares", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "CVAT_ConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consultant [Member]" } } }, "localname": "ConsultantMember", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "CVAT_Covid19PolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Covid-19" } } }, "localname": "Covid19PolicyTextBlock", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "CVAT_DesmetBallestraMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Desmet Ballestra [Member]" } } }, "localname": "DesmetBallestraMember", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraDetailsNarrative", "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "CVAT_DesmetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Desmet [Member]" } } }, "localname": "DesmetMember", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraDetailsNarrative" ], "xbrltype": "domainItemType" }, "CVAT_DisclosureOperatingLeaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease" } } }, "localname": "DisclosureOperatingLeaseAbstract", "nsuri": "http://ctinanotech.com/20220630", "xbrltype": "stringItemType" }, "CVAT_EIDLMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EIDL [Member]" } } }, "localname": "EIDLMember", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/NotesPayableDetails", "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "CVAT_EWMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "E W [Member]" } } }, "localname": "EWMember", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "CVAT_EarningsPerSharesBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss per common share:" } } }, "localname": "EarningsPerSharesBasicAndDilutedAbstract", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-NetLossPerShare" ], "xbrltype": "stringItemType" }, "CVAT_EquityMethodInvestmentsRollforwardTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of equity method investment" } } }, "localname": "EquityMethodInvestmentsRollforwardTextBlock", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentTables" ], "xbrltype": "textBlockItemType" }, "CVAT_FairValueOfCommonStockIssuedAsCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[custom:FairValueOfCommonStockIssuedAsCompensation]" } } }, "localname": "FairValueOfCommonStockIssuedAsCompensation", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "CVAT_FairValueOfCommonStockIssuedAsCompensationShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:FairValueOfCommonStockIssuedAsCompensationShares]" } } }, "localname": "FairValueOfCommonStockIssuedAsCompensationShares", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "CVAT_FairValueOfCommonStockIssuedForServicesCashFlow": { "auth_ref": [], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "FairValueOfCommonStockIssuedForServicesCashFlow", "verboseLabel": "Fair value of common stock issued for services" } } }, "localname": "FairValueOfCommonStockIssuedForServicesCashFlow", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CVAT_FairValueOfCommonStockIssuedForServicesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:FairValueOfCommonStockIssuedForServicesShares]" } } }, "localname": "FairValueOfCommonStockIssuedForServicesShares", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "CVAT_FairValueOfCommonStockIssuedToSettleLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Fair value of common stock issued to settle liabilities" } } }, "localname": "FairValueOfCommonStockIssuedToSettleLiabilities", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "CVAT_FairValueOfCommonStockIssuedToSettleLiabilitiesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair value of common stock issued to settle liabilities, shares" } } }, "localname": "FairValueOfCommonStockIssuedToSettleLiabilitiesShares", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "CVAT_FairValueOfCommonStockIssuedUponExerciseOfWarrantsAndOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Fair value of common stock issued upon exercise of warrants and options" } } }, "localname": "FairValueOfCommonStockIssuedUponExerciseOfWarrantsAndOptions", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "CVAT_FairValueOfCommonStockIssuedUponExerciseOfWarrantsAndOptionsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:FairValueOfCommonStockIssuedUponExerciseOfWarrantsAndOptionsShares]" } } }, "localname": "FairValueOfCommonStockIssuedUponExerciseOfWarrantsAndOptionsShares", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "CVAT_FairValueOfWarrantsGrantedForServices": { "auth_ref": [], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "FairValueOfWarrantsGrantedForServices", "verboseLabel": "Fair value of warrants granted for services" } } }, "localname": "FairValueOfWarrantsGrantedForServices", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CVAT_FormerAccruedPayrollMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Former Accrued Payroll [Member]" } } }, "localname": "FormerAccruedPayrollMember", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "CVAT_GrossProfitShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Gross Profit Share [Member]" } } }, "localname": "GrossProfitShareMember", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraDetailsNarrative" ], "xbrltype": "domainItemType" }, "CVAT_ImpairmentOfEquipment": { "auth_ref": [], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Impairment of equipment" } } }, "localname": "ImpairmentOfEquipment", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows", "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "CVAT_IncomeLossFromJointVenture": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net income" } } }, "localname": "IncomeLossFromJointVenture", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Ameredev" ], "xbrltype": "monetaryItemType" }, "CVAT_LiabilitiesSettledWithCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Liabilities settled with common stock" } } }, "localname": "LiabilitiesSettledWithCommonStock", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CVAT_LossOnSettlementOfLiabilities": { "auth_ref": [], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Loss on settlement of liabilities", "negatedLabel": "Loss on settlement of liabilities" } } }, "localname": "LossOnSettlementOfLiabilities", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows", "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "CVAT_NanoReactorSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nano Reactor Sales [Member]" } } }, "localname": "NanoReactorSalesMember", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraDetailsNarrative" ], "xbrltype": "domainItemType" }, "CVAT_PPP2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "P P P 2 [Member]" } } }, "localname": "PPP2Member", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/NotesPayableDetails", "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "CVAT_PPPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PPP [Member]" } } }, "localname": "PPPMember", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/NotesPayableDetails", "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "CVAT_Price1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Price 1 [Member]" } } }, "localname": "Price1Member", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionsByExercisePrice" ], "xbrltype": "domainItemType" }, "CVAT_PropertyAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and equipment useful life" } } }, "localname": "PropertyAndEquipmentUsefulLife", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "CVAT_ReactorSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reactor Sales [Member]" } } }, "localname": "ReactorSalesMember", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "CVAT_RevenueFromJointVenture": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "RevenueFromJointVenture", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromJointVenture", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Ameredev" ], "xbrltype": "monetaryItemType" }, "CVAT_ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of warrants outstanding and exercisable" } } }, "localname": "ScheduleOfWarrantsOutstandingAndExercisableTableTextBlock", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "CVAT_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrant shares exercisable", "label": "Number of warrant shares exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantsByExercisePrice" ], "xbrltype": "sharesItemType" }, "CVAT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Exercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted-Average Remaining Contractual Life Exercised" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Exercised", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity" ], "xbrltype": "durationItemType" }, "CVAT_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Expired": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted-Average Remaining Contractual Life Expired" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2Expired", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity" ], "xbrltype": "durationItemType" }, "CVAT_StockIssuedForLiabilitiesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:StockIssuedForLiabilitiesShares]" } } }, "localname": "StockIssuedForLiabilitiesShares", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "CVAT_StockIssuedForLiabilitiesValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[custom:StockIssuedForLiabilitiesValue]" } } }, "localname": "StockIssuedForLiabilitiesValue", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "CVAT_StockIssuedToWarrantAndOptionHoldersShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:StockIssuedToWarrantAndOptionHoldersShares]" } } }, "localname": "StockIssuedToWarrantAndOptionHoldersShares", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "CVAT_StockIssuedToWarrantAndOptionHoldersValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[custom:StockIssuedToWarrantAndOptionHoldersValue]" } } }, "localname": "StockIssuedToWarrantAndOptionHoldersValue", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "CVAT_UsageFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "UsageFees", "negatedLabel": "Usage fees paid to Cavitation and Delaware" } } }, "localname": "UsageFees", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Ameredev" ], "xbrltype": "monetaryItemType" }, "CVAT_UsageFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Usage Fees [Member]" } } }, "localname": "UsageFeesMember", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "CVAT_WarrantPrice1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "$0.03-$0.05 [Member]" } } }, "localname": "WarrantPrice1Member", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantsByExercisePrice" ], "xbrltype": "domainItemType" }, "CVAT_WarrantPrice2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "$0.08-$0.12 [Member]" } } }, "localname": "WarrantPrice2Member", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantsByExercisePrice" ], "xbrltype": "domainItemType" }, "CVAT_WarrantsIssuedForServicesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants issued for services shares" } } }, "localname": "WarrantsIssuedForServicesShares", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "CVAT_WarrantsIssuedForServicesValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Warrants issued for services value" } } }, "localname": "WarrantsIssuedForServicesValue", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "CVAT_WarrantsIssuedNewShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[custom:WarrantsIssuedNewShares]" } } }, "localname": "WarrantsIssuedNewShares", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "CVAT_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "CVAT_WeightedAverageRemaingContractualLifeWarrantsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaing contractual life, warrants granted", "label": "Weighted average remaing contractual life, warrants granted" } } }, "localname": "WeightedAverageRemaingContractualLifeWarrantsGranted", "nsuri": "http://ctinanotech.com/20220630", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantActivity" ], "xbrltype": "durationItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r510", "r512", "r513" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r510", "r512", "r513" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r510", "r512", "r513" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r510", "r512", "r513" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r502" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r501" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r508" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://ctinanotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r37", "r39", "r89", "r90", "r219", "r256" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraDetailsNarrative", "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Ameredev" ], "xbrltype": "domainItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "label": "Executive Officer [Member]" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r164", "r290", "r295", "r468" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraDetailsNarrative", "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative", "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r164", "r290", "r295", "r468" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraDetailsNarrative", "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative", "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r162", "r196", "r197", "r290", "r293", "r429", "r466", "r467" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraDetailsNarrative", "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r162", "r196", "r197", "r290", "r293", "r429", "r466", "r467" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraDetailsNarrative", "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r38", "r39", "r89", "r90", "r219", "r256" ], "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraDetailsNarrative", "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Ameredev" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r28", "r425" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Ameredev" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r166", "r167" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r13", "r190" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r19", "r425" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r93", "r94", "r95", "r343", "r344", "r345", "r383" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r214", "r269", "r276" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Fair value of warrants granted for services" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising expense" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r15", "r86", "r144", "r154", "r160", "r178", "r201", "r202", "r203", "r205", "r206", "r207", "r208", "r209", "r210", "r212", "r213", "r374", "r377", "r388", "r423", "r425", "r443", "r456" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets", "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Ameredev" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r27", "r86", "r178", "r201", "r202", "r203", "r205", "r206", "r207", "r208", "r209", "r210", "r212", "r213", "r374", "r377", "r388", "r423", "r425" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r306", "r307", "r308", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r321", "r322", "r323", "r324", "r325", "r326", "r328", "r329", "r331", "r332", "r336", "r337", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-Assumptions", "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity", "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionsByExercisePrice", "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantActivity", "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantsByExercisePrice", "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Cash": { "auth_ref": [ "r10", "r425", "r475", "r476" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Ameredev", "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r10", "r71" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r64", "r71", "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r64", "r389" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r10" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r16", "r17", "r18", "r83", "r86", "r108", "r112", "r113", "r115", "r117", "r124", "r125", "r126", "r178", "r201", "r206", "r207", "r208", "r212", "r213", "r253", "r254", "r258", "r262", "r269", "r388", "r515" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Weighted average exercise price warrants outstanding", "periodEndLabel": "Weighted average exercise price, warrants outstanding, ending price", "periodStartLabel": "Weighted average exercise price, warrants outstanding, beginning price", "verboseLabel": "Warrant exercisable price per share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantActivity", "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantsByExercisePrice", "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Number of warrant shares outstanding", "periodEndLabel": "Warrants outstanding, ending balance", "periodStartLabel": "Warrants outstanding, beginning balance" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantActivity", "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantsByExercisePrice" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r35", "r446", "r460" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r193", "r194", "r195", "r198", "r494" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r93", "r94", "r383" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r269" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18", "r425" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value, 1,000,000,000 shares authorized, 276,698,831 and 208,267,444 shares issued and outstanding as June 30, 2022 and 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r133", "r134", "r164", "r386", "r387", "r493" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r133", "r134", "r164", "r386", "r387", "r474", "r493" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r133", "r134", "r164", "r386", "r387", "r474", "r493" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r129", "r454" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentrations" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r133", "r134", "r164", "r386", "r387" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r133", "r134", "r164", "r386", "r387", "r493" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r78", "r376" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r279", "r280", "r291" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r279", "r280", "r291" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Customer advances" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r74", "r75", "r76" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r74", "r75", "r76" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Issued" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r53", "r86", "r178", "r201", "r202", "r203", "r206", "r207", "r208", "r209", "r210", "r212", "r213", "r388" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "negatedLabel": "Cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r132", "r164" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r82", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r232", "r239", "r240", "r242", "r249" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Notes Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "Debt Instrument, Decrease, Forgiveness" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r33", "r235", "r398" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/NotesPayableDetails", "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r34", "r85", "r91", "r215", "r216", "r217", "r218", "r219", "r220", "r222", "r228", "r229", "r230", "r231", "r233", "r234", "r235", "r236", "r237", "r238", "r241", "r243", "r244", "r245", "r246", "r270", "r273", "r274", "r275", "r397", "r398", "r400", "r401", "r453" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/NotesPayableDetails", "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r357" ], "calculation": { "http://ctinanotech.com/role/IncomeTaxesDetails-DeferredTaxAssetsAndLiabilities": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total net deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/IncomeTaxesDetails-DeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r359" ], "calculation": { "http://ctinanotech.com/role/IncomeTaxesDetails-DeferredTaxAssetsAndLiabilities": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/IncomeTaxesDetails-DeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r363", "r364" ], "calculation": { "http://ctinanotech.com/role/IncomeTaxesDetails-DeferredTaxAssetsAndLiabilities": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net Operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/IncomeTaxesDetails-DeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r363", "r364" ], "calculation": { "http://ctinanotech.com/role/IncomeTaxesDetails-DeferredTaxAssetsAndLiabilities": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Stock compensation expense" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/IncomeTaxesDetails-DeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r358" ], "calculation": { "http://ctinanotech.com/role/IncomeTaxesDetails-DeferredTaxAssetsAndLiabilities": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less valuation discount" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/IncomeTaxesDetails-DeferredTaxAssetsAndLiabilities" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r69", "r188" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r69", "r142" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r290", "r293", "r294", "r295", "r296", "r297", "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r28", "r88", "r204", "r206", "r207", "r211", "r212", "r213", "r419" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Related party payable" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss per share," } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r50", "r98", "r99", "r100", "r101", "r102", "r106", "r108", "r115", "r116", "r117", "r120", "r121", "r384", "r385", "r449", "r464" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfOperationsParenthetical", "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-NetLossPerShare" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding," } } }, "localname": "EarningsPerShareBasicOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r50", "r98", "r99", "r100", "r101", "r102", "r108", "r115", "r116", "r117", "r120", "r121", "r384", "r385", "r449", "r464" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfOperationsParenthetical", "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-NetLossPerShare" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r118", "r119" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax provision" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/IncomeTaxesDetails-TaxReconciliation" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r87", "r353", "r369" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "negatedLabel": "Federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/IncomeTaxesDetails-TaxReconciliation" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": { "auth_ref": [ "r353", "r369" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.", "label": "Net operating loss/carryforward" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/IncomeTaxesDetails-TaxReconciliation" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r353", "r369" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "negatedLabel": "State income taxes, net of Federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/IncomeTaxesDetails-TaxReconciliation" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r31" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued payroll and payroll taxes \u2013 related parties" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r445", "r461" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Employee-related Liabilities" } } }, "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquipmentExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents equipment expense including depreciation, repairs, rentals, and service contract costs. This item also includes equipment purchases which do not qualify for capitalization in accordance with the entity's accounting policy. This item may also include furniture expenses.", "label": "Equipment Expense" } } }, "localname": "EquipmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-PropertyAndEquipment", "http://ctinanotech.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r43", "r44", "r45", "r93", "r94", "r95", "r97", "r103", "r105", "r123", "r181", "r269", "r276", "r343", "r344", "r345", "r366", "r367", "r383", "r390", "r391", "r392", "r393", "r394", "r395", "r415", "r469", "r470", "r471" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "auth_ref": [ "r48", "r63", "r69", "r462" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.", "label": "Distribution from equity method investment", "negatedLabel": "Proceeds from Equity Method Investment, Distribution" } } }, "localname": "EquityMethodInvestmentDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows", "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Rollforward" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "auth_ref": [ "r1", "r86", "r178", "r388" ], "lang": { "en-us": { "role": { "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment, Nonconsolidated Investee [Axis]" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Ameredev" ], "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "auth_ref": [ "r1", "r86", "r178", "r388" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity." } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Ameredev" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r11", "r145", "r174" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Rollforward" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r180" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Investment in equity method investment" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestment" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsMember": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Investment in the stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition.", "label": "Equity Method Investments [Member]" } } }, "localname": "EquityMethodInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Rollforward" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r63", "r176", "r388" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investment" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsTextBlock": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.", "label": "Statement of operations for Ameredev" } } }, "localname": "EquityMethodInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-PropertyAndEquipment", "http://ctinanotech.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r69", "r247", "r248" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain on forgiveness of PPP Loan", "negatedLabel": "Gain on forgiveness of PPP note payable", "negatedTerseLabel": "Gain (Loss) on Extinguishment of Debt", "verboseLabel": "Gain on forgiveness of note payable" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows", "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations", "http://ctinanotech.com/role/NotesPayableDetailsNarrative", "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r54" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r52", "r86", "r144", "r153", "r156", "r159", "r161", "r178", "r201", "r202", "r203", "r206", "r207", "r208", "r209", "r210", "r212", "r213", "r388" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r48", "r69", "r143", "r174", "r447", "r462" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Loss from equity method investment", "negatedLabel": "Loss from equity method investment", "negatedTerseLabel": "Income (Loss) from Equity Method Investments", "verboseLabel": "Equity in earnings of equity method investment" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows", "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations", "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Rollforward", "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r87", "r354", "r355", "r361", "r368", "r370", "r371", "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r42", "r351", "r352", "r355", "r356", "r360", "r365" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r68" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r68", "r426" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "verboseLabel": "Customer advances" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r68" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Due to Related Parties", "verboseLabel": "Related party payable" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r68" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "verboseLabel": "Accrued payroll and payroll taxes \u2013 related parties" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r68" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effect of changes in:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r68", "r407" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r68" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r68" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r109", "r110", "r111", "r117" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Dilutive effect of outstanding stock options and warrants" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-NetLossPerShare" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r46", "r141", "r396", "r399", "r450" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r62", "r66", "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r25", "r425" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r9", "r24", "r79", "r122", "r182", "r183", "r184", "r427" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Rollforward" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value." } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Rollforward" ], "xbrltype": "domainItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r69" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims", "verboseLabel": "Fair value of common stock issued upon exercise of warrants and options" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease cost table" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-PropertyAndEquipment", "http://ctinanotech.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r412" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Schedule of lease liability maturities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r412" ], "calculation": { "http://ctinanotech.com/role/OperatingLeaseDetails-OperatingLeaseMinimumPayments": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseDetails-OperatingLeaseMinimumPayments" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r412" ], "calculation": { "http://ctinanotech.com/role/OperatingLeaseDetails-OperatingLeaseMinimumPayments": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseDetails-OperatingLeaseMinimumPayments" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r412" ], "calculation": { "http://ctinanotech.com/role/OperatingLeaseDetails-OperatingLeaseMinimumPayments": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseDetails-OperatingLeaseMinimumPayments" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r412" ], "calculation": { "http://ctinanotech.com/role/OperatingLeaseDetails-OperatingLeaseMinimumPayments": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseDetails-OperatingLeaseMinimumPayments" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r412" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Imputed interest/present value" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseDetails-OperatingLeaseMinimumPayments" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "verboseLabel": "Operating Lease" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OperatingLease" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r30", "r86", "r155", "r178", "r201", "r202", "r203", "r206", "r207", "r208", "r209", "r210", "r212", "r213", "r375", "r377", "r378", "r388", "r423", "r424" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r23", "r86", "r178", "r388", "r425", "r444", "r458" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Total liabilities and equity", "totalLabel": "Total liabilities and stockholders' equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets", "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Ameredev" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r8", "r32", "r86", "r178", "r201", "r202", "r203", "r206", "r207", "r208", "r209", "r210", "r212", "r213", "r375", "r377", "r378", "r388", "r423", "r424", "r425" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermInvestmentsAndReceivablesNet": { "auth_ref": [ "r15" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle) and amount due to the Entity from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such investments and receivables to an amount that approximates their net realizable value.", "label": "Equity method investment" } } }, "localname": "LongTermInvestmentsAndReceivablesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r34" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes payable, non-current", "terseLabel": "Note payable", "verboseLabel": "Notes Payable" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets", "http://ctinanotech.com/role/NotesPayableDetails", "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/NotesPayableDetails", "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r34", "r200" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/NotesPayableDetails", "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r64" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Cash generated from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r64" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r64", "r67", "r70" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows", "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r40", "r41", "r45", "r49", "r70", "r86", "r96", "r98", "r99", "r100", "r101", "r104", "r105", "r114", "r144", "r153", "r156", "r159", "r161", "r178", "r201", "r202", "r203", "r206", "r207", "r208", "r209", "r210", "r212", "r213", "r385", "r388", "r448", "r463" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "negatedLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows", "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations", "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-NetLossPerShare", "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r56" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Other, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income (Expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-PropertyAndEquipment", "http://ctinanotech.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "negatedLabel": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations", "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Ameredev" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r144", "r153", "r156", "r159", "r161" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r406", "r413" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r403" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Total operating lease liabilities", "verboseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost", "http://ctinanotech.com/role/OperatingLeaseDetails-OperatingLeaseMinimumPayments" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r403" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liability, current portion", "verboseLabel": "Short-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets", "http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r403" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability, non-current portion", "verboseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets", "http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePaymentsUse": { "auth_ref": [ "r404", "r407" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.", "label": "Cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "OperatingLeasePaymentsUse", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r402" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use asset", "verboseLabel": "Long-term right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets", "http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r410", "r413" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r409", "r413" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining lease term - operating leases (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OperatingLeaseDetails-LeaseCost" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r362" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Net operating loss" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r3", "r92", "r138", "r379" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization and Summary of Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r14", "r442", "r455" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesMember": { "auth_ref": [ "r380", "r381" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other liabilities.", "label": "Other Liabilities [Member]" } } }, "localname": "OtherLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_OtherMachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services.", "label": "Other Machinery and Equipment [Member]" } } }, "localname": "OtherMachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-PropertyAndEquipment", "http://ctinanotech.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PartnersCapital": { "auth_ref": [ "r276" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of ownership interest of different classes of partners in limited partnership.", "label": "Partners equity" } } }, "localname": "PartnersCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Ameredev" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r58" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Contributions to equity method investment", "negatedLabel": "Capital contribution to equity investment" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows", "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Rollforward" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r59" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r17", "r253" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r17", "r253" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r17", "r425" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2022 and 2021, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r6", "r26", "r185", "r186" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r60" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoans": { "auth_ref": [ "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from principal payments made on loans related to operating activities.", "label": "Proceeds from loan" } } }, "localname": "ProceedsFromLoans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r61" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from notes payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-PropertyAndEquipment", "http://ctinanotech.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r192", "r495", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property, Plant and Equipment, Estimated Useful Lives", "verboseLabel": "Property and equipment useful life" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-PropertyAndEquipment" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r12", "r189" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "verboseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-PropertyAndEquipment", "http://ctinanotech.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r191", "r425", "r452", "r459" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "verboseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets", "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Ameredev", "http://ctinanotech.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r191", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-PropertyAndEquipment", "http://ctinanotech.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r168", "r170", "r171", "r172" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Accounts Receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r302", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r302", "r418", "r420", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r416", "r417", "r419", "r421", "r422" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r350", "r428", "r498" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expenses", "verboseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations", "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r276", "r425", "r457", "r472", "r473" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r93", "r94", "r95", "r97", "r103", "r105", "r181", "r343", "r344", "r345", "r366", "r367", "r383", "r469", "r471" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r139", "r140", "r152", "r157", "r158", "r162", "r163", "r164", "r289", "r290", "r429" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue", "verboseLabel": "Revenue from Contract with Customer, Including Assessed Tax" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations", "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r292", "r300" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Contracts with Desmet Ballestra" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestra" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r51", "r204", "r206", "r207", "r211", "r212", "r213", "r477" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue - related party" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r80", "r81" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r47", "r86", "r139", "r140", "r152", "r157", "r158", "r162", "r163", "r164", "r178", "r201", "r202", "r203", "r206", "r207", "r208", "r209", "r210", "r212", "r213", "r388", "r451" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ContractsWithDesmetBallestraDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r408", "r413" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Operating lease right-of-use assets" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r133", "r164" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of antidilutive shares" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "Assumptions" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Income Tax Provision" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of notes payable" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Basic and diluted loss per common share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Ameredev" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r1", "r86", "r177", "r178", "r388" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Ameredev" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Net Investment Income [Line Items]" } } }, "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Rollforward" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": { "auth_ref": [ "r55", "r57", "r465" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments.", "label": "Investment Income [Table]" } } }, "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetails-Rollforward" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-PropertyAndEquipment", "http://ctinanotech.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r303", "r304", "r306", "r307", "r308", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r321", "r322", "r323", "r324", "r325", "r326", "r328", "r329", "r331", "r332", "r336", "r337", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-Assumptions", "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity", "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantActivity" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionsByExercisePrice", "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantsByExercisePrice" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Schedule of options outstanding and exercisable" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r310", "r327", "r330" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Stock Option activity table" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r16", "r17", "r18", "r83", "r124", "r125", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r258", "r262", "r267", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r277", "r305" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of warrant activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r146", "r147", "r148", "r149", "r150", "r151", "r163" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Warrants granted", "verboseLabel": "Warrants granted to purchase common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantActivity", "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Weighted average exercise price, warrants granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantActivity" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining contractual life", "verboseLabel": "Weighted average remaining life warrants outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantActivity", "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantsByExercisePrice" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-Assumptions" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-Assumptions" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-Assumptions" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-Assumptions", "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity", "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantActivity" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "negatedLabel": "Warrants exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantActivity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Expirations", "negatedLabel": "Warrants expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantActivity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Number of shares exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionsByExercisePrice" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "Options expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r342" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r311", "r312" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Number of shares outstanding", "periodEndLabel": "Options outstanding, ending balance", "periodStartLabel": "Options outstanding, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity", "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionsByExercisePrice" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r311", "r312" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Weighted average exercise price options outstanding", "periodEndLabel": "Weighted average exercise price, options outstanding, ending price", "periodStartLabel": "Weighted average exercise price, options outstanding, beginning price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity", "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionsByExercisePrice" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r306", "r307", "r308", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r321", "r322", "r323", "r324", "r325", "r326", "r328", "r329", "r331", "r332", "r336", "r337", "r338", "r339", "r340" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-Assumptions", "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity", "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionsByExercisePrice", "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantActivity", "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantsByExercisePrice", "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted average exercise price, options exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Weighted average exercise price, options expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted average exercise price, options forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted average exercise price, options granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r309", "r334", "r335", "r336", "r337", "r340", "r346", "r347" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionsByExercisePrice", "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantsByExercisePrice" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionsByExercisePrice", "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantsByExercisePrice" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionsByExercisePrice", "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantsByExercisePrice" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-Assumptions" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining contractual life, options outstanding", "verboseLabel": "Weighted average remaining life options outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity", "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionsByExercisePrice" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining life options exercisable" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionsByExercisePrice" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Warranty Policy" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r16", "r17", "r18", "r83", "r86", "r108", "r112", "r113", "r115", "r117", "r124", "r125", "r126", "r178", "r201", "r206", "r207", "r208", "r212", "r213", "r253", "r254", "r258", "r262", "r269", "r388", "r515" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r36", "r43", "r44", "r45", "r93", "r94", "r95", "r97", "r103", "r105", "r123", "r181", "r269", "r276", "r343", "r344", "r345", "r366", "r367", "r383", "r390", "r391", "r392", "r393", "r394", "r395", "r415", "r469", "r470", "r471" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r93", "r94", "r95", "r123", "r429" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://ctinanotech.com/role/InvestmentInEquityMethodInvestmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Fair value of common stock issued as compensation, shares", "verboseLabel": "Stock issued new, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r17", "r18", "r269", "r276" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Common stock issued for cash, shares", "verboseLabel": "Stock issued new, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares issued for compensation, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r269", "r276", "r316" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Common stock issued upon exercise of options, shares", "negatedLabel": "Options exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Fair value of common stock issued for services", "verboseLabel": "Stock Issued During Period, Value, Issued for Services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r17", "r18", "r269", "r276" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Common stock issued for cash" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r36", "r269", "r276" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Cashless exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares", "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionActivity", "http://ctinanotech.com/role/StockholdersDeficitDetails-OptionsByExercisePrice" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r21", "r22", "r86", "r169", "r178", "r388", "r425" ], "calculation": { "http://ctinanotech.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders' equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets", "http://ctinanotech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' equity (deficit):" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r84", "r254", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r268", "r276", "r278", "r382" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders\u2019 Deficit" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cumulative amount of cash and other consideration received by subsidiary or equity method investee in exchange for shares or stock issued or sold. Include amounts of cash received, fair value of non-cash assets received, fair value of liabilities assumed, and fair value of any other forms of consideration.", "label": "Net cash proceeds" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Going Concern" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r127", "r128", "r130", "r131", "r135", "r136", "r137" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantExercisePriceIncrease": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.", "label": "Exercise price" } } }, "localname": "WarrantExercisePriceIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares", "http://ctinanotech.com/role/StockholdersDeficitDetails-Assumptions", "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantActivity", "http://ctinanotech.com/role/StockholdersDeficitDetails-WarrantsByExercisePrice", "http://ctinanotech.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r107", "r117" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "Weighted average shares \u2013 diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfOperationsParenthetical", "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-NetLossPerShare" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r106", "r117" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Weighted average common shares \u2013 basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://ctinanotech.com/role/ConsolidatedStatementsOfOperationsParenthetical", "http://ctinanotech.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails-NetLossPerShare" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1828-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r138": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=123583895&loc=d3e30768-111565" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "https://asc.fasb.org/topic&trid=2196965" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r278": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r347": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r373": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r379": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r414": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r422": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04.2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r499": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r500": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r501": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r502": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r503": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r504": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r505": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r506": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r507": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r508": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r509": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r510": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r511": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r512": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r513": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r514": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r515": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r516": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r517": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r518": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r519": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" } }, "version": "2.1" } ZIP 68 0001683168-22-006887-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-22-006887-xbrl.zip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end

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